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Summary
Macrophages are an important part of the innate immune response. They are capable of
sensing pathogens via pattern recognition receptors (PRRs) and then initiating an appro-
priate inflammatory response. Dysregulation of the inflammatory response can result in
chronic inflammation and tissue damage. This thesis aimed to investigate signaling path-
ways regulating production of cytokines and chemokines in response to PRR agonists.
Interleukin (IL)-10 is a potent anti-inflammatory cytokine which suppresses the produc-
tion of pro-inflammatory cytokines such as TNFa, IL-6 and IL-12. In this thesis, a require-
ment for an interferon (IFN) b-mediated feedback loop was identified for sustained tran-
scription of IL-10 in response to lipopolysaccharide (LPS), a Toll-like receptor (TLR)4
agonist. Ruxolitinib treatment of macrophages led to an increase in pro-inflammatory
cytokine production in response to LPS. Another JAK inhibitor, Tofacitinib, also blocked
the sustained transcription of IL-10 and led to elevated secretion of pro-inflammatory cy-
tokines in response to LPS.
The IFNb-mediated feedback loop also regulated the transcription of another mediator in
the inflammatory response, monocyte chemotactic protein-1 (MCP-1). Blocking a type
I IFN-mediated feedback loop prevented maximal transcription and secretion of MCP-1
in response to LPS or poly(I:C). IFNb directly activated MCP-1 transcription and was
shown to promote binding of STAT1 to a STAT binding site in the MCP-1 promoter.
Numerous transcription factors such as CREB, Sp1 and NFkB play a role in regulating
cytokine production in response to LPS. Other transcription factors may be important
in mediating TLR signaling. MEF2D was identified as being phosphorylated at Ser121
in response to LPS. Interestingly, phosphorylation of STAT3 was increased in MEF2D-
deficient macrophages compared to wildtype macrophages. MEF2D KO macrophages
have elevated levels of IL-10 mRNA and protein. Elevated secretion of IL-10 resulted in
decreased levels of pro-inflammatory cytokines TNFa, IL-6 and IL-12. IL-10 mRNA lev-
els were increased in response to a range of TLR agonists. Expression of the regulatory
xii
macrophage markers (Arg1, LIGHT and SphK1) was enhanced in MEF2D-deficient cells.
Regulatory macrophages are characterised by high expression of IL-10 amongst other
markers. Interestingly, Zymosan stimulation of macrophages leads to a regulatory-like
phenotype. Expression of SphK1 mRNA is strongly induced by Zymosan but not by
LPS. Three SphK inhibitors were used to investigate the role of SphK1 in the Zymosan-
stimulated macrophages. Interestingly, SphK inhibitors blocked the transcription of IL-10
in response to Zymosan. Treatment of Zymosan-stimulated macrophages with SphK in-
hibitors also reduced phosphorylation of Akt and STAT3. LPS-stimulated macrophages
had lower IL-10 secretion and reduced activation of Akt and STAT3 when treated with a
SphK inhibitor. Addition of exogenous DHS1P or sphingosine 1-phosphate (S1P) did not
restore phosphorylation of STAT3 in the presence of a SphK inhibitor. This suggests the
SphK inhibitors had off-target effects that reduced IL-10 transcription.
The work presented in this thesis demonstrates novel pathways that regulate the transcrip-
tion of the important mediators, IL-10 and MCP-1.
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Chapter 1
Introduction
1.1 Innate immune response
Inflammatory responses have evolved to protect a host from infection and other insults
such as cardiac infarction. Infections induce an innate immune response that leads to
inflammation. The macroscopic symptoms of the inflammatory response are redness,
swelling, heat, pain and loss of tissue function. At the cellular and molecular level, the
inflammatory response is characterized by the production of pro-inflammatory cytokines,
interferons and chemokines leading to the recruitment of other immune cells (Kawai and
Akira, 2010). The inflammatory response will promote the removal of detrimental stimuli
and help promote the healing process. It is then rapidly terminated and damaged tissues
healed. Failure to terminate the inflammatory response leads to overproduction of cy-
tokines, termed a “cytokine storm”, which can cause tissue damage, organ failure and
death.
The innate immune response triggers an inflammatory response after recognition of mi-
crobial infection or tissue damage. Macrophages, dendritic cells (DCs) and neutrophils
are involved in the innate immune system and therefore must be capable of sensing and
responding to various pathogens (Hespel and Moser, 2012; Savina and Amigorena, 2007;
Basset et al., 2003; Medzhitov and Janeway, 2000). Macrophages, DCs and neutrophils
are also able to phagocytose infectious particles and in the case of macrophages and DCs
present them to other immune cells to drive the adaptive immune response (Basset et al.,
1
2003; Medzhitov and Janeway, 2000). In order to generate and then terminate the in-
flammatory response to prevent the development of cytokine storms, innate immune cells
must initiate signaling to drive the inflammatory response and then appropriately signal
to promote resolution of inflammation (Liew et al., 2005).
1.1.1 Innate immune signaling
Signaling is the process of transmitting a signal from one place to another such as from
the cell membrane to the nucleus. Signaling often works in a cascade or pathway and re-
quires the sequential activation of signaling molecules, although signaling pathways often
crosstalk and form networks exhibiting both classical negative feedback and positive feed
forward signaling. Small post-translational protein modifications including phosphoryla-
tion, ubiquitination, SUMOylation, acetylation and glycosylation are often used within
signaling pathways (Liu et al., 2013; Karve and Cheema, 2011; Prabakaran et al., 2012).
Phosphorylation is the reversible addition of a phosphate group to OH groups located
on tyrosine, threonine or serine amino acid side chains. Two classes of enzyme mediate
this phosphorylation; kinases which catalyse the addition of phosphate and phosphatases,
which catalyse the removal of a phosphate group. Phosphorylation works in many ways
and can lead to activation, inhibition, translocation, sequestration, altered binding prop-
erties or degradation of the modified protein (Ubersax and Ferrell, 2007; Cohen, 2000).
In macrophages, signaling is triggered by receptors located at the plasma membrane, en-
dosome or within the cytoplasm responding to a microbial infection and the signaling
pathways activated produce the desired immune response.
1.2 Macrophage polarisation
Recent work in the field has been focused on macrophage polarization. Initially, the model
proposed for T cell polarization was adopted to explain macrophage polarization (Gordon,
2003). Thus, classically activated macrophages which demonstrated a pro-inflammatory
phenotype and were induced by interferon (IFN)g and tumour necrosis factor (TNFa)
were classed as M1 macrophages. The alternatively activated macrophages, which pro-
duce high levels of IL-10 and thus have an anti-inflammatory phenotype that can be in-
2
duced with IL-4 treatment, were termed M2 macrophages. Subsequent studies identified
the need for further, more precise definitions and led to the M2 macrophage subtypes,
M2a and M2b macrophages (Martinez et al., 2008). An alternative classification replaced
the M2a and M2b terms with regulatory and wound healing macrophages respectively
(Edwards et al., 2006; Mosser and Edwards, 2008), with the suggestion of increased plas-
ticity allowing macrophages to possess characteristics of host-defense, immune regulation
and wound healing, such as the macrophages found in obese patients which demonstrate
both wound healing and classically activated characteristics. It remains unclear whether
macrophage polarisation is a stable phenotype or rather a context-dependent response
based upon the incoming signals.
1.2.1 Classically-activated macrophages
A combination of IFNg and TNFa led to macrophages with a high microbicidal activity,
which produced high levels of pro-inflammatory cytokines (Mackaness, 1977; O’Shea
and Murray, 2008). IFNg can be produced by both innate and adaptive immune cells but
a likely source in the innate immune response to infection is from natural killer (NK)
cells. This will then induce a macrophage population secreting pro-inflammatory cy-
tokines, oxygen and nitrogen radicals, thus increasing killing ability and promoting better
resistance to infection (Dale et al., 2008). Due to the rapid and transient nature of the NK
cell response, an adaptive immune cell, such as Th1 cells, would be required to maintain
the IFNg levels for the classically activated macrophages.
Classically activated macrophages are vital to host defense. Mice lacking IFNg or humans
with mutations in those signaling pathways are more susceptible to infections by viruses,
bacteria and protozoa. Classically activated macrophages may be insufficiently activated
in these situations, although other immune cells also respond to IFNg (Mackaness, 1977;
Dale et al., 2008; Gordon and Taylor, 2005). The high levels of pro-inflammatory cy-
tokines secreted by classically activated macrophages can, if not properly regulated, lead
to immunopathology such as that seen in inflammatory bowel disease or rheumatoid
arthritis (RA) (Zhang and Mosser, 2008; Szekanecz and Koch, 2007).
3
1.2.2 Wound-healing macrophages
Wound-healing macrophages develop in response to innate or adaptive signals and one
of the first innate signals caused by tissue injury is release of interleukin (IL)-4 (Loke
et al., 2007). IL-4 can be released from basophils and mast cells in response to injury
but also in response to chitin which is found in some fungi and parasites (Brandt et al.,
2000; Reese et al., 2007). One key effect of IL-4 on macrophages is to induce arginase,
an enzyme that catalyses the production of ornithine from arginine (Kreider et al., 2007).
Ornithine is a precursor to collagens and polyamines and thus the macrophage is ready to
produce extracellular matrix (ECM). Increased arginase activity, not only promotes ECM
deposition, it also reduces the levels of nitrogen radicals by competing with nitric oxide
synthase 2 (NOS2/iNOS) for arginine, thus promoting wound healing and limiting classi-
cal activation of the macrophage (Munder, 2009).
In addition to IL-4 release from granulocytes, adaptive immune cells such as Th2 cells
also secrete IL-4. Th2 immune responses can be induced at mucosal surfaces, such as
the lungs or intestines, and at non-mucosal surfaces, often in response to helminth infec-
tion (Reese et al., 2007; Wilson et al., 2007). A Th2 immune response is characterised
by IL-4 and IL-13 secretion. IL-4 or IL-13 treatment of macrophages in vitro leads
to macrophages that secrete ECM components and produce much lower levels of pro-
inflammatory cytokines, oxygen and nitrogen radicals compared to classically activated
macrophages (Edwards et al., 2006). Alternatively activated macrophages are important
to helminth and nematode clearance, although precisely how this occurs is unclear (An-
thony et al., 2006; Zhao et al., 2008). Wound-healing macrophages express YM1,YM2
and acidic mammalian chitinase (Raes et al., 2002; Zhu et al., 2004). These proteins
do not seem to affect chitins found on pathogens but appear to play a role in matrix re-
organisation (Bleau et al., 1999; Fusetti et al., 2002). Similarly to classically activated
macrophages, control of wound-healing macrophage responses are important to prevent
immunopathology. Chronic schistosomiasis leads to tissue fibrosis and this is attributed
to deregulated wound-healing macrophage activity (Hesse et al., 2001).
4
1.2.3 Regulatory macrophages
Both innate and adaptive immune responses can induce a regulatory macrophage popu-
lation. Interestingly, stress responses can also affect macrophages through glucocorticoid
release from adrenal cells (Sternberg, 2006; Mosser and Edwards, 2008). Glucocorti-
coids, such as dexamethasone, inhibit transcription of pro-inflammatory cytokine genes
and decrease mRNA stability (Sternberg, 2006). For example, dexamethasone represses
TNFa, IL-1b and COX2 in a DUSP1-dependent manner (Abraham et al., 2006). Gluco-
corticoids can also induce expression of DUSP1, which can target p38. It has been shown
that iNOS, an important characteristic of classically activated macrophages, is induced by
LPS stimulation in a p38-dependent manner (Turpeinen et al., 2011). Furthermore, this
study demonstrated that DUSP1-deficient cells have enhanced iNOS expression compared
to wildtype cells.
Regulatory macrophages can develop during later stages of adaptive immune responses to
dampen the response and thereby limit inflammation. Activation of extracellular signal-
regulated kinase (ERK)1/2 is important in the development of regulatory macrophages
as it allows hyper-secretion of IL-10 by modifying the IL-10 locus (Lucas et al., 2005).
In vitro stimulation of macrophages with a Toll-like receptor (TLR) agonist and IgG im-
mune complexes induces a regulatory macrophage population secreting high levels of
IL-10 (Gerber and Mosser, 2001). Other stimuli also act as a signal for differentiation
to regulatory macrophages, including prostaglandins, IL-10, adenosine and sphingosine
1-phosphate (Strassmann et al., 1994; Haskó et al., 2007; Weigert et al., 2007).
Regulatory macrophage subpopulations differ in some characteristics due to the differ-
ent stimuli. However, most require two stimuli to induce the regulatory phenotype.
The key characteristic of regulatory macrophages is high levels of IL-10 secretion cou-
pled with down-regulation of IL-12 production leading to a high IL-10:IL-12 ratio (Ed-
wards et al., 2006; Gerber and Mosser, 2001). IL-10 is a potent anti-inflammatory cy-
tokine and therefore it is the hyper-secretion of IL-10 that is responsible for regulatory
macrophages limiting inflammation. In contrast with wound-healing macrophages, regu-
latory macrophages do not affect ECM composition, although they continue to function
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as antigen-presenting cells (APCs) due to high levels of CD80 and CD86, which are both
important co-stimulatory molecules (Edwards et al., 2006).
Regulatory macrophages are important for limiting inflammation and thereby preventing
immunopathology, however this ability can be utilised by pathogens. At one stage in
the life cycle of the intracellular protozoan Leishmania spp., the protozoan is capable
of binding to host IgG which activates the FcgR, the macrophage Fc receptor for IgG.
This stimulation initiates signaling that induces a regulatory macrophage phenotype and
allows intracellular growth (Miles et al., 2005). A second example is that of African
trypanosomes that escape the humoral immune response by altering their main surface
antigen. This leads to the formation of immune complexes that will bind FcgR, inducing
a regulatory phenotype (Baetselier et al., 2001).
1.2.4 Macrophage phenotype markers
Expression of specific markers has been used to identify the polarisation state of macrophages
within an experimental system (Mosser and Edwards, 2008). Many different markers have
been suggested, however some markers may be shared between phenotypes and others do
not translate into human systems. This may be as result of transient expression and the
short stimulation times used to induce polarisation. However, they still function as use-
ful markers to identify changes in macrophages phenotype (figure 1.1). Recent work has
shown that prostaglandin E2 (PGE2) can alter the phenotype of macrophages leading to
elevated levels of IL-10 and the expression of regulatory macrophage markers such as
LIGHT and SphK1 (MacKenzie et al., 2013a).
1.3 Pattern recognition receptors
In macrophages, the recognition of pathogens is mediated by a group of receptors known
as Pattern recognition receptors (PRRs) (table 1.1). These germline-encoded receptors
are capable of recognizing pathogen associated molecular patterns (PAMPs), which are
groups of molecules with conserved patterns that are associated with pathogens and are
recognised by the host (Kawai and Akira, 2011). PRRs recognise structures that are
6
Figure 1.1: Macrophage phenotypes
Macrophages can be polarised into three phenotypes; classically activated, wound healing and regulatory.
Macrophages display sufficient plasticity to switch between phenotypes or share certain characteristics.
Classically activated macrophages are generated in response to TNFa or IFNg and are characterised by
production of IL-12 and iNOS. Wound healing macrophages are induced in response to IL-4 or IL-13 and
are characterised by expression of proteins associated with extracellular matrix remodelling. Regulatory
macrophages are generated often in response to TLR agonist and a second stimuli such as immune com-
plexes. Regulatory macrophages are characterised by a high IL-10:IL12 ratio and expression of SphK1 and
LIGHT.
conserved across microbial species and, more recently, have been identified as being re-
sponsible for recognising endogenous molecules from damaged cells, damage-associated
molecular patterns (DAMPs). One family of PRRs is the TLRs. These type I membrane
proteins recognize a variety of PAMPs such as lipids, nucleic acids and carbohydrates
from viruses, bacteria, fungi and protozoa. In addition to TLRs, other PRRs are found in
innate immune cells. C-type lectin receptors, Nod-like receptors, RigI-like receptors and
DNA receptors all function to recognize pathogens. Recognition of PAMPs results in the
initiation of transcription of genes involved in the inflammatory response. The pattern of
genes induced varies between the activated PRRs.
1.3.1 Toll-like Receptors
TLRs can be found upon the surface of many cells including macrophages and also
within cells on endosomes and lysosomes. TLRs have N-terminal leucine-rich repeats
(LRRs) followed by a transmembrane region and a cytoplasmic Toll/IL-1R homology
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(TIR) domain (Akira and Takeda, 2004b). Different TLRs recognise different conserved
structures (table 1.1). TLR2 in complex with TLR1 or TLR6 recognises di- and tri-
acylated lipids respectively from bacteria, mycoplasma, fungi and viruses. The TLR1/2
or TLR2/6 heterodimers formM shaped structures and their ligands bind to internal pock-
ets within the complexes (Jin et al., 2007). TLR10 possesses a similar sequence identity
to TLR1 and TLR6, although the TLR10 ligand has not yet been identified. TLR4 will
bind lipopolysaccharide (LPS), a major component of Gram negative bacterial cell walls.
TLR4 binds LPS in conjunction with CD14 and MD2 (Kim et al., 2007a; Park et al.,
2009). TLR4 can also sense viral envelope proteins (Kurt-Jones et al., 2000).
TLR5 is highly expressed by dendritic cells and recognises flagellin from flagellated bac-
teria. Flagellin-activated DCs can then trigger B and T cell responses (Uematsu et al.,
2008). Mice deficient for TLR5 had elevated pro-inflammatory gene expression in the
intestine along with colitis with incomplete penetrance (Carvalho et al., 2012). Interest-
ingly, TLR11 which is present in mice, but not humans, is broadly homologous to TLR5.
TLR11 will recognise uropathogenic bacteria and also a profilin like molecule from pro-
tozoa (Yarovinsky et al., 2005). More recently, it has been identified as being protective
in response to Salmonella infection (Shi et al., 2012).
TLRs 3, 7, 8 and 9 bind nucleic acids derived from bacteria and viruses. These nucleic
acid-sensing TLRs are found at the endosome and can also sense endogenous nucleic
acids (Akira and Takeda, 2004b). TLR3 will sense viral dsRNA in the endolysosome. The
structure of TLR3 bound to dsRNA shows dsRNA bound to the N- and C-terminal regions
of the LRRs and promotes dimerisation of two TLR3 molecules (Choe et al., 2005; Liu
et al., 2008b). Mouse TLR7 and human TLR7/8 bind ssRNA from RNA viruses and
from bacteria such as Group B Streptococcus (Mancuso et al., 2009). TLR9 will bind and
recognize unmethylated CpG sequences in DNA from bacteria and viruses. A key feature
of signaling from TLR3 is the induction of type I interferons as well as pro-inflammatory
cytokines. The pattern of cytokine production downstream of TLR7, 8 and 9 is cell type-
dependent.
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1.3.2 C-type lectin receptors
C-type lectin receptors (CLRs) recognize carbohydrates from fungal pathogens and initi-
ate downstream signaling (reviewed in Kerrigan and Brown, 2011; Hardison and Brown,
2012). The CLR family includes Dectin-1, Dectin-2 and Mincle. Signaling downstream
of Dectin-1 involves recruitment of Src and Syk and activates a complex containing
CARD9, Multi and Bcl10 (Rogers et al., 2005). Dectin-1 signaling can activate MAPK
and NFkB signaling and leads to the production of cytokines and chemokines (Gross
et al., 2006; Goodridge et al., 2007). Dectin-1 specifically recognizes b1-3 glucans (Tay-
lor et al., 2007) and can be activated by Zymosan; a crude preparation from fungal cell
wells, which also results in TLR2/6 activation. Curdlan, a purified b-glucan, will also
activate Dectin-1 signaling.
Dectin-1 signaling is important in the response to fungal infections (Gross et al., 2006;
Taylor et al., 2007; Werner et al., 2009; Saijo et al., 2007; Ferwerda et al., 2009), as well as
in triggering adaptive immune responses such as Th1, Th17 and cytotoxic T-cell responses
(Reid et al., 2009; Kerrigan and Brown, 2010). In particular, Dectin-1 dependent trigger-
ing of Th17 responses has been shown to contribute to fungal clearance (LeibundGut-
Landmann et al., 2007). Several factors caused by Dectin-1 stimulation of dendritic cells
are thought to enhance Th17 responses. Firstly, increased ratio of IL-23 compared to
IL-12 production thus limiting Th1 differentiation and promoting Th17 cells (Smeekens
et al., 2010). Secondly, b-glucans cause the secretion of prostaglandin E2 (PGE2), which
can induce IL-6 and IL-23, both important in Th17 polarisation (LeibundGut-Landmann
et al., 2007). Zymosan stimulation of macrophages results in a significant secretion of
IL-10, surprsingly, Zymosan-stimulated macrophages are resistant to the IL-10 mediated
repression of pro-inflammatory cytokines (Elcombe et al., 2013). Zymosan stimulation
also induces regulatory macrophage markers such as SphK1 and LIGHT (Elcombe et al.,
2013).
1.4 TLR signaling
Once TLRs have bound their agonists, signaling is initiated via adaptor proteins and leads
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Table 1.1: Pattern recognition receptors
Name Ligand Pathogens detected Signaling Adaptor
TLR1 Triacyl lipopeptide Bacteria MyD88
TLR2 Lipoprotein Bacteria, Viruses, Parasites MyD88
TLR3 dsRNA Viruses TRIF
TLR4 Lipopolysaccharide Bacteria, Viruses MyD88/TRIF
TLR5 Flagellin Bacteria MyD88
TLR6 Diacyl lipopeptide Bacteria MyD88
TLR7/8 ssRNA Viruses, Bacteria MyD88
TLR9 CpG-DNA Viruses, Bacteria, Protozoa MyD88
TLR10 Unknown Unknown Unknown
TLR11 Profilin-like molecule Protozoa MyD88
TLR12 Profilin-like molecule Protozoa MyD88
TLR13 23S rRNA Bacteria MyD88
Dectin-1 b-glucan Fungi Syk
Dectin-2 b-glucan Fungi Syk
MINCLE SAP130 Fungi Syk
NOD1 iE-DAP Bacteria RIP2
NOD2 MDP Bacteria RIP2
RIG-I short dsRNA Viruses IPS-1
MDA-5 long dsRNA RNA viruses IPS-1
LGP2 Unknown RNA viruses Unknown
cGAS dsDNA DNA viruses STING
DAI dsDNA DNA viruses STING
AIM2 dsDNA DNA viruses ASC
DHX9 dsDNA DNA viruses MyD88
DHX36 dsDNA DNA viruses MyD88
to the transcription of distinct genes depending on the TLR activated (Akira and Takeda,
2004b). These distinct transcriptional programmes are partly explained by the signaling
molecules used. TLRs can be broadly split into two groups, which use either the adaptors
TRIF or MyD88. All TLRs except TLR3 signal via MyD88. TLRs 1, 2, 4 and 6 are found
at the plasma membrane. TLR3, 7/8 and 9 are located on the endosome. In addition to
MyD88, TLR4 is capable of signaling via TRIF and its partner adaptor TRAM.
1.4.1 MyD88 signaling
MyD88 contains a death domain (DD) and a TIR domain, which mediates recruitment
to the TIR domain of the receptor. In the case of TLR4 and TLR2, MyD88 recruitment
occurs via the adpator protein Mal. MyD88 signaling results in the recruitment of IL-1R-
associated kinase (IRAK)4 (Lin et al., 2010; Warner and Núñez, 2013). IRAK4 interacts
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with MyD88 via its own DD and is a serine/threonine kinase (figure 1.2). IRAK4 will ac-
tivate IRAKs 1 and 2 (Kawagoe et al., 2008). The activated IRAKs can then interact with
TRAF6. TRAF6 is an E3 ubiquitin ligase and in conjunction with Ubc13 and Uev1A, the
formation of a Lys-63 linked polyubiquitin chain on TRAF6 and IRAK1 is catalysed.
Following the ubiquitination of TRAF6, a complex of TGFb-activated kinase 1 (TAK1),
TAK1-binding protein 1(TAB1), TAB2 and TAB3 is activated as TAB2/3 bind to polyu-
biquitin chains through zinc finger-type ubiquitin-binding domains (Mendoza et al., 2008;
Wang et al., 2001; Kanayama et al., 2004; Sato et al., 2005). In addition, NEMO is
also capable of binding polyubiquitin chains, bringing TAK1 into proximity with the
NEMO/IKKa/IKKb complex (Wu et al., 2006). TAK1 will phosphorylate and activate
the NEMO/IKKa/IKKb complex (Sato et al., 2005). Active IKKa/IKKbwill in turn phos-
phorylate IkBa. Once phosphorylated, IkBa becomes ubiquitinated and degraded by the
proteasome (Chen et al., 1996). This allows NFkB to translocate to the nucleus and drive
transcription (Vallabhapurapu and Karin, 2009).
In addition to recognition of lysine-linked polyubiquitin chains, NEMO can bind to linear
ubiquitin chains. It has been shown that the linear ubiquitin chain assembly complex,
which consists of HOIP, HOIL-1 and sharpin, generates polyubiquitin chains which are
linked C-terminal to N-terminal (Kirisako et al., 2006; Stieglitz et al., 2012; Tokunaga
et al., 2011). Several studies have demonstrated the importance of linear ubiquitin chains
in NFkB activation. NEMO binds linear ubiquitin chains via its UBAN motif and bind-
ing to linear chains is required for maximal NFkB activation (Rahighi et al., 2009; Ken-
sche et al., 2012; Tokunaga et al., 2009; Emmerich et al., 2013). Many of these studies
used mouse embryonic fibroblasts stimulated with IL-1 to investigate the role of ubiquitin
chains, although evidence for these chains downstream of TLRs in macrophages is more
controversial (see (Clark et al., 2013)).
TAK1 and IKKs can also activate mitogen-activated protein kinase (MAPK) signaling,
which activate Sp1, CREB, AP-1 and other transcription factors that promote gene tran-
scription. A series of studies has shown that for activation of ERK1/2 in macrophages,
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IKK activation is required to release inhibition of Tpl2 by p105 and ABIN2 (Beinke et al.,
2004; Roget et al., 2012; Robinson et al., 2007; Lang et al., 2004; Gantke et al., 2012).
TAK1 is thought to be the MAP3K for the JNK pathway, as myeloid-specific deletion
of TAK1 prevented activation of JNK as well as NFkB (Eftychi et al., 2012) and, in line
with this, TAK1 is required for JNK activation in response to TLR agonists in B cells
(Sato et al., 2005).
Figure 1.2: TLR4 signaling
A) LPS can bind to TLR4 in complex with MD2 and CD14 at the plasma membrane. This leads to the
recruitment of Mal and MyD88. IRAK1, 2 and 4 are recruited and this leads to the activation of TRAF6.
TRAF6 can then form K63-linked polyubiquitin chains that promote activation of TAK1. TAK1 is respon-
sible for activation of the IKKs which can activate NFkB signaling and ERK signaling via Tpl2. TAK1 may
also activate p38 and JNK signaling. Other MAP3Ks are expected to be activated in response to TLR4 sig-
naling. Additionally, IRF5 is activated downstream of TRAF6, although the precise mechanism is unclear.
B) TLR4 can also be internalised to the endosome where it recruits TRAM and TRIF to initiate downstream
signaling. TRAF3 and TRAF6 are recruited and activate TBK1/IKKe, which in turn activate IRF3/7. TRIF
can also recruit RIP1, which leads to the activation of NFkB and MAPK signaling.
In plasmacytoid DCs, TLR7 and TLR9 also induce the production of type I interferons
via a complex of IRAK1, TRAF6, TRAF3 and IKKa. In plasmacytoid DCs, this complex
phosphorylates IRF7, which translocates to the nucleus to drive type I interferon expres-
sion (Honda et al., 2006). In conventional DCs, IRF3 is activated and is responsible for
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type I interferon gene transcription (Negishi et al., 2006; Schmitz et al., 2007; Honda
et al., 2006).
1.4.2 TRIF signaling
TRIF will interact with TRAF3 and TRAF6 via TRAF-binding motifs (figure 1.2) (Kawai
and Akira, 2010). TRIF also contains a receptor-interacting protein (RIP) homotypic
interaction motif (RHIM) that allows interactions with RIP1 and RIP3. RIP1 becomes
polyubiquitinated in response to TLR4 activation and this is dependent on interaction with
TRADD, FADD and RIP1. Polyubiquitinated RIP1 can then activate the TAK1 complex,
which results in NFkB and MAPK activation (Cusson-Hermance et al., 2005). TRIF
signaling also results in the activation of TBK1/IKKe which will phosphorylate IRF3,
active IRF3 can then induce transcription (Yamamoto et al., 2002; Oshiumi et al., 2003;
Hoebe et al., 2003; Fitzgerald et al., 2003). Importantly, IRF3 mediates the transcription
of type I interferons (Honda et al., 2006).
1.5 MAPK signaling
Mitogen activated protein kinases (MAPKs) are Ser/Thr kinases of which 14 have been
identified in mammals (reviewed in Cargnello and Roux, 2011). MAPK signaling clas-
sically involves a three-tiered kinase cascade (see figure 1.3). Stimulation results in the
activation of MAPK kinase kinases (MAP3Ks). MAP3Ks will then phosphorylate MAPK
kinases (MAP2Ks). MAP2Ks phosphorylate the conserved Thr and Tyr of the TXY mo-
tif in the activation loop of the kinase domain of MAPK. Active MAPKs phosphorylate
many targets including transcription factors which can then initiate transcription .
1.5.1 TLR-induced MAPK signaling
The identity of all the MAP3Ks responsible for activation downstream of TLR signaling
is still being elucidated. Tpl2 is responsible for the activation of MEK1/2-ERK1/2 in
macrophages (Beinke et al., 2004). Recent studies have suggested that TAK1 is required
for JNK activation in macrophages, although other kinases have been suggested including
ASK1 (Eftychi et al., 2012). The MAP3K responsible for p38 activation is still unclear
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with TAK1, ASK1 and MEKK3 all being suggested (Ajibade et al., 2012; Matsuzawa
et al., 2005; Huang et al., 2004; Kim et al., 2007b). Cell type specific deletion of poten-
tial MAP3Ks will be required to identify the responsible kinase in the context of TLR
signaling in macrophages.
1.5.2 ERK1/2
ERK1 was the first identified mammalian MAPK and was phosphorylated in response
to growth factors (Cooper et al., 1982; Kazlauskas and Cooper, 1988). ERK1 and 2
share 83% amino acid identity and are widely expressed. In most cell types, ERK1/2 are
activated downstream of Raf-MKK1/2. However, in macrophages, Tpl2/Cot is utilised
in response to TLR agonists (reviewed in Raman et al., 2007; Shaul and Seger, 2007).
MEK1/2 are two MAP2Ks that become phosphorylated by Raf or Tpl2, depending on
cell type, and then activate ERK1/2.
The ERK1/2 pathway is important in cytokine production from macrophages via effects
on transcription and post-transcriptionally. Through use of MEK1 and MEK2 inhibitors
and the analysis of Tpl2-/- mice, it has been shown that ERK1/2 induce TNFa, IL-1b
and IL-10 production and negatively regulate IL-12, IFNb and NOS2 (Kaiser et al., 2009;
Mielke et al., 2009; Dumitru et al., 2000). ERK1/2 is also important for the induction of
chemokines such as MCP-1 (Bandow et al., 2012). ERK1/2 also induce the transcription
of DUSP1, DUSP2 and DUSP4 resulting in negative feedback loops (Brondello et al.,
1997; Cagnol and Rivard, 2013). DUSP4 will dephosphorylate and inhibit ERK1/2 while
DUSP1 targets p38 and JNKs and DUSP2 inactivates JNKs (Lang et al., 2003; Huang
et al., 2000). ERK1/2 phosphorylates and activates MSKs and RSKs (Deak et al., 1998;
McCoy et al., 2007; Dalby et al., 1998).
1.5.3 p38
p38a was identified in 1994 and, subsequently, 3 other isoforms have been found to make
up the p38 family, which are responsive to stress stimuli (Han et al., 1994; Lee et al.,
1994; Rouse et al., 1994). p38a and b are widely expressed, whereas p38g and p38d have
more restricted expression profiles (Cuadrado and Nebreda, 2010; Jiang et al., 1996). p38
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isoforms are activated by environmental stresses and inflammatory cytokines and MKK3
and MKK6 are responsible for their activation through phosphorylation of a TGY mo-
tif (Dérijard et al., 1995; Han et al., 1996; Stein et al., 1996; Cuadrado and Nebreda,
2010). Many MAP3Ks can activate MKK3/6 including MEKK1-4, ASK1, Tpl2, TAK1
and TAO1/2 (Cuadrado and Nebreda, 2010). p38a can also activate multiple kinases
downstream including MNK1/2, MSK1/2 and MK2/3 (Ananieva et al., 2008; Cargnello
and Roux, 2011).
The four p38 isoforms have been well studied through genetic and chemical approaches.
p38a and b are sensitive to most common p38 inhibitors and these inhibitors are pro-
tective in autoimmune and inflammatory models (Cohen, 2009). The role of p38b in
cytokine production is minimal, as p38b deficiency has little effect on their production
from myeloid cells (Beardmore et al., 2005). Deletion of p38a from macrophages leads
to reduced TNFa after TLR stimulation and confers greater resistance to endotoxic shock
compared to wild-type mice (Kang et al., 2008). Using a chemical genetic approach to
render either p38a or p38b insensitive to common p38 inhibitors has shown that the in-
hibition of p38a is crucial to the inhibitors’ effects on TNFa production and in arthritis
models (O’Keefe et al., 2007). Recent work has shown that p38a has cell specific roles.
A study using myeloid-specific deletion of p38a demonstrated the importance of p38a in
rheumatoid arthritis. Unexpectedly, mice lacking p38a in macrophages showed increased
disease severity and delayed resolution as well as elevated synovial levels of IL-6 and
IL-1 (Guma et al., 2012). This is in contrast to the protective effect of p38 inhibitors,
suggesting p38 may have either pro- or anti-inflammatory roles depending on cell type.
One anti-inflammatory role of p38 is to drive transcription of IL-10 via MSK1/2 thus ini-
tiating negative feedback pathways to limit TLR signaling (Kim et al., 2008a; Ananieva
et al., 2008). Another feedback pathway regulated by p38 involves the phosphorylation of
TAB1 and TAB3 and then results in inhibition of TAK1. As a result, p38 inhibitors cause
JNK1/2 and ERK1/2 hyperactivation (Cheung et al., 2003; Mendoza et al., 2008). p38
also drives transcription of dusp1, which encodes a phosphatase that dephosphorylates
p38a and JNKs and thus sets up a negative feedback pathway (Hammer et al., 2006; Zhao
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et al., 2006; Kim et al., 2008a; Ananieva et al., 2008).
p38g and p38d are required for maintaining Tpl2 stability as myeloid cells lacking p38g
and p38d have decreased Tpl2 levels (Risco et al., 2012). Reduced TNFa levels are evi-
dent in LPS-stimulated liver macrophages from mice lacking p38g and p38d. p38g and
p38d phosphorylate and inhibit eukaryotic elongation factor 2 (eEF2) kinase, promoting
TNF elongation as eEF2 becomes dephosphorylated and activated (González-Terán et al.,
2013). However, the changes in Tpl2 protein levels may partly explain the changes seen
in TNFa levels in myeloid cells lacking p38g and p38d (Risco et al., 2012).
1.5.4 JNK
Stress stimuli promote the phosphorylation of JNKs and there are 3 JNK isoforms; JNK1
and JNK2 are widely expressed, while JNK3 has a more restricted distribution (Rincón
and Davis, 2009; Kyriakis and Avruch, 1996; Kyriakis et al., 1991, 1994; Dérijard et al.,
1994; Bode and Dong, 2007). JNKs are phosphorylated by MKK4 and MKK7 which can
be activated by several MAP3Ks including MKK1-4, Tpl2, TAO1/2, TAK1 and ASK1/2
(Bogoyevitch et al., 2010; Kyriakis and Avruch, 2001;Wagner and Nebreda, 2009; Lawler
et al., 1998). JNK1/2 are activated in response to multiple stimuli in macrophages (Rincón
and Davis, 2009). A well known target of JNK is c-Jun but other transcription factors such
as ATF2, Elk1 and JunB are also phosphorylated (Weston and Davis, 2002; Raman et al.,
2007; Bogoyevitch et al., 2010).
Jnk1 and Jnk2 deficiency leads to embyronic lethality but conditional deletion of JNK1
and JNK2 in myeloid cells has demonstrated some of the physiological roles of these
kinases (Kuan et al., 1999; Sabapathy et al., 1999). Mice with myeloid cells lacking
JNK1 and 2 become obese when on a high-fat diet but do not develop insulin resistance
like wild-type mice (Han et al., 2013). Also, macrophages from these mice fail to polarise
to the M1 classically activated phenotype (Martinez et al., 2009). This pro-inflammatory
role for JNKs is further illustrated by reduced expression of classical M1 macrophage-
specific genes in bone marrow-derived macrophages (BMDMs) from mice lacking JNK1
and JNK2 in myeloid cells stimulated with IFNg or LPS (Martinez et al., 2009).
17
1.5.5 ERK5
ERK5 was identified in 1995 and is a 98 kDa protein and therefore is also called Big
MAPK (BMK) (Zhou et al., 1995; Lee et al., 1995). ERK5 has homology to the ERK1/2
kinase domain and shares the TEY motif in the activation loop but has a large unique
C-terminal domain (Drew et al., 2012; Zhou et al., 1995; Lee et al., 1995). ERK5 is
activated by MEK5, which is thought to be activated by MEKK2/3 (Chao et al., 1999;
Zhou et al., 1995; Sun et al., 2001; Nakamura and Johnson, 2003). ERK5 has a range
of substrates including c-Myc, c-Fos and MEF2 family members (English et al., 1998;
Kato et al., 1997, 2000; Terasawa et al., 2003). ERK5 is widely expressed and activated
in response to oxidative stress and growth factors (Lee et al., 1995; Abe et al., 1996; Kato
et al., 1998; Kamakura et al., 1999). Deletion of erk5 is embryonic lethal with defective
vasculature evident at embryonic days 9.5-11.5 (Regan et al., 2002; Sohn et al., 2002; Yan
et al., 2003; Pi et al., 2004).
1.6 MAPK activated protein kinases
MAPKs have a number of downstream targets including further kinases. There are a
group of kinases activated by MAPKs known as MAPK activated protein kinases (MAP-
KAPKs or MKs) (reviewed in Cargnello and Roux, 2011; Arthur and Ley, 2013). These
are RSK1-4, MSK1/2, MNK1/2, MK2/3 and MK5. These kinases are activated by their
upstream MAPK and thus contain an activation loop sequence that these kinases can
recognise. ERK1/2 can activate RSKs, MSKs or MNKs. p38 isoforms will phosphorylate
the MSKs and MNK1 similarly to ERK1/2. They also activate MK2 and MK3. Lastly,
MK5 is phosphorylated by the atypical MAPKs, ERK3 and ERK4.
1.6.1 MSK
ERK and p38 MAPKs target two nuclear protein kinases – MSK1 and MSK2. MSK1/2
were identified through genome-wide homology searches to RSK or through yeast two-
hybrid screens using p38a bait (Deak et al., 1998; New et al., 1999; Pierrat et al., 1998).
MSK1 and MSK2 are 63% identical and interact with ERK1/2 and p38 isoforms through
the MAPK binding domain near their C-terminus (Tomás-Zuber et al., 2001). MSKs
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have two autonomous kinase domains; the N-terminal kinase domain is related to the
AGC family and the C-terminal kinase domain has a CAMK-like sequence. Both iso-
forms are widely expressed and are located within the nucleus due to a functional nuclear
localisation signal (Deak et al., 1998; Pierrat et al., 1998).
Phosphorylation of MSK1/2 by ERK or p38 MAPK leads to their activation and they
have a number of key targets in the immune response (Deak et al., 1998; Pierrat et al.,
1998; McCoy et al., 2007; Tomás-Zuber et al., 2001; Wiggin et al., 2002). MSK inter-
acts with ERK or p38 via its MAPK binding domain leading to phosphorylation of three
Pro-directed sites on MSK; Ser360, Thr581 and Thr700. Phosphorylation of Thr700 is
thought to relieve auto-inhibition of the C-terminal kinase domain and along with the
phosphorylation of Thr581 within the activation domain of the C-terminal kinase domain
results in an active C-terminal kinase domain that phosphorylates two sites within the
linker region of MSK and one site (Ser212) within the activation loop of the N-terminal
kinase domain (McCoy et al., 2007). The active N-terminal kinase domain can then phos-
phorylate target substrates.
MSK1/2 can phosphorylate the transcription factor CREB on Ser133 (Deak et al., 1998;
Pierrat et al., 1998; Hamm et al., 2002; Lee et al., 2003; Wiggin et al., 2002). CREB
recognizes and binds CRE sites in promoter regions of many genes including c-Fos, JunB
and Egr1 (Lonze and Ginty, 2002). Phosphorylation of Ser133 was thought to promote
recruitment of p300/CBP and lead to the initiation of transcription, however recent work
has suggested that downstream of MSK, Ser133 phosphorylation does not lead to strong
recruitment of these co-activators (Naqvi et al., 2014). MSKs also phosphorylate the
closely related transcription factor ATF1 at Ser63 (Wiggin et al., 2002). MSKs are also
crucial in driving the transcription of the important anti-inflammatory mediators, DUSP1,
IL-1ra and IL-10 (Ananieva et al., 2008; Darragh et al., 2010). MSK1 and 2 deficient
mice are hypersensitive to endotoxic shock and demonstrate prolonged inflammation af-
ter toxic contact eczema (Ananieva et al., 2008). This hyper-inflammation is probably due
to the loss of the anti-inflammatory mediators under the control of MSKs.
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MSKs also target two proteins involved in shaping the chromatin environment; histone
H3 and HMGN1 (Soloaga et al., 2003). Histone H3 is phosphorylated at Ser10 by MSKs.
The C-terminal tail of histone H3 undergoes numerous post-translational modifications
(PTMs) and embryonic fibroblasts from mice lacking MSK1 and MSK2 lacked phospho-
rylation of histone H3 in response to stress or mitogens (Soloaga et al., 2003). Histone H3
is additionally phosphorylated at Ser28 by MSKs (Dyson et al., 2005). These two serine
residues lie in a putative 14-3-3 binding site, which may alter binding of repressors to
promoter regions (Macdonald et al., 2005). Interestingly, phosphorylation of histone H3
was shown to block the binding of HP1, a transcriptional repressor (Zeng et al., 2010).
HMGN1 regulates chromatin compacting and studies using HMGN1-null cells suggest it
suppresses histone H3 phosphorylation (Hock et al., 2007; Lim et al., 2004; Vermeulen
et al., 2009). Therefore the role of MSK-mediated phosphorylation of HMGN1 at Ser6
may be to allow MSK-mediated phosphorylation of core histones by affecting the inter-
action between HMGN1 and nucleosomes.
1.6.2 MK2/3
MAPK-activated protein kinase 2 (MK2) and 3 were identified as p38 substrates and share
75% amino acid identity (Rouse et al., 1994; McLaughlin et al., 1996; Zu et al., 1994;
Stokoe et al., 1993). Both MK2 and 3 contain a NLS found at their C terminus (Smith
et al., 2000). The NLS is found within the D domain that is important for interactions
with p38a and b. MK2 and 3 also possess a NES that promotes nuclear export following
stimulation (Ben-Levy et al., 1998; Engel et al., 1998). MK2 and MK3 are widely ex-
pressed, particularly in muscle and kidney (Engel et al., 1993; Stokoe et al., 1992).
In quiescent cells, MK2 and MK3 are predominantly found within the nucleus (Engel
et al., 1998; Neufeld et al., 2000; Ben-Levy et al., 1998). Stimulation results in an
exportin-1-dependent export of these proteins. Unmasking of the NES appears to be
regulated by phosphorylation and thus stress stimulation and kinase activation results in
MK2/3 export to the cytoplasm (Engel et al., 1998). Stimuli that activate p38 result in
activation of MK2/3 and this activation can be blocked by p38 inhibitors and is absent in
p38a-deficient cells (Freshney et al., 1994; Rouse et al., 1994; Clifton et al., 1996; Adams
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et al., 2000). Activated p38a phosphorylates MK2 at a threonine residue within its activa-
tion loop and at second threonine within a hinge region which regulates auto-inhibition.
Phosphorylation of the hinge region leads to conformational change, releasing a helix
from the kinase domain and exposing the NES (Ben-Levy et al., 1995; White et al., 2007;
Meng et al., 2002; Engel et al., 1998). p38a and MK2 mutually stabilise each other and
deletion of one leads to reduced expression of the other (Gaestel, 2006; Kotlyarov et al.,
2002; Sudo et al., 2005).
p38 is important in many processes, including cytokine production and gene expression,
and MK2 appears to be important in many of these (Gaestel, 2006; Ronkina et al., 2008).
Notably, following LPS stimulation, MK2 is important in regulating the cytokine response
through post-transcriptional mechanisms. MK2 promotes stability and/or translation of
IL-6 and TNFa (Kotlyarov et al., 1999; Neininger et al., 2002). MK2-deficient mice
are more resistant to endotoxic shock but more susceptible to bacterial infection (Lehner
et al., 2002). MK2 can bind or phosphorylate numerous proteins, including TTP and
HuR, which can bind AU-rich elements (AREs) (Neininger et al., 2002; Winzen et al.,
1999; Mahtani et al., 2001; Tran et al., 2003). MK2 can therefore regulate stability of
mRNAs containing AREs such as TNFa and IL-6. MK2 has been shown to phosphorylate
TTP at Ser52 and Ser178. p38 inhibitors promote localisation of TTP to the nucleus,
proteasomal degradation and loss of phosphorylation at Ser52 and Ser178 (Brook et al.,
2006). The control of TTP stability and expression by MK2 was shown to influence TNFa
mRNA stability as TTP binds an ARE and destabilises TNFa mRNA. MK2-deficient
macrophages produce significantly less TNFa mRNA in response to LPS, while TTP
knockout macrophages produce large amounts of TNFa (Hitti et al., 2006). Recently,
it has been shown that phosphorylation of TTP by MK2 decreases its binding to AREs.
It also reduces displacement of HuR and therefore allows HuR-mediated translation of
TNFa mRNA (Tiedje et al., 2012).
1.7 NFkB
NFkB is an important transcription factor in many cellular processes including cancer
and the innate immune response (reviewed in Ben-Neriah and Karin, 2011; Hayden and
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Ghosh, 2011). NFkB plays an important role in driving the transcription of pro-inflammatory
cytokines and anti-inflammatory cytokines. NFkB signaling is activated in response to
multiple stimuli including pathogens, cytokines and other stressful conditions. Due to the
number of important processes that are controlled by NFkB, the activation of NFkB is
regulated to prevent inappropriate activation that can be linked to autoimmune diseases
and chronic inflammation (Toubi and Shoenfeld, 2004).
1.7.1 Canonical NFkB signaling
In resting cells under normal conditions, NFkB is found bound to the inhibitory protein,
IkBa. IkBamasks the nuclear localisation signal (NLS) found on NFkB. Thus, the NFkB-
IkBa complex remains in the cytoplasm and NFkB cannot bind to DNA and drive tran-
scription. Downstream of TLR activation, TRAF3/6 activate IkB kinases (IKKs) . The
IKK complex will phosphorylate IkB on two serine residues in the cytoplasm, leading
to K48-coupled ubiquitination which marks IkB for proteasomal degradation (Mercurio
et al., 1997; Zandi et al., 1997; Rothwarf et al., 1998; Ghosh and Baltimore, 1990; Ja-
cobs and Harrison, 1998; Sen and Baltimore, 1986). This frees NFkB from the repressive
function of IkB leading to translocation of NFkB to the nucleus where it binds to target
sequences within the promoter of NFkB-responsive genes (Huang and Miyamoto, 2001;
Huang et al., 2000).
1.7.2 Non-canonical NFkB signaling
In addition to the canonical pathway, NFkB can be activated by another mechanism. In
resting conditions, TRAF3 promotes the degradation of NIK via the proteasome. Fol-
lowing stimulation, TRAF3 is degraded and NIK is stabilised. NIK then activates IKKa
which in turn phosphorylates p100. Phosphorylated p100 becomes ubiquitinated and un-
dergoes partial processing. p52 forms dimers with RelB and is able to drive transcription
of NFkB-dependent genes (Zarnegar et al., 2008; Vallabhapurapu et al., 2008).
1.7.3 NFkB family
The NFkB family consists of RelA, RelB, c-Rel, p50 and p52. These family members
share the Rel homology domain (RHD) that contains a highly conserved DNA-binding
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domain (DBD). NFkB family members exist as hetero- or homodimers and the RHD fa-
cilitates dimerisation (Liu et al., 1994a,b; Nolan and Baltimore, 1992; Dobrzanski et al.,
1993; Basith et al., 2013). RelA, RelB and c-Rel contain a C-terminal transcriptional acti-
vation domain (TAD) that will stimulate transcription of target genes. p50, p52 and Relish
possess a long ankyrin repeat-containing domain at their C-terminal and thus cannot ac-
tivate transcription as homodimers. These dimers will bind to a 10 base pair sequence of
DNA using the RHD domains which form b-sandwich structures to make contacts to the
phosphate backbone as well as specific interactions with DNA bases (Müller et al., 1995;
Dobrzanski et al., 1993; Liu et al., 1994a,b).
1.7.4 NFkB dependent genes
TLR signaling activates NFkB in macrophages and NFkB is required for the transcription
of many genes crucial to the innate immune response. NFkB plays a role in controlling
the induction of four important pro-inflammatory cytokines, IL-1b, IL-6, IL-12(p40) and
TNFa, as well as many other pro-inflammatory cytokines, chemokines, immunoreceptors,
transcription factors and important pro-resolution factors such as IL-10 (reviewed in Pahl
(1999); Blackwell and Christman (1997); Saraiva and O’Garra (2010)).
1.8 Immune response mediators
The signaling processes downstream of TLRs are required to induce a transcriptional
programme that allows the generation of an immune response (Medzhitov and Horng,
2009). The immune response involves the production of pro-inflammatory cytokines,
anti-inflammatory cytokines, chemokines, interferons and prostaglandins. These effector
molecules are secreted by macrophages and then can act in a number of ways. Some
molecules will act in an autocrine or paracrine manner creating feedforward or feedback
signaling loops. Chemokines will establish a chemo-attractant gradient leading to the
recruitment of other immune cells, which is important in the formation of an adaptive
immune response (Ransohoff, 2009). Pro-inflammatory cytokines such as interleukin
(IL)-1b, IL-6, IL-12 and tumour necrosis factor-a (TNFa) are secreted by macrophages
in response to TLR stimulation. These cytokines act to maintain a pro-inflammatory
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environment to promote clearance of the pathogen. However, prolonged inflammatory
responses can lead to chronic inflammation and tissue damage. Therefore the production
of anti-inflammatory cytokines such as IL-10 is critical (Goldszmid and Trinchieri, 2012).
As monocyte chemotactic protein-1, prostaglandin E2 and interleukin-10 are relevant to
this thesis, they will be discussed in more detail.
1.8.1 Chemokines
Chemokines can be broadly split into four groups based on the arrangements of key cys-
teine residues within their structure (Ransohoff, 2009). Chemokines are responsible for
creating chemotactic gradients to attract immune cells (Zlotnik and Yoshie, 2012). In-
flammatory chemokines are released during infection and recruit immune cells such as
macrophages, neutrophils and T cells to sites of inflammation. Homeostatic chemokines
are important in tissue maintenance and development. Homeostatic chemokines can
guide cells to certain locations for appropriate maturation during development or to sites
where they are required for screening for pathogens. Chemokines mediate their effects by
binding to their cognate receptors which are members of the G-protein coupled receptor
(GPCR) family.
1.8.1.1 Monocyte chemotactic proteins
Monocyte chemotactic proteins (MCPs) form a subfamily of 4 proteins (MCP-1, 2, 3
and 4). MCP-1 displays over 60% homology with other members of the MCP family
(Melgarejo et al., 2009). MCP-1/CCL2 is encoded by the ccl2 gene and can be pro-
duced by several cell types including macrophages in response to different stimuli (Yadav
et al., 2010). In response to LPS, MCP-1 is produced by macrophages in a Tpl2/ERK1/2-
dependent manner (Bandow et al., 2012). Other transcription factors have also been im-
plicated in controlling transcription of MCP-1. Sp-1 is thought to promote the assembly of
complexes at the promoter to initiate MCP-1 gene expression in response to TNFa (Ping
et al., 2000). Using EMSA and small molecule inhibitors, it has been shown that NFkB,
AP-1 and CREB may regulate hydrogen peroxide-induced MCP-1 transcription in BR10
cells, a macrophage cell line (Jaramillo and Olivier, 2002). Several studies have proposed
regulation of MCP-1 transcription by STAT transcription factors. In an osteoblast cell
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line, STAT1 and STAT3 were required for maximal MCP-1 expression in response to on-
costatin M, which activates JAK through two cell surface receptors (Kok et al., 2009).
Furthermore, MCP-1 expression in macrophages was dependent on IFNb signaling via
STAT4 (Iida et al., 2011).
MCP-1 triggers chemotaxis in monocytes, memory T lymphocytes and natural killer cells
through CCR2 (Deshmane et al., 2009; Yadav et al., 2010; Handel and Domaille, 1996).
Knockout of MCP-1 negatively affects monocyte recruitment in a number of contexts
including intraperitoneal thioglycollate administration, induction of delayed-type hyper-
sensitivity models and in response to Schistosoma mansoni eggs (Lu et al., 1998). MCP-1
has been shown to be detrimental in certain diseases. MCP-1 will induce immune cell
infiltration and stimulate histamine release from mast cells and basophils and thereby pro-
mote allergic inflammation (Luster and Rothenberg, 1997). Interestingly, MCP-1 protein
levels are elevated in the plasma of patients with RA and diabetes (Rantapää-Dahlqvist
et al., 2007; Kamei et al., 2006). Nucleotide polymorphisms that result in elevated levels
of MCP-1 have been identified in several pathologies. An A-2518G promoter polymor-
phism is linked to infection withMycobacterium tuberculosis. Individuals with the AG or
GG genotypes were more susceptible to tuberculosis. These individuals also had altered
expression of inflammatory mediators, with increased levels of MCP-1 and decreased
levels of IL-12(p40) (Flores-Villanueva et al., 2005). The A-2518G polymorphism has
also been linked to increased susceptibility to psoriasis (Wang et al., 2008). Two other
polymorphisms, G-928C and G-362C, have also been implicated in increased disease
risk. Individuals with the polymorphisms were identified in being more at risk for carotid
atherosclerosis and these polymorphisms also correlated to elevated expression of MCP-
1. Interestingly, G-362C is situated within a STAT binding site in the MCP-1 promoter
(Nyquist et al., 2010).
1.8.2 Prostaglandin E2
Prostaglandins are synthesized from arachidonic acid by cyclooxgenases and PG syn-
thases (Phipps et al., 1991; Kalinski, 2012). PGE2 is synthesized in a multi-step process,
although the rate-limiting step is controlled by the inducible enzyme, cyclooxgenase 2
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(COX2). PGE2 is rapidly degraded in vivo by 15-hydroxyprostaglandin dehydrogenase
(15-PDGH) (Tai et al., 2002). Myeloid and stromal cells produce PGE2, which is secreted
and then can activate four GPCRs, EP1-4. EP2 and EP4 activate the cAMP-PKA-CREB
pathway by activating adenylate cyclase (Fujino et al., 2005; Hata and Breyer, 2004). EP1
signaling results in calcium release, whilst signaling from EP3 is through Gi and inhibits
adenylate cyclase (Hata and Breyer, 2004; Sugimoto et al., 1992). EP1-4 are expressed
on multiple cells and can influence a range of processes including haematopoesis, vascu-
lar permeability and smooth muscle function (Kalinski, 2012). PGE2 can also modulate
the inflammatory response. It has been shown to promote the attraction and activation
of macrophages and mast cells, but also has anti-inflammatory roles. PGE2 induces ex-
pression of IL-10, the potent anti-inflammatory cytokine (Strassmann et al., 1994). It has
been shown that PGE2 boosts TLR-stimulated IL-10 production by activating the CREB
transcription co-factor, CRTC3. Notably, PGE2 also repressed pro-inflammatory cytokine
production independently of IL-10 (MacKenzie et al., 2013a). Interestingly, COX2 induc-
tion in macrophages is MSK-dependent in response to LPS (MacKenzie et al., 2013b). In
macrophages, PGE2 reduces the phagocytic capabilities of alveolar macrophages and lim-
its pathogen killing (Aronoff et al., 2004; Serezani et al., 2007).
1.8.3 Pro-resolution factors
Unrestricted inflammation will result in tissue damage and potentially septic shock, there-
fore the fine tuning of the inflammatory response is crucial (Goldszmid and Trinchieri,
2012). The resolution of inflammation is mediated by several cytokines including IL-10
and IL-1ra. IL-1ra is an antagonist of the IL-1 receptor and will therefore block the pro-
inflammatory signals of IL-1b (Garlanda et al., 2013). IL-10 is a potent anti-inflammatory
cytokine and through JAK/STAT signaling drives a transcriptional programme known as
the anti-inflammatory response (AIR) (Hutchins et al., 2013; Ouyang et al., 2011).
1.9 JAK/STAT signaling
JAK/STAT signaling is a key mediator of cytokine responses (O’Shea and Plenge, 2012).
There are 4 janus kinases (JAK)s, JAK1, 2, 3 and Tyk2 and seven signal transducers and
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activators of transcription (STAT) isoforms (STAT1, 2, 3, 4, 5a, 5b and 6), which are
activated by different cytokines and other growth factors (table 1.2). JAK/STAT signaling
is important in immune responses and other cellular processes (O’Shea and Plenge, 2012;
O’Shea et al., 2013a).
Table 1.2: JAK/STAT signaling combinations
Cytokine Receptor JAKs STATs Response
IFNg IFNgR1+2 JAK1/JAK2 STAT1 Antiviral and microbial responses
IFNa/b IFNaR1+2 JAK1/Tyk2 STAT1/2 Viral response
IL-4 IL-4Ra+gc JAK1/JAK3 STAT6 Th2 differentiation
IL-6 IL-6Ra+gp130 JAK1/JAK2 STAT3 Inflammatory response
IL-10 IL-10Ra+b JAK1/Tyk2 STAT3 Anti-inflammatory response
IL-12 IL-12Rb1+2 JAK2/Tyk2 STAT4 Th1 differentiation
1.9.1 JAKs
The 4 JAK isoforms are required to transduce the signals from multiple cytokines which
are important in immune cell differentiation and function as well as being associated
with other diseases including myelofibrosis. JAKs are large intracellular tyrosine kinases
which possess seven regions of conserved homology. Janus homology domain (JH) 1 is
the kinase domain and contains two conserved tyrosine residues required for activation
(Feng et al., 1997; Zhou et al., 1997). Phosphorylation of these tyrosine residues results
in a conformational change which improves substrate binding. JH2 is a pseudokinase do-
main and is thought to regulate activity of the kinase domain (Chen et al., 2000; Saharinen
et al., 2000). JH3-4 resemble Src-homology-2 (SH2) domains and are therefore important
in binding to phosphorylated tyrosine residues (Kampa and Burnside, 2000). JH5-7 are
found at the amino terminal end of JAKs and form a FERM (band 4.1 ezrin, radixin and
moesin) domain, which aids association of JAKs to cytokine receptors (Zhou et al., 2001;
Hilkens et al., 2001; Chen et al., 1997). The primary substrates of JAKs are their receptors
and STATs, which are a group of transcription factors responsible for driving the cellular
response to the cytokine signal.
1.9.2 STATs
STAT proteins are approximately 800 amino acids in length and consist of a N-terminal
domain, coiled-coil domain, DNA binding domain, linker region, SH2 domain and a
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C-terminal transactivation domain. Each STAT has a conserved tyrosine residue phos-
phorylated by JAKs and STAT1, 3, 4 and 5 have a conserved serine residue (Decker
and Kovarik, 2000). A conserved arginine residue is found within the N-terminal do-
main. Arginine 31 of STAT1 is methylated and prevents binding of the protein inhibitor
of activated STATs (PIAS1) and this results in increased transcriptional activity (Mowen
et al., 2001). The coiled-coil domain promotes interactions with other proteins, for exam-
ple STAT1 with IRF9 and STAT3 with c-Jun (Horvath et al., 1996; Zhang et al., 1999).
The DNA-binding domains within a STAT dimer recognises the palindromic sequence
TTCN(3/4)GAA (Seidel et al., 1995). The transcriptional activation domain shows se-
quence diversity between STAT proteins, although the functional relevance for this is
unclear.
The seven STAT proteins are cytoplasmically located until phosphorylation by a JAK.
Phosphorylation of a key conserved tyrosine residue near the C-terminus leads to dimeri-
sation via SH2 domains (Darnell et al., 1994). The activated dimer then translocates to the
nucleus via importin a/b (McBride et al., 2002). The STAT dimer then binds to promoter
regions of genes to drive transcription of these genes (Darnell et al., 1994). For example,
IFNg activates JAK1/JAK2 leading to the phosphorylation of STAT1. The STAT1 homod-
imer will then bind to gamma-activated site (GAS) motif and drive transcription. Gene
knockout of STAT proteins has demonstrated their importance in immune development
and function. (see table 1.3)
Table 1.3: Gene knockout of JAK and STAT proteins
JAK/STAT Phenotype
JAK1 perinatal lethality due to neurologic defects, severe combined immunodeficiency
JAK2 in utero lethality due to absence of erythropoesis
JAK3 severe combined immunodeficiency
TYK2 normal development, increased susceptibility to infection
STAT1 impaired anti-viral response, increased tumours
STAT2 impaired anti-viral response
STAT3 embryonically lethal, refractory to IL-10 treatment
STAT4 defective Th1 differentiation
STAT5a defective mammary gland development
STAT5b impaired sexually dimorphic growth
STAT6 defective Th2 differentiation
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1.10 IL-10
IL-10 is a key anti-inflammatory cytokine and was discovered in the 1990s. IL-10 is
produced by many immune cells in response to inflammatory stimuli and then can act
on multiple cell types to limit inflammation (Saraiva and O’Garra, 2010; Ouyang et al.,
2011). The importance of IL-10 in resolving inflammation and preventing disease is un-
derlined by the development of colitis in IL-10 deficient mice (Kühn et al., 1993). To
further illustrate the role that IL-10 plays, it has been shown that mutations in IL-10 or
the IL-10 receptors in humans leads to the early onset of severe colitis (Glocker et al.,
2011). However, in some circumstances IL-10 can be detrimental. IL-10 has been shown
to promote B cell viability and induce IgA secretion (Defrance et al., 1992; Rousset et al.,
1992; Go et al., 1990). Interestingly, IL-10 neutralising antibodies protected severe com-
bined immunodeficiency mice injected with PBMCs from SLE patients. Treatment with
the IL-10 neutralising antibody led to reduced levels of autoantibodies, thus reducing the
severity of the response (Llorente et al., 1995). Understanding the mechanisms controlling
IL-10 production and how this varies in a cell- and stimulus-specific manner is therefore
of great importance. The mouse Il10 promoter has been well studied (reviewed in Saraiva
and O’Garra, 2010). Several transcription factors have been shown to bind to the pro-
moter including NFkB, GATA3, STAT, MAF, CREB and SP1 (table 1.4). The importance
of each transcription factor within different cell types and in response to different stimuli
is not fully understood.
1.10.1 IL-10 transcription in T cells
1.10.1.1 Th2 cells
In T cells, several transcription factors have been identified as being important in IL-10
production. Th2 cells produce IL-4, IL-5, IL-13 and IL-10 and also promote antibody
class switching in B cells (Mosmann et al., 1986; Fiorentino et al., 1989). IL-4 stimulates
Th2 cell proliferation through the activity of NFAT, GATA3 and c-Maf. IL-4 stimula-
tion induces IL-10 production via several mechanisms. NFAT is dephosphorylated and
is translocated to the nucleus, where in complex with IRF4, it drives IL-10 transcription
(Lee et al., 2009). IL-4 also has some indirect effects on IL-10 transcription by promoting
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chromatin remodeling and histone modifications at the Il10 locus through up-regulation
of GATA3 (Shoemaker et al., 2006; Chang et al., 2007b; Scheinman and Avni, 2009).
The IL-4 dependent up-regulation of GATA3 is thought to occur via STAT6-mediated
transcription of the GATA3 gene and through p38-mediated phosphorylation of GATA3
resulting in translocation to the nucleus (Ouyang et al., 2000; Maneechotesuwan et al.,
2007).
c-Maf has also been linked to IL-10 producing Th2 cells, although this may be through
an indirect effect by promoting IL-4 production (Ho et al., 1996; Kim et al., 1999). Th2
cells express the bZip transcription factor, NFIL3, at higher levels than Th1 cells and
knockout of NFIL3 affects cytokine production in Th2 cells, notably decreasing IL-10
production (Kashiwada et al., 2011; Motomura et al., 2011). The effects of NFIL3 on
IL-10 production in Th1 cells is less clear and the mechanism by which NFIL3 regulates
IL-10 transcription is unknown.
1.10.1.2 Th1 cells
Under specific conditions, Th1 cells can also produce IL-10 (O’Garra and Vieira, 2007).
In vivo this has been demonstrated during malaria, leishmaniasis and toxoplasmosis in-
fections (Jankovic et al., 2007; Freitas do Rosário et al., 2012; Anderson et al., 2007).
IL-10 producing Th1 cells can be generated in vitro through high doses of antigen in the
presence of IL-12 (Saraiva et al., 2009). These stimuli led to prolonged ERK activation
and active STAT4 dimers and results in IL-10 production, which also correlates with c-
Maf expression. Co-stimulation of TCR with TGFb induces a IFNg+IL-10+ population
of T cells and recruitment of SMAD4 to the IL10 promoter has been shown through ChIP
assays (Huss et al., 2011).
1.10.1.3 Regulatory T Cells
Regulatory T cells can be classed into groups based on expression of Foxp3. CD4+Foxp3+
cells are the classical regulatory T cells (Treg) and CD4+Foxp3- cells are known as type
1 regulatory T cells (Tr1) (Brunkow et al., 2001; Groux et al., 1997; Vieira et al., 2004).
CD4+Foxp3+ Tregs can secrete IL-10 and a population of Foxp3+IL-10+ cells can be
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found in the periphery (Maynard et al., 2007). Interestingly, TGFb promoted IL-10 pro-
duction in CD4+Foxp3+ cells. Expression of IL-10 has been linked to levels of the tran-
scriptional regulator Blimp-1, whilst knockout of Blimp-1 did not affect Treg develop-
ment, it did prevent IL-10 secretion following TCR triggering (Cretney et al., 2011). ChIP
assays showed that both IRF4 and Blimp-1 are recruited to the IL-10 locus and the impor-
tance of IRF4 was further underscored as IRF4 knockout T cells lack Blimp-1 expression
and fail to develop into Tregs (Cretney et al., 2011). Blimp-1 is also important for IL-10
production from CD8 and Tr1 cells, although IL-10 production from Th2 cells derived
in vitro from Blimp-1 knockout mice was normal (Sun et al., 2011; Iwasaki et al., 2013;
Kallies et al., 2006).
Tr1 cells are characterised by high levels of IL-10 production along with differing amounts
of IFNg, IL-2 and IL-5. Tr1 cells can be derived from naive CD4 cells using various con-
ditions, recently a strong indication for TGFb and IL-27 in Tr1 development has been
reported (Awasthi et al., 2007; Murugaiyan et al., 2009). The effects of IL-27 on Tr1
development are starting to be elucidated. Naive CD4 cells, cultured in the presence of
anti-CD3, anti-CD8 and IL-27, required STAT1 and STAT3 for maximal IL-10 produc-
tion (Iwasaki et al., 2013). The requirement of STAT3 for maximal IL-10 production can
be linked to its role in the induction of egr2. Whilst a direct effect of egr2 on the IL-10
promoter was not shown, egr2 knockout results in ablated IL-10 production and loss of
Blimp1 expression (Iwasaki et al., 2013). IL-27 also induces expression of the aryl hy-
drocarbon receptor (AhR). Knockdown of AhR using siRNA resulted in decreased IL-10
secretion from Tr1 cells, whilst AhR ligands increased IL-27-mediated IL-10 production
(Apetoh et al., 2010). In the same study, it was shown that c-Maf siRNA also inhibited
IL-10 expression and that both c-Maf and AhR were found at the IL-10 promoter in ChIP
assays. The importance of AhR in Tr1 and IL-10 induction is also mirrored in human T
cells (Gandhi et al., 2010).
Another affect of AhR ligands is to potentiate IL-21 production in IL-27 stimulated Tr1
cells and both AhR and c-Maf were bound to the IL-21 promoter (Apetoh et al., 2010). IL-
21 acts as an autocrine stimulus for T cells and knockout of the IL-21 receptor decreased
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IL-10 induction in Tr1 cells (Pot et al., 2009). Recently, a requirement for STAT3 in IL-
21-induced IL-10 production was shown, although whether this is a direct effect on the
IL-10 promoter or not is unknown (Spolski et al., 2009).
1.10.1.4 Th17 cells
Th17 cells are important in regulating bacterial and fungal infections but have been linked
to the development of autoimmune diseases (Bi et al., 2007; Weaver et al., 2006). TGFb
and IL-6 are used to generate Th17 cells in vitro and these cytokines induce c-Maf ex-
pression, which correlates to IL-10 expression. STAT3 knockout does not affect TGFb-
and IL-6-induced IL-10 expression but blocked the effects of IL-27 preventing IL-10 in-
duction (Xu et al., 2009). In addition to inducing c-Maf, TGFb and IL-6 also induce egr2
expression, which interacts with the transcription factor BATF and prevents BATF bind-
ing to the IL-17 promoter (Miao et al., 2013). Although it can block IL-17 induction,
whether egr2 can induce IL-10 expression, as in Tr1 cells, is unknown. BATF lacks a
functional transcriptional activation domain and acts as both an activator and repressor of
transcription (Murphy et al., 2013). BATF knockout blocks in vitro Th17 differentiation,
possibly due to cooperation between BATF and IRF4 at important loci including IL-10
and Blimp-1 (Ciofani et al., 2012; Schraml et al., 2009; Li et al., 2012).
1.10.1.5 Cytotoxic T cells
Cytotoxic CD8+ T cells can produce IL-10 and this is evident in lung diseases triggered
by influenza and other viruses (Palmer et al., 2010; Sun et al., 2009). Additionally, in a
model of acute viral encephalitis, CD8+ T cells found in the CNS produced IL-10 (Tran-
dem et al., 2011). The molecular mechanisms behind IL-10 production in CD8+ T cells
are not well elucidated. However, small molecule inhibitors have implicated both ERK1/2
and p38 pathways (Trandem et al., 2011). Similarly to other T cells, IL-27 induces IL-10
secretion in CD8+ T cells. IL-27 and IL-2 act together to induce Blimp-1 and CTLs from
Blimp-1 knockout mice secreted less IL-10 in an influenza infection model (Sun et al.,
2011).
Further work will be required to identify the signaling pathways and transcription factors
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that directly regulate IL-10 transcription downstream of both the TCR and IL-27. Also,
comparisons between specific T cell subsets are required to identify general and specific
mechanisms that regulate IL-10 transcription in T cells.
1.10.2 IL-10 production by B cells
Early in vitro studies demonstrated IL-10 transcription in B cells stimulated with anti-Ig
and anti-CD40. This was a delayed response with transcription measured after 4 days,
however, co-stimulation with IL-12 accelerated expression of IL-10 (Skok et al., 1999).
B cells express numerous receptors including TLRs. TLR2, 4 and 9 agonists induce IL-10
production and MyD88 knockout ablates TLR-induced IL-10 in B cells (Sayi et al., 2011;
Wagner et al., 2004; Agrawal and Gupta, 2011). The intracellular pathways downstream
of TLR activation in B cells that result in IL-10 transcription are poorly understood.
TLR9 activation results in the activation of Bruton’s tyrosine kinase (Btk). Btk knockout
B cells do not secrete IL-10 although it is unclear what role Btk plays in inducing IL-10
(Lee et al., 2008). A similar role for Btk has been described in macrophages (Schmidt
et al., 2006). EMSA data suggests reduced NFkB activity in Btk knockout cells, how-
ever deletion of p65RelA did not alter IL-10 production following TLR9 stimulation (Lee
et al., 2008). TLR agonists can work in synergism with IFNa to induce greater amounts
of IL-10 compared to TLR stimulation alone (Zhang et al., 2007; Giordani et al., 2009).
Similarly, anti IgM antibodies potentiate IL-10 production from LPS-stimulated B cells.
This increase is dependent on Ca2+ signaling through the ER Ca2+ sensors, stromal inter-
action molecule (STIM) 1 and 2 (Matsumoto et al., 2011).
1.10.3 IL-10 transcription in macrophages and dendritic cells
Macrophages and dendritic cells form part of the innate immune response and detect
pathogens through PRRs such as the TLRs and C-type lectin receptors (Medzhitov, 2007;
Kawai and Akira, 2010). These receptors initiate downstream signaling that activates
MAPK and NFkB. IL-10 production downstream of these pathways has been well studied.
All TLRs signal through the MyD88 adaptor, except for TLR3 which signals via TRIF.
TLR4 recruits both adaptor molecules when activated (Akira and Takeda, 2004a,b). Both
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MyD88- and TRIF-dependent signaling is able to induce IL-10 and knockout of MyD88
or TRIF causes decreased IL-10 production from LPS stimulated macrophages compared
to wild-type cells (Boonstra et al., 2006). The specific contributions of MyD88 and TRIF
is not clear yet, as only double knockout of MyD88 and TRIF will completely block
activation of MAPK and NFkB (Yamamoto et al., 2003).
1.10.3.1 TLR-induced IL-10 transcription
Downstream of MyD88, TRAF6 is an important molecule in regulating MAPK and NFkB
activation. The importance of TRAF6 is stimulus specific, as in response to CpG, a
TLR9 agonist, TRAF6 knockout BMDMs do not induce IL-10 transcription, whilst LPS-
stimulated BMDMs from TRAF6 deficient mice had normal IL-10 induction (Häcker
et al., 2006). TRAF3 is, however, critical to IL-10 induction in response to both CpG
and LPS, as well as the TRIF-dependent agonist poly(I:C) (Häcker et al., 2006). The
mechanism of TRIF-dependent IL-10 induction is not fully understood. It has been pro-
posed that TRAF3 modulates IL-10 induction as it controls production of type I inter-
feron (Yamamoto et al., 2003). It has been suggested that sustained IL-10 production in
macrophages in response to TLR4 stimulation is dependent on an IFNb feedback loop
(Chang et al., 2007a).
Further downstream of TLRs, both MAPK and NFkB are implicated in IL-10 induction.
Inhibitors of the ERK1/2 pathway reduce IL-10 secretion from macrophages (Liu et al.,
2006). Furthermore, knockout of Tpl2 or p105 (NFKB1), which are required for ERK1/2
activation by TLRs, reduced IL-10 production in response to TLRs (Banerjee et al., 2006).
Expression of a Raf:ER fusion protein restores ERK1/2 activation in p105 KOmice by ac-
tivating the Raf-MEK-ERK pathway, however this only partially restored the induction of
IL-10. Whilst ERK1/2 activation has been restored, the limited IL-10 levels suggests that
p105 may induce IL-10 production via additional mechanisms (Banerjee et al., 2006).
In addition to binding to Tpl2, p105 can be partially processed leaving the p50 NFkB
subunit. Using a combination of luciferase assays, ChIP and reconstitution of NFKB1
deficient cells with p50 protein, a direct role for p50 in inducing IL-10 transcription has
been suggested (Cao et al., 2006).
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Other NFkB family members have been implicated in IL-10 production. Another study
suggested a macrophage-specific role for NFkB p65 in IL-10 gene expression (Saraiva
et al., 2005). Using DNase I digestion, a potential site for NFkB was located in TLR-
stimulated macrophages but not in PMA/ionomycin-stimulated Th2 cells (Saraiva et al.,
2005). This study also showed that BAY 11-7082, a compound originally described as
an IKK inhibitor, could reduce LPS-stimulated IL-10 transcription. The interpretation of
results using this inhibitor is, however, complicated by the requirement of IKK to acti-
vate Tpl2 and thus ERK1/2 downstream of TLR signaling. In addition, a recent study
has found that BAY 11-7082 acts by inhibiting the E3 ligases involved in Tak1 activation
upstream of IKK and not as a direct IKK inhibitor (Strickson et al., 2013).
Four isoforms of p38 MAPK exist in mammalian cells, and p38a, g and d are important
in macrophages (reviewed in Arthur and Ley, 2013). Knockout of p38a or treatment with
p38a/b inhibitors reduces IL-10 secretion in macrophages (Kim et al., 2008a). The im-
portance of p38a in regulating IL-10 has been further underlined by studies on DUSP1
knockout mice. DUSP1 is a dual specificity phosphatase that is involved in deactivating
p38a signaling in response to LPS. Macrophages from DUSP1 knockout mice display
prolonged p38a activation relative to wild type cells and, interestingly, they also exhibit
increased IL-10 production (Salojin et al., 2006). A role for p38 g and d in the regu-
lation of IL-10 has also recently been identified. p38 g and d are not affected by con-
ventional p38 inhibitors and relatively little is known about their function. However, the
use of p38g/d double knockout mice has shown that p38 g and d are required for normal
LPS-induced IL-10 production (Risco et al., 2012). Deletion of p38g/d may indirectly af-
fect IL-10 production as steady state levels of Tpl2 protein expression are reduced in the
p38g/d double knockout mice. Consequently, macrophages from p38g/d double knockout
mice fail to activate ERK1/2 downstream of TLR activation (Risco et al., 2012).
ERK1/2 and p38a have many targets including downstream kinases and several transcrip-
tion factors and could therefore regulate IL-10 transcription via several potential mecha-
nisms. Both ERK1/2 and p38a directly phosphorylate the transcription factor, SP1, and
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numerous studies using IL-10 promoter reporter genes have shown that SP1 binding sites
are required for inducing IL-10 transcription (Tan and Khachigian, 2009; D’Addario et al.,
2006; Ma et al., 2001; Brightbill et al., 2000; Tone et al., 2000). ChIP assays have also
demonstrated the recruitment of SP1 to the IL-10 promoter (Zhang et al., 2006). Thus
the phosphorylation of SP1, or the related factor SP3, by ERK1/2 or p38 may be an ad-
ditional mechanism by which ERK1/2 or p38 regulate IL-10 transcription. The precise
mechanisms by which ERK1/2 and p38 MAPKs regulate IL-10 production are not fully
elucidated, but as discussed below, the activation of downstream kinases is involved.
1.10.3.2 MSK1/2 and CREB mediated IL-10 transcription
A well established mechanism is the ability of ERK1/2 and p38 to activate the nuclear
kinases, MSK1 and MSK2. In mice, double knockout of MSK1 and MSK2 or small
molecule inhibitors of MSK reduced LPS-stimulated production of IL-10 by macrophages
(Ananieva et al., 2008; Naqvi et al., 2012). Lower levels of IL-10 cause a less effective
anti-inflammatory response. As a result of this, MSK1/2 knockout mice produce elevated
levels of TNFa, IL-6 and IL-12 and are sensitized to endotoxic shock. MSKs control
IL-10 production via the regulation of IL-10 mRNA transcription (Ananieva et al., 2008).
MSKs have several targets that might explain their ability to regulate IL-10 transcription.
MSKs can phosphorylate histone H3 on Ser10 and Ser28 (Dyson et al., 2005; Soloaga
et al., 2003). Phosphorylation of histone H3 may affect the chromatin structure. No-
tably, it has been shown that ERK1/2, an upstream activator of MSK1/2, is required for
H3 phosphorylation at the IL-10 promoter in response to stimulation of macrophages by
immune complexes (Bettelli et al., 1998; Zhang et al., 2006).
Another target of MSKs is the transcription factor CREB, which is phosphorylated on
Ser133 (Wiggin et al., 2002). In addition to binding sites for other transcription factors,
the IL-10 promoter contains a CREB binding site (Gee et al., 2006). The importance of
CREB to IL-10 induction has been demonstrated using mice with a Ser133Ala knockin
mutation in the endogenous CREB gene. Mutation of the phosphorylation site on CREB
resulted in lower IL-10 transcription compared to wild type cells in response to LPS or
Zymosan (Ananieva et al., 2008; Elcombe et al., 2013). In addition to MSK, PKA can
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also phosphorylate CREB at Ser133 and promote the recruitment of the co-activators CBP
and p300, however PKA is only able to weakly activate IL-10 transcription (MacKenzie
et al., 2013a). CBP/p300 recruitment is less evident following CREB phosphorylation on
Ser133 by MSKs (Naqvi et al., 2014). This could indicate a requirement for additional
inputs in CREB regulation downstream of TLR signaling. In addition to Ser133 phospho-
rylation, CREB has also been reported to be regulated by phosphorylation on other sites
(Johannessen et al., 2004).
GSK3 can phosphorylate CREB at Ser139, although the functional consequence of this is
less clear, with conflicting reports suggesting the activation or repression of transcription
(Tyson et al., 2002; Tullai et al., 2007; Hu et al., 2006). In favour of GSK3 repressing
CREB-mediated transcription, inhibition or knockdown of GSK3b has been found to in-
crease IL-10 production in LPS stimulated monocytes (Martin et al., 2005). Knockdown
of GSK3 resulted in increased association of CREB with CBP. A further study supported
the repressive role of GSK3 as inhibition of GSK3 was found to promote IL-10 induction
by IFNb in dendritic cells (Wang et al., 2011).
1.10.3.3 MK2/3-mediated IL-10 transcription
In addition to MSKs, other MAPK activated kinases are thought to regulate IL-10 pro-
duction. p38a activates the kinases MK2 and MK3 and double knockout of both MK2
and MK3 or knockout of MK2 alone in macrophages resulted in reduced IL-10 mRNA
induction (Ehlting et al., 2011). Small molecule inhibitors suggested that MK2 might
phosphorylate CREB downstream of TLRs (Mellett et al., 2011), however off-target ef-
fects of these inhibitors could not be excluded. Against this, knockout of MSK1/2 or
MSK inhibitors, which do not target MK2/3, block CREB phosphorylation in response
to TLR stimulation (Naqvi et al., 2012; Ananieva et al., 2008). MK2 therefore may act
through regulating the activity of another transcription or via a post-transcription mech-
anism. MK2 is known to phosphorylate the mRNA binding protein TTP and as a result
stabilise mRNAs targeted by TTP (Ronkina et al., 2010). IL-10 has been identified as a
TTP target and MK2 has been found to regulate IL-10 mRNA stability (Stoecklin et al.,
2008; Ehlting et al., 2011). An additional indirect role may account for the reduced IL-10
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transcription caused by MK2 deficiency. MK2/3 are required to maintain p38a protein
levels (Ronkina et al., 2007) and, therefore, a significant reduction in p38a protein levels
in MK2/3 knockouts could result in the decreased IL-10 production observed.
1.10.3.4 Synergistic induction of TLR-induced IL-10 transcription
TLR-induced IL-10 production from macrophages can be synergistically increased by
several stimuli, including PGE2, b-glucans and IL-4. In the case of IL-4, a role for c-Maf
has been identified as c-Maf is able to directly bind the IL-10 promoter (Cao et al., 2005).
The regulation of c-Maf is not well understood but it has proposed that p38 can phospho-
rylate it (Sii-Felice et al., 2005). IL-4 was found to increase c-Maf expression and the
ability of IL-4 to act in combination with LPS to induce IL-10 required c-Maf expression.
In c-Maf knockout cells, the ability of LPS alone to induce IL-10 in macrophages was
reduced, as was the synergistic effect of IL-4 and LPS (Cao et al., 2005).
PGE2 increases the induction of IL-10 in response to LPS via its ability to increase cAMP
and, therefore, activate PKA (Kim et al., 2011; MacKenzie et al., 2013a). In line with
this, cAMP analogues or phosphodiesterase inhibitors, which increase cAMP levels, also
increase IL-10 induction in response to TLR agonists (Feng et al., 2000; Eigler et al.,
1998). PKA phosphorylates CREB on Ser133, but the effect of PGE2 on IL-10 transcrip-
tion was independent of Ser133 phosphorylation as shown in CREB Ser133Ala knockin
macrophages (MacKenzie et al., 2013a; Clark et al., 2012). The molecular mechanism of
the CREB Ser133-independent increase in response to PGE2 was shown to be dependent
on the CREB co-activator protein, CRTC3. In unstimulated cells, phosphorylated CRTC3
is retained in the cytoplasm through binding to 14-3-3 proteins. PKA phosphorylates the
kinase SIK2 and this inhibits the ability of SIK2 to phosphorylate its substrate, CRTC3.
Thus, CRTC3 becomes dephosphorylated and translocates to the nucleus, where it can in-
duce transcription of CREB dependent genes including IL-10 (MacKenzie et al., 2013a;
Clark et al., 2012). The regulation of CREB activity by MSKs and CRTCs is important in
modulating transcription of CREB-driven genes as it has been shown that CREB is found
at CRE elements before and during stimulation. In Raw264.7 cells, a macrophage cell
line, CREB was found bound to CRE response elements within the COX2 promoter prior
38
to treatment with LPS (Kang et al., 2006). Therefore, CREB transcriptional is controlled
by its interactions with proteins such as MSKs and CRTCs, rather than recruitment to
CRE sites.
PGE2 stimulates macrophages via the EP2 and EP4 receptors, which are GPCRs that el-
evate intracellular levels of cAMP by activating adenylate cyclase. Macrophages express
multiple GPCRs and therefore GPCRs may function as a general mechanism by which
the production of IL-10 by macrophages can be augmented. Recently, bile acids, acting
via the GPCR, G protein-coupled bile acid receptor 1 (GPBAR1), have been shown to
increase LPS induced IL-10 production (Haselow et al., 2013). Although this study im-
plicated CREB downstream of GPBAR1 activation, it did not identify if this was a CREB
Ser133 phosphorylation- or a CRTC3-dependent mechanism. Adenosine is another com-
pound that can increase TLR-induced cytokine production and is known to act via GPCRs
(reviewed in Haskó et al., 2007). The precise molecular mechanisms required to modulate
macrophage cytokine production by adenosine are currently unclear, but could involve
the cAMP-PKA pathway. In support of this, knockdown of CREB using shRNA blocked
the ability of the adenosine receptor agonist 5’-N-ethylcarboxamidoadenosine (NECA)
to potentiate TLR-induced IL-10 production. Adenosine is also important for maximal
IL-10 production by macrophages in response to heat killed E. coli, as IL-10 produc-
tion was reduced by knockout of the A2A adenosine receptor (Csóka et al., 2007). The
same study also demonstrated that knockout of C/EBPb blocked adenosine-induced IL-10
production, which is supported by previous reporter gene studies showing that the IL-10
promoter contains functional C/EBP binding sites (Liu et al., 2003b).
C-type lectins are also able to modulate TLR induced cytokine production. Dectin-1,
which is activated by b-glucan, was the first of these to be described (Kerrigan and Brown,
2011). Stimulation of Dectin-1 alone is sufficient to induce IL-10 transcription, but it is
well established that it can act in concert with TLRs. Thus agonists, such as Zymosan,
that activate both TLRs and Dectin-1 result in high levels of IL-10 transcription. Both the
MAPK – MSK1/2 – CREB pathway as well as CRTC2 have been implicated in the mech-
anism that results in high IL-10 induction (Elcombe et al., 2013; Kelly et al., 2010; Slack
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et al., 2007; Alvarez et al., 2009). Other C-type lectins including macrophage galactose
lectin (MGL) and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN) have also been reported to promote IL-10 expression although the
signaling downstream of these receptors is less clearly understood and additional studies
are required (van Vliet et al., 2013; Gringhuis et al., 2007).
Macrophages express receptors that recognise phagocytic cells, but are also shared in
pathogen recognition (Stuart and Ezekowitz, 2005). In contrast to pathogen recognition,
however, phagocytosis of apoptotic cells results in an anti-inflammatory response char-
acterised by IL-10, PGE2 and TGFb (Voll et al., 1997). Several studies have suggested
that the failure to remove apoptotic cells and suppress the immune response contribute
to the development of autoimmune diseases and chronic inflammation (Herrmann et al.,
1998; Gal et al., 2000; Camenisch et al., 1999). LPS-activated PBMCs in the presence
of apoptotic peripheral blood lymphocytes produce higher levels of IL-10 compared to
PBMCs stimulated with LPS alone and a similar finding was reported for LPS-stimulated
human monocytes in the presence of apoptotic neutrophils (Voll et al., 1997; Byrne and
Reen, 2002). Apoptotic neutrophils alone failed to induce IL-10 production in unstimu-
lated monocytes (Byrne and Reen, 2002). The molecular mechanism behind this increase
has started to be elucidated, it has been shown that the production of IL-10 in response
to apoptotic cells is dependent on CD36, p38 and the TALE homeoprotein Pre-B-cell
leukemia homeobox 1 (Pbx1) (Chung et al., 2007). This suggests that IL-10 production
from macrophages can be influenced not only by cytokines and other signaling molecules
but by other signals including apoptotic cells.
1.10.3.5 Autocrine IL-10 signaling
Notably, IL-10 may promote its own transcription in macrophages and/or monocytes.
Stimulation of monocyte-derived macrophages with IL-10 leads to an increase in IL-10
mRNA and resulted in increased IL-10 secretion (Staples et al., 2007). The same study
suggested that this was a STAT3-dependent increase, as IL-10 promoter fragments with
mutated STAT sites failed to drive luciferase reporters in response to IL-10 stimulation. A
later study demonstrated that peritoneal macrophages from animals with a macrophage-
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specific deletion of Stat3 gene lacked IL-10 production (Cheng et al., 2003).
1.10.4 IL-10 signaling
IL-10 acts via the IL-10 receptor to stimulate JAK-STAT signaling in its target cells (fig-
ure 1.4). The IL-10 receptor is a heterodimeric complex consisting IL-10R1 and IL-10R2
chains (Kotenko et al., 1997; Tan et al., 2001). IL-10R1 binds IL-10 with high affinity
and is unique to the IL-10 receptor, while IL-10R2 also forms part of the receptors for
IL-20, IL-22, and IL-28 (Yoon et al., 2010). Both receptor subunits are required for IL-10
dependent signaling and knockout of either IL-10R1 or IL-10R2 in mice is sufficient to
block the anti-inflammatory effects of IL-10 (Pils et al., 2010; Spencer et al., 1998). Ac-
tivation of the IL-10 receptor leads to the phosphorylation of JAK1 and Tyk2 (Finbloom
and Winestock, 1995; Ho et al., 1995). It has been suggested that IL-10R1 recruits JAK1
and IL-10R2 binds Tyk2 (reviewed in Ouyang et al., 2011), although definitive evidence
for the differential binding of JAK1 and Tyk2 to IL-10R1 and IL-10R2 is lacking.
Studies on JAK1 knockout mice have demonstrated a key role for JAK1 in mediating the
effects of IL-10. JAK1 deletion is perinatally lethal, however, using macrophages cultured
from JAK1 deficient embryos, it has been shown that JAK1 is essential for the ability of
IL-10 to repress LPS-induced TNFa production (Rodig et al., 1998). Although, IL-10R1,
IL-10R2 and JAK1 are required for IL-10 function, the role of Tyk2 in mediating the
effects of IL-10 is less clear. Initial reports on Tyk2 knockout mice showed that phospho-
rylation of STAT3 in response to IL-10 was normal and that the anti-inflammatory effect
of IL-10 was unaffected as measured by repression of TNFa production in macrophages
(Shimoda et al., 2000; Karaghiosoff et al., 2000). A later study has found that Tyk2 dele-
tion led to reduced STAT3 phosphorylation in response to IL-10 in macrophages, although
STAT3 protein levels were also reduced in the Tyk2 deficient cells (Shaw et al., 2006).
The role of Tyk2 in human cells is also unclear. JAK inhibitors with enhanced selectivity
for JAK1 vs Tyk2 are much more effective at blocking IL-10 responses in human cells
relative to Tyk2 selective inhibitors (Sohn et al., 2013). In contrast to this, PBMCs from a
patient with an inactive mutant form of Tyk2 were reported to show a reduced ability for
IL-10 to inhibit LPS induced TNFa production (Minegishi et al., 2006). These differences
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may demonstrate the relative importance of Tyk2 in IL-10 signaling in different species,
genetic backgrounds or macrophage subtypes. In addition to other variables, other JAK
isoforms may compensate for the loss of Tyk2 function in the Tyk2 knockout mice.
IL-10 binding to the receptor leads to JAK dependent phosphorylation of the receptor,
which allows the recruitment of STATs. High concentrations of IL-10 can promote STAT1
and STAT3 recruitment and tyrosine phosphorylation, however STAT3 is thought to be the
critical isoform for the anti-inflammatory effects of IL-10 (Riley et al., 1999; Meraz et al.,
1996). JAK1 and Tyk2 phosphorylate STAT3 on tyrosine 705 leading to its dissociation
from the receptor and the formation of an active homodimer. STAT3 dimers can then
translocate to the nucleus where they will bind to STAT consensus sequences within pro-
moter regions of their target genes. Similar to JAK1 deficient macrophages, STAT3 condi-
tional knockout macrophages are also refractory to IL-10 treatment (Takeda et al., 1999).
While STAT3 is required for the actions of IL-10, STAT3 phosphorylation alone does
not explain how IL-10 represses cytokine production. For example, other cytokines such
as IL-6 also induce STAT3 phosphorylation but do not reproduce the anti-inflammatory
actions of IL-10. Precisely how IL-10 induced STAT3 phosphorylation affects cell func-
tion is not fully understood (Bazzoni et al., 2010; Hutchins et al., 2013; Murray, 2005).
Several mechanisms have been suggested, including the induction of anti-inflammatory
mediators, regulation of the transcription or mRNA stability of specific genes or modula-
tion of intracellular signaling. It is likely that IL-10 will induce multiple events that allow
the generation of anti-inflammatory response and more work is required to understand
further the effects of IL-10.
1.10.5 Role of IL-10 in vivo
1.10.5.1 T-cell derived IL-10
IL-10 is critical to maintaining control of the immune system and loss of IL-10 exacer-
bates inflammation in a wide range of models (reviewed in Ouyang et al., 2011; Redford
et al., 2011; Wilson and Brooks, 2011; O’Garra et al., 2008). Many types of immune
cell have the potential to produce IL-10 and it is therefore necessary to understand what
cell type is the major source in different disease contexts. The effect of cell type specific
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Figure 1.4: IL-10 signaling
IL-10 binds to IL-10R1 and IL-10R2 and leads to the activation of JAK1 and Tyk2. JAK1 and Tyk2
phosphorylate Tyr705 on STAT3. Phosphorylated STAT3 molecules dissociate from the receptor and form
dimers. STAT3 dimers translocate to the nucleus and bind to promoters of genes involved in the anti-
inflammatory response.
IL-10 or IL-10 receptor knockout has now been reported in several immune models. Total
IL-10 knockout mice develop spontaneous inflammation in the gut (Kühn et al., 1993).
Gnotobiotic IL-10 knockout mice do not develop colitis, demonstrating that IL-10 is im-
portant in controlling the host response to gut flora. The clinical relevance of IL-10 in
colitis has been confirmed by mutations that block IL-10 function in humans resulting in
the development of severe early onset colitis (Glocker et al., 2009, 2010). Original studies
using reconstitution experiments and more recent studies using the deletion of IL-10 in
either B cells, T cells or myeloid cells show that B cell or myeloid cell deletion of IL-10
does not result in the spontaneous development of colitis in mice, while deletion of IL-10
specifically in T cells does (Madan et al., 2009; Roers et al., 2004).
Conditional IL-10 knockouts have also demonstrated a role for T cell-derived IL-10 in hy-
44
persensitivity. T cell-specific deletion of IL-10 increased reaction to 2,4-dinitrochlorobenzene
(DNCB) in contact hypersensitivity (Roers et al., 2004). Furthermore, Treg-specific IL-10
deletion increased contact hypersensitivity to 1-fluoro-2,4-dinitrobenzene (DNFB) and al-
lergic lung inflammation in response to sensitization to ovalbumin (Rubtsov et al., 2008).
T cell-specific deletion of IL-10 has demonstrated the importance of T cells as a source
of IL-10 in combating infections. Interestingly, IL-10 can have beneficial or detrimen-
tal effects and the balance between this is dependent on the model (Ouyang et al., 2011;
Redford et al., 2011; Wilson and Brooks, 2011; O’Garra et al., 2008). As IL-10 is anti-
inflammatory, the loss of IL-10 can cause an enhanced immune reaction, which results in
faster pathogen clearance. Alternatively, loss of IL-10 may allow excessive inflammation
and therefore the development of cytokine storms resulting in tissue damage or mortality
(Saraiva and O’Garra, 2010; O’Garra et al., 2008).
1.10.5.2 B-cell and myeloid cell derived IL-10
B cells have been shown to produce IL-10 in several in vivo models including i.p. in-
jection of LPS, EAE, colitis and infection (reviewed in Kalampokis et al., 2013; Vitale
et al., 2010). Only a small proportion of B cells can produce IL-10 and these cells are
known as B10 cells. In vivo, B10 cells appear to play important roles as demonstrated in
experimental autoimmune encephalomyelitis (EAE), a mouse model for multiple sclero-
sis. EAE has both an induction phase with active disease, followed by a remission phase
in which disease activity reduces. Mice with a disruption in the Ig m heavy chain (mMT),
have a lack of B cells and develop a non-remitting form of EAE. This suggest an impor-
tant role for B cells in this model and, significantly, transfer of wild type B cells restored
remission. However, B cells from IL-10 deficient mice were unable to do this (Fillatreau
et al., 2002). Another study has shown that total IL-10 knockout results in an increased
severity of EAE (Bettelli et al., 1998).
Total IL-10 knockout leads to an increased sensitivity to endotoxic shock induced by LPS
and elevated levels of pro-inflammatory cytokines such as TNFa, IL-12 and IL-6 were
also observed. Using Vert-X IL-10 reporter mice, B cells were shown to be the major
source of splenic IL-10 in LPS treated mice, while in the blood, CD11b+ myeloid cells
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were the major source of IL-10 (Madan et al., 2009). Deletion of IL-10 in myeloid cells
increased lethality and TNFa production relative to wild type mice following i.p. injection
of LPS. Deletion of IL-10 in T cell or B cells, however, did not sensitize mice to LPS;
thus demonstrating the differing contribution of individual cell types to the model studied
(Madan et al., 2009; Siewe et al., 2006). Interestingly, the effect of myeloid specific
IL-10 deletion was not as severe as the total IL-10 knockout, which suggests another
IL-10-producing cell is important in this model.
1.10.5.3 Mast cell-derived IL-10
Mast cells have also been found to produce IL-10 in vivo. Mast-cell derived IL-10 is
important in the context of chronic bladder infection (Chan et al., 2013). In this study,
reconstitution of mast cell-deficient mice with IL-10-deficient bone marrow-derived mast
cells (BMMCs) led to lower bacterial persistence compared to control mice. A similar
decrease in bacterial persistence was evident in Mcpt5-cre IL-10 fl/fl (a mast-cell specific
deletion of IL-10) and IL10-/- mice. This study demonstrated that mast cells are a major
source of IL-10 within the bladder and that mast cell-derived IL-10 allows a chronic in-
fection to be established.
The importance of IL-10 in regulating the immune response and promoting resolution
is underlined by the detrimental effect that loss of IL-10 has in inflammatory and disease
models. Therefore it is important to understand the mechanisms that govern the regulation
of IL-10 transcription and how different signals can modulate the transcription of IL-10.
1.11 Type I interferons
Type I interferons were described originally as being responsible for the ability of a viral
infection to generate resistance to infection with a different virus (Isaacs and Lindenmann,
1957; Nagano and Kojima, 1958). IFNa and IFNb are the most widely expressed type I
interferons (Decker et al., 2005). Type I interferons are often produced in response to
viral nucleic acids sensed by cytosolic receptors such as RIG-I or endosomal receptors
such as TLR3 and TLR7 (Kawai and Akira, 2010). Recognition of nucleic acids by the
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appropriate TLR leads to the activation of IRF3 or IRF7 and results in the transcription
of type I interferon genes. Notably, IFNb can drive a positive feedback loop by induc-
ing IRF7 expression which results in the transcription of type I interferon genes (Marié
et al., 1998). More recently, it has been shown that type I interferons can be produced
downstream of NOD-like receptors (Pandey et al., 2009; Watanabe et al., 2010). NOD1
and NOD2 recognise peptides from bacterial cell walls and initiate signaling via Rip2
leading to NFkB activation. Additionally, RIP2 can interact with TRAF3 and activates
TBK1 resulting in IRF7 activation and the transcription of IFNb. Type I interferons are
crucial to the immune response and induce transcription of a subset of genes known as
interferon-stimulated genes (ISGs).
1.11.1 IFNb signaling
Type I interferons signal through a heterodimeric receptors consisting of the IFNAR1
and IFNAR2 chains (Taniguchi and Takaoka, 2001; Trinchieri, 2010). IFNb binds to the
type I interferon receptor and thus activates Tyk2 and JAK1, leading to recruitment and
tyrosine phosphorylation of STAT1 and STAT2 molecules (Li et al., 1996, 1997). STAT1
and STAT2 molecules will recognise phosphorylated tyrosine residues through their SH2
domains and form a heterodimer. STAT1-STAT2 heterodimers form a complex with IRF9
and then translocate to the nucleus. This complex is known as IFN-stimulated gene factor
3 (ISGF3) and induces transcription of ISGs (figure 1.5).
1.11.2 IFNb in the immune response
Type I interferons are crucial in anti-viral responses and are also induced during bacte-
rial infections. However, type I interferons can also play detrimental roles in some con-
texts (reviewed in Yao et al., 2013; Asselah, 2012; Rönnblom and Eloranta, 2013; Inoue
and Shinohara, 2013; Banchereau and Pascual, 2006). IFNb will induce transcription of
the ISGs which include PKR, CXCL10, CCL2 and CCL7 (Schoggins and Rice, 2011;
Trinchieri, 2010). The expression of this subset of genes is designed to increase the abil-
ity of cells to detect and eliminate viruses. It will also enhance leukocyte recruitment to
promote pathogen clearance. Type I interferon signaling has also been implicated in sev-
eral diseases. In systemic lupus erythematosus, overproduction of IFN leads to peripheral
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Figure 1.5: Type I interferon signaling
Type I interferons bind to the type I IFN receptor and this leads to activation of JAK1 and Tyk2. JAK1
and Tyk2 then phosphorylate STAT1 on Tyr701 and STAT2 on Tyr689. STAT1 and STAT2 dissociate from
the receptor and form a dimer. In the cytoplasm, they interact with IRF9 to form the complex known as
IFN-stimulated gene factor 3 (ISGF3). ISGF3 translocates to the nucleus and binds to promoters of target
genes involved in the anti-viral response.
tolerance breakdown (reviewed in Banchereau and Pascual, 2006). This is caused by the
activation of myeloid dendritic cells, which leads to the activation of auto reactive T cells
and expansion of auto reactive B cells. An increase of apoptotic cells, which can be cap-
tured by DCs, leads to an amplification of this autoimmune reaction. Recent treatment
strategies have targeted blocking IFNa, its receptor or the plasmacytoid DC responsible
for producing large amount of IFNa (Kirou and Gkrouzman, 2013).
1.11.3 Effects of type I interferon on TLR signaling
Type I interferons are induced downstream of several TLRs including TLR4. Intraperi-
toneal injection of LPS, which activates TLR4, causes endotoxic shock and, dependent
on dose, lethality. It has been shown that deficiency in type I interferons reduces LPS-
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induced lethality in mice (Karaghiosoff et al., 2003). Similar results are seen with mice
lacking STAT1 and Tyk2 which are activated downstream of type I IFN signaling (Kamezaki
et al., 2004). Interestingly, mice lacking the type I IFN receptor have increased mortality
in a model of cecal ligation and puncture (CLP)-induced sepsis (Kelly-Scumpia et al.,
2010). In contrast, STAT1- (and to some extent Tyk2-) deficient mice are protected from
CLP-induced sepsis (Herzig et al., 2012). Deletion of STAT1 may block signaling down-
stream of type II interferons as well as type I interferons, thus complicating interpretation
of the results. Blocking type I interferon signaling leads to abnormal responses and un-
derlines their role in regulating TLR signaling. Recently, the importance of IFNb was
demonstrated for immunity to C.albicans (del Fresno et al., 2013). Dectin-1 stimulation
initiated IFNb production in a Syk-IRF5 dependent manner. Deficiency of the type I
interferon receptor reduced survival following infection.
1.11.4 JAK inhibitors
Cytokines control the growth and differentiation of haematopoietic cells as well as reg-
ulating the immune response. It is also becoming clear that cytokines play an important
role in immune-mediated diseases but also in other pathologies, including atherosclerosis
and cancer. Therefore, the ability to therapeutically target the action of cytokines would
have health benefits. Most cytokines signal via JAK/STAT pathways and with the ability
to design specific inhibitors of kinases, the four JAK family members became attractive
targets (Kontzias et al., 2012).
1.11.4.1 Ruxolitinib
Ruxolitinib (INCB018424) entered clinical trials in 2007 and has 3.3nM and 2.8nM IC50
against JAK1 and JAK2, respectively (Mesa et al., 2012; Quintás-Cardama et al., 2010). It
has 6-fold selectivity over Tyk2 (19nM) and much higher selectivity over JAK3 (428nM)
(Quintás-Cardama et al., 2010). Ruxolitinib is currently used to treat myeloproliferative
disorders and is also undergoing clinical trials now as a treatment for plaque psoriasis
(Punwani et al., 2012; Fridman et al., 2011). In the phase III clinical trials for use against
myelofibrosis, Ruxolitinib reduced spleen volume, improved symptoms and improved
overall survival compared to placebo (Harrison et al., 2012; Verstovsek et al., 2012).
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1.11.4.2 Tofacitinib
Tofacitinib (CP690550) was developed by Pfizer and is now approved for the treatment
of RA (Burmester et al., 2013; Fleischmann et al., 2012b,a; van der Heijde et al., 2013;
Yamaoka and Tanaka, 2014). Tofacitinib is described as a selective JAK1/JAK3 inhibitor
with IC50 of 2.2nM for JAK3 (Ghoreschi et al., 2011). In trials, Tofacitinib improved the
ACR (American College of Rheumatology) score by 20% in 67% of patients compared
to 25% who received a placebo. Tofacitinib is also being trialled for use against psoriasis
and improved the psoriasis area and severity index (PASI) score by more than 75% in 25-
67% of patients, depending on dose, compared to only 2% of patients receiving placebo
(Ports et al., 2013; Mamolo et al., 2013; Boy et al., 2009). The effectiveness of JAK
inhibition is also being examined in the treatment of inflammatory bowel disease (IBD)
(Vuitton et al., 2013; Coskun et al., 2013) Tofacitinib is FDA approved but has side effects
including neutropenia that may be linked to JAK2 inhibition (Gupta et al., 2010; Salgado
et al., 2013).
1.11.4.3 Other JAK inhibitors for inflammatory diseases
Other JAK inhibitors are being used in clinical trials. Ruxolitinib and Tofacitinib have
been approved for clinical use. Three other compounds, Baricitinib, Decernotinib and
Filgotinib, are in clinical development. Baricitinib is developed by Incyte who developed
Ruxolitnib and has a similar chemical structure (Fridman et al., 2010; Clark et al., 2014).
It has a similar specificity for JAK1/2 over JAK3. Baricitinib has shown efficacy in a
rodent model of arthritis and can block IL-6 and IL-23 signaling. Baricitinib has com-
pleted phase 2 studies for RA. Decernotinib is being developed for RA and is currently
in phase II trials. Decernotinib is a potent JAK3 inhibitor with low nM IC50 for JAK3.
Decernotinib was shown to improve histological scores and reduce ankle swelling and
paw weight in a rat model of collagen-induced arthritis (Fleischmann, 2012; Clark et al.,
2014). Filgotinib is being developed by Galapagos and has completed a phase II trial for
RA (Norman, 2012; Van Rompaey et al., 2013). Filgotinib shows selectivity for JAK1
over the other JAKs (Clark et al., 2014).
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1.11.5 IRF3 and IRF7
IRF3 and IRF7 are highly homologous and act as important regulators of type I interferon
gene expression (Honda et al., 2006). IRF3 is constitutively expressed and resides in the
cytosol in resting cells. Viral infection stimulates the phosphorylation, dimerisation and
nuclear translocation of IRF3 (Lin et al., 1998; Sato et al., 1998b; Yoneyama et al., 1998).
Phosphorylation at Ser386 is thought to be required for activation and results in either the
phosphorylated serine interacting with a hydrophobic pocket on another IRF3 molecule
or the introduction of conformational change which allows IRF dimerisation (Mori et al.,
2004; Takahasi et al., 2003; Qin et al., 2003). Once dimerised and in the nucleus, IRF3
homodimers or IRF3/IRF7 heterodimers will bind to target DNA sequence and recruit the
coactivators CBP and p300 (Lin et al., 1998; Sato et al., 1998b; Yoneyama et al., 1998).
IRF7 is expressed at low levels and is induced by type I interferon signaling (Marié et al.,
1998; Sato et al., 1998a). Similarly to IRF3, IRF7 becomes phosphorylated following
viral infection and thus results in dimerisation and nuclear translocation. IRF7 can effi-
ciently induce transcription of both IFNa genes and the IFNb gene, whereas IRF3 pref-
erentially activates the IFNb gene (Marié et al., 1998; Sato et al., 1998a). IRF7 exhibits
a very short half life of approximately 0.5-1hr as it is subject to ubiquitin-mediated pro-
teasomal degradation (Sato et al., 2000; Yu et al., 2005). This rapid turnover of IRF7
may act to curtail the induction of type I interferon gene expression. Both IRF3 and IRF7
can be activated downstream of cytosolic PRRs such as RIG-I and from transmembrane
receptors such as TLR3.
1.12 Aims
The aim of this thesis was to identify pathways that regulate the production of IL-10.
Transcription of IL-10 is controlled by several transcription factors including CREB and
NFkB. Other pathways may regulate the production of IL-10 in macrophages. The im-
portance of IFNb-mediated feedback was examined on IL-10 production. Additionally,
the role of IFNb-mediated feedback was investigated on MCP-1 production. The tran-
scription factor, MEF2D, has been implicated in IL-10 transcription in T cells (Liopeta
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et al., 2009) and its role in macrophage function was examined. Lastly, the importance of
sphingosine kinase 1, a marker of the regulatory macrophage phenotype, was examined in
Zymosan-stimulated macrophages and its role in regulating IL-10 production in response
to Zymosan stimulation.
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Chapter 2
Materials and Methods
2.1 Materials
All chemicals were obtained from Sigma or VWR unless otherwise stated. All solutions
were prepared using deionised water (MilliQ system, Millipore) and were autoclaved at
121°C, 15 psi for 20 minutes where appropriate.
2.2 Common solutions
Common solutions used throughout the work are listed in table 2.1.
2.3 Animals
IFNabR knockout mice were obtained from Dr Anne O’Garra (National Institute of Medi-
cal Research). IL-10 knockout mice were obtained from the Jackson Laboratory. IFNabR
knockout mice and IL-10 knockout mice were backcrossed with C57BL/6J mice for a
minimum of 12 generations. MEF2D KO mice were generated through crossing a floxed
allele with Bal1, to generate total MEF2D knockout mice (See Appendix E- MEF2D tar-
geting strategy). MEF2D knockout mice have been backcrossed onto C57Bl/6J for at
least 6 generations. ERK5 mice were obtained from Dr Cathy Tournier (University of
Manchester). ERK5 cKO mice were generated through crossing a floxed allele with Vav,
to generate a conditional ERK5 knockout mice. All mice were maintained in specific
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Table 2.1: Common solutions
Solution
5x Sample Buffer 250 mM Tris-HCl pH 6.8
32.5% (v/v) Glycerol
5% (w/v) Sodium Dodecyl Sulphate
5% (v/v) 2-b-Mercaptoethanol
SDS-PAGE Running Buffer 25 mM Tris
192 mM Glycine
0.1% (w/v) SDS
SDS-PAGE Separating Gel 0.375 M Tris-HCl pH 8.6
10% (w/v) 29:1 Acrylamide:Bis-acrylamide
0.01% (w/v) Sodium Dodecyl Sulphate
0.034% (w/v) Ammonium Persulphate
0.08% (v/v) Temed
SDS-PAGE Stacking Gel 0.124 M Tris-HCl pH 6.8
3.73% (w/v) 29:1 Acrylamide:Bis-acrylamide
0.01% (w/v) Sodium Dodecyl Sulphate
0.085% (w/v) Ammonium Persulphate
0.1% (v/v) Temed
Transfer Buffer 48 mM Tris
39 mM Glycine
20% (v/v) Methanol
Tris Buffered Saline and Tween (TBS-T) 50 mM Tris pH 7.5
150 mM NaCl
0.1% (v/v) Tween-20
Triton Lysis Buffer 50 mM Tris-HCl pH 7.5
1 mM EDTA
1 mM EGTA
1 % (v/v) Triton X-100
1 mM Sodium Orthovanodate
50 mM Sodium Fluoride
5 mM Sodium Pyrophosphate
10 mM Sodium b-Glycerophosphate
0.27M Sucrose
0.1% 2-b-Mercaptoethanol
1x protease inhibitor tablet (Roche)
pathogen free conditions and in line with United Kingdom and European Union regula-
tions. Work was approved by local ethical review and was carried out under the authority
of a Home Office project license.
All routine animal care and biopsies were undertaken by the staff of the Transgenic Unit,
University of Dundee. All mouse colony maintenance and breeding was organised by Dr.
Arthur. PCR genotyping of mouse biopsies was undertaken by Julia Carr (MRC PPU,
University of Dundee) and Dr. Arthur.
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2.4 Cell culture
2.4.1 Isolation and culture of BMDMs
Bone marrow-derived macrophages (BMDMs) were derived from adult mice. Mice were
sacrificed and femurs removed under sterile conditions. The femurs were flushed with
sterile PBS to remove the bone marrow. The bone marrow suspension was passed through
a 100 µm cell strainer (BD Biosciences) and then centrifuged at 900 rpm for 5 minutes.
The supernatant was aspirated and the pellet resuspended in 20 ml of BMDM media
(DMEM (Gibco) with 10% heat inactivated FBS (Biosera), 5 mM L-Glutamine (Gibco),
100 U/ml penicillin G (Gibco), 100 µg/ml streptomycin (Gibco), 0.25 µg/ml amphotericin
(Gibco) and 5 ng/ml M-CSF (R&D Systems)). The cell suspension was plated onto two
10 cm bacteriological grade plates and incubated at 37°C in 5% CO2 for seven days.
After seven days, the media was aspirated and the plates washed with PBS. The cells were
then detached with PBS containing 0.5 mM EDTA and scraped. The cell suspension was
centrifuged at 900 rpm for 5 minutes and the supernatant aspirated. The pellet was resus-
pended in BMDM media and replated in 6-well or 12-well plates. Cells were incubated
overnight at 37°C in 5% CO2. Cell counts were performed using Trypan Blue (Gibco)
and a haemocytometer.
2.4.2 Culture of Raw 264.7 and HeLa cells
Raw 264.7 and HeLa cells were cultured in DMEM containing 10% (v/v) FBS (Biosera),
2 mM L-Glutamine, (Gibco), 100 U/ml penicillin G (Gibco), 100 µg/ml streptomycin
(Gibco) in 75 cm2 flasks for routine maintenance at 37°C in 5% CO2. Cells were replated
in 10 cm plates or 6 well plates for experiments.
2.4.3 Stimulation of cells
Cells were incubated with or without inhibitors at the final concentration indicated in
table 2.2 for 1 hour before stimulation. Inhibitors were dissolved in DMSO and added to
the culture medium. Cells were stimulated for various times with various agonists: 100
ng/ml LPS (Sigma, from Escherichia coli 026:B6), 1 µg/ml Pam3CSK4 (Invivogen), 2
55
µM CPG (Invivogen), 10 µg/ml poly(I:C), 1 µg/ml R848, 200 µg/ml Zymosan (Sigma),
10 µg/ml Curdlan (Sigma), 1 µM S1P, 10 µM DHS1P, 100 ng/ml EGF or 0.5M Sorbitol.
Recombinant mouse IL-10 (R&D Systems) was added at 100 ng/ml and recombinant
mouse IFNb (PBL interferon) at 500 U/ml. IL-10 neutralising antibody (provided by
Anne O’Garra, National Institute of Medical Research) was used at 2.5 mg/ml. Culture
media was aspirated or collected for cytokine analysis and cells were lysed for protein or
RNA as described in section 2.5 or 2.6.
Table 2.2: Small molecule inhibitors
Name Target Conc. Stock Conc. Source Reference
Ruxolitinib JAK1/2 0.5 µM 0.5 mM Selleck Chemicals (Quintás-Cardama et al., 2010)
Tofacitinib JAK1/3 5 µM 5 mM Selleck Chemicals (Manshouri et al., 2008)
SK1-I SphK1 10 µM 10 mM Enzo Life Sciences (Paugh et al., 2008b)
SK1 II SphK1/2 10 µM 10 mM Merck (French et al., 2003)
PF-543 SphK1 5 µM 5 mM Millipore (Schnute et al., 2012)
THI S1P lyase 5 µM 5 mM Sigma (Schwab et al., 2005)
ERK5-IN-1 ERK5 5 µM 5 mM Nathanael Gray (Deng et al., 2013)
2.5 Lysis for protein
Cells were washed twice with ice-cold PBS and then lysed using Triton Lysis buffer (ta-
ble 2.1). Cell lysates were collected on ice using a cell scraper and transferred to a 1.5 ml
tube. Lysates were centrifuged at 14,000 rpm for 10 minutes at 4°C. Supernatants were
transferred to a new 1.5 ml tube and stored at -80°C.
2.5.1 Determination of protein concentration by Bradford assay
Clarified lysate was diluted where appropriate and 5 µl added to 250 µl of Coomassie
Bradford reagent (Thermo) in a 96-well plate in triplicate. The absorbance at 595 nm
was read against a blank sample using a Versamax tunable microplate reader (Molecular
Devices) and Softmax pro 4.0 software. The protein concentration was calculated using
the average absorbance against a standard curve of known BSA concentrations.
2.6 Lysis for RNA and RNA isolation
Culture medium was aspirated and RLT lysis buffer (a proprietary lysis buffer for lysing
cells and tissues prior to RNA isolation) with 1% (v/v) 2-b-Mercaptoethanol added. Cells
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were collected using a scraper and the lysate added to a QIAshredder column (Qiagen).
The column was centrifuged at 13,000rpm for 2 minutes and the column and lysate stored
at -80°C. Total RNA was extracted from the lysate using RNeasy micro kit (Qiagen)
following the manufacturer’s instructions. RNA was eluted in 15 µl of RNase free water
and stored at -80°C.
2.6.1 Determination of RNA concentration and reverse transcription
1.5 µl of the eluate was quantified using Nanodrop 1000 (Thermo Scientific) as per the
manufacturer’s instructions. Absorbance at 260 nm was read and concentration deter-
mined using the following equation:
A= ebc
where A is the absorbance, e is the extinction coefficient (0.025 (mg/ml)-1 cm-1), b is the
length of the light path and c is the concentration of the RNA in the solution.
0.5 to 1 µg of RNA was reverse transcribed using iScript (Bio-Rad) in a 20 µl reaction
volume containing 4 µl iScript reaction mix and 1 µl iScript reverse transcriptase as per
the manufacturer’s instructions. Samples were incubated at 25°C for 5 minutes, 42°C for
30 minutes and then 85°C for 5 minutes. Samples were diluted 1:10 with RNase free
water and stored at -20°C.
2.7 Real Time-Quantitative PCR
2.7.1 qPCR reaction and cycling conditions
Quantitative PCR was performed in 96- or 384-well plates (BioRad) using a SYBR green
based detection system, SsoFast EvaGreen Supermix (BioRad), with a CFX 96 or CFX
384 thermal cycler (BioRad). Each reaction compromised 6.6 µl SYBR, 2.4 µl nuclease
free water, 0.5 µl 10 µM sense primer, 0.5 µl 10 µM antisense primer and 4 µl cDNA.
Samples were heated to 95°C for 30 seconds and then underwent 40-50 cycles of 95°C
for 1 second and 60°C for 25 seconds. This was followed by 95°C for 1 minute, 65°C for
1 minute then 0.5°C increments every 5 seconds to calculate a melt curve.
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2.7.2 qPCR analysis
Each sample was quantified in duplicate and an average cycle threshold value taken. 18S
ribosomal RNA values were used for normalisation. The relative mRNA levels were
calculated using the following equation:
RelativemRNA level =
E (ctuc ctus)u
E (ctrc ctrs)r
where E is efficiency of PCR, Ct is the threshold cycle, u is the mRNA of interest, r is the
18S ribosomal RNA, s is the sample and c is the unstimulated control.
2.7.3 qPCR primers
Primers were designed using Beacon Designer 7.0 software programme and custom syn-
thesised by Invitrogen. The primers were reconstituted to 100 µM in RNase free water
and then diluted to 10 µM for use. All primers were stored at -20°C. Primer sequences
are shown in table 2.3.
Table 2.3: qPCR primers
Primer Name Sense Antisense
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
IL-10 CCCTTTGCTATGGTGTCCTTTC GATCTCCCTGGTTTCTCTTCCC
Arg-1 CTCCAAGCCAAAGTCCTTAGAG AGGAGCTGTCATTAGGGACATC
COX2 AATATCAGGTCATTGGTGGAGAGG TCAGACCAGGCACCAGACC
Interferon b GGAAAAGCAAGAGGAAAGATTGAC CCACCATCCAGGCGTAGC
IL-1b GACGGACCCCAAAAGATGAAGG GTGATACTGCCTGCCTGAAGC
IL-6 TTCCATCCAGTTGCCTTCTTG AGGTCTGTTGGGAGTGGTATC
IL-12a (p35) TATCTCTATGGTCAGCGTTCC TGGTCTTCAGCAGGTTTCG
IL-12b (p40) TCATCAGGGACATCATCAAACC TGAGGGAGAAGTAGGAATGGG
IL-27 (p28) GAGGAGGACAAGGAGGAAGAGG GGGAGTGAAGGAGCTGGTAGC
LIGHT CTGCATCAACGTCTTGGAGA GATACGTCAAGCCCCTCAAG
Nur77 CCTGTTGCTAGAGTCTGCCTTC CAATCCAATCACCAAAGCCACG
MCP-1 TTTGAATGTGAAGTTGACCCGTAAATC TCACTGTCACACTGGTCACTCC
A20 ACTGGAATGACGAATGG CTTCTGAGGATGTTGCT
DUSP1 CCACAGGACACCGCACAAG AGCGAAGAAGGAGCGACAATC
DUSP2 CGTGCCGTGGTGCTGGATG TGAAACCGCCTCGCAAGAAGC
DUSP5 CTGAGTGCTGTGTGGATGTG TAGGCGACGCTGAGAACG
c-Jun CGCCTCGTTCCTCCAGTC ACGTGAGAAGGTCCGAGTTC
SPHK1 ACAGCAGTGTGCAGTTGATGA GGCAGTCATGTCCGGTGATG
TNFa CAGACCCTCACACTCAGATCATC GGCTACAGGCTTGTCACTCG
EBI3 GCCGCTCCCCTGGTTA CAATGAAGGACGTGGATCTGGTC
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2.8 Cytokine secretion determination by Luminex-based assay
Culture supernatant was collected following stimulation and was stored at -80°C. Sam-
ples were thawed and secreted cytokines measured by the Luminex-based Bioplex assay
(BioRad) as per the manufacturer’s instructions.
2.9 Detection of protein by western blotting
2.9.1 Resolution of protein samples by SDS-PAGE
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis was performed using the
ATTO system (ATTO corporation). Samples were denatured by adding 5x sample buffer
containing fresh 0.1% (v/v) 2-b-Mercaptoethanol and heated for 10 mins at 95°C. 30 µg of
protein of each sample was loaded onto 10% Tris-glycine gels with Tris-glycine running
buffer. Gels were run at a constant voltage of 100V for 180 minutes. Solutions required
for polyacrylamide gels are shown in table 2.1.
2.9.2 Electrophoretic transfer of protein from SDS PAGE gels
Proteins were transferred from SDS-PAGE gels onto nitrocellulose membranes using
Mini Trans-Blot Electrophoretic Transfer Cell (BioRad). Blotting pads and nitrocellu-
lose membranes were equilibrated in transfer buffer prior to use. The gel sandwich was
set up as followed from cathode side to anode side: blotting pad, Whatman 3 MM paper,
gel, nitrocellulose membrane, Whatman 3 MM paper, blotting pad. The gel sandwich was
placed in the Transfer Cell and completely submerged in transfer buffer. The transfer was
carried out at 100V for 1 hour.
2.9.3 Western blotting
Membranes were blocked by incubation in TBS-T containing 5% (w/v) dried milk pow-
der at room temperature. The membranes were subsequently incubated overnight at 4°C
in primary antibody diluted in TBS-T containing 5% (w/v) dried milk powder. The an-
tibodies used are listed in table 2.4. Membranes were washed three times in TBS-T and
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then incubated with horseradish-peroxidase conjugated secondary antibody at room tem-
perature for 1 hour. Secondary antibodies were used at 1:2000 (anti-Rabbit IgG), 1:2000
(anti-Goat IgG) 1:1000 (anti-Mouse IgG) and 1:2000 (anti-Sheep IgG). Immunoreactive
proteins were visualised using ECL reagent (Amersham GE) according to the manufac-
turer’s instructions and by subsequent exposure to X-ray film (Konica Minolta), which
was developed and fixed in an automatic processor.
Table 2.4: Antibodies
Protein Epitope Concentration Source #
ERK1/2 Total 1:1000 Cell Signaling 9102
ERK1/2 phospho (T202/Y204) 1:1000 Cell Signaling 9101
ERK5 Total 1:2000 Sigma E1523
p38 Total 1:1000 Cell Signaling 9212
p38 phospho (T180/Y182) 1:1000 Cell Signaling 9211
JNK phospho (T183/Y185) 1:1000 Invitrogen 44682G
STAT1 Total 1:1000 Cell Signaling 9172
STAT1 phospho (Y701) 1:1000 Cell Signaling 9167
STAT2 phospho (Y689) 1:1000 Abcam 53132
STAT3 Total 1:1000 Cell Signaling 4904
STAT3 phospho (Y705) 1:1000 Cell Signaling 9131
IkBa Total 1:1000 Cell Signaling 4814
IkBa phospho (S32) 1:1000 Cell Signaling 2859
p105 phospho (S933) 1:1000 Cell Signaling 4806
COX2 Total (M-19) 1:1000 Santa Cruz sc-1747
Akt Total 1 mg/ml DSTT S742B/2nd
Akt phospho (T308) 1 mg/ml Cell Signaling 9275
Akt phospho (S473) 1 mg/ml Cell Signaling 9271
A20 Total 1:1000 Cell Signaling 5630
MEF2D Total 1:1000 BD Transduction 610774
MEF2D phospho (S121) 1 mg/ml DSTT R3084/3rd
.
2.10 Immunoprecipitation
Protein G sepharose slurry was centrifuged at 14,000 rpm for 1 min at 4°C and the super-
natant aspirated. Protein G sepharose was then washed twice with triton lysis buffer. 1 µg
of antibody was added for each immunoprecipitation and coupled to the beads for 1 hour
at 4°C on a shaking platform. Antibody-coupled protein G sepharose was then washed
three times with triton lysis buffer and then 0.2-0.5 mg of protein lysate was added. Lysate
and coupled antibody was incubated for 3 hours at 4°C on a shaking platform. Immuno-
precipitations with phospho antibodies also contained 10 µg of dephospho-peptide per 1
µg of antibody at the coupling stage. Immunoprecipitation reactions were washed twice
in lysis buffer and then resuspended in 2x sample buffer. Samples were then heated at
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95°C for 10 minutes prior to SDS-PAGE and western blotting analysis.
2.11 Lipidmass spectrometry (performed by JeremyC. Allegood, School ofMedicine,
Virginia Commonwealth University)
2.11.1 Materials
Internal standards were purchased from Avanti Polar Lipids (Alabaster, AL). Internal
standards were added to samples in 20 mL ethanol:methanol:water (7:2:1) as a cocktail
of 500 pmol each. Standards for sphingoid bases and sphingoid base 1-phosphates were
17-carbon chain length analogs: C17-sphingosine, (2S,3R,4E)-2-aminoheptadec-4-ene-
1,3-diol (d17:1-So); C17-sphinganine, (2S,3R)-2-aminoheptadecane-1,3-diol (d17:0-Sa);
C17-sphingosine 1-phosphate, heptadecasphing-4-enine-1-phosphate (d17:1-So1P); and
C17-sphinganine 1-phosphate, heptadecasphinganine-1-phosphate (d17:0-Sa1P). Standards
for N-acyl sphingolipids were C12-fatty acid analogs: C12-Cer, N-(dodecanoyl)-sphing-
4-enine (d18:1/C12:0); C12-Cer 1-phosphate, N-(dodecanoyl)-sphing-4-enine-1-phosphate
(d18:1/C12:0-Cer1P); C12-sphingomyelin, N-(dodecanoyl)-sphing-4-enine-1-phosphocholine
(d18:1/C12:0-SM); and C12-glucosylceramide, N-(dodecanoyl)-1-b-glucosyl-sphing-4-
eine. The HPLC grade solvents (chloroform, # EM-CX1050; and methanol, # EM-
MX0475, as well as formic acid (ACS grade, # EM-FX0440-7), were obtained from
VWR (West Chester, PA). For LC-MS/MS analyses, a Shimadzu LC-20 AD binary pump
system coupled to a SIL-20AC autoinjector and DGU20A3 degasser coupled to an ABI
4000 quadrupole/linear ion trap (QTrap) (Applied Biosystems, Foster City, CA) operating
in a triple quadrupole mode was used. Q1 and Q3 was set to pass molecularly distinctive
precursor and product ions (or a scan across multiple m/z in Q1 or Q3), using N2 to col-
lisionally induce dissociations in Q2 (which was offset from Q1 by 30-120 eV); the ion
source temperature set to 500 °C.
2.11.2 Extraction of sphingolipids
Cells were collected by scraping and transferred into 13 x 100 mm borosilicate tubes with
a Teflon-lined cap (catalog #60827-453, VWR, West Chester, PA). Then 1 mL of CH3OH
and 0.5 mL of CHCl3 were added along with the internal standard cocktail (500 pmol of
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each species dissolved in a final total volume of 20 ml of ethanol:methanol:water 7:2:1).
The contents were dispersed using an ultra sonicator at room temperature for 30 s. This
single phase mixture was incubated at 48°C overnight. After cooling, 75 ml of 1 M KOH
in CH3OH was added and, after brief sonication, incubated in a shaking water bath for
2 h at 37°C to cleave potentially interfering glycerolipids. The extract was brought to
neutral pH with 6 ml of glacial acetic acid, then the extract was centrifuged using a table-
top centrifuge, and the supernatant was removed by a Pasteur pipette and transferred to
a new tube. The extract was reduced to dryness using a Speed Vac. The dried residue
was reconstituted in 0.5 ml of the starting mobile phase solvent for LC-MS/MS analysis,
sonicated for ca 15 sec, then centrifuged for 5 min in a tabletop centrifuge before transfer
of the clear supernatant to the autoinjector vial for analysis.
2.11.3 LC-MS/MS of sphingoid bases, sphingoid base 1-phosphates and complex
sphingolipids
These compounds were separated by reverse phase LC using a Supelco 2.1 (i.d.) x 50
mm Ascentis C18 column (Sigma, St. Louis, MO) and a binary solvent system at a flow
rate of 0.5 mL/min with a column oven set to 35°C. Prior to injection of the sample,
the column was equilibrated for 0.5 min with a solvent mixture of 95% Moble phase A1
(CH3OH/H2O/HCOOH, 58/41/1, v/v/v, with 5 mM ammonium formate) and 5% Mobile
phase B1 (CH3OH/HCOOH, 99/1, v/v, with 5 mM ammonium formate), and after sample
injection (typically 40 mL), the A1/B1 ratio was maintained at 95/5 for 2.25 min, followed
by a linear gradient to 100% B1 over 1.5 min, which was held at 100% B1 for 5.5 min,
followed by a 0.5 min gradient return to 95/5 A1/B1. The column was re-equilibrated
with 95:5 A1/B1 for 0.5 min before the next run.
2.12 SILAC and Mass Spectrometry (Mass spectrometry performed by Matthias
Trost, University of Dundee)
Raw 264.7 cells were labeled with amino acids synthesised with stable isotopes of carbon,
nitrogen and hydrogen. Cells were grown in DMEM media containing exclusively ‘light’
or ‘medium’ forms of arginine and lysine: the ‘light’ amino acids contain the common
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isotopes of hydrogen, carbon and nitrogen and the ‘medium’ amino acids contain 6 13C
atoms and 4 deuterium (2H) atoms respectively. Cells were passaged at least five times in
the SILAC media to ensure complete labelling of amino acids within the cell. Cells were
stimulated with LPS for 30 minutes, washed with ice cold PBS and lysed in 8M urea.
Protein levels were determined by Bradford assay (section 2.5.1). Equal amounts of pro-
tein from each SILAC condition were mixed. The cysteine residues in the protein sample
were reduced by incubation in 75 mL 10 mM dithiothreitiol/0.1 M ammonium biocarbon-
ate at 65 ºC for 45 min and then alkylated using 75 mL 50 mM iodoacetamide at room
temperature for 20 min. The samples were then washed in 50% methanol/0.1M ammo-
nium bicarbonate to remove any remaining reducing and alkylating reagents. The soluble
proteins were then digested with trypsin. Phospho-peptides were then enriched by se-
quential hydrophilic chromatography followed by Fe3+-immobilized metal affinity chro-
matography. Phospho-peptides were measured by tandem mass spectroscopy on Thermo
Fisher Scientific LTQ Orbitrap Velos instrument set to perform top-15 data-dependent
collision-induced dissociation analysis in the 350–1600 m/z range using a resolution of
60,000 for the precursor scan and a minimal intensity for sequencing of 10,000 counts.
Monoisotopic precursor selection was used, and +1 as well as unassigned charge states
were excluded from sequencing. Dynamic exclusion was set to a repeat count of 2 within
30 s, with exclusion duration of 90 s and an exclusion mass width of 10 ppm. The rela-
tive amounts of equivalent peptides bearing differently labeled amino acids were analyzed
using MaxQuant.
2.13 Chromatin Immunoprecipitations
Wildtype BMDMs were stimulated with 500 U/ml of IFNb for 30 mins. At harvest, cells
were cross-linked with 1% formaldehyde at room temperature for 10 mins. Glycine was
added to a final concentration of 0.125M for 5 mins at room temperature. Cells were
washed twice with 10 mL of ice-cold PBS and then scraped into 2mL ice cold PBS before
being centrifuged at 1000 rpm in an Avanti benchtop centrifuge at 4ºC for 10 mins. The
supernatant was removed and the pellet was resuspended in 0.5 ml of lysis buffer (1%
SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 1 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml
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aprotinin) and left on ice for 10 mins. Samples were then sonicated at 4ºC, 8 times 15
seconds on, 30 seconds off, using a VibraCell (Sonics) sonicator at 50% power. Super-
natant was recovered by centrifugation at 12,000 rpm for 10 mins at 4ºC.
Protein was normalised to the least concentrated sample using Bradfords reagent before
being diluted 10 fold in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris-HCl, pH 8.1). Samples were then pre-cleared for 2 hours at 4ºC with 2 mg of
sheared salmon sperm DNA (Sigma) and 20 mL of protein G-Sepharose (50% slurry). At
this stage, 10% of the material was kept and stored at -20ºC as input material. Immunopre-
cipitations were performed overnight with specific antibodies - aSTAT1 and aIgG antibod-
ies from Cell Signaling - (1mg per IP), with the addition of BRIJ-35 (Merck Biosciences)
detergent to a final concentration of 0.1%. All the required Protein G-Sepharose beads (30
mL per IP of 50% slurry in dilution buffer) were diluted to 1400 mL in dilution buffer and
aliquoted equally, into low adhesion tubes (StarLab, E1415-1510), among the number of
samples required. The beads were spun down (1,000rpm, 30 sec at 4ºC) and supernatant
discarded. The immune complexes were captured by addition of the IP solution to the
beads along with 2 mg salmon sperm DNA for 1 hour at 4ºC. The immunoprecipitates
were washed sequentially for 5 mins each at 4ºC in 1mL Wash Buffer 1 (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), 1mL Wash Buffer
2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl),
and 1mLWash Buffer 3 (0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA,
10 mM Tris-HCl, pH 8.1). Beads were washed twice with Tris-EDTA (TE) buffer (10mM
Tris-HCl, pH 7.5 and 1mM EDTA) and eluted with 140 mL of Elution Buffer (1% SDS,
0.1 M NaHCO3). To reverse the crosslinks, samples, including the stored inputs, were
incubated in 0.2M NaCl at 65ºC overnight. Supernatants were then incubated for 1 h at
45ºC with Proteinase K (20 mg each, 40mM Tris-HCl pH6.5, and 10mM EDTA). DNA
was cleaned using PCR purification columns (Qiagen) according to the manufacturers’
instructions, into a final volume of 40 mL.
Analysis of ChIP was performed by qPCR. STAT1 or IgG ChIP DNA from either un-
stimulated or IFNb-stimulated cells was analyzed to test for the presence of STAT1 tar-
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get sequences in the promoter regions of CCL2 (Forward- CACTTCCTGGAAACACC-
CGA and Reverse- CTTGGTGCCAAGGAGTAGCA) and a region in the GAPDH with
no known STAT binding site (Forward- AGTGCCAGCCTCGTCCCGTAGACAAAATG
and Reverse- AAGTGGGCCCCGGCCTTCTCCAT). ChIP data was calculated as per-
centage of input DNA for each sample.
Table 2.5: ChIP buffers
Solution
1x Lysis Buffer
1% SDS
10mM EDTA pH 8.1
50mM Tris-HCl pH 8.1
1mM PMSF
1x Dilution Buffer
1% Triton X-100
2mM EDTA pH 8.1
150mM NaCl
20mM Tris-HCl pH 8.1
1x Wash Buffer 1
0.1% SDS
1% Triton X-100
2mM EDTA pH 8.1
20mM Tris-HCl pH 8.1
150mM NaCl
1x Wash Buffer 2
0.1% SDS
1% Triton X-100
2mM EDTA pH 8.1
20mM Tris-HCl pH 8.1
500mM NaCl
1x Wash Buffer 3
0.1M LiCl
1% NP-40
1% Deoxycholate
1mM EDTA
10mM Tris-HCl pH 8.1
2.14 Statistical Analysis
Student’s T test or ANOVA was performed as appropriate between groups. A p value >
0.05 is indicated as ns. Significant results are indicated as follows; * (p  0.05), ** (p 
0.01), *** (p  0.001), **** (p  0.0001).
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Chapter 3
Results- Role of IFNb signaling in IL-10
production
JAKs have been associated with inflammatory diseases such as Rheumatoid Arthritis (RA)
and Crohn’s Disease (Ports et al., 2013; Yamaoka and Tanaka, 2014; Vuitton et al., 2013;
Mesa et al., 2012). The importance of JAKs in the context of inflammation and immune
signaling is therefore in need of further elucidation to allow the development of specific
and less harmful treatments for inflammatory diseases such as RA.
Several cytokines can act in an autocrine or paracrine manner to modulate the macrophage
response. IL-10 is an important anti-inflammatory cytokine and promotes the resolution
of inflammation via JAK/STAT signaling (Ouyang et al., 2011). Interferon b is an im-
portant mediator of the antiviral response and also activates JAK/STAT signaling (van
Boxel-Dezaire et al., 2006; Stetson and Medzhitov, 2006). The action of JAKs and the
effects of JAK inhibitors has been studied extensively within the adaptive immune system
(Ghoreschi et al., 2011; Egwuagu, 2009; Oyamada et al., 2009; Mahmud et al., 2013;
Ross et al., 2007). However the contribution of JAKs within the innate immune response
is less clearly defined. Macrophages, in response to TLR stimulation, will produce and
secrete both IL-10 and IFNb, which can signal via JAK/STAT to modulate the inflamma-
tory response. To examine the role of JAKs in LPS-stimulated BMDMs, a clinical JAK
inhibitor, Ruxolitinib, was used.
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3.1 In vitro specificity of Ruxolitinib and ability to block JAK/STAT signaling
Ruxolitinib was first tested at 1 and 0.1 µM against an in-house kinase panel which con-
tains JAK2 to determine its selectivity. Ruxolitinib strongly inhibited JAK2 (2% remain-
ing activity) at both concentrations (figure 3.1). It also inhibited TrkA by 68% and at 1 µM
had moderate effects on MARK3, PHK and IRAK1. To further examine the specificity
of Ruxolitinib, IC50s were calculated for JAK2, MARK3, TrkA and IRAK1. Ruxolitinib
inhibited JAK2 with an IC50 of 8nM (figure 3.2). While IC50 values for TrkA (192nM),
IRAK1 (565nM) and MARK3 (617nM) were over 20 fold higher.
IC50 values for Ruxolitinib were then determined against each of the JAK family mem-
bers. Ruxolitinib showed similar IC50s for JAK1, JAK2 and Tyk2 with a ~10 fold higher
IC50 for JAK3 (figure 3.3). Ruxolitinib is reported in the literature as a JAK1/2 inhibitor
and this data supports these reports (Quintás-Cardama et al., 2010).
Next, the ability of Ruxolitinib to block STAT activation downstream of IL-10 and IFNb
signaling in BMDMs was examined. Both IL-10 and IFNb activate JAK1 and Tyk2,
downstream of IL-10R and the type I interferon receptor respectively (Finbloom and
Winestock, 1995; Ho et al., 1995; Velazquez et al., 1992; John et al., 1991). At high con-
centrations, both STAT1 and STAT3 can become phosphorylated in response to IL-10.
However, STAT3 seems to be the dominant isoform for mediating IL-10 effects (Takeda
et al., 1999). IL-10 signaling leads to phosphorylation of tyrosine 705 on STAT3 by JAK1
and Tyk2 (Ananieva et al., 2008; Takeda et al., 1999; Shaw et al., 2006; Karaghiosoff et al.,
2000). IFNb signaling will cause phosphorylation of tyrosine 701 on STAT1 by JAK1 and
Tyk2 (Schindler et al., 1992; John et al., 1991; Velazquez et al., 1992). IL-10 stimulation
for 30 minutes leads to strong phosphorylation of Y705 on STAT3 (figure 3.4). Ruxoli-
tinib was capable of blocking tyrosine phosphorylation of STAT3 downstream of IL-10
stimulation at 0.5 µM. IFNb stimulation for 30 minutes induced strong tyrosine phospho-
rylation of STAT1. This phosphorylation event was also blocked by the addition of 0.5
µM of Ruxolitinib.
Macrophages secrete both IL-10 and IFNb in response to LPS and this will lead to STAT
phosphorylation. It has previously been shown that IL-10 is required for the phosphory-
lation of STAT3 on Tyr705 downstream of LPS signaling (Ananieva et al., 2008). WT
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Figure 3.2: IC50s for Ruxolitinib against TrkA, MARK3, IRAK1 and JAK2
Ruxolitinib was screened against TrkA, MARK3, IRAK1 and JAK2 by the International Center for Kinase
Profiling to calculate IC50s.
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Figure 3.3: Ruxolitinib IC50s against each JAK family member
IC50s were calculated for Ruxolitinib against each JAK family member by Reaction Biology (MA, USA).
and IFNabR KO macrophages were stimulated with LPS and levels of phosphorylated
STAT1 and STAT3 were measured to examine which isoforms were affected by loss of
IFNb signaling. LPS stimulation in wildtype BMDMs induced phosphorylation of both
STAT1 and STAT3 at 2 hours (figure 3.5). IFNabR KO BMDMs did not demonstrate any
phosphorylation of STAT1 showing a requirement for IFNb feedback, additionally they
also exhibit decreased levels of STAT1 total protein. IFNabR KO macrophages demon-
strated normal STAT3 phosphorylation at 2 hours, but at later time points (6 hours) show
reduced phosphorylation of STAT3 compared to wild-type controls.
LPS stimulation of macrophages causes the production of cytokines including IFNb and
IL-10, which will activate STAT1 and STAT3 respectively (Ananieva et al., 2008 and
figure 3.5). LPS stimulated macrophages were pre-treated with Ruxolitinib and the ef-
fects on STAT phosphorylation measured. LPS treatment of macrophages leads to the
activation of MAPK pathways as demonstrated by phosphorylation of ERK1/2, p38 and
JNK after 20 minutes (figure 3.6). TLR4 signaling also induced the activation of NFkB as
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Figure 3.4: Ruxolitinib blocks IL-10 and IFNb signaling
Bone marrow-derived macrophages were pre-treated with the indicated concentrations of Ruxolitinib for 1
hour before stimulation with A) 100 ng/mL of IL-10 for 30 minutes or B) 500 U/mL IFNb for 30 minutes.
Cells were lysed in triton lysis buffer and lysates resolved by SDS-PAGE. Proteins were transferred to nitro-
cellulose membranes and blotted with antibodies to A) phospho STAT3 (Y705), STAT3 and GAPDH or B)
phospho STAT1 (Y701), STAT1 and GAPDH. Results are representative of two independent experiments.
judged by degradation of IkBa, which is degraded in response to phosphorylation by IKK,
and by the phosphorylation of p105 after 20 minutes. These effects were not affected by
Ruxolitinib. LPS stimulation induces transcription and secretion of multiple cytokines in-
cluding IL-10 and IFNb and this leads to STAT phosphorylation from 2 hours. At 0.5 µM,
Ruxolitinib blocked activation of STAT1 and STAT3 judged by tyrosine phosphorylation,
at Y701 and Y705 respectively, in response to LPS figure 3.6.
3.2 Effects of Ruxolitinib on IL-10 transcription and secretion
Ruxolitinib could block LPS-induced STAT phosphorylation either by blocking JAK sig-
naling downstram of IL-10 or IFNb or by inhibiting the secretion of these cytokines by
LPS stimulated macrophages. The effects of Ruxolitinib on IL-10 transcription and se-
cretion were therefore examined. LPS stimulation of cells led to induction of IL-10 tran-
scription from 1 hour that peaked at 4 hours before decreasing to basal around 24 hours.
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Figure 3.5: Deletion of type I IFN receptor blocks LPS-induced STAT1 phosphorylation
Bone marrow was isolated from wild-type and IFNabR KO mice. Bone marrow-derived macrophages
were stimulated with 100 ng/mL of LPS. Cells were lysed in triton lysis buffer and lysates resolved by
SDS-PAGE. Proteins were transferred to nitrocellulose membranes and blotted with antibodies to phospho
STAT1 (Y701), STAT1, phospho STAT3 (Y705), STAT3 and GAPDH. Results are representative of three
independent experiments
Ruxolitinib pre-treatment of BMDMs prior to LPS stimulation did not affect IL-10 tran-
scription at early time points (1 hour), however IL-10 mRNA levels were decreased at
later time points (4, 8 and 16 hours) (figure 3.7).
The IL-10 promoter contains potential STAT binding sites (Benkhart et al., 2000; Staples
et al., 2007; Ziegler-Heitbrock et al., 2003). Autocrine IL-10 mediated STAT3 phospho-
rylation downstream of LPS and therefore Ruxolitinib treatment could have disrupted a
positive feedback pathway that sustains IL-10 transcription. To determine if this was oc-
curring, an anti-IL-10 neutralising antibody was used in combination with LPS stimula-
tion to specifically block the function of IL-10. LPS stimulation for 2 hours induced IL-10
mRNA transcription comparable to that seen in previous experiments. Treatment with the
neutralising antibody did not affect IL-10 transcription compared with LPS stimulation
alone (figure 3.8), nor did treatment with an isotype control affect IL-10 transcription. To
validate that the IL-10 neutralising antibody had blocked IL-10 signaling, TNFa mRNA
levels were also measured. LPS alone induced TNFa transcription which was strongly in-
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Figure 3.6: Ruxolitinib blocks LPS-induced STAT phosphorylation
Bone marrow-derived macrophages were pre-treated with 0.5 µM of Ruxolitinib for 1 hour before stimula-
tion with 100 ng/mL of LPS. Cells were lysed in triton lysis buffer and lysates resolved by SDS-PAGE. Pro-
teins were transferred to nitrocellulose membranes and blotted with antibodies to phospho STAT1 (Y701),
phospho STAT3 (Y705), phospho STAT3 (S727), STAT3, phospho p105, phospho IkBa, IkBa, phospho
JNK, phospho p38, p38, phospho ERK1/2 and ERK1/2. Results are representative of three independent
experiments.
creased in the presence of the neutralising antibody. The isotype control did not increase
TNFa mRNA levels (figure 3.8).
Another effect of Ruxolitinib was to block the phosphorylation of STAT1 at Y701 in
response to LPS (figure 3.6) suggesting that the IFNb feedback loop was being blocked
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Figure 3.7: Ruxolitinib prevents sustained IL-10 transcription
Bone marrow-derived macrophages were pre-treated with 0.5 µM of Ruxolitinib for 1 hour before stimula-
tion with 100 ng/mL of LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the
Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was car-
ried out using SYBR-green based detection methods. Levels of 18S were used as a normalization control,
and fold induction was calculated for IL-10 mRNA. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
(see figure 3.5). To investigate whether the IFNb feedback loop was involved in IL-10
transcription, BMDMs were cultured from wild-type and type I IFN receptor (IFNabR)
KO mice and stimulated with LPS. In WT cells, LPS stimulation once again induced a
similar pattern of IL-10 transcription from 1 hour leading to a peak between 4 and 8 hours
before decreasing to basal at 24 hours. Similarly to treatment with Ruxolitinib (figure 3.7),
IL-10 transcription was unaffected at early time points (1 hour) by deletion of the type
I interferon receptor (figure 3.9). Interestingly, at later time points, IL-10 transcription
was reduced in the IFNabR KO BMDMs compared to their wild-type counterparts. This
indicates that IL-10 transcription is sustained by the IFNb feedback loop and would be
consistent with the effect of Ruxolitinib treatment on IL-10 induction.
3.3 The role of IFNb signaling in IL-10 transcription
The above results would suggest that IFNb sustains LPS-induced IL-10 transcription.
In order to test if IFNb could directly activate the IL-10 promoter, wild-type primary
macrophages were stimulated with IFNb in the presence or absence of the JAK inhibitor,
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Figure 3.8: IL-10 feedback does not drive IL-10 transcription
Bone marrow-derived macrophages were treated with 100 ng/mL of LPS or a combination of LPS and anti-
IL-10 neutralising antibody or an isotype control for 2 hours for IL-10 measurement and TNFa measure-
ment. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction was
calculated for IL-10 and TNFa mRNA. n=4, error bars represent the standard deviation from independent
cultures from four mice per genotype.
Ruxolitinib. IFNb stimulation induced IL-10 mRNA from 2 hours up until 12 hours. This
induction was blocked by Ruxolitinib, suggesting that IFNb is mediating its effects on
IL-10 transcription via the JAK/STAT pathway (figure 3.10). IFNb induction of IL-10
transcription appears to be delayed suggesting a requirement for an intermediate.
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Figure 3.9: Type I IFN receptor deficiency causes loss of sustained IL-10 transcription
Bone marrow was isolated from wild-type and IFNabR KO mice. Bone marrow-derived macrophage were
stimulated with 100 ng/mL of LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified
using the Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR
was carried out using SYBR-green based detection methods. Levels of 18S were used as a normalization
control, and fold induction was calculated for IL-10 mRNA. n=4, error bars represent the standard deviation
from independent cultures from four mice per genotype.
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Figure 3.10: IFNb stimulates IL-10 transcription
Bone marrow-derived macrophages were pre-treated with 0.5 µM of Ruxolitinib for 1 hour before stimula-
tion with 500 U/mL of IFNb. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the
Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was car-
ried out using SYBR-green based detection methods. Levels of 18S were used as a normalization control,
and fold induction was calculated for IL-10 mRNA. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
The role of IL-27 in IL-10 transcription has been investigated and results have been pub-
lished suggesting it may be a necessary intermediate for IL-10 transcription (Iyer et al.,
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2010; Molle et al., 2010; Fitzgerald et al., 2013). IL-27 is a dimeric protein, consisting
of p28 and EBI3, and a member of the IL-12 family. To understand the role of IL-27
in regulating IL-10 transcription, mRNA levels of the two IL-27 subunits were measured
in IFNb stimulated primary macrophages. IL-27(p28) mRNA is induced in response to
IFNb and this occured with similar kinetics to that of IL-10 suggesting that IL-27 is not re-
quired for IL-10 transcription in response to IFNb (figure 3.11a). Induction of IL-27(p28)
is blocked by the JAK inhibitor, Ruxolitinib. EBI3 was not induced by IFNb stimulation
(figure 3.11b).
The importance of JAKs in the IFNb feedback control of IL-10 production downstream of
TLR4 was demonstrated when wild-type and IFNabR KO BMDMs were stimulated with
LPS in the presence or absence of Ruxolitinib. LPS stimulation of wildtype BMDMs
led to secretion of IL-10 into the culture media, which peaked at 8 hours (figure 3.12).
Treatment of wildtype macrophages with Ruxolitinib did not affect initial IL-10 secretion
at 4 hours but did reduce IL-10 secretion at 8, 16 and 24 hours. IFNabR KO BMDMs
produced similar levels of IL-10 to wildtype macrophages at 4 hours, however at later
time points the type I interferon receptor deficient macrophages secreted lower levels of
IL-10 compared to wild type macrophages. In fact, IFNabR KO macrophages produced
similar amounts of IL-10 to Ruxolitinib-treated wildtype BMDMs. Ruxolitinib treatment
of IFNabRKO BMDMs did not affect IL-10 secretion compared to LPS stimulation alone
of the knockout macrophages. This suggests that the effects seen with Ruxolitinib upon
IL-10 transcription are due to blocking an IFNb-mediated feedback loop.
3.4 Blocking JAK signaling abolishes the IL-10 mediated negative feedback loop
Reduced levels of IL-10 and/or a block in IL-10 signaling may result in reduced suppres-
sive effects on pro-inflammatory cytokines such as TNFa, IL-6 and IL-12. Wild-type and
IFNabR KO BMDMs were stimulated with LPS in the presence or absence of Ruxoli-
tinib and transcription and secretion of pro-inflammatory cytokines was measured. At 0.5
µM, Ruxolitinib pre-treatment enhanced the transcription and secretion of several pro-
inflammatory cytokines, namely TNFa, IL-6 and IL-12 in response to LPS compared to
LPS-alone treatment (figure 3.13). IFNabR KO BMDMs demonstrated similar levels of
pro-inflammatory cytokines to wildtype controls except in the case of IL-6 suggesting
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Figure 3.11: IFNb induces IL-27 (p28) mRNA with similar kinetics to IL-10
Bone marrow-derived macrophages were pre-treated with 0.5 µM of Ruxolitinib for 1 hour before stimula-
tion with 500 U/mL of IFNb. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the
Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was car-
ried out using SYBR-green based detection methods. Levels of 18S were used as a normalization control,
and fold induction was calculated for IL-27(p28) and EBI3 mRNA. n=4, error bars represent the standard
deviation from independent cultures from four mice per genotype.
a requirement for IFNb in IL-6 transcription. Ruxolitinib treatment strongly increased
levels of TNFa, IL-6 and IL-12 in IFNabR KO BMDMs. This indicates that although,
Ruxolitinib blocks both IL-10 and IFNb feedback, the effects of Ruxolitinib treatment
on TNFa and IL-12 levels are due to inhibition of IL-10-STAT3 signaling. The block
of IFNb by Ruxolitinib has minimal effects on TNFa and IL-12 levels as deletion of the
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Figure 3.12: Type I IFN receptor deficiency causes reduced IL-10 secretion at late time points
Bone marrow was isolated from wild-type and IFNabR KO mice. Bone marrow-derived macrophage were
pre-treated with 0.5 µM of Ruxolitinib for 1 hour before stimulation with 100 ng/mL of LPS. Culture super-
natant was collected and IL-10 secretion measured by Bioplex (Bio-Rad) according to the manufacturers
protocol. n=4, error bars represent the standard deviation from independent cultures from four mice per
genotype.
type I interferon receptor only affects IL-10-STAT3 signaling at late time points, whilst
IL-10-STAT3 signaling at early time points is required for reducing TNFa and IL-12 lev-
els. However, IL-6 levels in Ruxolitinib pre-treated IFNabR KO macrophages did not
increase to the same degree as wild-type cells, further suggesting a role for IFNb feed-
back in maintaining IL-6 transcription.
To further investigate this requirement, WT macrophages were stimulated with IFNb and
IL-6 mRNA measured. IFNb stimulated IL-6 transcription from 1 hour, peaking at 8
hours (figure 3.14). This induction was blocked by the JAK inhibitor, Ruxolitinib. This
data along with that seen in the IFNabR KO cells suggests that although IFNb and IL-10
pathways are important in modulating IL-6 transcription, other JAK-dependent pathways
may also contribute.
3.5 Comparison of Tofacitinib and Ruxolitinib
In addition to Ruxolitinib, other JAK inhibitors are available and some are in clinical use,
such as Tofacitinib. While Ruxolitinib showed selectivity for JAK2 within the panel of
121 kinases screened, off-target effects can not be ruled out, therefore a second inhibitor
was used to corroborate the observed results. To determine if Tofacitinib was suitable
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Figure 3.13: Ruxolitinib leads to enhanced pro-inflammatory cytokine transcription and secretion in
response to LPS
Bone marrow-derived macrophages from WT and IFNabR KO mice were pre-treated with 0.5 µM of Rux-
olitinib for 1 hour before stimulation with 100 ng/ml LPS. A) Culture supernatant was collected and TNFa,
IL-12(p70), IL-12(p40) and IL-6 secretion measured by Bioplex (Bio-Rad) according to the manufacturers
protocol. B) Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen mi-
croRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using
SYBR-green based detection methods. Levels of 18S were used as a normalization control, and fold in-
duction was calculated for TNFa, IL-12(p35), IL-12(p40) and IL-6 mRNA. n=4, error bars represent the
standard deviation from independent cultures from four mice per genotype.
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Figure 3.14: IFNb induces IL-6 mRNA transcription
Bone marrow-derived macrophages were pre-treated with 0.5 µM of Ruxolitinib for 1 hour before stimula-
tion with 500 U/mL of IFNb. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the
Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was car-
ried out using SYBR-green based detection methods. Levels of 18S were used as a normalization control,
and fold induction was calculated for IL-6 mRNA. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
for selectively blocking JAK activity, a kinase screen was performed. Tofacitinib was
screened at 1 µM and 0.1 µM. Tofacitinib strongly reduced JAK2 activity (figure 3.15)
and did not strongly target other kinases present in the kinase panel.
Next, the ability of Tofacitinib to block different JAK family members was measured
through calculation of IC50s performed by Reaction Biology (MA, USA). Tofacitinib
demonstrates similar IC50s for JAK1/3 with higher IC50s for JAK2 and Tyk2 (figure 3.16a).
The comparative IC50s for Ruxolitinib and Tofacitinib for each JAK family member are
shown (figure 3.16b), this demonstrates that Ruxolitinib and Tofacitinib have similar po-
tency against JAK1 but differing potencies against JAK2, JAK3 and Tyk2.
To test whether Tofacitinib effectively blocked JAK activity within cells, BMDMs were
incubated with increasing concentrations of Tofacitinib for 1 hour before stimulation with
100 ng/ml IL-10 for 30 minutes. IL-10 induces STAT3 phosphorylation of Y705 through
activation of JAK1/Tyk2 (figure 3.17a). 5 µM of Tofacitinib was sufficient to block phos-
phorylation of STAT3 in response to IL-10 stimulation. IFNb stimulation of macrophages
also activates JAK1/Tyk2 and leads to phosphorylation of STAT1 at Y701 (figure 3.17b).
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Figure 3.16: Tofacitinib IC50s against JAK family members
IC50s were calculated for (A) Tofacitinib against each JAK family member by Reaction Biology (MA,
USA). Relative IC50s for Ruxolitinib and Tofacitinib against each JAK family member are shown (B).
In response to IFNb, 0.5 µM Tofacitinib was sufficient to block tyrosine phosphorylation
of STAT1. Based on IC50 data obtained which showed that Tofacitinib and Ruxolitinib
had differing IC50s for Tyk2 whilst their IC50s for JAK1 are comparable, the higher con-
centration required to block IL-10 signaling suggests that IL-10 signaling is potentially
more Tyk2-dependent. Although inhibitor data has suggested the importance of Tyk2 in
IL-10 signaling, studies using Tyk2-deficient mice have demonstrated a redundant role
for Tyk2 in IL-10 signaling (Karaghiosoff et al., 2000; Shimoda et al., 2000).
In order to see if Tofacitinib had effects on IL-10 transcription that were consistent with
those observed with Ruxolitinib treatment, BMDMs were pre-incubated with 5 µM To-
facitinib prior to LPS stimulation for a timecourse of 16 hours. LPS induced IL-10 tran-
scription, which peaked around 4 hours before declining at 8 and 16 hours (figure 3.18a).
Tofacitinib treatment did not strongly decrease IL-10 transcription at 1 hour, but led to
marked reduction from 4 hours onward. IL-10 secretion was also quantified and was
strongly induced by LPS at 8 and 16 hours (figure 3.18b). In line with the mRNA data,
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Figure 3.17: Tofacitinib blocks IFNb and IL-10 signaling
Bone marrow-derived macrophages were pre-treated with the indicated concentrations of Tofacitinib for
1 hour before stimulation with A) 100 ng/mL of IL-10 or B) 500 U/mL IFNb. Cells were lysed in triton
lysis buffer and lysates resolved by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and
blotted with antibodies to A) phospho STAT3 (Y705), STAT3 and GAPDH or B) phospho STAT1 (Y701),
STAT1 and GAPDH. Results are representative of two independent experiments.
Tofacitinib reduced IL-10 secretion at 8 and 16 hours.
Due to the block of IL-10-STAT3 signaling, pro-inflammatory cytokines levels should be
increased when BMDMs are pre-treated with Tofacitinib. LPS stimulation of macrophages
induced TNFa, IL-6 and IL-12 (p40) and IL-12(p70) from 8 to 24 hours (figure 3.19). To-
facitinib treatment strongly increased pro-inflammatory cytokine secretion from 8 hours
onwards, correlating with the effects seen on pro-inflammatory cytokine secretion with
Ruxolitinib treatment.
3.6 IFNb signaling sustains expression of LPS-induced MCP-1
Several reports have suggested that JAK/STAT, especially IFNb, signaling is important in
expression of b-chemokines (Fantuzzi et al., 2001; Nakano et al., 2012; Iida et al., 2011;
Nyquist et al., 2010; Kok et al., 2009). MCP-1 is a b-chemokine which is strongly induced
in macrophages stimulated with LPS. I therefore examined the role of IFNb or IL-10 me-
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Figure 3.18: Tofacitinib reduces LPS-induced IL-10 transcription and secretion at late time points
Bone marrow-derived macrophages were pre-treated with 5 µM of Tofacitinib for 1 hour before stimulation
with 100 ng/mL of LPS. A) Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the
Qiagen microRNeasy kit. Total RNAwas reverse transcribed using iScript (Bio-Rad) and qPCR was carried
out using SYBR-green based detection methods. Levels of 18S were used as a normalization control, and
fold induction was calculated for IL-10 mRNA. B) Culture supernatant was collected and IL-10 secretion
measured by Bioplex (Bio-Rad) according to the manufacturers protocol. n=4, error bars represent the
standard deviation from independent cultures from four mice per genotype.
diated feedback control of MCP-1 production. The importance of LPS-induced IFNb on
MCP-1 levels was examined. Wildtype and IFNabR KO macrophages were stimulated
with LPS in the presence or absence of Ruxolitinib. LPS induced transcription of MCP-1
in wildtype cells from 1 hour until 24 hours, peaking at 4 hours (figure 3.20a). Treatment
of wildtype cells with Ruxolitinib prior to LPS stimulation resulted in increased transcrip-
tion at 1 hour compared to macrophages treated with LPS alone. However, from 4 hours
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Figure 3.19: Tofacitinib treatment increases pro-inflammatory cytokine secretion in response to LPS
Bone marrow-derived macrophages were pre-treated with 5 µM of Tofacitinib for 1 hour before stimulation
with 100 ng/mL of LPS. Culture supernatant was collected and cytokine secretion measured by Bioplex
(Bio-Rad) according to the manufacturers protocol. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
onwards, treatment with Ruxolitinib resulted in decreased transcription of MCP-1 com-
pared to macrophages treated with LPS alone. IFNabR KO macrophages had a similar
transcriptional profile to wildtype macrophages pretreated with Ruxolitinib with a peak
at 1 hour and mRNA levels near to basal from 8 hours onwards. Ruxolitinib treatment
of IFNabR KO macrophages did not alter the induction of MCP-1 in response to LPS,
suggesting that IFNb signaling through IFNabR is responsible for maintaining MCP-1
transcription.
MCP-1 protein levels were also measured following LPS treatment in the presence or
absence of Ruxolitinib in wildtype and IFNabR KO BMDMs. LPS stimulated secretion
of MCP-1 from wildtype BMDMs that increased throughout the 24 hour timecourse (fig-
ure 3.20b). Treatment with Ruxolitinib did not affect the initial secretion of MCP-1 at 4
or 8 hours, however at 16 and 24 hours, Ruxolitinib treatment caused a strong reduction
in MCP-1 levels compared to wildtype controls. Deletion of the IFNabR, similar to Rux-
olitinib, did not affect the initial production of MCP-1 in response to LPS. At 16 and 24
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hours following LPS stimulation, IFNabR KO macrophages secreted reduced amounts of
MCP-1 compared to LPS-stimulated wildtype macrophages. Treatment of IFNabR KO
BMDMs with Ruxolitinib prior to LPS stimulation did not alter MCP-1 secretion com-
pared to LPS-stimulated IFNabR KO BMDMs. In line with the mRNA data, MCP-1
requires IFNb signaling for sustained production in response to LPS stimulation.
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Figure 3.20: IFNb signaling sustains expression of LPS-induced MCP-1
Bone marrow-derived macrophages were pre-treated with 0.5 µM of Ruxolitinib for 1 hour before stim-
ulation with 100 ng/mL of LPS. A) Cells were lysed with RLT buffer (Qiagen) and total RNA purified
using the Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR
was carried out using SYBR-green based detection methods. Levels of 18S were used as a normalization
control, and fold induction was calculated for MCP-1 mRNA. B) Culture supernatant was collected and
MCP-1 secretion measured by Bioplex (Bio-Rad) according to the manufacturers protocol. n=4, error bars
represent the standard deviation from independent cultures from four mice per genotype.
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3.7 IFNb induces MCP-1 in a JAK-dependent manner
The above data suggests a requirement for IFNb to maintain MCP-1 expression following
LPS stimulation. To determine if this was a direct activation of the MCP-1 promoter by
IFNb, macrophages were stimulated with IFNb in the presence or absence of Ruxolitinib.
IFNb induced MCP-1 expression after 1 hour of stimulation and expression remained rel-
atively constant across the 12 hour timecourse (figure 3.21a). Treatment with Ruxolitinib,
blocked the induction of MCP-1 by IFNb. IFNb treatment promoted secretion of MCP-1
at 4 hours and MCP-1 levels were increased at 8 and, again, at 12 hours (figure 3.21b).
In line with the mRNA data, treatment with Ruxolitinib blocked production of MCP-1 in
response to IFNb.
3.8 STAT1 binds to the MCP-1 promoter in response to IFNb
IFNb induces activation of JAK1 and Tyk2 and the phosphorylation of STAT1 and STAT2.
IFNb can initiate transcription of MCP-1, although whether this is STAT-dependent is
unclear. Interestingly, STAT1 phosphorylation is lost in LPS-stimulated macrophages
from IFNabR KO mice, which produce decreased levels of MCP-1 in response to LPS
(figure 3.5). To determine whether deletion of the IFNabR also blocked phosphoryla-
tion of STAT2 in LPS-stimulated macrophages, BMDMs were isolated from wildtype
and IFNabR KO mice and stimulated with LPS for 6 hours. STAT2 phosphorylation
was induced by LPS after 2 hours of stimulation and was still present after 6 hours (fig-
ure 3.22). Phosphorylation of STAT2 at Tyr689 was not detectable in BMDMs isolated
from IFNabR KO mice.
Furthermore, a STAT binding site is present within the MCP-1 (ccl2) promoter (fig-
ure 3.23a). To determine if IFNb-induced MCP-1 expression was through activation of
STAT1 and recruitment to the MCP-1 promoter, macrophages were stimulated with IFNb
for 30 mins and STAT1 chromatin immunoprecipitations performed. Upon stimulation
with IFNb, a marked increase in STAT1 was found at the MCP-1 promoter compared to
an IgG negative control and in the unstimulated state with STAT1 and IgG (figure 3.23b).
STAT1 and IgG showed no increase in recruitment to the gapdh promoter in resting or
IFNb-stimulated cells (figure 3.23c).
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Figure 3.21: IFNb induces MCP-1 expression and secretion
Bone marrow-derived macrophages were pre-treated with 0.5 µM of Ruxolitinib for 1 hour before stimula-
tion with 500 U/ml IFNb. A) Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the
Qiagen microRNeasy kit. Total RNAwas reverse transcribed using iScript (Bio-Rad) and qPCR was carried
out using SYBR-green based detection methods. Levels of 18S were used as a normalization control, and
fold induction was calculated for MCP-1 mRNA. B) Culture supernatant was collected and MCP-1 secre-
tion measured by Bioplex (Bio-Rad) according to the manufacturers protocol. n=4, error bars represent the
standard deviation from independent cultures from four mice per genotype.
3.9 MCP-1 production downstream of TLR3 requires IFNb feedback signaling
Poly(I:C) activates TLR3 signaling and stimulates biphasic production of IFNb, which is
dependent on type I IFN signaling (Honda et al., 2006; Enesa et al., 2012; Marié et al.,
1998). The effect of poly(I:C) on MCP-1 expression was therefore examined. As ex-
pected, poly(I:C) strongly induced IFNb transcription in a biphasic manner which was
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Figure 3.22: STAT2 phosphorylation requires IFNb-mediated feedback signaling in response to LPS
Bone marrow was isolated from wild-type and IFNabR KO mice. Bone marrow-derived macrophages
were stimulated with 100 ng/mL of LPS. Cells were lysed in triton lysis buffer and lysates resolved by
SDS-PAGE. Proteins were transferred to nitrocellulose membranes and blotted with antibodies to phospho
STAT2 (Y689) and ERK2. Results are representative of two independent experiments.
absent in the IFNabR knockout cells (figure 3.24).
Macrophages stimulated with poly(I:C) initiated transcription of MCP-1, which was sus-
tained throughout the 24 hour timecourse (figure 3.25a). Poly(I:C) stimulation led to
lower mRNA levels of MCP-1 compared to LPS stimulation (see figure 3.20). IFNabR
KO macrophages stimulated with poly(I:C) induced MCP-1 mRNA expression, which
was similar to that seen in wildtype macrophages. However, at later time points, MCP-1
mRNA levels were strongly decreased compared to wildtype cells. Poly(I:C) also in-
duced MCP-1 secretion at 8 hours and was increased at 24 hours. Deletion of IFNabR
in macrophages caused reduced levels of MCP-1 secretion in response to poly(I:C) com-
pared to wildtype macrophages (figure 3.25b).
3.10 Discussion
The importance of JAKs in the development of immune cells and in regulating the adap-
tive immune response has been well studied. The role of JAK signaling within the innate
immune response is less well understood. TLR activation leads to the rapid production
of numerous cytokines and chemokines which initiate and control the inflammatory re-
sponse required to combat infection. The production of these cytokines and chemokines
is dependent on many signaling pathways including MAPK, NFkB, IRF and autocrine
pathways. For example, both IL-10 and IFNb establish autocrine pathways which are
mediated by JAK/STAT signaling. IL-10 establishes an anti-inflammatory response that
results in the suppression of TNFa, IL-6 and IL-12 (Fiorentino et al., 1991; Murray, 2005;
Hutchins et al., 2013). IFNb has been shown to mediate a feedback pathway in dendritic
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Figure 3.23: IFNb stimulation recruits STAT1 to the MCP-1 promoter
A) To analyse STAT1 recruitment to the MCP-1 promoter by ChIP, qPCR using primers designed to cover
a potential STAT-binding site in the ccl2 (MCP-1) promoter were designed. BMDMs were isolated from
wild-type mice and stimulated with 500 U/ml IFNb for 30 min. Cells were cross-linked and STAT1 or
control IgG immunoprecipitations performed. ChIP signals relative to input for a region of B) GAPDH
gene and C) the STAT binding region of the ccl2 promoter are shown. Error bars represent the s.e.m. of
stimulations from 4 independent cultures of BMDMs.
cells, required to maintain IL-12 transcription (Gautier et al., 2005). The results presented
in this chapter demonstrate a requirement for IFNb to maintain transcription of IL-10 in
response to TLR4 activation with LPS. Furthermore, IFNb was shown to directly induce
IL-10 mRNA levels.
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Figure 3.24: Biphasic induction of IFNb by poly(I:C) requires the type I interferon receptor
Bone marrow-derived macrophages from WT and IFNabR KO mice were stimulated with 10 mg/ml
poly(I:C). Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction
was calculated for IFNb mRNA. n=4, error bars represent the standard deviation from independent cultures
from four mice per genotype.
3.10.1 IFNb-mediated feedback pathway sustains IL-10 transcription
TLR4 is a potent producer of IFNb, other TLRs expressed by macrophages do not all pro-
duce similar levels of IFNb when stimulated. Therefore it is unclear if the IFNb-mediated
feedback loop is required to sustain transcription of IL-10 in response to other TLR ago-
nists. Equally, it is unknown whether IFNb maintains IL-10 transcription in response to
agonists for other PRRs.
In addition to IL-10 and IFNb, LPS-stimulated macrophages produce other cytokines
that will activate JAK/STAT signaling. Therefore, the effects seen with Ruxolitinib treat-
ment on LPS-stimulated macrophage cytokine production could be linked to blocking
JAK/STAT signaling mediated by other cytokines and stimuli. However, the data above
suggests that IL-10 and IFNb are the predominant feedback mechanisms within TLR-
stimulated macrophages. Deletion of IL-10 results in a loss of STAT3 phosphorylation
at Tyr705 and deletion of the type I interferon receptor, which will block IFNb signal-
ing, caused loss of STAT1 phosphorylation at Tyr701, suggesting that STAT1 and STAT3
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Figure 3.25: Poly(I:C)-induced MCP-1 expression requires biphasic IFNb induction
Bone marrow-derived macrophages from WT and IFNabR KO mice were stimulated with 10 mg/ml
poly(I:C). A) Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen mi-
croRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out
using SYBR-green based detection methods. Levels of 18S were used as a normalization control, and fold
induction was calculated for MCP-1 mRNA. B) Culture supernatant was collected and MCP-1 secretion
measured by Bioplex (Bio-Rad) according to the manufacturers protocol. n=4, error bars represent the
standard deviation from independent cultures from four mice per genotype.
primarily mediate effects of IFNb and IL-10 respectively (Ananieva et al., 2008 and fig-
ure 3.5).
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Interestingly, deletion of IFNabR did not affect the initial phase of IL-10 transcription nor
did treatment with Ruxolitinib (figure 3.7 and figure 3.9). Other signaling pathways and
transcription factors have been implicated in regulating the initial transcription of IL-10,
including CREB, Sp1 and NFkB (Saraiva et al., 2005; Brightbill et al., 2000; Ma et al.,
2001; Elcombe et al., 2013).
The results above demonstrate a requirement for IFNb in sustaining IL-10 transcription
in response to TLR4 stimulation. IFNb will activate STAT1 downstream of the type I
receptor via JAK1 and Tyk2. STAT1 could therefore be directly binding to the IL-10
promoter and regulating its transcription. In line with this, treatment of LPS-stimulated
cells with Ruxolitinib resulted in the loss of STAT1 phosphorylation which correlated
with loss of sustained IL-10 transcription (figure 3.6). Equally, deletion of the type I
interferon receptor caused a similar loss of STAT1 phosphorylation, which correlated
with decreased IL-10 transcription at late time points (figure 3.5). Therefore active STAT1
could be required for maintaining IL-10 transcription. However, the requirement for an
intermediate between IFNb signaling and sustaining IL-10 transcription cannot be ruled
out. One study has suggested a role for IL-27, a member of the IL-12 cytokine family, in
the induction of IL-10 in response to IFNb (Iyer et al., 2010). Contrary to this study, the
induction of IL-27 in response to IFNb occurred with the same kinetics as those of IL-10
(see figure 3.10 and figure 3.11), which suggests that IL-27 may not be required for IL-10
transcription in response to IFNb.
3.10.2 Ruxolitinib affects the production of pro-inflammatory cytokines
Importantly, deletion of the type I interferon receptor does not affect the negative feedback
loop of IL-10 that represses the pro-inflammatory cytokine TNFa. Macrophages from
IFNabR KO mice do not display elevated levels of TNFa compared to wildtype controls
(figure 3.13). This correlates with the result that deletion of IFNabR does not affect the
initial transcription or secretion of IL-10. Early release of IL-10 is responsible for the neg-
ative feedback loop, which is partly mediated by phosphorylated STAT3 downstream of
IL-10R (Takeda et al., 1999; Riley et al., 1999). In line with this, the Ruxolitinib-induced
increase in TNFa level in LPS-stimulated macrophages was not affected by IFNabR KO.
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Deletion of IFNabR moderately affected IL-12(p35) and IL-12(p40) transcription and
this was reflected in secreted levels of IL-12(p40) and the dimer of the p35 and p40 sub-
units, IL-12(p70). Interestingly, a study in dendritic cells has identified a role for IFNb in
maintaining IL-12 transcription (Gautier et al., 2005). Using mice deficient in IFNabR or
STAT1, they demonstrated that IFNbmaintained transcription of both IL-12(p35) and IL-
12(p40) in response to TLR agonists. Whilst the changes in IL-12 transcription affected
secretion of the IL-12(p70) dimer, levels of IL-12(p40) were unaffected. This study sug-
gested that IL-12 mRNA was affected more than protein levels by IFNb signaling, which
is in agreement with results presented above.
IL-6 is also repressed by IL-10 and treatment with Ruxolitinib increased IL-6 levels in
wildtype macrophages by blocking IL-10 signaling. In contrast to TNFa, knockout of
the type I receptor strongly reduced IL-6 transcription and secretion from LPS-stimulated
macrophages (figure 3.13). In addition to this, deletion of the type I IFN receptor reduced
the increase caused by Ruxolitinib treatment of LPS-stimulated macrophages. These re-
sults suggested that IFNb can positively regulate IL-6 transcription. A direct role for IFNb
stimulating IL-6 transcription was also demonstrated (figure 3.14). These results are sup-
ported by other studies that demonstrate a role for IFNb in maintaining IL-6 transcription.
In IFNb knockout macrophages, array profiling demonstrated that IL-6 was less strongly
induced in response to LPS compared to wildtype macrophages (Thomas et al., 2006). In
addition to this, the importance of the IFN feedback loop was also demonstrated for IL-6
in dendritic cells (Yasuda et al., 2007).
JAK inhibitors, such as Ruxolitinib and Tofacitinib, are proposed to be effective in the
treatment of a range of autoimmune diseases (O’Shea et al., 2013b). An important part
of the therapeutic benefit achieved is through blocking JAK signaling within the adap-
tive immune system. Interestingly, both Ruxolitinib and Tofacitinib result in increased
pro-inflammatory cytokine secretion from bone marrow-derived macrophages stimulated
with LPS, due to inhibition of IL-10 signaling (figure 3.13 and figure 3.19). Ruxolitinib
has been shown to prevent DC maturation and function by affecting cytokine levels and
their ability to activate T cells (Heine et al., 2013). In vivo it has been shown to reduce
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cytotoxic T cell responses following OVA/CpG injection into mice and delay clearance
of an adenovirus. Tofacitinib has been shown to elevate levels of IL-10 and reduce those
of the pro-inflammatory cytokines, TNFa, IL-6 and IL-12 in response to i.p. injection of
LPS into DBA/1J mice (Ghoreschi et al., 2011). This is in contrast to the results seen in
isolated BMDMs, where Tofacitinib treatment elevates pro-inflammatory cytokine levels
(figure 3.19). This may be due to the contribution of multiple cell types to the inflamma-
tory response and whose cytokine production may be regulated in different ways by JAKs
compared to macrophages.
In vivo, macrophages would be primed by IFNg, whilst isolated macrophages are naive
prior to LPS stimulation (Hu et al., 2005). JAK inhibitors would block this priming and
thereby reduce the pro-inflammatory potential of macrophages. Equally, IFNb can prime
macrophages, which would also be blocked by JAK inhibitors (Thomas et al., 2006; Hu
et al., 2008). Deletion of IFNb, STAT1 or Tyk2 renders mice less sensitive to LPS-induced
endotoxic shock (Thomas et al., 2006; Karaghiosoff et al., 2000).
Lastly, the concentration of Tofacitinib is important and directly relates to its ability to
block IL-10 and/or IFNb signaling. Whether the concentration used during the in vivo
studies compares to the dose used in BMDMs to block both IL-10 and IFNb signaling is
unclear. This could partially explain the discrepancy between in vivo and in vitro effects
on pro-inflammatory cytokine production as the in vivo dose of Tofacitinib may have been
unable to block the anti-inflammatory effects of IL-10.
3.10.3 Comparison of Ruxolitinib and Tofacitinib
Ruxolitinib and Tofacitinib are structurally distinct inhibitors of JAKs and have similar
effects on pro-inflammatory cytokine secretion from LPS-stimulated macrophages. No-
tably, Tofacitinib inhibited IFNb signaling more potently than IL-10 signaling, whereas
Ruxolitinib inhibited both signaling pathways at a similar concentration. Both IFNb and
IL-10 signal through JAK1 and Tyk2. The results above show that Tofacitinib has similar
IC50s for JAK1 and JAK3, but higher IC50s for JAK2 and Tyk2 (figure 3.16). Interest-
ingly, some studies have noted that a higher concentration of Tofacitinib is required to
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block STAT1 and STAT3 phosphorylation in response to IL-6 (Ghoreschi et al., 2011;
Rosengren et al., 2012). IL-6 is reported to signal through JAK1, JAK2 and Tyk2. It
could be suggested that Tyk2 is more important in phosphorylation of STAT3 compared
to STAT1 phosphorylation. However, studies with Tyk2 knockout mice have shown nor-
mal phosphorylation of STAT3 in response to IL-10 but decreased IFNb-induced STAT1
phosphorylation (Karaghiosoff et al., 2000; Shimoda et al., 2000).
3.10.4 Transcription of MCP-1 is sustained by the IFNb-mediated feedback path-
way
The importance of the IFNb-mediated feedback pathway in modulating the production
of cytokines and chemokines from LPS-stimulated macrophages was further underlined
by the requirement for IFNb and STAT1 signaling in inducing transcription of MCP-1,
a b-chemokine (figure 3.20, figure 3.23). Macrophages also require the IFNb-mediated
feedback pathway to sustain transcription of MCP-1 in response to poly(I:C), a TLR3
agonist. Ruxolitinib blocks direct activation of MCP-1 transcription by IFNb.
IFNb can activate both STAT1 and STAT2, which can form a complex with IRF9. Deletion
of the type I receptor blocks both STAT1 and STAT2 phosphorylation in response to LPS.
The results above demonstrate that STAT1 is recruited to the ccl2 (MCP-1) promoter
in response to IFNb. In line with this, other studies have identified STAT binding sites
within the ccl2 promoter (Zhou et al., 1998; Shyy et al., 1990). STAT2 may also be
important in regulating transcription of MCP-1. In a model of colitis, mice deficient for
STAT2 produced less MCP-1 (Gamero et al., 2010). Other studies have suggested roles
for STAT4 and STAT6 respectively in regulating MCP-1 transcription (Iida et al., 2011;
Tang et al., 2011), however my work suggests a dominant role for STAT1 and/or STAT2.
3.10.5 The importance of MCP-1 in viral infection
Interestingly, MCP-1 is induced by IFNb, which is important for promoting an anti-viral
response. This might suggest that MCP-1 is important for combating viral infections.
Several studies have examined mice deficient for MCP-1 or, its receptor, CCR2 in viral
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infection models. In a model of influenza pneumonia, WT mice have elevated pulmonary
MCP-1 levels. Notably, MCP-1 KO mice suffered from an increased viral load along
with diminished influx of macrophages and granulocytes. MCP-1 deficient mice also
exhibited increased pro-inflammatory mediators such as TNFa and IL-6 (Dessing et al.,
2007). MCP-1- and CCR2-deficient mice were infected with murine cytomegalovirus
(CMV) and showed reduced accumulation of macrophages and NK cells compared to
wildtype mice. In addition to reduced immune cell trafficking, mice lacking either MCP-
1 or CCR2 had increased viral titers (Hokeness et al., 2005). Following West Nile virus
infection, knockout of CCR2 caused reduced monocyte accumulation in the brain and
increased mortality from encephalitis (Lim et al., 2011). These studies demonstrate a
clear role for MCP-1 in the anti-viral response and therefore suggests that the prolonged
transcription and secretion of MCP-1 promoted by the IFNb-mediated feedback pathway
is important for an appropriate and effective anti-viral response.
3.10.6 Conclusion
LPS-stimulated macrophages produce a number of cytokines and chemokines as part of
the inflammatory response. Regulation of these inflammatory mediators is important
to promote resolution and prevent tissue damage from excessive or chronic inflamma-
tion. Numerous pathways control the production of IL-10, an important inflammatory
cytokine. The data presented in this chapter demonstrate that an IFNb-mediated feed-
back pathway is required for sustained transcription and secretion of IL-10. Additionally,
IFNb can directly activate IL-10 transcription and this induction can be blocked by the
JAK inhibitor Ruxolitinib. Treatment of wildtype cells with Ruxolitinib will increase pro-
inflammatory cytokine production by inhibiting the IL-10-mediated anti-inflammatory re-
sponse. Deletion of the type I IFN receptor did not increase secretion of pro-inflammatory
cytokines, TNFa and IL-12. However, IL-6 transcription was reduced in type I IFN
receptor-deficient macrophages. A structurally distinct JAK inhibitor, Tofacitinib, also
had similar effects on IL-10 and pro-inflammatory cytokine production. Notably, Tofaci-
tinib required a 10-fold higher concentration to block IL-10 signaling compared to IFNb,
whereas Ruxolitinib inhibited both pathways with similar potency.
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In addition to regulating IL-10 transcription, the IFNb-mediated feedback pathway was
also required for sustained MCP-1 transcription. Deletion of IFNabR from macrophages
reduced MCP-1 mRNA and protein levels at late time points following LPS and poly(I:C)
stimulation. Similarly to IL-10, MCP-1 transcription was directly induced in response to
IFNb in a JAK-dependent manner. Furthermore, in response to IFNb, STAT1 was shown
to be recruited to the ccl2 promoter.
Together these results demonstrate the importance of the IFNb-mediated feedback path-
way in promoting an appropriate and effective immune response figure 3.26. This feed-
back pathway is important in the resolution of inflammation by maintaining IL-10 tran-
scription and the migration of immune cells by promoting MCP-1 transcription in re-
sponse to bacterial and viral ligands.
Figure 3.26: Importance of the type I interferon-mediated feedback loop in LPS-stimulated
macrophages
In response to LPS, the transcription of TNF, IL-6, IL-12, MCP-1, IL-10 and IFNb is induced. IL-10 can
feedback through the IL-10R and repress transcription of TNF, IL-6 and IL-12. IFNb also establishes a
feedback loop that enhances the sustained transcription of IL-6, IL-10 and MCP-1. Ruxolitinib, the JAK
inhibitor, blocks the actions of both IL-10 and IFNb feedback pathways resulting in enhanced secretion of
TNF, IL-6 and IL-12. Secretion of IL-10 and MCP-1, in response to LPS, is reduced at late time points in
the presence of Ruxolitinib.
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Chapter 4
Results- MEF2D negatively regulates
IL-10 transcription
4.1 Myocyte enhancer factor 2
The MEF2 (myocyte enhancer factor 2) transcription factor family has been implicated
in immune cell development but a role in the context of TLR signaling has not yet been
identified (Black and Olson, 1998; Potthoff and Olson, 2007). MEF2 factors are evo-
lutionary conserved and function as part of an ancient network regulating muscle cells.
MEF2 factors recognise a conserved sequence (YTA(A/T)4TAR) in many muscle-specific
genes and loss of function studies have demonstrated the importance of MEF2 factors in
muscle gene expression during embryogenesis. In addition, MEF2 factors have also been
shown to respond to mitogenic signals, while their expression and function is controlled
by numerous inputs to modulate the transcriptional programme produced.
4.1.1 MEF2 structure and function
MEF2 was originally described as binding an A/T rich DNA sequence in the muscle
creatine kinase enhancer (Gossett et al., 1989). This A/T rich sequence was recognized to
be conserved and found in many skeletal and cardiac muscle genes (Bassel-Duby et al.,
1992; Muscat et al., 1992). Early studies showed that mutation of the binding site strongly
reduced expression of these genes and that ectopic expression of MEF2 would induce
expression. In vertebrates, the MEF2 family consists of 4 isoforms; A, B, C and D, each
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encoded by a different gene located on different chromosomes (Pollock and Treisman,
1991; Yu et al., 1992; Breitbart et al., 1993; Hobson et al., 1995; Suzuki et al., 1996).
Only one MEF2 gene is present in the genomes of Drosophilia and C.elegans (Lilly et al.,
1994; Nguyen et al., 1994; Dichoso et al., 2000).
Figure 4.1: MEF2 family
A) MEF2 consists of a DNA binding domain formed from a MADS box and MEF2 domain and long C-
terminal transcription activation domain. MEF2 proteins can interact with a number of proteins including
kinases such as p38, transcription factors such as NFAT and GATA as well as transcription cofactors such
as p300 and HDACs. B) In vertebrates, there are four MEF2 family members each encoded by a gene with
several splice variants. Exons connected by lines are used alternatively.
MEF2 transcription factors consist of a N-terminal MADS box and MEF2 domain and
long C-terminal transcription activation domain. The MADS box is a 57-amino acid mo-
tif that can act as a minimal DNA binding domain (DBD) (Shore and Sharrocks, 1995).
Together, the MADS box and the 279-amino acid MEF2 domain form a high-affinity
DBD (Molkentin et al., 1996a). The MADS box contains several invariant residues im-
portant for DNA recognition which are conserved with other MADS-box family mem-
bers. The DBD is also important for dimerization and the dimer is capable of recognising
DNA oligonucleotides. MEF2 transcription factors will bind their consensus sequence
as homo- or heterodimers (Pollock and Treisman, 1991; Yu et al., 1992). Interaction be-
tween MEF2 proteins and other MADS-box factors do not occur, suggesting the residues
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required for mediating MEF2 dimerisation are not conserved outside of the MEF2 family.
The MEF2 isoforms show around 50% amino acid homology overall, with 95% similar-
ity within the MADS box and MEF2 domain (Black and Olson, 1998). The C-terminal
regions show sequence diversity. The crystal structure of the DBD fromMEF2A has been
solved and shows that the MADS-box and MEF2 domain form a tightly folded structure
(Wu et al., 2010). A MEF2 DBD dimer consists of a six-strand beta sheet sandwiched
by a pair of a-helices above and below. The beta sheet acts as a core for protein folding,
whilst the a-helices bind to DNA and promote protein-protein interactions. The a1-helix
and the N-terminal extension of the MADS-box are the important regions for mediating
DNA sequence recognition (Wu et al., 2010; Santelli and Richmond, 2000).
MEF2 transcription factors bind the same consensus sequence, although MEF2B has re-
duced affinity compared to the other family members (Pollock and Treisman, 1991; Yu
et al., 1992; Molkentin et al., 1996b). Nucleotides flanking the A/T rich sequence also
affect MEF2 binding to DNA sequences (Andres et al., 1995; Fickett, 1996). Whilst the
MADS-box and MEF2 domain are sufficient for DNA binding, they lack transcriptional
activity. The C-terminal regions of the MEF2 family members contain a transcriptional
activation domain (TAD). The C-termini share little sequence homology except in certain
short acidic exons and in four conserved Ser/Thr rich regions. MEF2A, C and D also
possess a nuclear localisation sequence at the extreme C-terminal region. Deletion of this
sequence in MEF2A renders it cytosolically located (Yu, 1996).
4.1.2 Regulation of MEF2 expression and activity
The expression of MEF2 factors is controlled at the transcriptional, translational and post-
translational levels. In vertebrates, mef2 transcripts are highly expressed in muscle cell
lineages (Edmondson et al., 1994). In addition to muscle cell expression, MEF2 is also
enriched in the developing central nervous system (Leifer et al., 1993, 1994; Lyons et al.,
1995). The expression pattern in adult tissues is still unclear with conflicting reports sug-
gesting either limited expression of the proteins to neural and muscle tissues or ubiquitous
expression of both transcripts and proteins (Pollock and Treisman, 1991; Chambers et al.,
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1992; Yu et al., 1992; Martin et al., 1993; McDermott et al., 1993; Dodou et al., 1995;
Ornatsky and McDermott, 1996). There is a conserved casein kinase II phosphorylation
site within the MADS-box of the MEF2 family members, although this site appears to be
constitutively phosphorylated in vivo and thus is unlikely to regulate MEF2 activity. Other
post-translation modifications including phosphorylation and sumoylation occur and can
alter MEF2 activity as discussed below (Molkentin et al., 1996c; Zhao et al., 1999; Gré-
goire et al., 2006, 2007; Kato et al., 1997; Han et al., 1997).
4.1.3 Knockout of MEF2 genes
The importance of each MEF2 factor in development is now being elucidated using
knockout models. MEF2A KO mice mostly die within the first week after birth through
cardiovascular defects, although skeletal muscle develops normally (Naya et al., 2002;
Potthoff et al., 2007). The remaining mice suffer from cardiac defects and mitochondrial
deficiency. They also suffer from the risk of sudden death. MEF2C knockout is embry-
onic lethal and the embryos show defects in cardiac morphogeneis at embryonic day 9
(Lin et al., 1997). The generation of conditional MEF2C knockout mice has shown the
importance of MEF2C in determining myeloid cell fate, possibly by regulating expres-
sion of c-Jun (Schüler et al., 2008). MEF2B null mice are viable with no obvious muscle
defects (Black and Olson, 1998). Global deletion of MEF2D has little effect on skeletal
muscle development and these mice appear normal in other respects (Potthoff et al., 2007).
Further study on MEF2D function using MEF2D-null mice and a transgenic model with
over-expression of MEF2D demonstrated that MEF2D is important in stress-dependent
cardiac growth (Kim et al., 2008b).
4.1.4 Signaling to MEF2
MEF2 proteins initiate transcription of genes and act as signaling endpoint for several
pathways. It has been shown that MAPK can phosphorylate MEF2 factors in yeast and
humans (Dodou and Treisman, 1997; Han et al., 1997; Kato et al., 1997). ERK5 is known
to phosphorylate MEF2 leading to augmented transcriptional activity (Yang et al., 1998;
Kasler et al., 2000). The C-terminal region will interact directly with the MADS-MEF2
domain of MEF2D and this interaction is required for full activation of MEF2D (Kasler
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et al., 2000).
p38 is known to phosphorylateMEF2 factors (Zhao et al., 1999; Han et al., 1997). p38 was
shown to phosphorylate MEF2A on two Thr residues leading to an increase in transcrip-
tional activity, however p38 was shown to be unable to phosphorylate MEF2B or MEF2D
(Zhao et al., 1999). A more recent study contradicted the work of Zhao et al, this study
demonstrated that p38 phosphorylated MEF2D and that p38-mediated phosphorylation
of MEF2D promoted interaction with Ash2L (Rampalli et al., 2007). Ash2L-containing
methyltransferase complex recruitment led to trimethylation of histone H3 Lys4, epige-
netically marking MEF2-regulated genes for expression in muscle progenitor cells.
Calcium signaling has also been implicated in regulating MEF2 function. Primarily, this
is mediated through regulating the activity of histone deacetylases (HDACs). The Class
IIa HDACs will form repressive complexes with MEF2 via the MADS-box at MEF2-
dependent genes (Bertos et al., 2001; McKinsey et al., 2001a). Calcium-regulated protein
kinases such as protein kinase D and calcium calmodulin-dependent protein kinases can
phosphorylate class IIa HDACs on conserved serine residues (Zhang et al., 2002; McK-
insey et al., 2001b). Phosphorylation of HDACs results in translocation to the cytoplasm
and thus allows activation of MEF2 and transcription of MEF2-dependent genes.
MEF2D is phosphorylated at Ser444 and mutation of this site to an alanine prevents
sumoylation of MEF2D at Lys439 (Grégoire et al., 2006). Mimicking phosphorylation
at Ser444 with a glutamate residue induced similar levels of sumoylation as seen in wild-
type MEF2D. Interestingly, Ser444 is an established CDK5 site based on in vitro studies
(Gong et al., 2003), suggesting that post-translational modifications can be regulated by
signaling events. Sumoylation at Lys439 and phosphorylation at Ser444 is known to in-
hibit the transcriptional activity of MEF2D (Zhu and Gulick, 2004; Grégoire and Yang,
2005; Gong et al., 2003; Zhao et al., 2005). This inhibition could be relieved through
the action of calcineurin, a phosphatase (Grégoire et al., 2006). This study demonstrated
that interplay between post-translational modifications affect the transcriptional activity
of MEF2D. It has also been shown that HDAC4 potentiates sumoylation of MEF2D and
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this may occur through recruitment of CDK5 (Grégoire et al., 2006). Similarly to cal-
cineurin opposing CDK5, the SUMO protease SENP3 reverses sumoylation of MEF2D,
enhancing transcriptional activity (Grégoire and Yang, 2005).
Protein kinase A signaling is thought to modulate MEF2 activity. Membrane depolari-
sation leads to cAMP-PKA pathway mediated activation of MEF2 which is required for
neuronal survival (Wang et al., 2005b). PKA was shown to phosphorylate MEF2 at Thr20
in vitro and increase DNA binding activity. Blocking the PKA pathway or expression of
a Thr20Ala mutant enhanced neuronal apoptosis upon membrane depolarisation. A later
study showed PKA could phosphorylate Ser121 and Ser190 of MEF2D in vitro and that
these phosphorylation events repressed transcriptional activity (Du et al., 2008). The over-
all role of PKA in modulating MEF2 activity is unclear and may be stimuli-specific and
subject to modulation by other post-translational modifications.
The transcriptional activity of MEF2D can also be regulated by small molecule inhibitors
that target proteins involved in modulating its activity. The CDK inhibitor, roscovitine,
was shown to reduce sumoylation of MEF2D by preventing phosphorylation at Ser444
(Grégoire et al., 2006). Another study used class II HDAC inhibitors to block MEF2D
transcriptional activity. This repression of activity was caused by stabilising the in-
hibitory HDAC3-HDAC4-MEF2D complex and reducing MEF2D gene expression (Neb-
bioso et al., 2009).
4.1.5 MEF2 factors in immune cells
The development and activation of T cells is a tightly regulated process mediated by many
signaling pathways including calcium signaling. Calcium signaling is important in TCR-
induced apoptosis (Woronicz et al., 1995). Nur77 is an important mediator of apoptosis in
T cells and the Nur77 promoter contains two MEF2 sites (Youn et al., 1999). It has been
reported that in resting T cells, MEF2 is complexed with HDAC7 and Cabin1, which act
as transcriptional repressors and reduce Nur77 expression (Dequiedt et al., 2003; Youn
et al., 2000). Within Cabin1, a C-terminal region is responsible for binding to calcineurin
and MEF2. Mice expressing a mutant version of Cabin1 lacking this region had normal
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Figure 4.2: Signaling input to MEF2
MEF2 activity and stability is regulated by numerous signaling inputs. Selected inputs are illustrated here.
p38 has been shown to phosphorylate and activate MEF2. PKA phosphorylates MEF2 at Thr20 and en-
hances DNA binding. PKA can also phosphorylate MEF2 at other sites and repress transcriptional activity.
ERK5 has been shown to phosphorylate MEF2 proteins at various sites. CDK5 can phosphorylate and
inhibit MEF2 and this is associated by sumoylation at a nearby residue. The sumoylation of MEF2 is
reversed by the SUMO protease SENP3. Calcium signaling inhibits the action of MEF2 by promoting
complex formation with Class II HDACs. This action is opposed by calcineurin
T and B cell development. Apoptosis of T cells was also unaffected, however, following
TCR stimulation, mutant T cells produced higher levels of IL-2, IL-4 and IFNg (Esau
et al., 2001). This data suggests Cabin1 plays an important role in controlling cytokine
production from T cells through MEF2 activity.
Furthermore, MEF2 activity is regulated following TCR activation. HDAC7 is phos-
phorylated by PKD1 and translocates to the nucleus with 14-3-3 proteins resulting in
active MEF2 (Parra et al., 2005). MEF2 is conversely regulated by the actions of pro-
tein phosphatase 1 and myosin phosphatase targeting subunit 1, which promotes nuclear
localisation of HDAC7 (Parra et al., 2007). HDAC4 and 5 were shown to interact with
MEF2D and repressed transcription. CAMK phosphorylation of the DNA binding do-
main in MEF2D relieved HDAC4/5-mediated repression of transcription (Lu et al., 2000).
HDAC4 was also shown to regulate the sumoylation of Lys424. HDAC4 was shown to
interact with the E2 conjugating enzyme Ubc9 and sumoylation of Lys424 inhibited tran-
scriptional activity. CBP was shown to be capable of acetylating MEF2 and this action
was opposed by SIRT1 (Zhao et al., 2005).
In addition to calcium signaling, cAMP signaling is also engaged in response to TCR
activation. It has been shown that IL-10 production in T lymphocytes can be strongly
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inhibited by cAMP elevating agents. Using luciferase reporters with the IL-10 promoter,
one study identified a fragment of the promoter, sensitive to cAMP-mediated inhibition,
that contained a MEF2 binding site. Over-expression of MEF2 increased IL-10 promoter
activity and stimulated binding to the IL-10 promoter which was sensitive to cAMP-
mediated inhibition (Liopeta et al., 2009).
MEF2 proteins have also been shown to play important roles in myeloid cells. Ectopic ex-
pression of MEF2C in C57Bl/6 mice lead to a six-fold reduction in Gr-1 positive cells (a
marker of granulocytic differentiation) from bone marrow (BM) cells cultured in G-CSF
(Schüler et al., 2008). It was also noted that MEF2C had varying levels of expression dur-
ing myelopoiesis. Interestingly, BM cells cultured in M-CSF had increased expression of
MEF2C compared to those untreated or cultured in GM-CSF. Bone marrow from mice
lacking MEF2C produced a lower percentage of CD11b+F4/80+ cells compared to con-
trols, although early myeloid differentiation of common myeloid, granulocyte-monocyte,
or megakaryocyte-erythroid progenitors was unaffected. As has been reported in other
studies, c-Jun is a target of MEF2C in myeloid cells, where deletion of MEF2C reduced
c-Jun expression. Over-expression of MEF2C enhanced c-Jun expression in response to
LPS treatment in NIH3T3 cells. (Schüler et al., 2008).
MEF2D has been shown to form a heterodimer with MEF2A in macrophage differenti-
ated HL60 cells (Aude-Garcia et al., 2010). The MEF2A/D dimer was proposed to be
important in differentiation through control of c-Jun and MEF2A was shown to be bound
to the c-Jun promoter by ChIP assay. MEF2A and MEF2D were also shown to be present
in primary human monocytes and macrophages (Aude-Garcia et al., 2010).
Although, MEF2D is thought to regulate IL-10 in T cells, the role ofMEF2D in macrophage-
derived IL-10 production is unclear. LPS stimulation of macrophages activates multiple
signaling pathways resulting in the activation of several transcription factors including
CREB, NF-kB, IRF3, IRF5 and IRF7. Other transcription factors such as MEF2D may
be activated and may play important roles in regulating transcription of key cytokines.
Identification of novel regulating pathways may provide new therapeutic targets. In order
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to identify other transcription factors activated in response to LPS, Raw264.7 cells were
cultured in light- or medium-conditioned SILAC media.
4.2 MEF2D is phosphorylated in response to LPS in Raw264.7 cells
Medium-labelled Raw264.7 cells were stimulated with LPS for 30 minutes and lysates
from light-labelled and medium-labelled Raw264.7 were mixed at a ratio of 1:1. Lysates
were enriched for phosphopeptides and then measured by MS/MS (figure 4.3).
Figure 4.3: Experimental procedure for SILAC
Light (R0K0) and Medium (R6K4)-labelled Raw264.7 cells were cultured. Medium-labelled cells were
stimulated with LPS and light-labelled cells unstimulated. Lysates were combined at 1:1 ratio and phospho-
peptides were enriched by immobilized metal-ion (Fe3+) chromatography. Phosphopeptides were analysed
by MS/MS. Peptides from medium-labelled cells are distinguished from peptides from light-labelled cells
and used to calculate the ratio of the peptide in medium-labelled cells compared to light-labelled cells.
Over 6000 phosphopeptides were identified and over 1000 of these peptides were more
than 3 fold up-regulated in response to LPS compared to unstimulated cells. Peptides
which were consistently up-regulated across 3 experiments were identified and further se-
lected for a role in regulating transcription. Phosphopeptides from MEF2D are presented
in figure 4.4 and the ratio of stimulated to unstimulated is shown. Five peptides were
identified as being phosphorylated in Raw 264.7 cells, however only two of these pep-
tides were differentially regulated in response to LPS stimulation. The RASEELDGFRR
peptide (119-130 mouse) showed 8 fold enrichment in phosphorylation in stimulated com-
pared to unstimulated Raw 264.7 cells. Phosphorylation at the Ser121 position has been
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identified in previous studies, including a large-scale phosphoproteomic study which iden-
tified the S121 phosphopeptide in the brain, heart, lung, kidney and spleen. (Huttlin et al.,
2010).
Figure 4.4: MEF2D peptides identified from LPS-stimulated SILAC Raw264.7 cells
Raw264.7 cells were unstimulated (Light condition) or stimulated with 100 ng/ml LPS for 30 mins (Medium
condition) and lysed in 8M urea. Lysates were quantified and mixed at a 1:1 ratio. Phosphopeptides were
enriched using immobilized metal-ion (Fe3+) chromatography and analysed via MS/MS. Phosphopeptides
identified from MEF2D are presented with ratio of stimulated:unstimulated (M:L) from 3 samples. Error
bars represent standard deviation
4.3 Characterisation of the S121 phosphorylation site on MEF2D
Antibodies were raised against the S121 peptide and tested through dot blots to determine
their specificity. When the phospho antibody was pre-incubated with S121 phosphopep-
tide it recognised neither the phospho- or dephosphopeptides (figure 4.5). When incu-
bated with the dephosphopeptide, the antibody was capable of recognising 100 ng of the
phosphopeptide only. The antibody alone demonstrates that it recognises predominantly
the phosphopeptide with some weak binding to the dephosphopeptide. The 1st and 2nd
bleeds bound the S121 peptide less strongly (data not shown) and therefore the 3rd bleed
was used.
Next, the phosphorylation ofMEF2D at S121 in response to LPSwas validated in Raw264.7
cells through immunoprecipitation. The phospho antibody was used to pull down phos-
phorylatedMEF2D and then immunoprecipitates were immunoblotted using a total MEF2D
antibody (BD Biosciences). Stimulation with LPS does not affect protein level of MEF2D
over 60 minutes (figure 4.6). Unstimulated cells do not demonstrate any phosphorylated
MEF2D at S121. After 15 and 30 minutes of LPS stimulation, a band is evident sug-
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Figure 4.5: Phospho S121 MEF2D antibody dot blots
Decreasing concentrations of the phosphorylated and dephosphorylated S121 peptide were spotted onto
nitrocellulose membrane before incubation with the S121 phospho antibody in the presence of 1 µg/ml
phosphopeptide, in the presence of 1 µg/ml dephosphopeptide or alone. Results are representative of two
independent experiments.
gesting that MEF2D is phosphorylated at S121 in response to LPS at these time points.
After 60 minutes of LPS stimulation, no MEF2D band is present suggesting that the phos-
phorylation event has been reversed, probably through the action of a phosphatase, since
MEF2D protein levels do not decrease.
4.4 Role of MEF2D in TLR signaling
In order to understand the role that MEF2D might have in TLR signaling, MEF2D KO
mice were generated. Previous work in the lab had generated a MEF2D floxed allele. This
was crossed with a bal1 (a constitutive cre) to generate total MEF2D knockout mice. Bone
marrow from wildtype and MEF2D KO mice was isolated and BMDMs cultured. First,
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Figure 4.6: MEF2D is phosphorylated at S121 in response to LPS in Raw264.7 cells
Raw264.7 cells were stimulated with 100 ng/ml LPS for the times indicated and lysed. MEF2D was im-
munoprecipitated from 500 µg cell lysate using the MEF2D S121 phosphoantibody in the presence of
the dephosphopeptide. Lysates and immunoprecipitate samples were seperated by SDS-PAGE and im-
munoblotted with a total MEF2D antibody. Results are representative of three independent experiments.
deletion of MEF2D was validated by detecting MEF2D protein. Unlike wildtype cells,
MEF2D KO macrophages have no detectable MEF2D (figure 4.7). LPS stimulation leads
to activation of MAPKs by 30 minutes, activation of p38 was similar in WT and MEF2D
KO macrophages. The initial induction of JNK was similar between WT and MEF2D
KO macrophages, however at 2 and 4 hours after stimulation there is a second wave of
activation in the WT macrophages not present in MEF2D-deficient BMDMs. Activation
of ERK1/2 and p105 was also comparable at 30 mins between wildtype and MEF2D-
deficient macrophages, however at later time points phosphorylation of ERK1/2 and p105
appears slightly reduced. Interestingly, MEF2D KO macrophages show enhanced STAT3
phosphorylation after 2 hours of LPS stimulation suggesting an alteration in cytokine
secretion. Previous work has shown that changes in IL-10 secretion from macrophages
are often reflected in STAT3 phosphorylation (figure 3.5, Ananieva et al., 2008). MEF2D
KO macrophages also had elevated levels of A20, a protein involved in inhibiting NFkB
responses, compared to wildtype macrophages.
Changes in MAPK phosphorylation could be through alterations in the abundance of dual-
specificity phosphatases. Data from a microarray experiment previously carried out in
the lab was analysed. Microarray profiling identified DUSP1, 2, 4 and 5 as being over
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Figure 4.7: TLR signaling in MEF2D KO BMDMs
BMDMs were generated from WT and MEF2D KO bone marrow and stimulated with 100 ng/ml LPS for
up to 6 hours. Cells were lysed and proteins separated by SDS-PAGE. Proteins were transferred to nitrocel-
lulose membranes and immunoblotted with antibodies to total IkB, phospho STAT3 (Y705), A20, phospho
p105, phospho JNK, phospho p38, phospho ERK1/2, ERK2 and MEF2D. Results are representative of
three independent experiments.
2.5 fold up-regulated in response to LPS in macrophages (see table 4.1). Wildtype and
MEF2D-deficient macrophages were stimulated with LPS and DUSP1, 2 and 5 mRNA
levels measured. LPS induced expression of DUSP5 at 1 hour in wildtype macrophages.
Expression of DUSP5 was elevated in MEF2D KO macrophages compared to wildtype
cells in response to LPS (figure 4.8). At 2 and 4 hours following stimulation with LPS,
DUSP1mRNA levels were marginally elevated inMEF2DKO cells compared to wildtype
cells. Expression of DUSP2 in response to LPS was not affected by deletion of MEF2D
in macrophages (figure 4.8).
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Table 4.1: DUSP expression in LPS stimulated macrophages
Accession Number Symbol Average Expression log(fold change)
NM_013642 Dusp1 12.10 2.80
NM_010090 Dusp2 7.51 3.81
NM_028207 Dusp3 10.22 -0.16
NM_176933 Dusp4 9.32 2.59
NM_001085390 Dusp5 9.10 4.40
NM_026268 Dusp6 8.61 -0.23
NM_153459 Dusp7 10.82 -0.14
NM_008748 Dusp8 7.02 2.22
NM_029352 Dusp9 6.61 0.25
NM_022019 Dusp10 6.67 0.30
NM_028099 Dusp11 9.84 -0.02
NM_023173 Dusp12 6.59 -0.28
NM_023173 Dusp12 5.00 -0.10
NM_001007268 Dusp13 6.40 -0.01
NM_019819 Dusp14 6.67 0.98
NM_001159376 Dusp15 3.44 -0.01
NM_130447 Dusp16 8.73 1.73
NM_173745 Dusp18 6.60 -0.14
NM_024438 Dusp19 7.62 0.06
NM_028568 Dusp21 3.33 -0.01
NM_001037955 Dusp22 9.33 -0.17
NM_026725 Dusp23 7.24 -0.06
NM_025869 Dusp26 4.69 -0.07
NM_001033344 Dusp27 3.91 -0.13
NM_175118 Dusp28 7.90 -0.25
4.5 Deletion ofMEF2D increases IL-10 transcription and decreases pro-inflammatory
cytokine secretion
Deletion of MEF2D from macrophages has small effects on the initial signaling events
seen upon LPS stimulation. Despite this, changes in STAT3 phosphorylation suggest
a modulation of cytokine levels, probably of IL-10. Therefore, WT and MEF2D KO
BMDMs were stimulated with LPS and IL-10 transcription and secretion measured. LPS
stimulation induced transcription of IL-10, which peaked at 2 hours. IL-10 mRNA levels
were close to basal at 12 hours. MEF2D KOmacrophages, in response to LPS, had higher
levels of IL-10 mRNA between 1 to 4 hours with IL-10 mRNA levels returning to levels
similar to that of wildtype macrophages from 8 hours onwards (figure 4.9).
MEF2D knockout increases IL-10 mRNA levels (figure 4.9), however whether this is a
change in the rate of transcription or an increase in mRNA stability is not evident from
this data. As MEF2D is a transcription factor, it may have a direct influence on transcrip-
tion of the il10 gene by binding to the IL-10 promoter. To investigate if MEF2D knockout
influenced mRNA transcription rates, primers were designed that recognise the primary
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Figure 4.8: DUSP5 mRNA is elevated in MEF2D KO macrophages
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction was
calculated for DUSP1, DUSP2 and DUSP5 mRNA. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
transcript of IL-10. By measuring levels of the IL-10 primary transcript, it would provide
an indication if increases in IL-10 mRNA levels were due to changes in transcription rate
or mRNA stability. Wildtype and MEF2D-deficient macrophages were stimulated with
LPS over a timecourse of 16 hours and IL-10 primary transcript levels measured by qPCR.
LPS induces a peak of IL-10 primary transcript at around 1 hour and this gradually de-
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Figure 4.9: MEF2D KO macrophages have higher IL-10 transcription and secretion
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction was
calculated for IL-10 mRNA. Culture supernatant was collected and IL-10 secretion measured by Bioplex
(Bio-Rad) according to the manufacturers protocol. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
creases over the 16 hour timecourse (figure 4.10). Deletion of MEF2D from macrophages
results in increased IL-10 primary transcript at 1, 4 and 8 hours of LPS stimulation. This
suggests that MEF2D affects IL-10 transcription thus causing increased IL-10 mRNA
levels and secretion.
IL-10 is an important anti-inflammatory cytokine and acts upon macrophages to reduce
pro-inflammatory cytokine transcription and secretion. The increased secretion of IL-
10 from MEF2D KO macrophages could lead to a reduction in pro-inflammatory cy-
tokines compared to wildtype macrophages. To test this, wildtype and MEF2D-deficient
macrophages were stimulated with LPS and the transcription and secretion of TNFa, IL-6
and IL-12(p40) were measured. LPS induced a peak of TNFa mRNA at 1 hour and this
returned to baseline by 12 hours (figure 4.11). Whilst the initial peak was comparable,
knockout of MEF2D resulted in decreased TNFa mRNA at late time points. This was
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Figure 4.10: Deletion of MEF2D causes increased IL-10 primary transcript levels
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction
was calculated for IL-10 primary transcript mRNA. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
reflected in the level of TNFa secretion which shows from 4 hours onwards that TNFa
levels are decreased in MEF2D-deficient macrophages. IL-6 mRNA levels peaked later
at around 4 hours in response to LPS and returned to baseline by 12 hours. Deficiency in
MEF2D led to a much lower peak of IL-6 at 4 hours and this remained reduced up to 12
hours. IL-6 secretion was lower from MEF2D KO BMDMs compared to WT BMDMs at
4 and 8 hours confirming the reduction seen in mRNA levels. IL-12(p70) is a heterodimer
of IL-12(p35) and IL-12(p40). IL-12(p35) is encoded by IL-12a and IL-12(p40) is en-
coded by IL-12b. LPS induced IL-12b mRNA levels in wildtype macrophages, which
peaks around 4 hours. In MEF2D knockout macrophages IL-12 (p40) mRNA levels were
decreased from 4 hours onwards. This reduced mRNA level correlated with a lower se-
cretion of IL-12 (p40) from 4 hours onwards in MEF2D-deficient BMDMs compared to
WT BMDMs (figure 4.11).
To determine if the changes in pro-inflammatory cytokine levels were solely due to the
increase in IL-10 secretion, WT and MEF2D KO BMDMs were stimulated with LPS
in the presence or absence of an IL-10 neutralising antibody. This antibody will block
IL-10 signaling by preventing IL-10 from binding to its receptor and should therefore
cause an increase in pro-inflammatory cytokine levels as the IL-10 mediated negative
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Figure 4.11: Reduced pro-inflammatory cytokines levels in MEF2D-deficient macrophages
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction was
calculated for TNFa, IL-6 and IL-12 (p40) mRNA. Culture supernatant was collected and TNFa, IL-6 and
IL-12 (p40) secretion measured by Bioplex (Bio-Rad) according to the manufacturers protocol. n=4, error
bars represent the standard deviation from independent cultures from four mice per genotype.
feedback is blocked. LPS stimulation of WT macrophages induced IL-6, TNFa, IL-
12(p40) and IL-12(p70) at 8 hours and these pro-inflammatory cytokines were decreased
in MEF2D-deficient macrophages in agreement with the data in figure 4.11 (figure 4.12).
In the presence of the neutralising antibody, LPS induced much higher levels of these
pro-inflammatory cytokines compared to LPS in the absence of the neutralising antibody.
The IL-10 neutralising antibody also increased the secretion of TNFa, IL-6 and IL-12 in
MEF2D knockout cells. In the case of TNFa and IL-6, secretion was comparable be-
tween wildtype and MEF2D-deficient macrophages in the presence of the IL-10 neutral-
ising antibody. There was a slight reduction in IL-12(p40) levels in MEF2D KO BMDMs
compared to WT BMDMs when pre-treated with the IL-10 neutralising antibody. Lev-
els of IL-12(p70) were lower in MEF2D knockout macrophages compared to wildtype
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macrophages in the presence of the IL-10 neutralising antibody (figure 4.12).
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Figure 4.12: IL-10 nAb rescues pro-inflammatory cytokine levels in MEF2D-deficient macrophages
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS for 8h in the presence or absence of 2.5 µg/ml IL-10 neutralising antibody. Culture supernatant was
collected and TNFa, IL-6 and IL-12 (p40) and IL-12 (p70) secretion measured by Bioplex (Bio-Rad) ac-
cording to the manufacturers protocol. n=4, error bars represent the standard deviation from independent
cultures from four mice per genotype.
The secretion of IL-12(p70) is reduced in MEF2D-deficient macrophages and therefore
the mRNA levels of IL-12a and IL-12b were analysed following LPS stimulation of wild-
type and MEF2D-deficient macrophages. LPS induced IL-12a transcription at 6 hours
and IL-12a was strongly repressed in MEF2D-deficient macrophages (figure 4.13). IL-
12b was induced by LPS stimulation of wildtype BMDMs and IL12b mRNA levels were
decreased in MEF2D knockout BMDMs in agreement with data presented in figure 4.11.
117
0"
20"
40"
60"
80"
100"
120"
140"
160"
Uns+mulated" LPS"
IL
71
2b
"m
RN
A"
(x
10
3"
fo
ld
"in
du
c+
on
)"
0"
2"
4"
6"
8"
10"
12"
Uns+mulated" LPS"
IL
71
2a
"m
RN
A"
(x
10
3"
fo
ld
"in
du
c+
on
)"
WT"
KO"
** 
*** 
Figure 4.13: IL-12a and IL-12b mRNA levels are reduced in MEF2D KO macrophages
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction was
calculated for IL-12a and IL-12b mRNA. n=4, error bars represent the standard deviation from independent
cultures from four mice per genotype.
4.6 Elevated IL-10 production in macrophages decreases COX2 mRNA
IL-10 has numerous effects on macrophages including reducing pro-inflammatory cy-
tokine production. Recently, the effect of IL-10 on COX2 mRNA has been elucidated. In
this study, it was shown that IL-10 led to a decrease in COX2 mRNA due to decreased
p38 activation which relinquished MK2-mediated inhibition of TTP. TTP was then able
to bind to and destabilise the COX2 mRNA (MacKenzie et al., 2013b). To examine if el-
evated IL-10 production in MEF2D-deficient macrophages affected COX2 mRNA levels,
wildtype and MEF2D knockout macrophages were stimulated with LPS. LPS induced
transcription of COX2, which peaked at 4 hours (figure 4.14a). COX2 mRNA levels
were decreased in MEF2D KO macrophages at 4, 8 and 12 hours compared to wildtype
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macrophages.
As MEF2Dmacrophages have elevated IL-10 production in response to LPS, the decrease
seen in COX2 is probably caused by IL-10 affecting TTP activity. To demonstrate that
changes in COX2 levels were dependent on IL-10 signaling, wildtype and MEF2D KO
macrophages were stimulated with LPS for 8 hours in the presence or absence of the
neutralising antibody. LPS induced COX2 mRNA expression in wildtype macrophages
and was reduced in MEF2D KO macrophages as in figure 4.14a. Treatment with the IL-
10 neutralising antibody increased COX2 expression in wild type cells in response to LPS
and levels of COX2 mRNA were similar in macrophages lacking MEF2D (figure 4.14b).
This suggests that decreases in COX2 mRNA in MEF2D KO macrophages are dependent
on IL-10 signaling.
4.7 Knockout of MEF2D enhances IL-10 transcription downstream of TLR ago-
nists
IL-10 is induced by activation of multiple pathways including other TLRs such as TLR1/2,
TLR3, TLR7/8 and TLR9. To determine if MEF2D’s effects on IL-10 were restricted to
TLR4, wildtype and MEF2D-deficient macrophages were stimulated with the TLR3 ag-
onist, poly(I:C), TLR1/2 agonist, Pam3CSK4, the TLR9 agonist, CpG and the TLR7/8
agonist, R848. Both TLR7/8 and TLR9 signal via the MyD88 adaptor and are found at
the endosome. TLR3 is also present at the endosome and signals via TRIF, whilst TLR1/2
recruits MyD88 and signals from the plasma membrane. Induction of IL-10 varied be-
tween the stimuli; poly(I:C) only weakly induces IL-10 mRNA and secretion at 8 hours.
Pam3CSK4, CpG and R848 all induce greater amounts of IL-10. At this time point,
mRNA and protein levels of IL-10 appear enhanced in the knockout macrophages com-
pared to wildtype in response to CpG and R848, however the affect of MEF2D deficiency
may affect IL-10 induction at earlier time points (figure 4.15).
IL-10 can repress pro-inflammatory cytokine production through IL-10R-JAK-STAT sig-
naling. The levels of IL-6, IL-12(p40) and TNFa were also measured to examine if
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Figure 4.14: COX2 mRNA is decreased in MEF2D KO macrophages in an IL-10 dependent manner
Bone marrow-derived macrophages fromWT and MEF2D KO mice were stimulated with A) 100 ng/mL of
LPS and B) 100 ng/mL of LPS for 8h in the presence or absence of 2.5 µg/ml IL-10 neutralising antibody.
Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy kit. Total
RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-green based
detection methods. Levels of 18S were used as a normalization control, and fold induction was calculated
for COX2 mRNA. n=4, error bars represent the standard deviation from independent cultures from four
mice per genotype.
MEF2D deficiency had affected production of pro-inflammatory cytokine in response
to these TLR agonists. IL-6 mRNA levels were comparable in response to Pam3CSK4
and R848 and may be increased in response to CpG. poly(I:C) did not induce detectable
amounts of IL-6 at the mRNA or protein level. Interestingly, IL-6 protein levels appear
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decreased in the MEF2D-deficient macrophages compared to wildtype macrophages in
response to CpG, Pam3CSK4 and R848.
IL-12(p40) mRNA was induced by CpG and R848 and to a lesser extent by Pam3CSK4.
mRNA levels of IL-12(p40) were comparable between wildtype andMEF2DKOBMDMs.
Protein levels of IL-12(p40) were slightly reduced in MEF2D-deficient macrophages
compared to wildtype in response to CpG, Pam3CSK4 and R848. Poly(I:C) weakly in-
duced IL-12(p40) mRNA and protein.
Induction of TNFa mRNA was evident in response to poly(I:C), CpG, Pam3CSK4 and
R848 in wildtype macrophages. mRNA levels of TNFawere reduced in CpG-, Pam3CSK4-
and R848-stimulated macrophages lacking MEF2D compared to wildtype macrophages.
The changes seen in TNFa mRNA levels were reflected in protein levels with decreased
TNFa secretion evident in MEF2D KO BMDMs in response to CpG, Pam3CSK4 and
R848. Poly(I:C)-induced TNFa protein was not detectable 8 hours after stimulation in
wildtype or MEF2D knockout cells (figure 4.15).
Both Pam3CSK4 and CpG stimulation led to reasonable induction of IL-10 and pro-
inflammatory cytokines, which was altered by deletion of MEF2D in macrophages. The
effects of MEF2D deficiency was examined in response to these two stimuli over a 24
hour timecourse. Stimulation of macrophages with Pam3CSK4 results in a biphasic in-
duction of IL-10 mRNA. Initial induction of IL-10 peaks around 1-4 hours with a second
higher peak evident at 16 hours (figure 4.16). MEF2D KO BMDMs demonstrated sim-
ilar kinetics of IL-10 mRNA induction although with a higher initial induction up to 8
hours. These increases in IL-10 mRNA levels were translated to higher secretion of IL-
10 at 8, 16 and 24 hours of Pam3CSK4 treatment. Treatment of macrophages with the
TLR9 agonist, CpG, resulted in a similar induction of IL-10 mRNA with an initial peak
at 1 hours and a second greater peak at 16 hours (figure 4.16). Notably, CpG stimula-
tion of MEF2D-deficient macrophages resulted in increased IL-10 mRNA levels through-
out the timecourse with increased mRNA levels. In line with the secretion data from
Pam3CSK4 stimulation, increased IL-10 mRNA levels seen in CpG-stimulated MEF2D
knockout macrophages translated to higher secretion of IL-10 at 8, 16 and 24 hours.
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Figure 4.15: MEF2D regulates IL-10 downstream of multiple TLR agonists
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 10 µg/ml
poly(I:C), 1 µg/ml Pam3CSK4, 2 µM CpG or 1 µg/ml R848. A) Cells were lysed with RLT buffer (Qi-
agen) and total RNA purified using the Qiagen microRNeasy kit. Total RNA was reverse transcribed using
iScript (Bio-Rad) and qPCR was carried out using SYBR-green based detection methods. Levels of 18S
were used as a normalization control, and fold induction was calculated for IL-10, IL-6, IL-12(p40) and
TNFa mRNA. B) Culture supernatant was collected and IL-10, IL-6, IL-12(p40) and TNFa secretion mea-
sured by Bioplex (Bio-Rad) according to the manufacturers protocol. n=4, error bars represent the standard
deviation from independent cultures from four mice per genotype.
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Figure 4.16: TLR1/2 and TLR9 agonists induce elevated IL-10 mRNA levels in MEF2D knockout
macrophages
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with (A+B) 1 µg/ml
Pam3CSK4 or (C+D) 2 µM CpG. A+C) Cells were lysed with RLT buffer (Qiagen) and total RNA purified
using the Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR
was carried out using SYBR-green based detection methods. Levels of 18S were used as a normalization
control, and fold induction was calculated for IL-10 mRNA. B+D) Culture supernatant was collected and
IL-10 secretion measured by Bioplex (Bio-Rad) according to the manufacturers protocol. n=4, error bars
represent the standard deviation from independent cultures from four mice per genotype.
4.8 Dectin-1-induced IL-10 mRNA levels are not affected by MEF2D deficiency
in macrophages
Other PRRs also induce the production of IL-10 in response to ligand binding. The C-type
lectin receptor, Dectin-1 binds b-(1-3)-glucans and activates MAPK and NFkB signaling
via the spleen tyrosine kinase (Syk). Zymosan is a crude preparation of Saccharomyces
cerevisiae cell wall and will activate Dectin-1 and TLR2. Curdlan is a polymer of b-
(1-3)-glucans, which specifically activates Dectin-1 without affecting TLR signaling. To
ascertain if the effect of MEF2D on IL-10 transcription and secretion were restricted to
TLR signaling, WT and MEF2D KO BMDMs were stimulated with Zymosan or Curdlan
for 8 or 16 hours and IL-10 secretion measured. Zymosan strongly induced a large amount
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of IL-10 at 8 hours in wildtype cells and MEF2D-deficient cells secreted similar amounts
of IL-10 at both 8 and 16 hours (figure 4.17). Curdlan specifically activates Dectin-1 and
stimulated lower secretion of IL-10 compared to Zymosan. However, similarly to Zy-
mosan, treatment of MEF2D-deficient BMDMs with Curdlan led to comparable secretion
of IL-10 at 8 and 16 hours compared to wildtype macrophages. This result suggests that
MEF2D regulation of IL-10 transcription is limited to TLR signaling in macrophages.
In line wth this, levels of pro-inflammatory cytokines were comparable between WT
and MEF2D KO BMDMs at 8 and 16 hours following LPS and Zymosan stimulation,
suggesting the IL-10-mediated negative feedback loop was unaffected in Zymosan- or
Curdlan-stimulated macrophages.
4.9 MEF2D deficiency alters macrophage phenotype
MEF2D deficiency enhances IL-10 secretion and results in decreased pro-inflammatory
cytokine secretion. The ratio of IL-10:IL-12 is often used to determine the phenotype of
macrophages and a high IL-10:IL-12 ratio is indicative of a regulatory macrophage. Reg-
ulatory macrophages also express other markers including Arg1, SphK1 and LIGHT. To
determine if MEF2D deficiency also affected regulatory macrophage markers, wildtype
and MEF2D knockout macrophages were stimulated with LPS and marker expression
measured by qPCR. LPS alone only weakly induced expression of Arg1, which encodes
arginase-1, at 16 hours (figure 4.18). Deletion of MEF2D led to higher levels of Arg1
expression at 8 and 16 hours in response to LPS. Expression of SphK1 is also induced
by LPS and peak mRNA levels are evident after 4 hours of stimulation. MEF2D KO
macrophages expressed higher levels of SphK1 mRNA at 8 hours compared to wildtype
macrophages. LIGHT is weakly induced by LPS alone, however in MEF2D-deficient
cells, LIGHT is more strongly expressed at 1 and 2 hours following LPS stimulation (fig-
ure 4.18).
4.10 MEF2D does not regulate classical MEF2 target genes in macrophages
Several studies have identifiedMEF2 consensus sequences in the promoter of many genes,
including Nur77 and c-Jun. In neurons, MEF2D is important for expression of the tran-
124
0"
200"
400"
600"
800"
1000"
1200"
0" 8" 16"
IL
*6
"(p
g/
m
l)"
Time"of"Zymosan"s<mula<on"(h)"
0"
20"
40"
60"
80"
100"
120"
0" 8" 16"
IL
*6
"(p
g/
m
l)"
Time"of""Curdlan"s<mula<on"(h)"
0"
10"
20"
30"
40"
50"
60"
70"
80"
90"
100"
0" 8" 16"
IL
*1
2(
p4
0)
"(p
g/
m
l)"
Time"of"Zymosan"s<mula<on"(h)"
0"
5"
10"
15"
20"
25"
30"
35"
0" 8" 16"
IL
*1
2(
p4
0)
"(p
g/
m
l)"
Time"of""Curdlan"s<mula<on"(h)"
0"
5"
10"
15"
20"
25"
30"
35"
40"
45"
0" 8" 16"
TN
Fα
"(n
g/
m
l)"
Time"of"Zymosan"s<mula<on"(h)"
0"
1"
2"
3"
4"
5"
6"
0" 8" 16"
TN
Fα
"(n
g/
m
l)"
Time"of""Curdlan"s<mula<on"(h)"
0"
200"
400"
600"
800"
1000"
1200"
1400"
1600"
0" 8" 16"
IL
*1
0"
(p
g/
m
l)"
Time"of"Zymosan"s<mula<on"(h)"
WT"
KO"
0"
20"
40"
60"
80"
100"
120"
140"
160"
180"
200"
0" 8" 16"
IL
*1
0"
(p
g/
m
l)"
Time"of"Curdlan"s<mula<on"(h)"
A) B) 
* 
* 
*** 
** 
* 
ns 
ns 
ns 
ns 
ns 
ns 
ns ns 
ns 
ns 
ns 
Figure 4.17: Dectin-1-mediated IL-10 secretion is not MEF2D-regulated
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with A) 200 µg/mL
Zymosan or B) 10 µg/mL Curdlan. Culture supernatant was collected and IL-10, IL-6, IL-12(p40) and
TNFa secretion measured by Bioplex (Bio-Rad) according to the manufacturers protocol. n=4, error bars
represent the standard deviation from independent cultures from four mice per genotype.
scription factor, Nur77 (Mount et al., 2013). In the macrophage differentiated HL60 cell
line, MEF2D is required for expression of c-Jun as well as for serum-induced c-Jun ex-
pression in HeLa and NIH3T3 cells (Aude-Garcia et al., 2010; Han and Prywes, 1995).
To investigate whether MEF2D might be important for the expression of these immediate
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Figure 4.18: Regulatory macrophage marker expression is enhanced in MEF2D KO macrophages
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction
was calculated for Arg1, SphK1 and LIGHT mRNA. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
early genes (IEGs) in LPS-stimulated macrophages, BMDMs from wildtype and MEF2D
KO mice were cultured and stimulated with LPS for a short timecourse over 120 min-
utes. LPS induced expression of c-Jun which peaked at 30 minutes and decreased to basal
levels by 90 minutes (figure 4.19). Deletion of MEF2D from macrophages did not al-
ter the induction of c-Jun by LPS. Nur77 expression was induced by LPS at 30 minutes
and persisted until 60 minutes before rapidly decreasing. MEF2D-deficient macrophages
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showed similar patterns of induction of Nur77 in response to LPS. These data suggest that
previously identified MEF2D target genes from cell lines are not regulated by MEF2D in
primary macrophages in response to TLR4 stimulation.
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Figure 4.19: c-Jun and Nur77 are not regulated by MEF2D in primary macrophages
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction was
calculated for c-Jun and Nur77 mRNA. n=4, error bars represent the standard deviation from independent
cultures from four mice per genotype.
4.11 MEF2D regulates transcription of A20
Levels of the protein A20 were increased in MEF2D knockout macrophages in response
to LPS compared to wildtype cells as shown in figure 4.7. To test if MEF2D was reg-
ulating the transcription of A20/TNFAIP3, wildtype and MEF2D-deficient macrophages
were stimulated with LPS and A20 mRNA levels measured. LPS induced A20 mRNA
transcription after 1 hour of stimulation and mRNA levels were detectable up to 16 hours
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post-stimulation. Macrophages lacking MEF2D had slightly higher levels of A20 mRNA
in response to LPS 1 hour after stimulation. Levels of A20 mRNA were comparable at
later time points (figure 4.20).
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Figure 4.20: A20 mRNA is elevated in MEF2D-deficient macrophages stimulated with LPS
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 100 ng/mL of
LPS. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the Qiagen microRNeasy
kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was carried out using SYBR-
green based detection methods. Levels of 18S were used as a normalization control, and fold induction was
calculated for A20 mRNA. n=4, error bars represent the standard deviation from independent cultures from
four mice per genotype.
MEF2D negatively regulated expression of IL-10 mRNA in response to multiple TLR
agonists (figure 4.9, figure 4.16). Therefore, MEF2D may regulate A20 mRNA levels
downstream of other TLRs. In order to examine if A20 expression was regulated by
MEF2D downstream of other TLR agonists, macrophages were isolated from wildtype
and MEF2D knockout mice and stimulated with Pam3CSK4 (TLR1/2 agonist) and CpG
(TLR9 agonist). Pam3CSK4 induced A20 expression in wildtype cells from 1 hour and
A20 mRNA levels were still elevated 16 hours post-stimulation (figure 4.21). MEF2D-
deficient macrophages had increased A20 mRNA levels throughout the timecourse fol-
lowing Pam3CSK4 stimulation compared to wildtype macrophages. CpG also induced
A20 mRNA expression in wildtype cells although to a lower extent than Pam3CSK4 or
LPS stimulation. Notably, A20 mRNA levels in MEF2D KO cells were greatly enhanced
after 1 hour and 8 hours of CpG stimulation compared to wildtype cells (figure 4.21).
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Figure 4.21: Pam3CSK4- and CpG-induced transcription of A20 is enhanced in MEF2D KO
macrophages
Bone marrow-derived macrophages from WT and MEF2D KO mice were stimulated with 1 mg/ml
Pam3CSK4 or 2 mM CpG. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using the
Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was car-
ried out using SYBR-green based detection methods. Levels of 18S were used as a normalization control,
and fold induction was calculated for A20 mRNA. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
4.12 Discussion
The MEF2 family of transcription factors are well known for their role in muscle de-
velopment but also have emerging functions in neuronal cell survival and immune cells.
The importance of MEF2D in macrophage function is poorly understood. TLR signaling
activates a multitude of transcription factors responsible for controlling transcription of
genes important in the inflammatory response. These transcription factors control expres-
sion of a diverse range of proteins including cytokines, chemokines, transcription factors
and other signaling molecules. The involvement of CREB, Ap1, Sp1/3, NFkB and IRFs
is well known within macrophages (Medzhitov and Horng, 2009; Sato et al., 1998b,a;
Ping et al., 2000; Elcombe et al., 2013; Saraiva et al., 2005). However, it is likely that
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other transcription factors play as yet unappreciated roles in regulating the inflammatory
response.
In this chapter, the importance of MEF2D in macrophages is demonstrated. In response to
LPS, MEF2D is phosphorylated on Ser121 as identified by SILAC and validated through
immunoprecipitations using a phospho-specific antibody. MEF2D knockout macrophages
stimulated with LPS had elevated STAT3 phosphorylation and altered activation of ERK1/2,
JNK and p105. Deletion of MEF2D from macrophages led to increased transcription and
secretion of IL-10, which resulted in decreased pro-inflammatory cytokine production.
MEF2D also regulated IL-10 transcription in response to other TLR agonists. In addi-
tion to regulating IL-10, deletion of MEF2D resulted in increased transcription of A20
in response to LPS, Pam3CSK4 and CpG. The increase in LPS-induced A20 mRNA ex-
pression was translated to increased protein levels. Together, these results suggest that
MEF2D is important in regulating the inflammatory response.
4.12.1 Phosphorylation of MEF2D
Five phosphopeptides were identified from MEF2D including the S121 peptide. This
phosphorylation site has been identified in other studies (Huttlin et al., 2010; Du et al.,
2008). Phospho-antibodies were raised against this peptide and the phosphorylation of
S121 was confirmed through immunoprecipitations and western blotting in Raw264.7
cells. The relevance of S121 phosphorylation in response to LPS in macrophages is still
unclear. It is unknown whether phosphorylation of S121 affects the localisation, DNA
binding activity, transcription activation activity or other post-translational modifications
(PTMs). Results show that MEF2D protein levels remain unchanged during a short stimu-
lation of LPS suggesting that phosphorylation of MEF2D does not affect protein stability
or induce its degradation. Numerous studies have identified PTMs of MEF2D including
phosphorylation and sumoylation (Du et al., 2008; Grégoire et al., 2006). The influence
that S121 phosphorylation has upon these reported modifications is unknown. It would
be beneficial to further investigate the relevance of S121 phosphorylation with regard to
other PTMs.
130
It would also be interesting to examine the role of this phosphorylation on MEF2D’s tran-
scription activity. ChIP assays could demonstrate the recruitment of MEF2D to specific
promoter sites and through mutating the S121 site to an alanine (S121A), an understand-
ing of its role in MEF2D DNA binding could be gained. Phosphorylation of MEF2D may
also regulate the ability of MEF2D to recruit the transcription machinery and/or other co-
factors and therefore may repress or promote transcription. WT and S121AMEF2D could
be transfected into cells and transcription of MEF2D target genes measured to investigate
the importance of S121 phosphorylation on MEF2D-mediated transcription. MEF2D
is known to interact with class II HDACs, which catalyse the deacetylation of histones
and therefore prevent transcription. Identification of MEF2D-HDAC interactions within
macrophages would be interesting, as would the role that S121 phosphorylation might
play in regulating this interaction.
LPS activates signaling through TLR4 by recruiting the MyD88 and TRIF adaptors which
activates a range of signaling molecules including MAPKs and IKKs. The signaling path-
way responsible for LPS-induced phosphorylation of S121 on MEF2D could be identified
using small molecule inhibitors and knockout mice. By identifying the pathway respon-
sible, another approach to understanding the relevance of the phosphorylation of MEF2D
at Ser121 would be available. It would also be interesting to determine which other TLR
agonists and stimuli may induce MEF2D phosphorylation at Ser121. The LPS-induced
phosphorylation of MEF2D at Ser121 is transient, being detectable 15 mins after LPS
stimulation, but no longer evident at 60 mins. As MEF2D protein levels remain constant
throughout this time period, it suggests the action of phosphatase. It would be of further
interest to identify the phosphatase that catalyses the dephosphorylation of MEF2D at
Ser121.
4.12.2 Deletion of MEF2D alters TLR4 signaling
Deletion of MEF2D affects the signaling downstream of TLR4. Phosphorylation of
ERK1/2, JNK and p105 was reduced in MEF2D KO macrophages compared to wild-
type macrophages after the initial activation at 30 minutes. In particular, the second wave
of JNK phosphorylation was not evident in MEF2D KO cells, perhaps suggesting a role
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for dual-specificity phosphatases (DUSPs). Equally, the reduction of ERK1/2 phospho-
rylation may be DUSP-dependent. DUSPs dephosphorylate the threonine and tyrosine
residues within the activation loop of MAPKs and are important in controlling MAPK
signaling (Lang et al., 2006; Caunt and Keyse, 2013). DUSP5 mRNA was shown to be
increased in MEF2D KO macrophages compared to wildtype macrophages. However,
DUSP5 is a very selective phosphatase for ERK2 and shows no activity towards JNK
or p38 (Mandl et al., 2005). DUSP1 mRNA was marginally elevated in MEF2D KO
BMDMs at 2 and 4 hours following LPS stimulation. DUSP1 targets p38 and JNK in
vivo and may explain some of the alterations to MAPK phosphorylation seen in MEF2D
KO macrophages (Chen et al., 2002). The impact of MEF2D deletion on DUSPs mRNA
and protein levels needs to be examined in greater detail.
Protein levels of A20 were increased in LPS-stimulated macrophages lacking MEF2D
compared to wildtype LPS-stimulated macrophages. A20 is zinc-finger protein and in-
hibits NFkB signaling (Heyninck and Beyaert, 1999). A20 has been implicated in regu-
lating immune responses and is now thought to regulate TLR signaling via interactions
with poly-ubiquitin chains (Kool et al., 2011; Maelfait et al., 2012; Matmati et al., 2011;
Verhelst et al., 2012). In MEF2D knockout macrophages, LPS-induced transcription of
A20 was increased compared to WT macrophages. MEF2D also repressed A20 transcrip-
tion downstream of TLR1/2 and TLR9 signaling. Interestingly, one study showed that
silencing of A20 with siRNA caused decreased IL-10 production in response to infec-
tion with Leishmania donovani (Srivastav et al., 2012). Deletion of A20 in mice leads
to the development of polyarthritis and high levels of pro-inflammatory cytokines in the
serum (Matmati et al., 2011). The impact that increased A20 has on macrophage func-
tion needs to be further examined. Changes in A20 protein level were not evident until
4 hours post-stimulation and therefore long timecourses would be required to understand
the importance of this increase.
4.12.3 TLR-induced IL-10 transcription is enhanced inMEF2D-deficient macrophages
LPS induces the anti-inflammatory cytokine, IL-10, which reduces pro-inflammatory
cytokine production through IL-10R-JAK-STAT3 signaling. The data presented above
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demonstrated that MEF2D deficient macrophages had enhanced transcription and secre-
tion of IL-10 and this led to enhanced STAT3 phosphorylation following LPS stimula-
tion. Furthermore, MEF2D knockout cells had decreased pro-inflammatory cytokine lev-
els compared to wildtype cells. Pre-treatment of wildtype and MEF2D-deficient BMDMs
with the IL-10 neutralising antibody resulted in similar levels of pro-inflammatory cy-
tokines in response to LPS, suggesting the reduction in pro-inflammatory cytokine levels
seen in MEF2D-deficient macrophages was due to the increase in IL-10-mediated signal-
ing.
IL-12 is a heterodimer formed of p35 and p40 subunits. Whilst levels of the p40 subunit
were similar in both wildtype and MEF2D-deficient macrophages in the presence of the
neutralising antibody. The p70 dimer was reduced in MEF2D knockout cells compared to
wildtype cells in the presence of the IL-10 neutralising antibody (figure 4.12). IL-12a en-
codes the p35 subunit of IL-12 and was reduced in LPS-stimulated macrophages lacking
MEF2D compared to control macrophages (figure 4.13). This suggests that IL-12a may
be regulated by MEF2D independently of the increased IL-10-STAT3 signaling. It would
be interesting to investigate if MEF2D directly affected IL-12a transcription or if MEF2D
regulates an intermediate that influences IL-12a transcription.
In addition to regulating IL-10 transcription downstream of TLR4, the data above demon-
strates that MEF2D also regulates IL-10 transcription in response to Pam3CSK4 (a TLR1/2
agonist), CpG (a TLR9 agonist) and R848 (a TLR7/8 agonist). TLR1/2, 4 and 9 all sig-
nal through the MyD88 adaptor and MEF2D may possibly regulate MyD88 signaling-
induced IL-10 transcription. It would be interesting to examine the role of MEF2D
downstream of TLR3 which signals via TRIF in more detail. Dectin-1 activation also
induces expression of IL-10 from macrophages. Dectin-1 signals via Syk and the data
presented suggests that MEF2D is not important in IL-10 transcription downstream of
Dectin-1. MEF2D therefore may only regulate IL-10 transcription downstream ofMyD88
in macrophages.
Interestingly, the murine IL-10 promoter contains a MEF2 binding site, as does the TN-
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FAIP3 (A20) promoter. The role of MEF2D in regulating transcription of these genes
may be through directly binding to the promoter and regulating transcription. MEF2D
may bind to the promoter and recruit class II HDACs to repress transcription or alterna-
tively recruit the cofactor, p300, to promote transcription (Nebbioso et al., 2009; Ma et al.,
2005). Through ChIP assays, the binding of MEF2D to the promoter of target genes could
be examined in unstimulated and stimulated cells.
4.12.4 Role for MEF2D in vivo
MEF2D deletion modulates the immune response of macrophage by increasing IL-10 lev-
els which cause decreased secretion of pro-inflammatory cytokines in response to LPS.
Therefore MEF2D deficiency in vivo could protect mice from endotoxic shock as well as
other inflammatory models such as contact hypersensitivity models which have previously
been shown to be affected by macrophage and dendritic cell responses (Girard-Madoux
et al., 2012; Siewe et al., 2006). However, predicting the effect of MEF2D deficiency on
in vivo responses is complicated by potential roles within other immune cell types, par-
ticularly B cells or T cells. It would be interesting to investigate the response of MEF2D
deficient mice to i.p injection of LPS, as well as to other inflammatory models such as
contact hypersensitivity or irritant responses.
4.12.5 Conclusion
MEF2D is an important transcription factor during development, particularly in muscle
and neural tissues. It also has roles in neuronal survival and immune cells. The results
presented in this chapter demonstrate that MEF2D is phosphorylated on Ser121 in re-
sponse to LPS. Deletion of MEF2D from macrophages alters the activation of key signal-
ing molecules, such as ERK1/2, JNK and p105, in response to LPS stimulation. Notably,
MEF2D controls the transcription of IL-10 and MEF2D KO macrophages produce el-
evated levels of IL-10 leading to a reduction in pro-inflammatory cytokine production.
TLR1/2- and TLR9-induced IL-10 production is also repressed by MEF2D. Deletion of
MEF2Dmay also promote a regulatory macrophage phenotype characterised by enhanced
expression of SphK1, Arg1 and LIGHT. In addition to changes in IL-10 transcription,
MEF2D deficiency in macrophages results in increased mRNA and protein levels of A20,
134
a negative regulator of NFkB.
Further work is required to understand the importance of MEF2D in macrophages. Firstly,
the relevance of MEF2D phosphorylation at Ser121 needs to be investigated. Ser121 may
alter the cellular localisation of MEF2D or regulate its ability to drive gene transcription
through a number of mechanisms. Secondly, the context of MEF2D repression of IL-10
needs to be further explored to determine if these effects are specific to MyD88 signaling
downstream of TLRs. It would be interesting to determine if MEF2D may regulate IL-10
transcription in other immune cell types, such as Tr1 cells and B10 cells, which have im-
portant roles in autoimmune diseases. The mechanism of MEF2D-mediated repression of
IL-10 transcription also needs to be elucidated. MEF2D is capable of binding consensus
sequences within the promoters of target genes and, therefore, may regulate IL-10 and
A20 directly. Lastly, the role of MEF2D in macrophages independently of IL-10 should
be studied. By creating a double knockout of MEF2D and IL-10, the function of MEF2D
regarding macrophage phenotype, IL-12a expression and A20 expression could be further
explored.
MEF2D is a novel regulator of IL-10 transcription in macrophages and also regulates
expression of other genes involved in the inflammatory response including A20 and IL-
12a. The full scope of MEF2D functions within macrophages and immune cells needs to
be examined further.
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Chapter 5
Results- Sphingosine kinase 1 and its
role in cytokine production
5.1 Sphingolipids
Sphingosine kinase is involved in sphingolipid metabolism and is upregulated in regu-
latory macrophages indicating a possible functional role (Edwards et al., 2006). Sphin-
golipids are a group of lipid mediators defined by the presence of a serine headgroup
with fatty acid tails (Maceyka et al., 2009; Pitson, 2011). Sphingolipid signaling has been
implicated in regulating numerous processes including cell growth, survival, differenti-
ation and migration. Among the sphingolipids, particular interest has been focused on
sphingosine, sphingosine 1-phosphate (S1P), ceramide and ceramide 1-phosphate (C1P).
The amount of each of these bioactive lipids is altered in response to extracellular stimuli
and can regulate a diverse range of cellular processes. Sphingolipid metabolism involves
multiple bidirectional pathways that can control flux through the biosynthetic or degrada-
tive pathways in both directions. Ceramide and sphingosine have pro-apoptotic and anti-
proliferative effects, however phosphorylation to C1P and S1P, respectively, leads to en-
hanced cell growth and survival (Maceyka et al., 2009; Pitson, 2011). S1P has been
implicated in several disease states including atherosclerosis, cancer and inflammatory
diseases.
136
5.1.1 Sphingolipid metabolism
Ceramide is the backbone of all sphingolipids and is both synthesised de novo and gen-
erated from the turnover of sphingolipids (Strub et al., 2010). At the endoplasmic retic-
ulum, serine and palmitoyl-CoA are condensed into 3-ketosphingaine which is quickly
reduced to dihydrosphingosine (figure 5.1). Dihydrosphingosine is then N-acylated and
a trans double bond introduced to form ceramide. Ceramide is trafficked to the Golgi
body where head groups are added. Removal of these head groups and deacylation pro-
duces sphingosine. Both sphingosine and dihydrosphingosine are only produced through
catabolism of other sphingolipids. Sphingosine can be either utilised to generate complex
sphingolipids or phosphorylated to produce S1P (Strub et al., 2010). S1P can be de-
graded by dephosphorylation by phosphatases including lysosomal phosphatases and two
S1P-specific phosphatases, SPP1 and 2 (Maceyka et al., 2007). Alternatively, S1P can be
cleaved by S1P lyase to produce ethanolamine phosphate and hexadecenal (Bandhuvula
and Saba, 2007).
5.1.2 Sphingosine 1-phosphate
S1P is a well-known pro-survival signal, but it is also important in other processes in-
cluding cell trafficking, differentiation, angiogenesis and inflammation (Maceyka et al.,
2002; Cyster, 2005; Payne et al., 2004). S1P is present at high nanomolar concentration in
the circulation and mediates its effects via five plasma membrane-located GPCRs (Rosen
and Goetzl, 2005; Spiegel and Milstien, 2000a; Hisano et al., 2012). The five receptors
are termed S1P1-5 and display differential tissue expression and are linked to various G
proteins. S1P has also been shown to possess intracellular signaling activities including
modulating HDAC activity and the ubiquitin ligase activity of TRAF2 (Hait et al., 2009;
Alvarez et al., 2010). The phosphorylation of sphingosine to S1P is catalysed by two
enzymes- SphK1 and SphK2. S1P can then be released into the extracellular fluid by
S1P transporters such as SPNS2 (Mitra et al., 2006; Nishi et al., 2013; Nagahashi et al.,
2012a).
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Figure 5.1: Synthesis and degradation of sphingosine 1-phosphate
Serine and palmitoyl CoA are condensed to 3-ketosphinganine, which is reduced to dihydrosphingosine.
Dihydrosphingosine is then converted to dihydroceramide and then to ceramide. Ceramide can then either
be phosphorylated to ceramide 1-phosphate, converted to sphingomyelin or converted to sphingosine. Sph-
ingosine can then be phosphorylated by sphingosine kinases to form sphingosine 1-phoshate. Sphingosine
1-phosphate is a substrate for sphigonsine 1-phosphate lyase and for phosphatases including sphingosine
1-phosphate phosphatase.
5.1.3 Sphingosine kinase 1 and 2
Sphingosine kinase (SphK) 1 and 2 are lipid kinases which phosphorylate sphingosine
leading to the production of S1P (Le Stunff et al., 2004). They are encoded by two genes,
SPHK1 and SPHK2, although there are a number of splice variants (Taha et al., 2006;
Pitson, 2011). SphK1 and 2 share a degree of sequence homology with five conserved
domains, although SphK2 is a larger protein (figure 5.2). Both possess five conserved
domains responsible for substrate binding and kinase activity (Liu et al., 2002). SphK2
possesses an additional N-terminal domain with a proline-rich polypeptide insert that is
not present in SphK1. SphK1 and 2 have different expression patterns during development
as well as different tissue distribution in adults (Taha et al., 2006). Differential tissue
expression and subcellular localisation suggests that SphK1 and SphK2may play different
physiological roles. Deletion of either SphK1 or SphK2 results in mice that are viable
and fertile (Allende et al., 2004; Mizugishi et al., 2005). Deletion of both SphK1 and
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2 produces mice which die in utero due to problems in angiogenesis and neurogenesis
(Mizugishi et al., 2005). Specific targeting of SphK1 reduces the severity and incidence
in a murine model of arthritis, whilst targeting of SphK2 caused a more severe disease
progression (Lai et al., 2009). In mast cells, only SphK1 is important in antigen-induced
degranulation and migration, although both isoforms are required for efficient cytokine
production (Oskeritzian et al., 2008). This suggests that SphK1 and SphK2 may have
different physiological roles. SphK1 and 2 can phosphorylate both dihydrosphingosine
and sphingosine.
Figure 5.2: SphK domain structure
A) Schematic representation of SphK1 and SphK2 showing the five conserved domains within the overall
structure. C1-3 form the catalytic domain of SphK. Transmembrane regions are present in SphK2 but
not SphK1. The calmodulin binding site is found at residues 191-206 in human SphK1. B) Alignment
of human SphK2 isoform a (NP_064511.2 ) and human SphK1 isoform 1 (NP_068807.2) using protein
BLAST (http://blast.ncbi.nlm.nih.gov/). Sequences in red demonstrate homology.
5.1.4 Sphingosine kinase 1 activation and localisation
SphK1 is ubiquitously expressed and activated by many diverse stimuli including growth
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factors and cytokines (Leclercq and Pitson, 2006). These stimuli lead to a rapid and
transient increase in cellular SphK1 activity that was shown to be mediated by phospho-
rylation on Ser225 by ERK1/2 (Pitson et al., 2003). This phosphorylation event resulted
in a 14-fold increase in catalytic activity although ATP and sphingosine affinities were un-
affected. This activation is transient due to dephosphorylation of Ser225 by PP2A (Barr
et al., 2008). Another function of phosphorylation on Ser225 is to change the cellular
localisation of SphK1 (Pitson et al., 2003). Normally located in the cytoplasm, phospho-
rylation at Ser225 is essential for the translocation of SphK1 to the plasma membrane.
The plasma membrane localisation is thought to be important as it allows release of S1P
or interactions with effector proteins.
The mechanism by which phosphorylation at Ser225 mediates plasma membrane local-
isation is not fully understood. Associations with phosphatidylserine, phosphatidic acid
and filamin have all been suggested (Stahelin et al., 2005; Delon et al., 2004; Maceyka
et al., 2008). Further work demonstrated a requirement for the calmodulin-binding site
in SphK1 for translocation to the plasma membrane (Jarman et al., 2010; Sutherland
et al., 2006). SphK1 was shown to interact with calcium and integrin-binding protein 1
(CIB1) via its calmodulin binding site in a calcium-dependent manner. CIB1 is a calcium-
myristoyl switch protein that translocates to the nucleus following calcium fluxes, which
have also been associated with SphK1 activation. Calcium flux leads to the translocation
and extrusion of the myristoyl tag on CIB1 allowing insertion into the plasma membrane
(Jarman et al., 2010; Spiegel and Milstien, 2000b). It has also been suggested that SphK1
is activated by PKCd downstream of EGF signaling, although whether this is a direct
phosphorylation event or via activation of ERK1/2 is unclear (Paugh et al., 2008a).
Phosphorylated SphK1 is found within membrane microdomains or lipid rafts in the
plasma membrane rather than having a diffuse distribution. This accumulation to lipid
rafts is shown to be required for its effects on cell growth (Hengst et al., 2009). Constitu-
tive localisation to lipid rafts by introducing the Lck tyrosine kinase myristoylation-dual
palmitoylation motif enhanced growth and survival in serum-deprived conditions (Pit-
son et al., 2005). Diffuse plasma membrane localisation of SphK1 by adding the single
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myristoylation site of c-Src led to inhibition of cell proliferation whilst retaining the anti-
apoptotic effects of SphK1 (Safadi-Chamberlain et al., 2005). Both human and murine
SphK1 splice variants have been shown to be constitutively located at the plasma mem-
brane due to additional sequences at the N-terminus, although the N-terminal sequences
differ between the human and murine variants (Venkataraman et al., 2006; Kihara et al.,
2006). The human SphK1b isoform has a potential palmitoylation site, which is known
to promote localisation to lipid rafts.
5.1.5 Sphingosine kinase 2 activation and localisation
SphK2 activity is also increased by certain stimuli, including EGF, IL-1 and TNFa, al-
though the Ser225 site present in SphK1 is not conserved (Alemany et al., 2007; Mas-
trandrea et al., 2005; Olivera et al., 2006; Hait et al., 2005). Instead, it has been proposed
that ERK1/2 might phosphorylate other residues such as Ser351 or Thr578 to activate
SphK2 (Hait et al., 2007). SphK2 is located in the nucleus and cytoplasm although its
distribution can change under certain conditions. Serum starvation appears to induce an
accumulation of SphK2 in the endoplasmic reticulum, whilst PKC activation results in a
decrease of nuclear SphK2 (Maceyka et al., 2005; Ding et al., 2007). SphK2 possesses
nuclear localisation and export signals (Igarashi et al., 2003). Phosphorylation of Ser383
or 385 by protein kinase D activates the NES (Ding et al., 2007). Nuclear SphK2 can form
a complex with histone H3 and HDAC1/2 (Hait et al., 2009). HDAC1 and 2 are direct
intracellular targets of S1P. S1P inhibits their HDAC activity and promotes transcription
of certain genes including c-fos. Phorbol esters strongly activate SphK2 resulting in in-
creased nuclear S1P and complexing with histone H3 and HDACs.
5.1.6 Extracellular sphingosine kinases
Interestingly, sphingosine kinases can be secreted from the cell and generate S1P in the
extracellular environment (Tani et al., 2007). SphK1 is released from cells via a non-
classical secretory pathway and this occurs in response to stress from fibroblasts or in
response to oxidised low-density lipoprotein immune complexes in macrophages (Waters
et al., 2003; Venkataraman et al., 2006; Soldi et al., 2007; Hammad et al., 2006). Another
study demonstrated release of SphK2 from cells undergoing apoptosis following caspase-
141
mediated cleavage of the N-terminus (Weigert et al., 2010). Extracellular SphK can use
ATP released by cells and sphingosine present due to degradation of sphingomyelin (Tani
et al., 2007; Elliott et al., 2009). S1P is subject to dephosphorylation by S1P phosphatases
and degradation by S1P lyases, however, when produced extracellularly, exposure to S1P
phosphatases or lyases will be limited. The role of extracellular SphKs is still unclear.
Recent studies have shown that secreted vesicles from human tumour cells contain SphK1
and sphingosine and they may be utilised to activate S1P1-5 signaling (Rigogliuso et al.,
2010). In apoptotic cells, the function of extracellular SphK activity may be to influence
the chemoattraction of phagocytic cells (Gude et al., 2008).
5.1.7 Therapeutic targeting of sphingosine 1-phosphate levels and function
S1P has many important roles and influences a range of processes including cell survival,
angiogenesis and immune responses. S1P can be controlled at numerous levels; regulat-
ing its synthesis, its degradation, its export and its signaling via receptors (Kunkel et al.,
2013). As a result, S1P levels can be affected by drugs targeting a range of enzymes
involved in S1P metabolism (figure 5.3). Due to the effects of SphK1 in regulating cell
survival over apoptosis, targeting SphK1 has mainly been considered for cancer treat-
ment. Several drugs are now in clinical trials that regulate the S1P axis. Fingolimod or
FTY720 is a modulator of S1P1 function, in the short term it acts as an agonist but can
promote receptor internalisation (Brinkmann et al., 2010). Fingolimod has been approved
for treatment of multiple sclerosis (Ingwersen et al., 2012). It is also being trialled in
schizophrenia and kidney transplants (Budde et al., 2002; Kunkel et al., 2013). The anti-
S1P monoclonal antibody, Sonepcizumab is being trialled in age-related macular degener-
ation and solid tumours (Sabbadini, 2011). S1P receptor agonists have been investigated
for effectiveness against ulcerative colitis, multiple sclerosis and plaque psoriasis (Kunkel
et al., 2013). A S1P lyase inhibitor, LX3305, has undergone phase I and II trials against
rheumatoid arthritis (Gräler, 2010; Fleischmann, 2012). The selective SphK2 inhibitor,
ABC294640, is in phase I clinical trials for pancreatic cancer (French et al., 2010). The
range of targets within the S1P axis should provide the ability to treat a range of diseases
in which S1P is implicated with some degree of tissue specificity and reduced side effects.
142
5.1.7.1 SphK inhibitors
Several SphK inhibitors have now been described, including SK1 I, SK1 II and, most
recently, PF-543 (Edmonds et al., 2011; French et al., 2003; Schnute et al., 2012; Paugh
et al., 2008b). SphK inhibitors should block the phosphorylation of sphingosine and thus
reduce the pool of S1P and thereby reduce or block S1P signaling both intracellularly and
extracellularly. SKI I targets SphK1 with a Ki of 10 mM in vitro and has been shown to
decrease cancer progression, angiogenesis and airway hyper responsiveness (Nagahashi
et al., 2012b; Paugh et al., 2008b; Kapitonov et al., 2009; Price et al., 2013). SKI II targets
both SphK1 and 2 (16 and 8 mM IC50 respectively in vitro) and limits cancer progression
(Gao et al., 2012). PF-543 was described more recently and is a sphingosine competitive
inhibitor with a nanomolar Ki (3.6 nM) for SphK1 in vitro. Notably, PF-543 is 100 fold
selective for SphK1 over the SphK2 isoform. PF-543 was shown to block S1P production
in the 1483 head neck carcinoma cells and in whole blood, although cell growth was
unaffected (Schnute et al., 2012).
5.1.8 S1P signaling
S1P binds to five different GPCRs and can then initiate downstream signaling through
various G proteins. S1P receptors have differential expression and are coupled to different
G proteins. S1P receptors are activated in an autocrine or paracrine manner. Signaling
from the five S1P receptors is described below.
5.1.8.1 S1P1 signaling
S1P1 is ubiquitously expressed with highest expression in brain, lung, spleen and the car-
diovascular system. S1P1 deletion is embryonically lethal due to haemorrhage. Lack of
S1P1 results in incomplete vascular maturation due to a failure of smooth muscle cell and
pericyte migration (Liu et al., 2000). Endothelial-specific deletion of S1P1 displays the
same vascular deficiencies as total deletion suggesting that S1P1 located on endothelial
cells is responsible for vascular maturation (Allende et al., 2003). S1P1, in conjunction
with S1P2 and S1P3, can increase vascular integrity to maintain endothelial and epithelial
barrier integrity (McVerry and Garcia, 2004; Singleton et al., 2006). Disruption of en-
dothelial barriers results in greater vascular permeability which is often evident in tumours
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Figure 5.3: Therapeutically targeting the sphingosine 1-phosphate axis
The sphingosine 1-phosphate axis can be therapeutically targeted at several points. Sphingosine is phos-
phorylated by sphingosine kinases which can be targeted to prevent the generation of S1P. Degradation
of S1P is catalysed by S1P lyase (SPL) and can be targeted to promote an accumulation of S1P. S1P can
have intracellular and extracellular effects. S1P is transported by SPNS2 or ABC transporters. Once in
the extracellular space, it can act in an autocrine or paracrine manner to initiate G protein-mediated signal-
ing. Sonepcizumab is a monoclonal antibody against S1P that prevents S1P signaling through its receptors.
Additionally, S1P receptors can be targeted with a range of agonists, antagonists or functional modulators
including fingolimod and ponesimod.
and during inflammation. siRNA-mediated silencing of S1P1 blocks barrier enhancement
and the same study identified Akt and Rac as effectors of S1P1 (Singleton et al., 2006).
A S1P1 selective antagonist showed that S1P1 is required for preserving vascular tone, a
role that has also been shown in vivo (Sanna et al., 2006; Finigan et al., 2005; McVerry
and Garcia, 2005). Interestingly, conditional SphK1/SphK2 double knockout mice have
normal vascular integrity, despite low levels of circulating S1P, which suggests that nor-
mal expression of S1P1 is more important to vascular integrity than the circulating level
of S1P (Pappu et al., 2007).
S1P1 is important in lymphocyte egress from lymph nodes. Resting T and B cells ex-
press S1P1 and silencing or deletion causes lymphopenia (Matloubian et al., 2004; Al-
lende et al., 2004). Transplantation of S1P1-deficient thymocytes and lymphocytes into
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wild-type mice also demonstrates the importance of S1P1 in controlling lymphocyte cir-
culation as the S1P1-deficient cells are sequestered in lymph nodes and Peyer’s patches
(Matloubian et al., 2004; Chi and Flavell, 2005).
5.1.8.2 S1P2 signaling
S1P2 is widely expressed among different cell types. Deletion of S1P2 does not affect
development, although S1P2-deficient mice develop sporadic seizures around 3-7 weeks
(MacLennan et al., 2001). It was shown in the same study that neocortical pyramidal
cells from S1P2-deficient mice display increased excitability. S1P2-deficient mice are
deaf, showing a requirement for S1P2 in auditory system development (Kono et al., 2007).
S1P2 is considered to oppose the actions of S1P1 and S1P3, which promote cell migra-
tion, as S1P2 inhibits cell migration (Lepley et al., 2005). Interestingly, S1P2 activates
ROCK/Rho to increase vascular permeability (Sanchez et al., 2007). In mast cells, S1P2
is necessary for degranulation, which correlates with the reliance seen on SphK1/2 ex-
pression for mast cell function (Jolly et al., 2004; Olivera et al., 2007; Oskeritzian et al.,
2008).
5.1.8.3 S1P3 signaling
S1P3 is expressed in lungs, kidney, spleen, intestines and the cardiovascular system. Dele-
tion of S1P3 does not cause any evident phenotypic effects (Ishii et al., 2001). Knockout of
S1P2 and S1P3 moderately increases perinatal lethality (Ishii et al., 2002). Triple knock-
out of S1P1-3 is embryonic lethal with severe vascular deficiencies (Kono et al., 2004).
The defects in vasculature seen in the S1P1-3 KO may be more severe than those seen in
the S1P1 deficient mice, suggesting roles for S1P2 and S1P3. Similarly to S1P2, S1P3
activates ROCK/Rho to regulate vascular permeability (Sanchez et al., 2007). S1P3 is ex-
pressed in myocytes and perivascular smooth muscle cells and activation of S1P3 in these
cells results in bradycardia and hypertension (Forrest et al., 2004).
5.1.8.4 S1P4 signaling
S1P4 is less widely expressed than S1P1-3, primarily being expressed in lymphoid tissue
including thymus, spleen, bone marrow and peripheral lymphocytes (Gräler et al., 1998;
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Kluk and Hla, 2002). S1P4 activates Gi and Gaq and over-expression of S1P4, in Jurkat
cells, increased cell motility in the absence of S1P (Gräler et al., 2003). S1P4 activation
leads to activation of ERK1/2 and phospholipase C (Van Brocklyn et al., 2000). In ad-
dition, S1P4 stimulation modulates calcium release from intracellular stores (Yamazaki
et al., 2000). In mouse T cells lacking endogenous S1P receptors, expression of S1P4
failed to initiate a chemotactic response when stimulated. However, S1P4 expression did
lead to increased secretion of IL-10 and reduced proliferation when activated with S1P
(Wang et al., 2005a).
5.1.8.5 S1P5 signaling
S1P5 is highly expressed in oligodendrocytes and natural killer (NK) cells (Im et al.,
2000; Terai et al., 2003; Walzer et al., 2007). Silencing of S1P5 expression does not affect
oligodendrocyte function (Jaillard et al., 2005). Stimulation of rat oligodendrocytes with
platelet-derived growth factor increased S1P1 expression whilst decreasing S1P5 expres-
sion (Jung et al., 2007). Activation of S1P5 results in the inhibition of ERK1/2 activity
due to phosphatase activity, thus S1P5 signaling inhibits cell proliferation (Gonda et al.,
1999; Im et al., 2000). The importance of S1P5 in NK cells has been described and this
study showed that NK cells lacking S1P5 are unable to properly home to inflamed organs
(Walzer et al., 2007).
5.1.9 S1P intracellular signaling
In addition to activating its receptors, S1P can also act in an intracellular manner (Spiegel
and Milstien, 2011). Deletion of S1P phosphatase and lyase from yeast cells results in
slow growth and a large accumulation in S1P. Deletion of the major SphK in yeast allows
normal cell growth again (Kim et al., 2000; Zhang et al., 2001). The inhibition of cell
growth may be caused by S1P-induced increases in intracellular calcium levels (Birch-
wood et al., 2001). Heat shock induces cell cycle arrest in yeast but it also increases
SphK activity and S1P accumulation suggesting a possible role for S1P in responses to
heat shock (Lanterman and Saba, 1998; Skrzypek et al., 1999). Heat shock tolerance can
be increased by deleting the S1P phosphatase or lyase (Skrzypek et al., 1999; Mao et al.,
1999; Mandala et al., 2000). Interestingly, no apparent cell surface receptor for S1P is
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encoded by the yeast genome and addition of exogenous S1P does not affect cell growth
suggesting an intracellular role for S1P (Lanterman and Saba, 1998).
Intracellular effects of S1P have also been identified in mammalian cells. Expression of
SphK1 leads to decreases in ceramide levels and increases in dihydrosphingosine levels
(Maceyka et al., 2005). The conversion of ceramide to dihydrosphingosine is catalysed
by a group of ceramide synthases (CerS). The changes in lipid levels caused by SphK1
expression suggests that S1P may inhibit a CerS. S1P was shown to be an in vitro non-
competitive inhibitor of CerS2 and further experiments identified two domains with ho-
mology to S1P receptors. A point mutation within each of the domains relieved S1P
inhibition on CerS2 (Laviad et al., 2008). However, CerS2 does not use C16 or C18 acyl
CoAs and ceramides produced from these substrates are the most affected by SphK1 ex-
pression (Maceyka et al., 2005). Further work is required to understand the role that S1P
has in modulating ceramide synthesis.
Whilst SphK1 normally translocates to the plasma membrane, both SphK1 and SphK2
can be targeted to other internal locations. Both Acy1 and RPK118 have been shown to
target SphK1 to internal membranes (Hayashi et al., 2002; Maceyka et al., 2004). SphK1
has also been identified at nascent phagosomes where it can then promote maturation into
phagolysosomes (Thompson et al., 2005). SphK1 over-expression has been shown to pro-
mote G1/S transition (Olivera et al., 1999). This regulation of cell cycle progression may
be explained by the finding that SphK1 is located at the nuclear envelope during S phase
(Kleuser et al., 2001). SphK2 is found in the nucleoplasm and contains a NES activated
by PKD (Ding et al., 2007). Whether translocation to the cytoplasm acts to reduce nuclear
S1P signaling or increase cytosolic S1P signaling is unclear. Notably, SphK1 or SphK2
targeted to the ER promotes apoptosis (Maceyka et al., 2005; Liu et al., 2003a).
The target of ER-localised S1P remains unknown. S1P can induce calcium release from
permeabilised cells in an inositol triphosphate receptor-independent manner (Mattie et al.,
1994). S1P also induced calcium release from cell fractions rich in rough, but not smooth,
ER (Ghosh et al., 1994). In line with this, over-expression of SphK2, that partially lo-
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calises to ER, also raised intracellular calcium (Maceyka et al., 2005). Mast cells derived
from SphK2-/- mice have defective calcium mobilisation in response to crosslinking of
the IgE receptor (Olivera et al., 2007). In HEK293 cells, microinjection of S1P can elevate
calcium levels in the presence of pertussis toxin, a GPCR inhibitor (Meyer zu Heringdorf
et al., 1998). Likewise, caged S1P, that forms S1P on exposure to light, induced increased
calcium levels in cells that do not respond to exogenous S1P (Meyer Zu Heringdorf et al.,
2003). These studies all propose a role for S1P as a second messenger responsible for
calcium mobilisation.
In addition to modulating calcium release, S1P has other effects that are S1P receptor-
independent. Over-expression of SphK1 leads to the survival of endothelial cells, possibly
due to expression of PECAM-1 and activation of Akt. These effects are not reproduced
by the addition of exogenous S1P (Limaye et al., 2005). SphKs can also phosphorylate
dihydrosphingosine to produce dihydrosphingosine 1-phosphate (DHS1P). Both DHS1P
and S1P bind and activate S1P receptors with similar affinities, however DHS1P does
not mimic all of the effects of S1P (Van Brocklyn et al., 1998; Suomalainen et al., 2005;
Morita et al., 2000). S1P protects male germ cells from apoptosis and similar effects
were seen in HL-60 and PC-12 cells (Suomalainen et al., 2005; Van Brocklyn et al.,
1998). DHS1P could not protect male germ cells from apoptosis (Suomalainen et al.,
2005). Interestingly, S1P-phosphonate protected HL-60 and PC-12 cells from apoptosis
despite failing to bind S1P receptors (Van Brocklyn et al., 1998). SphK1 over-expression
in embryonic fibroblasts from S1P-receptor knockout mice enhanced growth and sur-
vival (Olivera et al., 2003). These results suggest that S1P has important intracellular
targets that protect cells from apoptosis. The FTY720 analog AAL(R) is phosphorylated
by SphK2 and only poorly by SphK1 and induces apoptosis in Jurkat cells and primary
splenocytes. AAL(R) did not induce apoptosis in cells from SphK2-/- mice (Don et al.,
2007). This suggests an intracellular action for S1P generated by SphK2 in promoting
apoptosis.
TNFa is known to induce SphK1 activity and the S1P produced may function intracellu-
larly (Xia et al., 1998). It was shown that S1P activates NFkB independently of S1P-
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receptors (Alvarez et al., 2010). Previously, it had been shown that SphK1 binds to
TRAF2 which is recruited to the TNFa receptor upon stimulation (Xia et al., 2002). It
has now been demonstrated that active SphK1 is important for the activation of NFkB as
S1P is a cofactor for TRAF2. TRAF2 is necessary for the ubiquitination of RIP1 (Alvarez
et al., 2010), which then recruits other proteins required for NFkB activation (Bhoj and
Chen, 2009; Ea et al., 2006). Interestingly, DHS1P is unable to mimic the actions of S1P
with TRAF2. Poly-ubiquitinated RIP1 is also prevented from interacting with pro-caspase
8 and thus this prevents apoptosis (Alvarez et al., 2010).
5.1.10 S1P in macrophages
Macrophages undergo apoptosis during microbial infection and the role of S1P in pro-
tecting from apoptosis in other cells is well known. S1P generated by apoptotic cells
was able to induce phosphoinositide 3-kinase (PI3K), ERK1/2 and Ca2+ signaling in
primary macrophages and this protected macrophages from TNFa-induced cell death
(Weigert et al., 2006). The activation of PI3K signaling resulted in the inhibition of
acid sphingomyelinase and therefore prevented ceramide accumulation. These changes
in ceramide levels were accompanied by increased expression of Bcl-XL and decreased
caspase-3 cleavage (Gómez-Muñoz et al., 2003). S1P has also been shown to prevent
cytochrome c and Smac/DIABLO translocation from the mitochondria to the cytosol fol-
lowing apoptosis-inducing stimuli and therefore prevents caspase-3 activation (Cuvillier
et al., 1996). In Raw 264.7 cells, LPS treatment induced activation of SphK1 and translo-
cation to the plasma membrane. Inhibition of SphK1 sensitised cells to LPS-induced cell
death, although it is unclear whether this is due to an intra- or extracellular signaling event
(Wu et al., 2004; Hammad et al., 2008).
Macrophages are recruited to sites of inflammation by chemokines and S1P acts as a
chemoattractant for primary human monocytes and macrophages in vitro as well as for
the monocytic cell lines U937 and THP-1 (Schwab and Cyster, 2007; Gude et al., 2008).
FTY-720, the S1P-receptor ligand, has been shown to reduce macrophage infiltration to
the CNS in vivo in a model of EAE (Fujino et al., 2003). FTY720 also reduced the number
of macrophages in atherosclerotic lesions (Theilmeier et al., 2006). The use of a S1P1-
149
specific agonist decreased macrophage infiltration in a model of experimental autoim-
mune myocarditis (Ogawa et al., 2007). These studies suggest an important role for S1P-
S1P1 in macrophage trafficking. The effects of FTY720 on monocyte-endothelium inter-
actions may partly explain reduced recruitment of macrophages to inflamed tissues. S1P
has been shown to prevent adhesion of monocytes to endothelium and this could be ex-
plained by S1P3-dependent production of nitric oxide inhibiting MCP-1, a chemokine re-
quired for monocyte adhesion (Bolick et al., 2005; Theilmeier et al., 2006). Interestingly,
intraocular injection of a monoclonal antibody, Sonepcizumab, reduced macrophage in-
filtration into the ischemic retina following induced ischemic retinopathy (Xie et al.,
2009). Although, scavenging S1P may alter macrophage infiltration by increasing apop-
tosis within macrophages.
Mycobacterium tuberculosis inhibits phagosome maturation and is though to prevent mat-
uration by inhibiting SphK1 translocation to nascent phagosomes. Dead M.tuberculosis,
however, activates SphK1 resulting in a calcium-dependent translocation to the phago-
some (Malik et al., 2003; Thompson et al., 2005). Addition of S1P to M.tuberculosis
infected human macrophages reduced pathogen viability by phospholipase D activation
and phagolysosome generation (Garg et al., 2004). Injection of S1P into mice infected
with Mycobacteria reduced pathogen growth and tissue damage. Treatment with sphin-
gosine had similar effects onMycobacteria, although no receptors are currently identified
for sphingosine, therefore sphingosine may enter the cell to enhance pathogen killing
(Garg et al., 2004; Gutierrez et al., 2009). Whether it then becomes phosphorylated or
whether S1P is dephosphorylated to sphingosine remains unclear. S1P may also con-
tribute to phagosome maturation by influencing actin assembly (Kuehnel et al., 2009a,b).
Furthermore, SphK2-/- mice have higher susceptibility to bacterial lung infection (Ze-
mann et al., 2007). These reports demonstrate a clear role for SphK-S1P in mediating
clearance of bacterial infections.
Extracellular effects of S1P are often considered to be anti-inflammatory. S1P stimu-
lation of alveolar macrophages led to production of reactive oxygen species, although
weakly compared to LPS (Hornuss et al., 2001). In fact, S1P was shown to block LPS-
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dependent NO production (Hughes et al., 2008). S1P treatment did promote vascular
endothelial growth factor (VEGF) production in human macrophages (Weis et al., 2009).
Macrophages pre-incubated with S1P or a S1P1-specific agonist, had reduced levels of
TNFa, MCP-1 and IL-12 following treatment with LPS (Hughes et al., 2008).
S1P was shown to increase COX-2 expression by regulating the localisation of the RNA
binding protein, HuR. Elimination of S1P from the supernatant reduced PGE2 production
in apoptotic cells (Johann et al., 2008). A micromolar dose of S1P may be able to in-
duce PGE2 secretion (Hammad et al., 2008). In PGE2-stimulated Raw 264.7 cells, S1P
increased cAMP levels through S1P2-G13 signaling (Jiang et al., 2007). PGE2 production
is an important constituent for resolution of inflammation (Bystrom et al., 2008). SphK1
expression is also evident in regulatory macrophages although a function has yet to be
described (Edwards et al., 2006). Interestingly, in Raw 264.7 cells, LPS induced SphK1
expression after 16 hours and was shown to be required for TNFa-induced PGE2 release
using SphK1 siRNA (Hammad et al., 2008).
Signaling from TLR4 has been shown to activate and increase expression of SphK1 (Wu
et al., 2004). S1P binding to S1P3 has been shown to affect induction of MCP-1, whereas
signaling via S1P2 contributes to IL-1 and IL-18 production (Keul et al., 2011; Skoura
et al., 2011). Deletion of SphK1 can protect mice from sepsis (Niessen et al., 2008). It
has been suggested that S1P is required for DC activation, which is required for systemic
inflammation during sepsis. In this proposed mechanism, S1P signals via S1P3 to regulate
the amplification of the inflammatory response as part of PAR1 signaling (Niessen et al.,
2008). These studies suggest a complex regulation of cytokine and chemokine production
by S1P.
Further examples of the anti-inflammatory aspects of S1P have been described in various
disease models. S1P is protective before and during atherosclerosis (Argraves and Ar-
graves, 2007). This may be partially explained by negative crosstalk between S1P1 and
S1P2 and TLR2 pathways (Dueñas et al., 2008). In a model of acute necrotising pancre-
atitis, S1P and FTY720 reduced NFkB activation resulting in reduced production of IL-1,
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IL-6 and TNFa (Liu et al., 2008a). Notably, S1P may promote Th2 responses. Knock-
down of SphK1 in a model of allergic arthritis led to reduced macrophage numbers and
reduced IL-4 and IL-5 secretion (Lai et al., 2008). This was further underlined by treat-
ment of murine fibrosis with the monoclonal antibody, Sonepcizumab, which neutralises
S1P. Sonepcizumab treatment reduced disease parameters in murine fibrosis (Caballero
et al., 2009; Meneghin and Hogaboam, 2007).
Immature DCs have low expression of CCR7 which makes them unresponsive to CCL19
preventing RAC activation and migration (König et al., 2010). In addition, S1P2 signaling
activates RHO leading to FLH2-mediated repression of S1P1 transcription. Maturation of
DCs results in CCR7 up-regulation and a down-regulation of S1P2. Together, this results
in RAC activation and migration. There is also less RHO-mediated repression of S1P1
transcription. Positioning of immature DCs within the spleen has been shown to be S1P1-
dependent (König et al., 2010). These results demonstrate how the expression profile of
the S1P receptors is carefully regulated by cells during their maturation.
5.2 Expression of Sphk1 in Zymosan-stimulated macrophages
Zymosan activates Dectin-1 and TLR2 signaling and in macrophages leads to high levels
of IL-10 and low levels of IL-12, which is often characteristic of regulatory macrophages.
Regulatory macrophages are thought to be induced by TLR agonists and a secondary stim-
ulus, such as PGE2, and are important in dampening the inflammatory response. Stud-
ies from other labs have identified markers, which are induced as part of the regulatory
macrophage phenotype (Edwards et al., 2006). Markers for wound-healing macrophages
have also been identified in various studies (Raes et al., 2002, 2005; Stein et al., 1992).
To examine which of these markers were induced by Zymosan, data from a microar-
ray experiment carried out by a previous PhD student in the lab was analysed. In this
experiment, wildtype bone marrow-derived macrophages were stimulated with LPS or
Zymosan for 1 or 8 hours and then expression of mRNA quantified. LPS and Zymosan
both strongly induced expression of IL-10 at 1 and 8 hours (figure 5.4), consistent with
mRNA analysis through qPCR. Markers of wound-healing (M2a) macrophages, Clec10a,
MRC1 and Ym1, showed moderate down-regulation with LPS and Zymosan at 8 hours.
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Arg1 was modestly induced by Zymosan at 8 hours, whilst remaining around basal levels
with LPS stimulation. SphK1 and LIGHT are considered markers of regulatory markers
(Edwards et al., 2006). LPS induced both LIGHT and Sphk1 at 1 hour before it returned
to basal expression. Notably, Zymosan induced sustained expression of both LIGHT and
SphK1. LIGHT is a member of the TNFa ligand family and may trigger signaling via
TNFRSF14. As SphK1 is important for the generation of S1P and as S1P has roles in the
immune system I investigated the role of SphK1 might play in Zymosan-induced cytokine
production.
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Figure 5.4: Expression of macrophage phenotype markers
BMDMs were stimulated with 100 ng/ml LPS or 200 µg/ml Zymosan for 1 or 8 hours. Cells were lysed
with RLT buffer (Qiagen) and total RNA purified using the Qiagen miniRNeasy kit. The arrays were gen-
erated by the Finnish Microarray and Sequencing Centre (Turku, Finland), according to the manufacturer’s
protocols. Four biological replicates were analyzed per group. The data analysis was carried out in the High
Performance Computing facility of the College of Life Sciences using Affymetrix Power Tools, R (version
2.13.1) – Bioconductor and Partek GS 6.5 (version 6.11.0321) software.
Firstly, the data from the microarray was validated. BMDMs were stimulated with LPS
and Zymosan over a 8 hour timecourse and SphK1 mRNA levels measured by qPCR. As
seen in the array data, SphK1 mRNA is induced by Zymosan treatment peaking at 6 hours
(figure 5.5). LPS only weakly induces SphK1 expression with a peak expression level at
2 hours. The induction of SphK1 by Zymosan suggests it may play a role in maintaining
or generating the phenotype observed in Zymosan-stimulated macrophages. One of these
features is high levels of IL-10 compared to LPS-stimulated macrophages. It is possible
that SphK1 may be important in driving the high levels of IL-10 secretion or that IL-10
may drive SphK1 expression in order to generate the regulatory phenotype observed in
Zymosan-stimulated macrophages. To address the possible function of SphK1, I used
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inhibitors of SphK1 to block its function in macrophages.
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Figure 5.5: Comparison of SphK1 expression in LPS- and Zymosan-stimulated macrophages
Bone marrow-derived macrophages from WT mice were stimulated with 100 ng/mL of LPS or 200 µg/ml
Zymosan for the times indicated. Cells were lysed with RLT buffer (Qiagen) and total RNA purified using
the Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-Rad) and qPCR was
carried out using SYBR-green based detection methods. Levels of 18S were used as a normalization control,
and fold induction was calculated for SphK1 mRNA. n=4, error bars represent the standard deviation from
independent cultures from four mice per genotype.
5.3 Characterisation of SphK inhibitors
Several SphK1 inhibitors have been described (Paugh et al., 2008b; French et al., 2003;
Schnute et al., 2012; Kunkel et al., 2013; Gräler, 2010). Paugh et al describe SK1 I as an
ATP-competitive inhibitor of SphK1, with minimal effects on SphK2 or PKC. In addition
to the ATP-competitive inhibitor, SK1 I, other inhibitors of SphK1 have been described.
Both SK1 II and PF-543 are substrate-competitive inhibitors of SphK1. However, SK1
II shows a similar IC50 for SphK2 (8 µM) as for SphK1 (16 µM) (French et al., 2003).
PF-543 is highly selective for SphK1 with a nanomolar Ki and only a small amount of
inhibition of SphK2 evident at 10 µM (Schnute et al., 2012).
In order to determine the selectivity of these structurally distinct inhibitors against protein
kinases, SK1 I, SK1 II and PF-543 were profiled against a panel of protein kinases. SK1
I and PF-543 demonstrated no specific inhibition of any protein kinase (figure 5.7A+C).
SK1 II caused considerable inhibition of several protein kinases including CAMK1, GCK,
MLK1, MLK3, PIM1 and PIM3 (all inhibited to below 40% remaining activity at 10 µM)
(figure 5.7+B). SK1 I is an ATP-competitive inhibitor and may have been expected to
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Figure 5.6: SphK inhibitor structures
Structures of three SphK inhibitors (SK1 I, SK1 II and PF-543) used in this study are presented here.
inhibit protein kinases rather than the substrate-competitive SK1 II.
Treatment of macrophages with Zymosan will lead to the activation of ERK1/2 which can
phosphorylate and activate SphK1 (Pitson et al., 2003). Active SphK1 should cause an in-
crease in S1P levels within the cell and this increase should be blocked by SphK inhibitors.
In addition, all three inhibitors were found to have acute effects in macrophages as dis-
cussed in section §5.4. In order to determine if Zymosan activated SphK1 and induced
S1P accumulation and if the SphK inhibitors prevented this S1P accumulation in cells,
macrophages were stimulated with Zymosan for 15 minutes and S1P levels were calcu-
lated via mass spectrometry. Zymosan treatment of BMDMs only weakly stimulated an
increase in S1P levels, although S1P levels were still decreased by the addition of SphK1
inhibitors (figure 5.8). Another product of SphK1 was also measured by mass spectrome-
try. SphK1 can also catalyse the phosphorylation of dihydrosphingosine (DHS) resulting
in dihydrosphingosine-1-phosphate (DHS1P). Interestingly, Zymosan stimulated a 2-fold
increase in DHS1P levels in macrophages and this increase was partially or completely
blocked by pre-treatment with SphK inhibitors. Levels of dihydrosphingosine were in-
creased in response to Zymosan treatment and this increase was inhibited by SK1 I and
SK1 II. Other sphingolipids and ceramides were also quantified and remained largely un-
changed (table 5.1). This data suggests that the three inhibitors used can block Zymosan-
stimulated SphK1 activity and particularly affect the accumulation of DHS1P.
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Figure 5.8: Zymosan induces DHS1P accumulation
BMDMs were pre-incubated with 10 µM SK1 I, 10 µM SK1 II and 5 µM PF-543 for 1 hour. BMDMs
were then stimulated with 200 µg/ml Zymosan for 15 minutes. Cells were lysed and the lysate quantified.
Spingholipids were extracted and then analysed by LC-MS/MS - (J Allegood, Virginia Commonwealth
University). n=3, error bars represent the standard deviation
5.4 SphK inhibitors reduce IL-10 transcription and secretion
In order to understand what effects SphK1 might have in Zymosan-induced cytokine pro-
duction, wildtype macrophages were pre-treated with SK1 I for 1 hour prior to treatment
with Zymosan and IL-10 mRNAmeasured by qPCR. Zymosan treatment of macrophages
led to a strong induction of IL-10 that peaked at 8 hours and returned to basal by 24 hours
(figure 5.9). Treatment of macrophages with SK1 I reduced IL-10 mRNA levels across
the 24 hour timecourse compared to Zymosan stimulation alone. Culture supernatant was
also collected and IL-10 secretion measured to determine if changes in mRNA levels seen
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with SK1 I treatment translated to changes in protein level. Zymosan stimulation led to
IL-10 secretion at 8 and 16 hours and this was reduced in macrophages pre-treated with
SK1 I (figure 5.9). This suggests that SphK1 activity is required for maximal production
of IL-10 from Zymosan-stimulated macrophages.
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Figure 5.9: Inhibition of SphK results in reduced IL-10 mRNA and secretion
Bone marrow-derived macrophages from WT mice were pretreated with 10 µM SK1 I for 1 hour before
stimulation with 200 µg/ml Zymosan for the times indicated. A) Cells were lysed with RLT buffer (Qiagen)
and total RNA purified using the Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript
(Bio-Rad) and qPCR was carried out using SYBR-green based detection methods. Levels of 18S were used
as a normalization control, and fold induction was calculated for IL-10 mRNA mRNA. B) Culture super-
natant was collected and IL-10 secretion measured by Bioplex (Bio-Rad) according to the manufacturers
protocol. n=4, error bars represent the standard deviation from independent cultures from four mice per
genotype.
Each SphK inhibitor is structurally distinct (see figure 5.6) and therefore SK1 II and PF-
543 were used to confirm the findings seen with SK1 I in figure 5.9. BMDMs were
pretreated with SK1 I, SK1 II and PF-543 for 1 hour before stimulation with Zymosan for
8 hours. The culture supernatant was collected and IL-10 secretion assayed by Bioplex.
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Zymosan stimulation of wild-type macrophages for 8 hours led to the secretion of around
1400 pg/ml of IL-10 similar to that seen in previous experiments. Pre-treatment with SK1
I again strongly repressed secretion of IL-10 (figure 5.10). Treatment with the structurally
distinct inhibitors, SK1 II and PF-543, also led to the marked reduction of IL-10 secretion
from Zymosan-stimulated macrophages. This corroborates the effect of SK1 I and sug-
gests that SphK1 does indeed play a role in maximal production of IL-10 downstream of
Zymosan.
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Figure 5.10: Structurally distinct SphK inhibitors reduce IL-10 secretion
Bone marrow-derived macrophages from WT mice were pretreated with SK1 I (10µM), SK1 II (10 µM)
or PF-543 (5 µM) for 1 hour before stimulation with 200 µg/ml Zymosan for 8 hours. Culture supernatant
was collected and IL-10 secretion measured by Bioplex (Bio-Rad) according to the manufacturers protocol.
n=4, error bars represent the standard deviation from independent cultures from four mice per genotype.
5.5 SphK inhibitors reduce Akt and STAT3 phosphorylation
Treatment of macrophages with SphK inhibitors leads to reduced IL-10 mRNA levels and
secretion. Both ERK1/2 and p38 regulate IL-10 transcription and therefore perturbations
in ERK or p38 activation may result in decreased IL-10 mRNA levels. In order to under-
stand if this reduction in IL-10 was due to deregulated signaling downstream of Zymosan,
macrophages were pretreated with SK1 I before stimulation with Zymosan. Cells were
then lysed and signaling events analysed by western blotting. Zymosan treatment led to
phosphorylation of the MAPKs, ERK1/2 and p38 after 30 minutes (figure 5.11). It also
led to phosphorylation of Akt at Ser473 30 minutes after stimulation. By two hours, Zy-
mosan treatment induced phosphorylation of STAT3 at Tyr705 which acts as a readout for
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IL-10 production. Treatment of macrophages with 10 µM SK1 I before stimulation with
Zymosan led to similar phosphorylation of ERK1/2 and p38. Phosphorylation of Akt at
S473 was reduced for the duration of the timecourse. In line with the changes seen in IL-
10 secretion, phosphorylation of Y705 of STAT3 was reduced in macrophages pre-treated
with SK1 I.
Figure 5.11: SK1 I reduces Akt and STAT3 phosphorylation in response to Zymosan
BMDMs were generated from WT bone marrow and pretreated with 10 µM SK1 I where indicated. Cells
were stimulated with 200 µg/ml Zymosan for up to 6 hours. Cells were lysed and proteins separated by
SDS-PAGE. Proteins were transferred to nitrocellulose membranes and immunoblotted with antibodies
to phospho STAT3 (Y705), phospho Akt (S473), phospho p38, phospho ERK1/2, ERK1/2. Results are
representative of two independent experiments.
The reduction in phosphorylation of Akt seen with SK1 I pre-treatment may be a result
of blocking S1P signaling or an off-target effect of the inhibitor. To validate the changes
in phosphorylation seen with SK1 I, the two structurally distinct SphK inhibitors, SK1 II
and PF-543 were also used to block SphK activity in Zymosan-stimulated macrophages.
BMDMs were stimulated with Zymosan alone for a 6 hour timecourse or pretreated with
SK1 II for 1 hour prior to Zymosan treatment. Treatment of macrophages with SK1 II
reduced the initial induction of phosphorylation of Akt at both T308 and S473 and the
phosphorylation at these sites was not sustained throughout the timecourse (figure 5.12).
Treatment with SK1 II also blocked phosphorylation of STAT3 at Y705. Treatment with
SK1 II reduced the sustained phosphorylation of ERK1/2 and p38 in response to Zy-
mosan. The loss of signaling of events seen with SK1 II correlate with those seen with
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SK1 I and furthermore loss of STAT3 phosphorylation corroborates the reductions seen
in IL-10 secretion associated with SK1 II pre-treatment (figure 5.10).
Figure 5.12: SK1 II blocks Akt and STAT3 phosphorylation in response to Zymosan
BMDMs were generated from WT bone marrow and pretreated with 10 µM SK1 II where indicated. Cells
were stimulated with 200 µg/ml Zymosan for up to 6 hours. Cells were lysed and proteins separated by
SDS-PAGE. Proteins were transferred to nitrocellulose membranes and immunoblotted with antibodies to
phospho STAT3 (Y705), phospho Akt (S473), phospho Akt (T308), phospho p38, phospho ERK1/2 and
ERK1/2. Results are representative of two independent experiments.
A third SphK1 inhibitor, PF-543, was also used to determine if the changes to signal-
ing observed with SK1 I and SK1 II were consistent. Pre-treatment with PF-543 caused
reduced phosphorylation of Akt at 30 minutes at both T308 and S473 (figure 5.13). Phos-
phorylation of STAT3 at Y705 was also reduced from 2 to 6 hours. Treatment with PF-543
reduced the sustained phosphorylation of ERK1/2 and p38 in response to Zymosan. The
effects of PF-543 were comparable to those of SK1 I and SK1 II. Along with the IL-
10 secretion data, the consistent reduction of Akt and STAT3 phosphorylation caused by
three structurally distinct SphK1 inhibitors suggests that SphK1 activity is important in
sustaining Akt activity and for maximal IL-10 secretion.
5.6 SphK inhibitors block LPS-stimulated STAT3 phosphorylation
Treatment of macrophages with SphK inhibitors leads to acute effects on cytokine produc-
tion prior to the induction of SphK1 mRNA (see figure 5.9 and figure 5.5). This suggests
that SphK1 may be expressed at a protein level in unstimulated macrophages and may
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Figure 5.13: PF-543 reduces Akt and STAT3 phosphorylation in response to Zymosan
BMDMs were generated from WT bone marrow and pretreated with 5 µM PF-543 where indicated. Cells
were stimulated with 200 µg/ml Zymosan for up to 6 hours. Cells were lysed and proteins separated by
SDS-PAGE. Proteins were transferred to nitrocellulose membranes and immunoblotted with antibodies to
phospho STAT3 (Y705), phospho Akt (S473), phospho Akt (T308), phospho p38, phospho ERK1/2 and
ERK1/2. Results are representative of two independent experiments.
play a role downstream of other PRRs. IL-10 secretion is also induced downstream of
TLR4. It would be interesting if SphK1 activity was also important in regulating IL-10
production in response to LPS, a TLR4 agonist. It was investigated whether SphK1 ac-
tivity was important in LPS stimulated macrophages by examining phosphorylation of
key signaling molecules. Macrophages were treated with LPS alone for 1 or 8 hours or
pre-treated with SphK1 inhibitors prior to LPS stimulation. LPS stimulation leads to ac-
tivation of ERK1/2 and p38 at 1 hour with some weak phosphorylation still detectable at
8 hours (figure 5.14). LPS also induced the degradation of IkB at 1 hour which indicates
activation of NFkB. IkB was detectable again at 8 hours. Akt was phosphorylated weakly
at 1 hour and showed stronger phosphorylation after 8 hours of LPS treatment. STAT3
was also strongly phosphorylated at 8 hours of LPS treatment. Treatment with SphK in-
hibitors strongly reduced Akt and STAT3 phosphorylation at 8 hours. Initial activation of
ERK1/2 and p38 was unaffected. Treatment of macrophages with SphK inhibitors did not
affect the initial degradation of IkB at 1 hour, however, at 8 hours IkB was undetectable
suggesting a failure to reexpress IkB or continued degradation of IkB.
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Figure 5.14: SphK1 inhibitors block LPS stimulated phosphorylation of Akt and STAT3
BMDMs were generated from WT bone marrow and pretreated with 10 µM SK1 I, 10 µM SK1 II or 5
µM PF-543 where indicated. Cells were stimulated with 100 ng/ml LPS for 1 or 8 hours. Cells were
lysed and proteins separated by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and
immunoblotted with antibodies to phospho STAT3 (Y705), phospho Akt (S473), Akt, IkBa, phospho p38,
phospho ERK1/2, ERK1/2. Results are representative of two independent experiments.
5.7 Exogenous DHS1P does not rescue the effects of SK1 I
SphK inhibitors block the phosphorylation of sphingosine resulting in a decrease in avail-
able DHS1P (figure 5.8). DHS1P can signal extracellularly via five GPCRs (S1P1-5) or
intracellularly. The effect of SphK inhibitors on STAT3 phosphorylation should there-
fore be overcome by the introduction of exogenous DHS1P. Initially, the concentration of
DHS1P required to stimulate cells was determined through titration of DHS1P. DHS1P
stimulation induced phosphorylation of ERK1/2 after 15 minutes. 10 µM of DHS1P in-
duced similar levels of ERK activation to that seen with EGF stimulation.
10 µM of DHS1P induced strong phosphorylation of ERK1/2 and was therefore selected
as an appropriate concentration to stimulate BMDMs. BMDMs were stimulated with
DHS1P alone which failed to induce STAT3 phosphorylation at Tyr705. Zymosan stimu-
lation of BMDMs led to a strong induction of phosphorylation at Tyr705 of STAT3. Pre-
treatment with SK1 I blocked the Zymosan-induced phosphorylation of STAT3 at Tyr705.
Interestingly, co-stimulation of macrophages with DHS1P and Zymosan lead to stronger
phosphorylation of STAT3 at Tyr705 compared to Zymosan stimulation alone. However,
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Figure 5.15: DHS1P titration in HeLa cells
Cells were stimulated with indicated concentrations of DHS1P or 100 ng/ml EGF for 15 mins. Cells were
lysed and proteins separated by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and
immunoblotted with antibodies to phospho ERK1/2 and ERK1/2. Results are representative of three inde-
pendent experiments.
pre-treatment of cells with SK1 I prevented phosphorylation of STAT3 by co-stimulation
with DHS1P and Zymosan (figure 5.16).
Figure 5.16: Exogenous DHS1P does not rescue STAT3 phosphorylation in SK1 I pre-treated
macrophages
BMDMs were pre-treated with 10 µM SK1 I where indicated. Cells were stimulated with 10 µM DHS1P,
200 µg/ml Zymosan or a combination of both for 4 hours where indicated. Cells were lysed and proteins
separated by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and immunoblotted with
antibodies to phospho STAT3 (Y705) and ERK1/2. Results are representative of two independent experi-
ments.
Whilst Zymosan stimulation did not lead to accumulation of S1P, treatment with SphK
inhibitors did reduce levels of S1P in macrophages compared to basal levels. To inves-
tigate if changes in S1P levels were responsible for the effects seen on STAT3 phospho-
rylation in macrophages, exogenous S1P was added to Zymosan-stimulated macrophages
in the presence or absence of PF-543. Treatment with PF-543 reduced the Zymosan-
induced phosphorylation at Tyr705 on STAT3, at both phosphorylation sites on Akt and
on ERK1/2. Costimulation of PF-543 pre-treated macrophages with S1P and Zymosan
did not rescue the reduction in phosphorylation nor did costimulation of macrophages
with S1P and Zymosan lead to greater phosphorylation of STAT3 or Akt compared to
165
Zymosan alone (figure 5.17). Pre-treatment of macrophages with THI (a S1P lyase in-
hibitor, which should elevate S1P levels) did not increase Zymosan-induced STAT3 or
Akt phosphorylation compared to Zymosan alone.
Figure 5.17: S1P addition does not rescue STAT3 phosphorylation in PF-543-treated macrophages
BMDMs were pre-treated with 5 µM PF-543 or 5 µM THI where indicated for 1 hour. Cells were stimulated
with 1 µM S1P, 200 µg/ml Zymosan or a combination of both for 4 hours where indicated. Cells were
lysed and proteins separated by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and
immunoblotted with antibodies to phospho STAT3 (Y705), phospho Akt (T308), phospho Akt (S473),
phospho p38 and phospho ERK1/2 and ERK1/2. Results are representative of two independent experiments.
5.8 Discussion
S1P signaling is important in many processes and in particular is required for appropriate
immune cell trafficking. The role of S1P, DHS1P and the sphingosine kinases 1 and 2
in regulating immune cell function is less well understood. Macrophages are part of the
innate immune response and are involved in the resolution of inflammation. Macrophages
can become polarised into different phenotypes of which the regulatory phenotype is char-
acterised by high levels of IL-10 production as well as expression of several markers in-
cluding SphK1. Zymosan-stimulated macrophages share several features with regulatory
macrophages including the high levels of IL-10 and expression of SphK1. The aim of this
work was to investigate a role for SphK1 in Zymosan-stimulated macrophages.
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The results presented in this chapter show that SphK1 expression is strongly up-regulated
in response to treatment with Zymosan after 8 hours and that LPS stimulation of macrophages
does not induce SphK1 expression. Interestingly, Zymosan treatment of macrophages
leads to an acute accumulation of DHS1P not S1P. This increase in DHS1P levels is
blocked by pre-treatment with each of three structurally distinct SphK inhibitors. Pre-
treatment of Zymosan-stimulated macrophages also affected the transcription and secre-
tion of the anti-inflammatory cytokine, IL-10. SphK inhibitors block the phosphorylation
of STAT3 at Tyr705, which is in line with decreased IL-10 secretion. Phosphorylation of
Akt at Thr308 and Ser473 is also reduced in SphK inhibitor-treated macrophages. In ad-
dition to blocking Zymosan-induced phosphorylation of STAT3 and Akt, SphK inhibitor
treatment reduced STAT3 and Akt phosphorylation in LPS-stimulated BMDMs. DHS1P
and S1P can signal via five plasma membrane-located GPCRs or via intracellular mecha-
nisms. Macrophages were treated with Zymosan and DHS1P or Zymosan and S1P in the
presence of a SphK inhibitor and neither DHS1P or S1P were able to rescue Zymosan-
induced phosphorylation of STAT3 in the presence of the SphK inhibitor.
5.8.1 Zymosan-induced expression and activation of SphK1
Zymosan stimulation of macrophages led to a strong induction of SphK1 mRNA expres-
sion by 8 hours. LPS stimulation does not result in a similar induction of SphK1 ex-
pression. The reasons behind the induction of SphK1 expression in response to Zymosan
signaling are unclear. It would be beneficial to measure the protein level of SphK at basal
conditions and following TLR4 and Dectin-1 stimulation as it would demonstrate whether
increased mRNA levels seen with Zymosan stimulation translated to an increased pool of
SphK1 which would be available to generate to DHS1P and S1P. However, there must be
a sufficient pool of SphK1 or SphK2 at basal conditions which allows for the rapid pro-
duction of DHS1P following 15 minutes of Zymosan stimulation (figure 5.8). A SphK1
antibody was tried, but failed to detect SphK1 in Zymosan-stimulated Raw264.7 cells.
Interestingly, intraplantar injection of Zymosan into wild type mice caused a decrease in
S1P levels at 1 hour and S1P levels were reduced by about 60% at 6 hours, although lev-
els increased back to basal at 48 hours (Linke et al., 2012). Unfortunately, measurements
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of DHS1P were not conducted in this study. In order to fully understand the importance
of S1P/DHS1P signaling in macrophages, the kinetics of sphingolipid levels need to be
measured over a timecourse following Zymosan stimulation. It has been reported that
SphK1 is activated via phosphorylation of Ser225 by ERK1/2 (Pitson et al., 2003), the
use of small molecule inhibitors could confirm this occurs in macrophage downstream
of Dectin-1 activation. Both Dectin-1 and TLR4 signaling activates ERK1/2. It would
also be interesting to see if TLR signaling also induced the accumulation of DHS1P and
whether the activation of SphK in macrophages is dependent on ERK1/2 activity.
5.8.2 SphK inhibitors block Zymosan-induced accumulation of DHS1P
In this study, three structurally distinct SphK inhibitors were used to determine the role
of SphK in Zymosan-stimulated macrophages. Each inhibitor was relatively selective
against the 120 or more protein kinases screened, however, more extensive screening
would be required to rule out any off-target protein kinases. Furthermore, each inhibitor
blocked the Zymosan-induced accumulation of DHS1P in macrophages. Treatment with
these SphK inhibitors also reduced levels of S1P in macrophages despite its production
not being induced by Zymosan. This suggests a turnover rate of S1P that is sensitive to
the inhibition of SphK for 1 hour.
5.8.3 Effects of SphK inhibitors on signaling and cytokine production
Zymosan-induced cytokine production was affected by pre-treatment of macrophages
with the SphK inhibitors. The results in this chapter show decreased mRNA and protein
levels of IL-10. In addition, signaling downstream of Zymosan was affected by the SphK
inhibitors. Phosphorylation of Akt at Thr308 and Ser473 was reduced in the presence of
the inhibitors. Also, STAT3 phosphorylation at Tyr705 was reduced. The reduced lev-
els of IL-10 could explain the reduced STAT3 phosphorylation as IL-10 leads to STAT3
phosphorylation via IL-10R-JAK. S1P and DHS1P can signal through five GPCRs or
intracellularly. Akt activation has been linked to signaling from GPCRs and this may ex-
plain the reduced activation of Akt evident in SphK inhibitor-treated macrophages (Murga
et al., 1998). However, if the effects seen on Akt activation and STAT3 phosphorylation
were caused by decreased S1P/DHS1P levels then the addition of exogenous lipid would
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be predicted to restore activation of Akt and STAT3 to levels seen in Zymosan-stimulated
macrophages. Addition of DHS1P did not restore STAT3 phosphorylation in Zymosan-
stimulated macrophages in the presence of SK1 I nor did S1P restore Akt or STAT3 phos-
phorylation in Zymosan-stimulated macrophages in the presence of PF-543. This would
suggest that the reduction in IL-10 transcription is the result of off-target effects of the
SphK inhibitors. Another explanation is that the addition of exogenous S1P/DHS1P may
not restore changes caused by reductions in intracellular sphingolipid levels as it may only
act on the five GPCRs located at the plasma membrane.
In order to validate the off-target effects of the SphK inhibitors, macrophages need to be
isolated from mice lacking SphK1 or SphK2. SphK1- or SphK2-deficient macrophages
would then be stimulated with Zymosan in the presence or absence of the SphK inhibitors
and cytokine production and signaling would be assessed. It would be predicted that the
inhibitors would still reduce STAT3 and Akt phosphorylation in SphK1/2-deficient cells
as seen in wildtype cells, although redundancy between SphK1 and SphK2 may compli-
cate the understanding of results obtained from single knockout macrophages. In sup-
port of this, deletion of SphK1 and SphK2 from macrophages did not alter macrophage
responses or the in vivo response to LPS injection. Furthermore, IL-10 serum levels fol-
lowing LPS injection were comparable between SphK1/2-deficient mice and control mice
(Xiong et al., 2013).
Interestingly, SphK inhibitors had similar effects on both LPS- and Zymosan-induced
signaling and cytokine production. LPS and Zymosan activate similar pathways and drive
transcription of many of the same cytokines and this suggests the SphK inhibitors inhibit
a shared component of LPS and Zymosan signaling.
5.8.4 Importance of SphK1 in the regulatory macrophage phenotype
Regulatory macrophages are characterised by high levels of IL-10 production and the ex-
pression of certain markers including SphK1. Interestingly, in IL-10 knockout macrophages,
SphK1 induction in response to Zymosan is reduced compared to wildtype macrophages
and LIGHT expression is similarly reduced (Elcombe et al., 2013). This suggests that the
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expression of IL-10 is required for maximal SphK1 expression. Notably, IL-10 knockout
macrophages fail to induce expression of SphK1 and LIGHT to similar levels as seen in
wildtype cells in response to LPS and PGE2 (MacKenzie et al., 2013a), suggesting the
importance of IL-10 in generating the regulatory phenotype. The importance of SphK1
in the induction or maintenance of the regulatory macrophage phenotype is unknown. It
would be interesting to determine if SphK1-deficient mice were able to generate regula-
tory macrophages as recognised by high levels of IL-10 and expression of LIGHT.
Other approaches could be used to further explore the role of SphK and S1P/DHS1P in
macrophage function. S1P/DHS1P is degraded by several enzymes including the sphin-
gosine 1-phosphate lyase. Inhibitors are available that block the action of the S1P lyase.
Primarily, it would be beneficial to see if these inhibitors increased intracellular concen-
trations of S1P and DHS1P in unstimulated and Zymosan-stimulated macrophages. Once
their effectiveness was established, then their effects on cytokine production and signaling
could be investigated. Another approach would be to characterise macrophage responses
from SphK1- and SphK2-deficient mice, however the complications of redundancy be-
tween the two isoforms may complicate the interpretation of the results. Both single
knockouts are viable but the double knockout is embryonic lethal (Mizugishi et al., 2005;
Allende et al., 2004). Recently, it was shown that conditional knockout of SphK1 and
SphK2 from macrophages did not alter the inflammatory response following LPS stimu-
lation suggesting SphK1 is not important in cytokine production in BMDMs (Xiong et al.,
2013).
SphK1 expression may not be intrinsically important to regulatory macrophage function
but may be important for controlling aspects of the immune response. The importance
of S1P in regulating immune cell function and trafficking is well established (Chi and
Flavell, 2005; Walzer et al., 2007; Niessen et al., 2008). Therefore SphK1 expression
may be important in regulatory macrophages by promoting recruitment of certain immune
cells or modulating the response of these cells. In particular, S1P is important for dendritic
cell and T cell localisation as well as being linked to NK cell function (Chi and Flavell,
2005; König et al., 2010; Pappu et al., 2007; Walzer et al., 2007). SphK function is also
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associated with appropriate mast cell function (Olivera et al., 2007; Oskeritzian et al.,
2008; Jolly et al., 2004). S1P is also important in regulating monocyte adhesion and
recruitment and therefore may be important in regulating macrophage migration (Bolick
et al., 2005; Keul et al., 2011; Maceyka et al., 2008). The complex range of processes that
can be influenced by the SphK/S1P axis may therefore be partially regulated by SphK1
expression in macrophages. Macrophage-specific deletion of SphK1 would allow the
dissection of the importance of the cellular source of S1P and DHS1P in determining the
immune response.
5.8.5 Control of SphK1 expression
Zymosan induces expression of Sphk1 by activating signaling downstream of Dectin-1
and TLRs. Dectin-1 signaling leads to the activation of NFkB and MAPKs, however
LPS signaling activates similar pathways and yet fails to induce SphK1 expression to
the same degree. Expression of SphK1 in response to Zymosan has been shown to be
blocked by a Syk inhibitor (Elcombe et al., 2013). The transcription factor Sp1 has been
shown to be important for SphK1 expression in response to nerve growth factor and was
shown to bind to the promoter region (Sobue et al., 2005). It has also been shown that
PGE2 in combination with LPS enhances SphK1 expression in a PKA-dependent manner
(MacKenzie et al., 2013a). It would be interesting to investigate the signaling pathways
and transcription factors that control expression of SphK1 in response to Zymosan.
5.8.6 Conclusion
S1P signaling has been implicated in regulating many aspect of immune cells. The re-
sults in this chapter demonstrate that Zymosan strongly induces SphK1 expression and
furthermore activates SphK in macrophages. Zymosan stimulation of macrophages led
to the accumulation of DHS1P, which was blocked by three structurally distinct SphK
inhibitors. SphK1 is a marker of regulatory macrophages which are also characterised by
high levels of IL-10 production.
Zymosan stimulated macrophages produce high amounts of IL-10 and pre-treatment of
macrophages with SphK inhibitors reduced transcription of IL-10 in response to Zy-
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mosan. The reduced transcription of IL-10 translated to lower levels of IL-10 protein. In
line with this, phosphorylation of STAT3 at Tyr705 which is mediated by IL-10R-JAK
was decreased in Zymosan-stimulated macrophages pre-treated with SphK inhibitors.
Inhibitor pre-treatment also reduced phosphorylation of Akt at two sites, Thr308 and
Ser473. Similar reductions in STAT3 and Akt phosphorylation were also evident in LPS-
stimulated macrophages pre-treated with SphK inhibitors. Addition of exogenous DHS1P
or S1P failed to restore phosphorylation of Akt or STAT3 to levels seen in Zymosan-
stimulated macrophages in the presence of a SphK inhibitor. This would suggest that the
SphK inhibitors target a shared component of TLR4 and Dectin-1 pathways which is im-
portant for driving transcription of IL-10 and the same or an additional target may also in-
fluence Akt activation. SphKs are activated in Zymosan-stimulated macrophages leading
to the accumulation of DHS1P. The relevance of this accumulation or of the Zymosan-
induced expression of SphK1 is unclear.
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Conclusions and future perspectives
The results presented in this thesis describe several mechanisms that regulate the tran-
scription of IL-10 in macrophages. The importance of IFNb signaling in sustaining tran-
scription of IL-10 following LPS stimulation was demonstrated. The JAK inhibitor, Rux-
olitinib, prevented maximal induction of IL-10, as did deletion of the type I IFN recep-
tor. Treatment with Ruxolitnib also increased pro-inflammatory cytokine production from
macrophages due to blocking the signaling of IL-10. Tofacitinib, another JAK inhibitor,
was shown to have a similar effect on cytokine production although a higher concentration
was required to block IL-10 signaling than that required for IFNb signaling. Both Ruxoli-
tinib treatment and deletion of the type I IFN receptor resulted in a loss of phosphorylated
STAT1 in response to LPS. The direct binding of STAT1 to the IL-10 promoter was not
shown and therefore it is unclear whether STAT1 directly regulates IL-10 or whether an
intermediate is required to drive IL-10 transcription downstream of IFNb signaling.
MCP-1 was also identified as requiring IFNb signaling for maximal transcription. MCP-1
transcription was directly stimulated by IFNb and the binding of STAT1 to a STAT bind-
ing site within the MCP-1 promoter was demonstrated in response to IFNb. MCP-1 is an
important chemokine and is required for appropriate responses to viral infections. Un-
fortunately, due to the changes in cytokine production caused by Ruxolitinib treatment or
deletion of the type I IFN receptor, it would not have been possible to demonstrate that
the reduced MCP-1 affected the immune response to viral or bacterial infection.
This thesis also describes the role ofMEF2D in regulating IL-10 transcription in macrophages.
MEF2D was phosphorylated in response to LPS at Ser121. The relevance of this phos-
phorylation event was not determined, however a specific phospho-antibody to this site
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was characterised. The function of Ser121 phosphorylation will need to be investigated
further. Phosphorylation of MEF2D at Ser121 may alter its DNA binding activity, cellular
localisation or interactions with co-activators/co-repressors. Stable expression of MEF2D
protein with the phosphorylation site mutated may help to determine the function of this
phosphorylation event. MEF2D negatively influences IL-10 transcription in response to
TLR agonists. Deletion of MEF2D increases IL-10 production and results in decreased
pro-inflammatory cytokine secretion. The mechanism through which MEF2D negatively
regulates IL-10 was not determined in this study. However, MEF2D KO macrophages
had elevated primary transcript levels of IL-10 suggesting that MEF2D affects transcrip-
tion of IL-10 rather than IL-10 mRNA stability. Analysis of MEF2D binding to the IL-10
promoter using chromatin immunoprecipitation may demonstrate whether this is a direct
effect of MEF2D at the IL-10 promoter or via an intermediate.
The control of IL-10 transcription is important due to its potent anti-inflammatory ef-
fects. Loss of IL-10 production leads to the development of colitis (Kühn et al., 1993),
therefore understanding pathways that regulate IL-10 production is important in a clinical
context. Understanding the pathways that regulate MEF2D activity may provide a novel
approach to influence IL-10 levels. In addition to its role in regulating IL-10 production
from macrophages, it would be important to determine if MEF2D regulates IL-10 produc-
tion in other cell types such as B10 cells and Tr1 cells, which produce high levels of IL-10.
MEF2D also influences A20 mRNA levels and this regulation needs to be studied in
greater detail. MEF2D may also bind to the A20 promoter which contains MEF2 consen-
sus sequences and therefore chromatin immunoprecipitations may demonstrate the direct
binding of MEF2D to the A20 promoter. A20 is a negative regulator of NFkB signaling
and is important in the termination of TLR signaling (Heyninck and Beyaert, 1999; Ver-
helst et al., 2012; Boone et al., 2004). Interestingly, A20 deficiency has been linked to
protection against influenza infection, however it has also been linked to the development
of polyarthritis (Maelfait et al., 2012; Matmati et al., 2011). The increased levels of A20
protein seen in MEF2D-deficient macrophages may therefore affect immune responses to
viral infection. The generation of MEF2D and IL-10 double knockout mice would allow
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the investigation of changes to A20 levels without the complicating factors of increased
IL-10 and decreased TNFa, IL-6 and IL-12 from macrophages.
The role of SphK1 in macrophages was investigated in the final part of this thesis. Zy-
mosan strongly induces the expression of SphK1, a marker of regulatory macrophages.
Zymosan stimulation activates SphK leading to the accumulation of DHS1P. Three struc-
turally distinct inhibitors blocked the accumulation of DHS1P in response to Zymosan
as well as reducing S1P levels. The effect of these inhibitors on macrophage cytokine
production and signaling was then examined. Each inhibitor reduced production of IL-
10 and reduced phosphorylation of Akt at Thr308 and Ser473 and STAT3 at Tyr705 in
response to Zymosan. The addition of exogenous DHS1P or S1P did not restore the phos-
phorylation of Akt or STAT3 in response to Zymosan in the presence of a SphK inhibitor.
The SphK inhibitors may therefore have off-target effects within macrophages that reduce
IL-10 production and reduce Akt activation.
The functional relevance of SphK1 expression in macrophages was not established. Zy-
mosan stimulation of SphK1- and SphK2-deficient macrophages would be necessary to
confirm that the effects of the inhibitors seen on IL-10 production and Akt activation were
not a result of SphK inhibition. Interestingly, LPS-stimulated macrophages were similary
sensitive to the SphK inhibitors despite not leading to induction of SphK1 expression.
However SphK1 is known to be activated by ERK1/2 which is activated by both Zymosan
and LPS stimulation. SphK1 expression in macrophages may not regulate macrophage
function but may influence the function or recruitment of immune cells in a paracine
manner.
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Appendices
Appendix A- Kinase selectivity screens for Ruxolitinib and Tofacitinib
The percentage in vitro kinase activity remaining relative to no inhibitor controls was
determined using in vitro kinase assays as described in the methods. Data represents the
average and range of duplicate measurements for each condition. n.d. = not determined
0.1 mM Ruxolitinib 1 mM Ruxolitinib 0.1 mM Tofacitinib 1 mM Tofacitinib
kinase % activity range % activity range % activity range % activity range
ABL 100 5 101 2 103 13 116 10
AMPK 107 6 89 10 83 1 95 5
ASK1 107 3 77 8 105 7 130 11
Aurora A 86 18 26 0 93 8 119 16
Aurora B 112 10 95 7 69 6 92 8
BRK 101 4 84 11 80 18 92 7
BRSK1 92 6 78 17 73 2 92 7
BRSK2 93 3 92 3 82 5 101 3
BTK 76 12 58 2 96 6 94 11
CAMK1 91 10 58 0 93 1 111 2
CAMKKb 100 17 104 2 139 15 116 10
CDK2 96 11 57 6 69 4 116 37
CHK1 99 0 106 7 86 13 88 1
CHK2 97 10 65 14 106 7 95 9
CK1 94 11 74 6 105 4 109 9
CK2 90 25 77 6 92 1 97 7
CLK2 73 2 21 2 106 10 108 1
CSK 91 23 63 6 84 7 78 3
DAPK1 88 39 61 64 145 5 123 11
DYRK1A 101 3 67 1 102 1 92 7
DYRK2 95 17 86 12 99 14 103 5
DYRK3 103 17 107 3 110 18 116 2
EF2K 82 15 83 12 103 1 100 2
EIF2AK3 89 2 94 2 114 8 97 9
EPH-A2 98 29 62 1 106 6 114 19
EPH-A4 85 4 58 5 121 2 109 3
EPH-B1 71 2 48 4 93 4 93 4
EPH-B2 132 38 79 7 91 10 121 12
EPH-B3 96 9 86 9 103 8 85 5
EPH-B4 78 9 59 0 131 46 120 4
ERK1 101 16 92 17 108 5 97 4
ERK2 115 15 102 3 99 17 97 10
ERK8 86 29 47 4 121 1 121 6
FGF-R1 79 9 34 4 42 4 85 3
GCK 86 9 44 2 87 0 109 7
GSK3b 100 8 62 4 110 2 108 9
HER4 106 6 90 5 116 8 121 19
HIPK1 102 4 95 6 90 4 112 4
HIPK2 94 3 69 2 128 21 117 6
HIPK3 116 3 114 7 109 14 108 3
IGF-1R 94 11 100 5 109 9 104 11
IKKb 101 18 76 15 126 3 105 2
IKKe 105 33 46 5 90 7 87 8
IR 95 9 89 1 87 8 105 9
IRAK1 63 12 19 4 111 4 106 3
IRAK4 89 27 97 7 80 1 87 0
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0.1 mM Ruxolitinib 1 mM Ruxolitinib 0.1 mM Tofacitinib 1 mM Tofacitinib
kinase % activity range % activity range % activity range % activity range
IRR 97 22 65 22 102 3 103 5
JAK2 3 1 2 1 3 1 4 0
JNK1 84 26 79 15 81 5 80 3
JNK2 105 37 89 13 88 9 94 4
JNK3 101 27 94 1 107 10 119 12
Lck 95 1 69 8 30 0 73 9
LKB1 106 36 87 13 95 5 101 9
MK2 102 13 102 9 91 11 82 7
MK3 89 1 101 2 118 7 91 4
MARK1 96 7 55 3 63 1 82 10
MARK2 97 6 42 7 85 4 98 1
MARK3 56 22 13 6 33 4 94 16
MARK4 94 20 88 1 86 1 93 2
MEKK1 89 31 89 6 83 80 97 7
MELK 81 11 42 7 74 5 115 12
MINK1 122 27 94 5 90 9 96 7
MKK1 108 10 73 6 67 6 105 6
MKK2 99 4 93 4 112 20 110 3
MKK6 95 5 101 8 89 2 97 8
MLK1 82 13 34 2 90 8 86 5
MLK3 65 20 27 5 75 1 83 12
MNK1 81 9 66 5 115 0 100 11
MNK2 88 11 39 1 64 10 97 2
MPSK1 104 4 101 5 83 14 94 10
MSK1 84 0 29 1 76 15 83 10
MST2 97 28 68 8 64 12 79 7
MST4 140 31 105 24 109 0 87 8
NEK2a 108 22 82 1 107 32 102 16
NEK6 84 10 83 22 90 5 87 3
NUAK1 89 24 26 1 30 2 74 5
OSR1 80 30 40 3 94 12 112 9
p38aMAPK 85 15 83 1 103 4 100 1
p38bMAPK 97 16 79 18 115 3 106 12
p38gMAPK 67 22 66 3 108 17 101 7
p38dMAPK 94 15 86 5 130 9 115 6
PAK2 88 24 84 9 114 2 99 2
PAK4 96 3 57 0 116 16 104 10
PAK5 94 15 72 4 94 4 86 7
PAK6 96 10 70 1 116 10 100 3
PDK1 101 37 66 8 123 3 107 14
PHK 60 3 15 0 85 11 96 2
PIM1 101 16 85 3 101 8 112 5
PIM2 87 5 90 12 121 21 102 5
PIM3 90 13 85 10 114 9 124 12
PKA 95 11 53 2 89 1 94 4
PKBa 93 24 77 15 125 4 115 1
PKBb 86 15 87 4 92 6 85 9
PKCa 88 14 67 5 71 0 96 0
PKCz 100 21 95 1 106 20 100 21
PKCg 93 8 80 2 102 5 99 11
PKD1 101 6 67 16 106 27 92 4
PLK1 108 1 95 6 121 18 128 7
PRAK 83 16 84 3 123 7 113 10
PRK2 84 5 61 7 22 0 50 2
RIPK2 108 17 78 4 92 3 91 9
ROCK 2 60 9 59 59 46 9 95 15
RSK1 82 6 68 9 76 23 96 6
RSK2 92 4 81 3 86 2 91 3
S6K1 79 23 53 2 77 16 88 0
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0.1 mM Ruxolitinib 1 mM Ruxolitinib 0.1 mM Tofacitinib 1 mM Tofacitinib
kinase % activity range % activity range % activity range % activity range
SGK1 100 13 75 10 106 19 92 2
SmMLCK 93 22 67 6 104 3 105 3
Src 67 14 62 4 90 7 92 5
SRPK1 85 13 67 4 89 8 84 6
STK33 108 1 84 7 103 19 98 4
SYK 96 18 83 30 152 16 131 7
TAK1 85 2 60 1 113 34 115 7
TAO1 104 1 85 15 103 4 104 12
TBK1 82 16 46 0 83 19 99 6
TIE2 98 4 78 3 106 19 99 1
TLK1 82 3 80 8 104 8 100 3
TrkA 32 1 18 3 87 11 106 13
TTK 95 7 44 2 115 7 99 3
VEG-FR 102 32 56 10 58 10 99 5
YES1 75 10 59 5 65 4 104 3
ZAP70 95 7 92 16 125 3 133 0
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Appendix B- Kinase selectivity screens for sphingosine kinase inhibitors
The percentage in vitro kinase activity remaining relative to no inhibitor controls was
determined using in vitro kinase assays as described in the methods. Data represents the
average and standard deviation of duplicate measurements for each condition. n.d. = not
determined
10 µM SKI I 10 µM SKI II 10 µM PF-543
protein kinase % activity st. dev. % activity st. dev. % activity st. dev.
ABL 109 10 75 5 94 3
AMPK 94 6 89 7 85 5
ASK1 94 0 83 1 94 5
Aurora A 92 15 59 5 100 2
Aurora B 93 0 89 4 100 6
BRK 104 2 73 3 116 14
BRSK1 97 1 73 11 112 4
BRSK2 108 7 80 4 90 7
BTK 103 15 80 12 112 4
CAMK1 89 5 22 1 99 11
CAMKKb 90 2 84 6 103 5
CDK2-Cyclin A 88 3 94 12 99 11
CDK9-Cyclin T1 n.d. n.d. n.d. n.d. 93 2
CHK1 86 9 131 24 89 6
CHK2 82 8 50 11 95 5
CK1g2 n.d. n.d. n.d. n.d. 94 11
CK1d 81 4 109 10 118 27
CK2 83 2 84 13 104 17
CLK2 97 11 75 0 86 6
CSK 98 5 75 11 116 1
DAPK1 103 18 89 16 93 10
DDR2 n.d. n.d. n.d. n.d. 86 2
DYRK1A 84 6 54 11 79 4
DYRK2 119 7 101 0 94 23
DYRK3 93 9 82 2 88 6
EF2K 69 1 85 6 85 2
EIF2AK3 n.d. n.d. n.d. n.d. 90 4
EPH-A2 91 6 80 6 95 12
EPH-A4 96 7 59 2 88 7
EPH-B1 115 18 86 14 96 15
EPH-B2 108 5 92 5 102 9
EPH-B3 86 0 117 4 103 6
EPH-B4 123 13 81 8 92 7
ERK1 85 4 86 23 94 15
ERK2 100 5 97 1 99 15
ERK5 n.d. n.d. n.d. n.d. 105 4
ERK8 77 0 59 1 81 14
FGF-R1 104 1 84 2 119 34
GCK 71 9 38 8 94 2
GSK3b 71 2 101 4 86 1
HER4 105 6 45 13 84 12
HIPK1 94 18 90 16 101 1
HIPK2 106 5 62 2 85 1
HIPK3 102 3 86 20 100 5
IGF-1R 93 14 89 10 64 11
IKKb 100 6 94 0 87 10
IKKe 86 4 84 3 91 5
IR 99 2 88 18 101 29
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10 µM SKI I 10 µM SKI II 10 µM PF-543
protein kinase % activity st. dev. % activity st. dev. % activity st. dev.
IRAK1 n.d. n.d. n.d. n.d. 92 3
IRAK4 67 1 86 3 105 3
IRR 100 5 76 22 83 3
JAK2 100 10 93 8 94 7
JNK1 90 21 84 4 100 3
JNK2 88 5 84 17 91 6
JNK3 98 8 88 3 99 6
Lck 84 11 84 3 113 9
LKB1 98 4 81 4 113 2
MAP4K3 n.d. n.d. n.d. n.d. 95 5
MAP4K5 n.d. n.d. n.d. n.d. 100 14
MAPKAP-K2 91 4 77 4 97 3
MAPKAP-K3 123 7 68 5 110 1
MARK1 104 6 91 14 123 25
MARK2 83 6 88 1 99 1
MARK3 105 0 85 10 112 0
MARK4 93 10 74 3 102 1
MEKK1 89 0 79 7 94 1
MELK 98 14 74 4 99 6
MINK1 111 13 44 1 96 2
MKK1 97 9 85 5 92 3
MKK2 109 19 82 4 106 26
MKK6 99 1 99 26 101 8
MLK1 100 3 30 3 96 2
MLK3 109 12 30 0 109 28
MNK1 93 1 93 4 86 3
MNK2 102 14 103 3 118 4
MPSK1 100 4 83 9 100 16
MSK1 95 1 93 7 124 1
MST2 94 7 73 5 96 5
MST3 n.d. n.d. n.d. n.d. 115 6
MST4 108 13 90 8 127 23
NEK2a 108 7 92 3 111 10
NEK6 84 9 102 19 111 13
NUAK1 101 5 66 8 102 10
OSR1 n.d. n.d. n.d. n.d. 106 0
p38a MAPK 80 9 47 9 91 7
p38b MAPK 95 2 64 6 97 5
p38d MAPK 90 1 104 5 92 3
p38g MAPK 87 5 106 16 112 13
PAK2 113 8 86 18 95 12
PAK4 85 5 93 2 82 7
PAK5 101 4 108 10 116 5
PAK6 103 5 84 6 95 7
PDGFRA n.d. n.d. n.d. n.d. 98 26
PDK1 122 9 86 6 117 22
PHK 76 0 79 1 126 12
PIM1 95 10 18 1 113 17
PIM2 97 2 74 0 86 12
PIM3 107 2 12 0 96 1
PINK n.d. n.d. n.d. n.d. 104 3
PKA 107 12 81 4 100 5
PKBa 107 24 107 7 89 11
PKBb 86 2 72 10 94 1
PKCa 89 5 106 12 111 6
PKCg 96 1 85 6 93 11
PKCz 92 5 99 6 99 4
PKD1 115 15 77 4 94 7
PLK1 96 3 97 5 103 1
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10 µM SKI I 10 µM SKI II 10 µM PF-543
protein kinase % activity st. dev. % activity st. dev. % activity st. dev.
PRAK 90 3 76 6 94 5
PRK2 58 1 81 8 76 0
RIPK2 100 4 70 3 102 8
ROCK 2 116 3 74 8 99 9
RSK1 81 8 109 3 110 13
RSK2 81 11 73 6 105 1
S6K1 100 0 80 2 109 4
SGK1 78 4 145 17 96 1
SIK2 n.d. n.d. n.d. n.d. 95 3
SIK3 n.d. n.d. n.d. n.d. 107 7
SmMLCK 91 15 51 3 109 3
Src 111 13 76 1 93 2
SRPK1 83 9 85 3 92 3
STK33 89 16 97 1 102 1
SYK 92 13 90 8 101 6
TAK1 111 2 100 8 106 1
TAO1 91 6 103 10 108 7
TBK1 93 1 92 4 110 7
TESK1 n.d. n.d. n.d. n.d. 109 10
TGFBR1 n.d. n.d. n.d. n.d. 114 19
TIE2 113 4 110 8 102 2
TLK1 n.d. n.d. n.d. n.d. 98 6
TrkA 86 0 107 20 107 25
TSSK1 n.d. n.d. n.d. n.d. 108 2
TTBK1 n.d. n.d. n.d. n.d. 74 7
TTBK2 n.d. n.d. n.d. n.d. 84 8
TTK 86 4 81 9 100 5
ULK1 n.d. n.d. n.d. n.d. 108 17
ULK2 n.d. n.d. n.d. n.d. 81 11
VEG-FR 83 4 59 1 80 7
WNK1 n.d. n.d. n.d. n.d. 111 0
YES1 109 2 61 5 95 0
ZAP70 92 0 129 31 95 18
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Appendix C- Mass spectrometry data from SILAC experiment from figure 4.4
Table 1 of 2
Protein Name Uniprot Position Peptide Sequence Ratio M/L
100 kDa coactivator Q78PY7 426 _VNVTVDYIRPAS(ph)PATETVPAFSER_ 2.0497
26S proteasome non-ATPase regulatory subunit 11 Q8BG32 14 _AQS(ph)LLSTDREASIDILHSIVKR_ 9.1192
26S proteasome non-ATPase regulatory subunit 2 Q8VDM4 361 _FGGS(ph)GSQVDSAR_ 2.4393
26S proteasome non-ATPase regulatory subunit 4 O35226 256 _RAAAASAAEAGIATPGT(ph)EDSDDALLK_ 3.0459
40S ribosomal protein S20 P60867 9 _DTGKT(ph)PVEPEVAIHR_ 13.9310
6-phosphofructokinase, liver type P12382 775 _TLS(ph)IDKGF_ 9.7890
60S acidic ribosomal protein P1 P47955 101 _KEES(ph)EES(ph)EDDM(ox)GFGLFD_ 6.7194
60S acidic ribosomal protein P1 P47955 104 _KEES(ph)EES(ph)EDDM(ox)GFGLFD_ 4.8244
60S ribosomal protein L24 Q3UW40 83 _AIT(ph)GASLADIMAK_ 8.4185
60S ribosomal protein L7-like 1 Q9D8M4 54 _RLES(ph)FVHDSWR_ 4.5002
A-kinase anchor protein 9 Q70FJ1 3676 _DGFGLS(ph)PGIEK_ 4.5009
Abelson tyrosine-protein kinase 2 Q4JIM5 936 _VPVLIS(ph)PTLK_ 8.5376
Acetylcholine receptor subunit beta P09690 478 _LILQGEAES(ph)R_ 4.1537
Acidic leucine-rich nuclear phosphoprotein 32 family member A O35381 17 _TPS(ph)DVKELVLDNCK_ 28.4010
Acidic nucleoplasmic DNA-binding protein 1 P59328 1077 _VVS(ph)EICETENQEETVKENLDLSKK_ 55.6860
Actin-binding protein 1 Q62418 291 _LRS(ph)PFLQK_ 4.4441
Actin-binding protein 1 Q62418 277 _AM(ox)S(ph)TTSVTSSQPGK_ 2.8880
Actin-binding protein anillin Q8K298 292 _AS(ph)SPVTAATFITENR_ 6.2051
Actin-binding protein anillin Q8K298 790 _TSVIS(ph)QSEFAPSK_ 4.3406
Activated Cdc42-associated guanine nucleotide exchange factor A2AF47 1352 _SQT(ph)M(ox)PALR_ 4.6970
Activated RNA polymerase II transcriptional coactivator p15 P11031 55 _QS(ph)SSSRDDNMFQIGK_ 7.9230
Activating transcription factor 2 P16951 72 _NCEEVGLFNELAS(ph)PFENEFKK_ 42.1110
Activating transcription factor 3 Q60765 162 _AQNGRT(ph)PEDERNLFIQQIK_ 17.6040
Activating transcription factor 4 Q61328 279 _APPDNLPS(ph)PGGSR_ 3.9011
Activator protein 1 P05627 63 _NSDLLTS(ph)PDVGLLK_ 8.3994
Adaptor-associated kinase 1 Q3UHJ0 621 _VGSLT(ph)PPS(ph)SPK_ 3.9064
Adducin-like protein 70 Q9QYB5 423 _HKSDVEIPATVTAFSFEDDSAPLS(ph)PLK_ 10.4070
Adducin-like protein 70 Q9QYB5 12 _(ac)SSDTSPAVVTT(ph)PPPPSMPHK_ 6.3421
Adenomatous polyposis coli protein Q61315 2713 _QSVGSGS(ph)PVQTVGLETR_ 5.6187
Adenosine monophosphate deaminase 2 (Isoform L) A2AE27 70 _S(ph)LPGNAPCLK_ 27.2500
Adenosine monophosphate deaminase 2 (Isoform L) A2AE27 160 _AKQDFLKTDS(ph)DSDLQLYK_ 15.0210
Adenosine monophosphate deaminase 2 (Isoform L) A2AE27 138 _QIS(ph)QDVKLEPDILLR_ 2.8002
Adhesion and degranulation promoting adaptor protein O35601 203 _HTFGQKPSLS(ph)TEDSQEENTSK_ 26.1100
ADP-ribosylation factor GTPase-activating protein 2 Q99K28 143 _HGTDLWIDSM(ox)NSAPS(ph)HSPEKK_ 7.1105
Adrenocortical dysplasia protein Q5EE38 20 _ELILGS(ph)ET(ph)LSSPR_ 2.6217
Adrenocortical dysplasia protein Q5EE38 22 _ELILGS(ph)ET(ph)LSSPR_ 2.6217
Afadin Q9QZQ1 1726 _TQVLS(ph)PDSLFTAK_ 10.7200
Afadin Q9QZQ1 1777 _S(ph)QDADLPGSSGAPENLTFK_ 3.3673
Afadin Q9QZQ1 655 _YVLSSQHRPDIS(ph)PTER_ 2.2574
AHNAK nucleoprotein 2 Q3URZ6 35 _KLS(ph)FSM(ox)PR_ 3.0450
Ahnak protein A0JLR7 2985 _GPSLDIKS(ph)PKLDVNAPDIDVHGPEGK_ 41.9810
Ahnak protein A0JLR7 5325 _GPSFNVAS(ph)PESDFGVSLKGPK_ 40.7930
Ahnak protein A0JLR7 4906 _VPDVDISS(ph)PGINVEAPDIHMK_ 36.3920
Ahnak protein A0JLR7 4686 _MPS(ph)LEVSVPK_ 35.7980
Ahnak protein A0JLR7 4975 _IKAPSFSVSAPQVS(ph)IPDVNVNLKGPK_ 35.0310
Ahnak protein A0JLR7 4740 _VDLETPSLDVHMES(ph)PDINIEGPDVK_ 25.0790
Ahnak protein A0JLR7 4298 _TPQIS(ph)MSDIDLNVK_ 18.7780
Ahnak protein A0JLR7 177 _EGVKDIDIT(ph)SPEFMIK_ 15.3540
Ahnak protein A0JLR7 4879 _MYFPDVEFDIKS(ph)PK_ 13.3400
Ahnak protein A0JLR7 4342 _LDIDT(ph)PDIDIHGPEGK_ 9.9429
Ahnak protein A0JLR7 2381 _ISMPDIDLHLKS(ph)PK_ 9.4088
Ahnak protein A0JLR7 5041 _MEGGSTEIGAQMPS(ph)LEGGLSTSDMK_ 9.3720
Ahnak protein A0JLR7 178 _EGVKDIDIT(ph)SPEFMIK_ 8.9735
Ahnak protein A0JLR7 496 _VKT(ph)PEMIIQKPK_ 8.5903
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Ahnak protein A0JLR7 4950 _VQANLDT(ph)PDINIEGPEAK_ 8.3631
Ahnak protein A0JLR7 5292 _LSSGQIS(ph)GPEIK_ 5.9896
Ahnak protein A0JLR7 5563 _SNS(ph)FSDEREFS(ph)APSTPTGTLEFAGGDAK_ 4.6212
Ahnak protein A0JLR7 5535 _ASLGSLEGEVEAEAS(ph)SPKGK_ 4.0238
Ahnak protein A0JLR7 4890 _FKAEAPLPS(ph)PKLEGEIK_ 3.9415
Ahnak protein A0JLR7 136 _LRS(ph)EDGVEGDLGETQSR_ 3.6377
Ahnak protein A0JLR7 4766 _FGFGAKS(ph)PK_ 3.6359
Ahnak protein A0JLR7 5605 _SKGHYEVT(ph)GSDDEAGKLQGSGVSLASK_ 2.2529
Ahnak protein A0JLR7 159 _RVT(ph)AYTVDVTGR_ 2.1025
Ahnak protein A0JLR7 94 _S(ph)PEPGQTWTHEVFSSR_ 2.6105
Ahnak protein A0JLR7 893 _FGMPGFKAES(ph)PEMEVNLPK_ 9.4471
AI607873 protein B2RWU7 106 _NGQEAGPAT(ph)PTSTTSHMLTSER_ 2.3523
Akt substrate of 160 kDa Q8BYJ6 324 _CSS(ph)VTGVMQK_ 5.1961
Akt substrate of 160 kDa Q8BYJ6 673 _AHGLRS(ph)PLLR_ 2.2629
Alkylated DNA repair protein alkB homolog 5 Q3TSG4 362 _RGS(ph)FSSENYWR_ 2.1991
Alpha-adducin Q9QYC0 11 _AAVVT(ph)SPPPTTAPHKER_ 4.0882
Alpha-PAK O88643 212 _SVIEPLPVT(ph)PTR_ 14.5440
Amino acid transport system xc- Q9WTR6 26 _LPS(ph)MGDQEPPGQEK_ 3.0970
AMMECR1-like protein Q3V0N3 161 _MNTASGALS(ph)PLPRPNGTANSTK_ 2.6189
Anaphase promoting complex subunit 1 A2ATQ4 688 _SFDFEGSLS(ph)PVIAPK_ 2.6709
Ancient ubiquitous protein 1 P70295 319 _LRPQSVQSSFPSPPS(ph)PSSDVQLTTLAHR_ 2.5991
Androgen-induced proliferation inhibitor Q4VA53 1358 _AES(ph)PETSAVESTQSTPQK_ 2.7543
Ankrd11 protein B2RY01 1091 _KAS(ph)FDQLR_ 3.9197
Ankyrin repeat domain-containing protein 55 Q8BLD6 474 _SRS(ph)EQDLLNNR_ 11.4170
Annexin A1 P10107 37 _GGPGSAVS(ph)PYPSFNVSSDVAALHK_ 7.9615
Antigen containing epitope to monoclonal antibody MMS-85/12 O35243 896 _TKS(ph)LLEDKVVSK_ 31.7580
Antigen containing epitope to monoclonal antibody MMS-85/12 O35243 1364 _RHLS(ph)EDSQATLLYSK_ 17.2800
Antigen containing epitope to monoclonal antibody MMS-85/12 O35243 656 _RTS(ph)TPVILEGAQEETDTR_ 6.0708
Antigen containing epitope to monoclonal antibody MMS-85/12 O35243 795 _RLS(ph)VLGR_ 4.9062
Aortic preferentially expressed protein 1 Q62407 2413 _RLS(ph)LSLSQK_ 2.2089
AP1 subunit gamma-binding protein 1 Q5SV85 576 _TADSVS(ph)PLEPPTKDTFPSAFASGAAQQTQTQVK_ 13.2090
AP1 subunit gamma-binding protein 1 Q5SV85 974 _DMMPQTTEQKEFES(ph)GDFQDFTR_ 5.4966
APG16-like 1 Q8C0J2 287 _S(ph)VSSIPVPQDIMDTHPASGK_ 5.1235
Apoptosis-stimulating of p53 protein 1 Q62415 335 _VNGTSSPQS(ph)PLSTSGR_ 5.6452
Apoptosis-stimulating of p53 protein 2 Q8CG79 561 _MLLS(ph)PGAPSGGQDQVLSPASK_ 11.2280
Apoptotic chromatin condensation inducer 1 B8JJ87 710 _HLS(ph)HPEPEQQHVIQR_ 7.7242
ARF GTPase-activating protein GIT1 Q68FF6 612 _HGSGADSDY(ph)ENTQS(ph)GDPLLGLEGKR_ 2.9365
Arfgef1 protein Q8BKL2 1566 _S(ph)VDIHDSIQPR_ 3.2505
Arfip1 protein A2RSX9 361 _LKT(ph)PGVDAPSWLEEQ_ 24.7510
Arginine glutamic acid dipeptide (RE) repeats A2A7T4 1258 _TLSEYARPHVMS(ph)PTNR_ 2.0051
Arhgap21 protein B2RWX1 928 _KGS(ph)SSEVFSDAAR_ 2.0221
ARID domain-containing protein 4B A2CG63 830 _YCS(ph)ADECLQTGSPGK_ 15.2720
Astrocytic phosphoprotein PEA-15 Q62048 116 _YKDIIRQPS(ph)EEEIIK_ 2.4348
AT-hook DNA-binding motif-containing protein 1 Q6PAL7 1060 _ASTVS(ph)PGGYMVPK_ 4.6963
AT-rich interactive domain-containing protein 1A A2BH40 1603 _TS(ph)PS(ph)KSPFLHSGMK_ 3.4040
AT-rich interactive domain-containing protein 1A A2BH40 1183 _S(ph)NSVGIQDAFPDGSDPTFQKR_ 5.5198
AT-rich interactive domain-containing protein 1A A2BH40 1185 _S(ph)NSVGIQDAFPDGSDPTFQKR_ 3.5919
Ataxia telangiectasia and Rad3-related protein Q9JKK8 438 _KLS(ph)SSLSSYK_ 22.5770
Ataxin-1 Q8C866 62 _HGS(ph)AGTSGEHGLQGMGLHK_ 16.4070
Ataxin-2-like protein Q7TQH0 499 _LSLT(ph)PTDVKELPTKEPSR_ 6.6047
Ataxin-2-like protein Q7TQH0 109 _GPPQS(ph)PVFEGVYNNSR_ 2.1097
ATM and Rad3-related-interacting protein Q8BMG1 14 _KQS(ph)GGLEPFPGLSR_ 4.9993
ATP citrate lyase Q3TED3 455 _TAS(ph)FSESRADEVAPAKK_ 3.2462
ATP-dependent DNA helicase 2 subunit 1 P23475 518 _RLGS(ph)LADEFK_ 10.0930
ATP-dependent helicase CHD8 Q09XV5 2040 _SRLTS(ph)QDYEVR_ 2.8221
ATP-dependent helicase SMARCAD1 Q04692 79 _KAS(ph)LSCFQNQR_ 2.6680
ATP-dependent helicase SMARCAD1 Q04692 81 _KAS(ph)LSCFQNQR_ 2.3415
ATP-dependent RNA helicase BRIP1 Q5SXJ3 970 _S(ph)DPGLRGESLQTMK_ 4.2282
ATP-dependent RNA helicase Dhx29 Q6PGC1 69 _IYSFNS(ph)ANDSGGSANLDK_ 38.8500
Autophagy-related protein 2 homolog B Q80XK6 1571 _DFATAPPT(ph)SPAK_ 5.9794
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Autophagy-related protein 2 homolog B Q80XK6 255 _LS(ph)PSWNPK_ 7.3830
Autophagy-related protein 2 homolog B Q80XK6 379 _KDS(ph)LSMGVSSEK_ 2.1052
AVO3 homolog Q6QI06 1461 _MFS(ph)HDGAGLSSGAGGLVK_ 23.5970
Axam2 Q91ZX6 332 _LGS(ph)GSNGLLR_ 4.7955
B aggressive lymphoma protein homolog Q8CAS9 42 _RGHS(ph)EGDYPPLR_ 3.3726
B-cell adapter for phosphoinositide 3-kinase Q9EQ32 629 _DRPPS(ph)SIYDPFAGMK_ 2.9633
Barren homolog protein 1 Q8C156 25 _GQQDVLSS(ph)PLER_ 9.9552
Basic SAP coiled-coil transcription activator Q8K4J6 349 _S(ph)LSTSSSPSSGTPGPSGLAR_ 3.1417
Basic SAP coiled-coil transcription activator Q8K4J6 548 _AASCCLS(ph)PGAR_ 11.0370
Basic SAP coiled-coil transcription activator Q8K4J6 423 _AYQDQVS(ph)PAPGAPK_ 6.9894
Basophilic leukemia-expressed protein Bles03 Q8VD62 36 _ARS(ph)WVGAER_ 4.2455
BCKD-kinase O55028 31 _S(ph)TSATDTHHVELAR_ 5.1256
Bcl-2-associated transcription factor 1 Q8K019 688 _LRCDS(ph)ADLR_ 2.1719
Bcl2 antagonist of cell death Q61337 155 _RMS(ph)DEFEGSFK_ 2.3092
Beige-like protein Q9ESE1 982 _KDSPIS(ph)PHFTR_ 2.2366
Beta enolase repressor factor 1 Q61624 311 _GGLLTSEEDSGFSTSPKDNS(ph)LPK_ 4.3202
Beta-adrenergic receptor kinase 1 Q99MK8 670 _NKPRS(ph)PVVELSK_ 4.5028
Beta-Pix Q9ES28 598 _KPS(ph)DEEFAVRK_ 2.7620
Binder of Rho GTPases 2 Q9CQC5 75 _AHS(ph)GQFPGHNDFFR_ 4.4837
Bobby sox homolog Q8VBW5 242 _QKS(ph)PLFQFAEISSR_ 2.6683
BolA-like protein 1 Q9D8S9 45 _AKLEQALS(ph)PEVLELR_ 7.9793
BPG-dependent PGAM 1 Q9DBJ1 31 _FSGWYDADLS(ph)PAGHEEAK_ 2.9618
Brain-specific gene 4 protein Q3U1Y4 961 _SLREPS(ph)SPMGR_ 3.0299
Breast carcinoma-amplified sequence 3 homolog Q8CCN5 886 _EGS(ph)IETLSNSSGSTSGSIPR_ 2.3181
Breast carcinoma-amplified sequence 3 homolog Q8CCN5 572 _VKSPPQISPS(ph)K_ 4.1473
Bromodomain adjacent to zinc finger domain protein 1A O88379 1545 _KRQS(ph)TESSPVPLNR_ 10.5320
Bruton tyrosine kinase-associated protein 135 Q3UHU8 744 _RPS(ph)TFGIPR_ 6.2015
BXMAS1-like protein 1 Q8R4Y0 271 _SPPQTVLQGSTYPKS(ph)PDSR_ 15.2230
c-Jun N-terminal kinase 2 Q9WTU6 185 _TACTNFMMTPY(ph)VVTR_ 17.7420
C-Jun-amino-terminal kinase-interacting protein 4 Q58A65 705 _DGGS(ph)VVGASVFYK_ 10.5380
C2PA Q9DC04 766 _NGGSMHHLS(ph)LFFTGHR_ 9.7578
C2PA Q9DC04 712 _THS(ph)EGSLLQESR_ 4.0243
Cadherin-associated Src substrate P30999 320 _LRS(ph)YEDMIGEEVPPDQYYWAPLAQHER_ 2.8125
Cadherin-associated Src substrate P30999 349 _GSLAS(ph)LDSLRK_ 2.2236
Calcium homeostasis endoplasmic reticulum protein Q8CGZ0 915 _SYS(ph)FIAR_ 10.5600
Calcium-dependent tyrosine kinase Q9QVP9 579 _YIEDEDY(ph)YKASVTR_ 2.6942
Calcium-dependent tyrosine kinase Q9QVP9 580 _YIEDEDY(ph)YKASVTR_ 2.1348
CALNUC Q02819 456 _KVPEQPPELPQLDS(ph)QHL_ 7.4883
CALNUC Q02819 368 _AQRLS(ph)QETEALGR_ 3.3632
CALNUC Q02819 85 _SGKLS(ph)QELDFVSHNVR_ 2.5595
Calpain inhibitor P51125 219 _EQKPFTPAS(ph)PVQSTPSKPSDK_ 4.2860
Cancer susceptibility candidate gene 5 protein homolog Q66JQ7 794 _IIS(ph)PSDITPGDLDK_ 10.1030
CAP-Gly domain-containing linker protein 2 Q9Z0H8 552 _LLS(ph)ASKEHQR_ 27.6600
Casitas B-lineage lymphoma proto-oncogene P22682 450 _QGAEGAPS(ph)PNYDDDDDERADDSLFMMK_ 2.8708
Caspase-like protein ESPL1 P60330 1320 _IAS(ph)VPPPLHNSSQK_ 5.7834
CCAAT displacement protein P53564 1471 _RPSSLQS(ph)LFGLPEAAGAR_ 8.6033
CCAAT displacement protein P53564 1506 _AAS(ph)REEPIEWEF_ 2.2942
CCAAT-binding transcription factor I subunit A P62960 210 _RPQYS(ph)NPPVQGEVMEGADNQGAGEQGRPVR_ 24.0580
CCAAT-binding transcription factor I subunit A P62960 126 _YLRS(ph)VGDGETVEFDVVEGEK_ 19.2040
CCT-alpha P49586 342 _WPFSGKT(ph)SPS(ph)SSPASLSR_ 5.8661
CD2-associated protein Q9JLQ0 404 _ASNLLRS(ph)PGAVYPK_ 11.3240
CD2-associated protein Q9JLQ0 458 _S(ph)VDLDAFVAR_ 2.5360
Cdc2-related kinase, arginine/serine-rich Q14AX6 610 _TQVS(ph)ITAAIPHLK_ 17.0930
CDC2-related protein kinase 5 Q69ZA1 440 _HSSIS(ph)PSTLTLK_ 9.5677
Cell cycle checkpoint protein RAD17 Q6NXW6 70 _GRLS(ph)LEQTHGLETSR_ 8.9839
Cell cycle regulatory protein p95 Q9R207 398 _KLS(ph)QETFNIK_ 6.6874
Cell death protein RIP Q60855 415 _RVS(ph)HDPFAQQR_ 3.2814
Cell death protein RIP Q60855 313 _EYPDQS(ph)PVLQR_ 2.5335
Cell division protein kinase 14 O35495 78 _TQS(ph)TFDPFEKPANQVK_ 7.7761
Cellubrevin P63024 48 _DQKLS(ph)ELDDRADALQAGASQFETSAAK_ 4.1180
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Centaurin-beta-2 Q6ZQK5 521 _YSALLS(ph)PSEQEKR_ 5.9467
Centaurin-delta-2 Q4LDD4 431 _LSS(ph)ASVLGVR_ 13.5260
Centaurin-gamma-2 Q8BXK8 422 _ATSACAPISS(ph)PK_ 4.2775
Centriolin A2AL36 832 _IHS(ph)PSDVLGK_ 13.0710
Centromere protein E Q6RT24 2426 _SKS(ph)LPAPHPIR_ 4.2736
Centromere/kinetochore protein zw10 homolog O54692 438 _EALPDLPS(ph)PDADHK_ 12.4070
Centrosomal protein of 170 kDa Q6A065 1150 _LGS(ph)LS(ph)ARSDSEATISR_ 2.7601
Centrosomal protein of 170 kDa Q6A065 443 _QKS(ph)EEPSVSLPFLQTALLR_ 2.4849
Centrosomal protein of 55 kDa Q8BT07 426 _S(ph)PSAALNDSLVECPK_ 2.8521
Centrosomal protein of 55 kDa Q8BT07 422 _AT(ph)SPKS(ph)PSAALNDSLVECPK_ 2.5577
Centrosomal protein of 55 kDa Q8BT07 423 _AT(ph)SPKS(ph)PSAALNDSLVECPK_ 2.0366
Centrosomin P23116 584 _LES(ph)LNIQR_ 4.0796
Ceramide transfer protein Q9EQG9 377 _S(ph)SSM(ox)SSIDLVSASDDVHR_ 5.2011
Chloride channel CLIC-like 1 A2AEM2 438 _FHS(ph)GNKS(ph)PEVLR_ 3.9380
Chromatin assembly factor 1 subunit A Q9QWF0 776 _LIS(ph)ENSAYEK_ 7.6784
Chromatin assembly factor 1 subunit B Q9D0N7 492 _RVT(ph)LNTLQTWGK_ 11.2920
Chromobox protein homolog 5 Q61686 93 _KSS(ph)FSNSADDIK_ 4.9591
Chromokinesin P33174 802 _TFS(ph)YDEIHGQDSGAEDSIAK_ 3.7476
Clathrin light polypeptide (Lca) B1AWD9 236 _MRS(ph)VLISLK_ 2.2273
Cleavage and polyadenylation specificity factor subunit 6 Q6NVF9 404 _EMDT(ph)ARTPLSEAEFEEIMNR_ 12.4460
CLIP-associating protein 1 Q80TV8 598 _S(ph)RSDIDVNAAASAK_ 2.8265
Coactivator independent of AF-2 Q91W39 377 _S(ph)SADSLPGPISR_ 4.2875
Coactivator of activating protein 1 and estrogen receptors Q8VH51 117 _IGLPHS(ph)IK_ 10.0810
Cofactor required for Sp1 transcriptional activation subunit 6 Q8VCD5 10 _AVRIS(ph)IESACEK_ 7.1002
Cofilin, non-muscle isoform P18760 41 _AVLFCLS(ph)EDKK_ 6.2318
Cohen syndrome protein 1 homolog Q80TY5 3045 _LVHNLTS(ph)PK_ 4.2082
Cohesin subunit SA-2 O35638 1197 _RGT(ph)SLMEDDEEPIVEDVMMSSEGR_ 2.0258
Cohesin subunit SA-2 O35638 1198 _RGT(ph)SLMEDDEEPIVEDVMMSSEGR_ 2.0020
Coiled-coil and C2 domain-containing protein 1B Q8BRN9 502 _KPAQT(ph)LVSPSHLLTEPK_ 17.2850
Coiled-coil and C2 domain-containing protein 1B Q8BRN9 499 _KPAQT(ph)LVSPSHLLTEPK_ 10.7480
Coiled-coil and C2 domain-containing protein 1B Q8BRN9 459 _KGSEQDS(ph)VAATLATAQK_ 4.5288
Collagen alpha-1(XX) chain Q923P0 774 _AIS(ph)QVESAEPR_ 6.3978
Connecdenn Q8K382 592 _S(ph)LEDLRAPK_ 2.6917
Constitutive coactivator of PPAR-gamma-like protein 2 Q8C3F2 436 _NQMGPIS(ph)PGKPMFSR_ 4.1297
Copper pump 1 Q64430 357 _VSIASEVESTASS(ph)PSSSSLQK_ 12.2050
Craniofacial development protein 1 O88271 202 _EKPQALVT(ph)SPATPLPAGSGIK_ 5.2869
CREB-regulated transcription coactivator 2 Q3U182 434 _VPLS(ph)PLSLPAGPADAR_ 4.3559
CREB-regulated transcription coactivator 3 Q91X84 126 _LT(ph)QY(ph)HGGS(ph)LPNVS(ph)QLR_ 2.2979
CREB-regulated transcription coactivator 3 Q91X84 393 _S(ph)NPSIQATLSK_ 3.7605
CREB-regulated transcription coactivator 3 Q91X84 434 _LFSLS(ph)NPSLSTTNLSGPSR_ 2.1424
CRK1 P47811 180 _HTDDEMT(ph)GYVATR_ 4.0098
CTTNBP2 N-terminal-like protein Q99LJ0 488 _DLS(ph)PTLLDNSAAK_ 3.7187
CTTNBP2 N-terminal-like protein Q99LJ0 522 _FTNQGPIKPVS(ph)PNSSPFGTDYR_ 2.3207
Cyclic AMP specific phosphodiesterase PDE4D5A O70286 69 _LSPVIS(ph)PR_ 9.9249
Cyclin fold protein 1 Q8BGU5 73 _ASTIFLSKS(ph)QTDVR_ 2.4956
Cyclin fold protein 1 Q8BGU5 25 _LES(ph)YRPDTDLSR_ 2.2715
Cysteine string protein P60904 8 _S(ph)LSTSGESLYHVLGLDKNATSDDIKK_ 6.5595
Cytoplasmic dynein 1 light intermediate chain 1 Q8R1Q8 414 _SVS(ph)SNVASVSPIPAGSKK_ 22.8600
Cytoplasmic dynein 1 light intermediate chain 1 Q8R1Q8 516 _KPASVSPTT(ph)PTS(ph)PTEGEAS_ 12.8980
Cytosolic Fe-S cluster assembly factor NUBP1 Q9R060 319 _IRDFCNSHQSHAETLIS(ph)P_ 5.4117
Cytosolic prostaglandin E2 synthase Q9R0Q7 85 _KGESGQS(ph)WPR_ 3.4111
Cytospin-B Q5SXY1 76 _T(ph)STSGAISELTESR_ 4.1663
Cytospin-B Q5SXY1 933 _LLS(ph)ASTGGLKPSK_ 16.7090
Cytospin-B Q5SXY1 847 _TPRS(ph)PLSGIPVR_ 3.9045
Cytospin-B Q5SXY1 810 _GVYVNRTS(ph)PAPSDSATTVK_ 2.6403
Dedicator of cytokinesis protein 7 Q8R1A4 1382 _M(ox)NS(ph)LTFKK_ 3.9412
Dedicator of cytokinesis protein 7 Q8R1A4 452 _TTS(ph)GDDACNLTSFRPATLTVANFFK_ 3.4390
Dedicator of cytokinesis protein 7 Q8R1A4 963 _MSS(ph)HTETSSFLQTLTGR_ 2.2405
Dedicator of cytokinesis protein 8 Q8C147 197 _GPLTS(ph)CDFDLR_ 25.0010
Dedicator of cytokinesis protein 8 Q8C147 452 _TLS(ph)LEENGVGSNFK_ 15.4830
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DENN/MADD domain containing 4C A2AJX5 1289 _NLADEIESYMNLKS(ph)PLGSK_ 10.0740
DENN/MADD domain containing 4C A2AJX5 1270 _TSDSEDKLFS(ph)PVISR_ 9.8842
DENN/MADD domain containing 4C A2AJX5 1145 _THS(ph)FENVNCHLADSR_ 5.7719
DENN/MADD domain containing 4C A2AJX5 1370 _STS(ph)LSALVR_ 3.0582
DENN/MADD domain containing 4C A2AJX5 1015 _HLQPT(ph)PEPQS(ph)PTEPPAWGSSIVK_ 11.6300
Densin-180-like protein Q80TH2 829 _VNGLCEDTAPS(ph)PGRVEPQK_ 2.3422
Deoxynucleotidyltransferase terminal-interacting protein 2 Q8R2M2 612 _AVIT(ph)PDFEKK_ 3.1425
Deoxynucleotidyltransferase terminal-interacting protein 2 Q8R2M2 248 _NMPNVS(ph)DSETYNSDFDDSSPR_ 2.0832
DEP domain-containing mTOR-interacting protein Q570Y9 260 _KSTS(ph)FMSVSPSK_ 9.9776
DET1- and DDB1-associated protein 1 Q9D9Z5 33 _RPS(ph)VYLPTR_ 5.1187
Deubiquitinating enzyme 10 P52479 364 _CSPPVPS(ph)PLASEK_ 8.5877
Deubiquitinating enzyme 20 Q8C6M1 334 _KFS(ph)WGQQR_ 2.4217
Deubiquitinating enzyme 24 B1AY13 2558 _TIS(ph)AQDTLAYATALLNEK_ 2.0627
Deubiquitinating enzyme 45 Q8K387 452 _KWPS(ph)EEEKTVVTHPK_ 2.2487
Diacylglycerol kinase zeta A2AHK0 900 _LQREPDGAGAKS(ph)PMCHQLSSK_ 5.9165
Diphosphoinositol pentakisphosphate kinase 1 A2ARP1 959 _ALQTS(ph)PQPVEGTGLPR_ 7.8221
Disabled homolog 2 P98078 727 _S(ph)ADNSLENPFSK_ 2.0662
Disabled homolog 2 P98078 32 _KGS(ph)EKTDEYLLAR_ 25.7920
Disco-interacting protein 2 homolog B Q3UH60 99 _YRS(ph)DIHTEAVQAALAK_ 2.7006
Disintegrin and metalloproteinase domain-containing protein 17 Q9Z0F8 752 _LQALQPAAMMPPVS(ph)AAPK_ 14.5360
Disintegrin and metalloproteinase domain-containing protein 17 Q9Z0F8 735 _IIKPFPAPQT(ph)PGR_ 2.0103
DmX-like protein 1 Q6PNC0 922 _ILS(ph)PFSQK_ 37.0010
DNA (cytosine-5)-methyltransferase 1 P13864 22 _SKS(ph)DSDTLSVETSPSSVATRR_ 4.0818
DNA polymerase alpha 70 kDa subunit P33611 125 _VS(ph)STPETPLTKR_ 3.5501
DNA polymerase delta subunit 3 Q9EQ28 454 _QVS(ph)ITGFFQK_ 26.5790
DNA replication licensing factor MCM2 P97310 21 _RRIS(ph)DPLTSSPGR_ 8.0594
DNA replication licensing factor MCM2 P97310 25 _RRIS(ph)DPLTSSPGR_ 2.1014
DNA replication licensing factor MCM6 P97311 699 _FNGS(ph)S(ph)EDASQETVSKPSLR_ 8.0407
DNA replication licensing factor MCM6 P97311 700 _FNGS(ph)S(ph)EDASQETVSKPSLR_ 2.1967
DNA topoisomerase 2-beta Q64511 1439 _SQDFGNLFSFPS(ph)YSQK_ 16.8610
DNA topoisomerase 2-binding protein 1 Q6ZQF0 863 _KLSS(ph)PLSEVIVR_ 2.0282
DNA-directed RNA polymerase I subunit E Q8K202 200 _DKLDS(ph)CIEAFGSTK_ 20.4360
Docking protein 1 P97465 269 _VGQAQDILRTDS(ph)HDGETEGK_ 3.8113
Docking protein 3 Q9QZK7 264 _LPELAM(ox)S(ph)PPCPLPR_ 2.1537
Double-stranded RNA-binding protein Staufen homolog 2 Q8CJ67 440 _VTSGTTLSYLS(ph)PK_ 10.3690
Down-regulated by CTNNB1 protein A Q6P9N1 465 _S(ph)PSPAIGCVAGADANR_ 8.0352
Down-regulator of transcription 1 Q91WV0 105 _KAS(ph)SRLENLGIPEEELLR_ 4.5970
Dual specificity mitogen-activated protein kinase kinase 2 Q63932 295 _ELEASFGRPVVDGADGEPHSVS(ph)PR_ 2.1947
Dual specificity mitogen-activated protein kinase kinase 2 Q63932 226 _LCDFGVSGQLIDSMANS(ph)FVGTR_ 7.0336
Dual specificity mitogen-activated protein kinase kinase 2 Q63932 23 _RKPVLPALTINPTIAEGPS(ph)PTSEGASEANLVDLQK_ 15.1880
Dual specificity mitogen-activated protein kinase kinase 3 O09110 218 _MCDFGISGYLVDS(ph)VAK_ 7.4416
Dynactin subunit 4 Q8CBY8 203 _AGAS(ph)ISTLAGLSLR_ 4.3400
Dysbindin Q91WZ8 11 _LLS(ph)VQQDFTSGLK_ 14.2170
Dystrophin-like protein Q8R516 251 _RVS(ph)ADGQPFQR_ 3.1106
E3 SUMO-protein ligase RanBP2 Q9ERU9 1438 _S(ph)ASSFVQTSFK_ 14.4770
E3 SUMO-protein ligase RanBP2 Q9ERU9 781 _HSTPS(ph)PTKYSLS(ph)PSK_ 6.6217
E3 SUMO-protein ligase RanBP2 Q9ERU9 790 _YSLSPS(ph)K_ 4.1412
E3 SUMO-protein ligase RanBP2 Q9ERU9 21 _YIASVQGSAPS(ph)PR_ 2.2879
E3 ubiquitin-protein ligase HUWE1 Q7TMY8 3759 _LGSSGLGS(ph)ASSIQAAVR_ 2.2153
E3 ubiquitin-protein ligase RLIM Q9WTV7 163 _RLS(ph)VENMESSSQR_ 3.7527
E3 ubiquitin-protein ligase TRIM33 Q99PP7 1134 _LKS(ph)DERPVHIK_ 5.4858
E3 ubiquitin-protein ligase UBR5 Q80TP3 1549 _RIS(ph)QSQPVR_ 5.2401
E4 promoter-binding protein 4 O08750 301 _GPIHS(ph)PVELQR_ 2.3066
Echinoderm microtubule-associated protein-like 3 Q8VC03 882 _VLGAGSSGPAPAT(ph)PSR_ 2.9360
EGR-1-binding protein 2 Q61127 367 _LHS(ph)EELGGPPLKK_ 43.9200
Elongin 110 kDa subunit Q8CB77 515 _AFSS(ph)PQEEEEAGFTGR_ 21.0930
Embryonic large molecule derived from yolk sac Q8CJF7 528 _CLVAGLLS(ph)PR_ 11.6200
Embryonic large molecule derived from yolk sac Q8CJF7 2198 _LVS(ph)PLASPVDEIK_ 2.3432
Ena/vasodilator-stimulated phosphoprotein-like P70429 335 _SNS(ph)VEKPVSSLLSR_ 2.4871
Ena/vasodilator-stimulated phosphoprotein-like P70429 373 _VKPAGS(ph)VNDVGLDALDLDR_ 2.3897
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Endofin Q80U44 906 _THS(ph)PTVEKPNNGLGDIIR_ 2.6648
Endonuclease/exonuclease/phosphatase family domain-containing protein 1 Q3TGW2 31 _KFS(ph)AACNFS(ph)NILVNQER_ 4.1417
Engulfment and cell motility protein 1 Q8BPU7 31 _KPLS(ph)AIIK_ 21.4870
Enhanced at puberty protein 1 Q8K3X4 127 _S(ph)PGPPPPVGVK_ 3.5772
Enhancer of mRNA-decapping protein 4 Q3UJB9 6 _(ac)ASCAS(ph)IDIEDATQHLR_ 11.7220
Enhancer of mRNA-decapping protein 4 Q3UJB9 426 _HTEVLPAEEENDS(ph)LGTESSHGAGALESAAGVLIK_ 5.0241
Enhancer of mRNA-decapping protein 4 Q3UJB9 620 _LQLDGSLTLNSSSSSLQAS(ph)PR_ 2.5689
Epidermal growth factor receptor substrate 15 P42567 324 _NITGSS(ph)PVADFSAIK_ 2.9250
Epidermal growth factor receptor substrate 15 P42567 779 _VGT(ph)PTRPCPPPPGK_ 2.4477
ERT1 P63085 183 _VADPDHDHTGFLT(ph)EY(ph)VATR_ 7.7634
ERT1 P63085 185 _VADPDHDHTGFLT(ph)EY(ph)VATR_ 2.6088
ERT2 Q63844 203 _IADPEHDHTGFLT(ph)EY(ph)VATR_ 17.6840
ERT2 Q63844 205 _IADPEHDHTGFLT(ph)EY(ph)VATR_ 4.4145
Erythrocyte protein band 4.1 A2A841 689 _HHAS(ph)ISELKK_ 3.2740
ETS domain transcriptional repressor PE1 Q8R4Z4 175 _FSASSLS(ph)ASGPESGVTTDR_ 2.7918
ETS domain-containing transcription factor ERF P70459 534 _RVS(ph)SDLQHATAQLSLEHRDS_ 2.8483
Eukaryotic translation initiation factor 2-alpha kinase 4 Q9QZ05 230 _AAAILHGGS(ph)PDFVGNGK_ 6.1477
Eukaryotic translation initiation factor 4E-binding protein 1 Q60876 64 _NS(ph)PVAKTPPKDLPAIPGVTSPTSDEPPMQASQSQLPSSPEDK_ 2.9012
Eukaryotic translation initiation factor 5 P59325 10 _SVS(ph)DQFYR_ 22.4860
Exportin-4 Q9ESJ0 521 _HQQQFLAS(ph)PGSSTIDNK_ 2.2228
Eyes absent homolog 3 P97480 210 _LPS(ph)DSSASPPLSQTTPNK_ 25.7010
F-box only protein 4 Q8CHQ0 11 _GAGS(ph)PPPASDWGR_ 5.3295
Factor for adipocyte differentiation 49 A2AAY5 291 _LGPS(ph)SPAHSGALDLDGVSR_ 8.2831
Far upstream element-binding protein 2 Q3U0V1 182 _VQIS(ph)PDSGGLPER_ 5.0426
FCH domain only protein 2 Q3UQN2 391 _VSIGNITLS(ph)PAVS(ph)RHSPVQMNR_ 2.3650
FERM domain-containing protein 4A Q8BIE6 723 _LLGSENDTGS(ph)PDFYTPR_ 3.5243
FGFR1 oncogene partner Q66JX5 158 _EKGPASVEGALDLSDGHPPS(ph)KSPEGK_ 4.8118
Filamin-B Q80X90 983 _LDVTILS(ph)PSRK_ 8.6443
Filamin-C Q8VHX6 2625 _GAS(ph)YSSIPK_ 32.4660
Filamin-C Q8VHX6 2234 _LGS(ph)FGSITR_ 12.6110
Filamin, alpha B7FAV0 2152 _RRAPS(ph)VANIGSHCDLSLK_ 3.0094
Filamin, alpha B7FAV0 968 _SPFSVGVSPS(ph)LDLSK_ 2.9010
Filamin, alpha B7FAV0 2180 _IPEISIQDMTAQVTS(ph)PSGK_ 2.8168
FK506-binding protein 15 Q6P9Q6 344 _SNS(ph)LSEQLTVNSNPDTVK_ 6.5178
FLI-LRR-associated protein 1 Q3UZ39 302 _AENQRPAEDSALS(ph)PGPLAGAK_ 2.4710
Fork head-related protein-like A Q9DBY0 558 _M(ox)TGS(ph)PTLVK_ 2.6559
Forkhead box O3a Q9WVH4 293 _WPGS(ph)PTSR_ 4.2179
Forkhead box protein P1 P58462 319 _RES(ph)LSHEEHPHSHPLYGHGVCK_ 11.2780
Formin-1 Q05860 396 _ART(ph)PETALEAFK_ 12.8670
Formin-1 Q05860 616 _KLTISLTQLS(ph)PSKDSK_ 6.6044
Formin-binding protein 1-like Q8K012 295 _TIS(ph)DGTISAAKQESGK_ 4.7175
Formin-binding protein 11 Q9R1C7 34 _RLS(ph)GSNLCSSSWVSADGFLR_ 3.4202
Formin-like protein 1 Q9JL26 509 _ILRGPGDVVSIEILPGAAAT(ph)PSGDDAQAPR_ 23.5270
Fragile site-associated protein homolog A2AAE1 2603 _YTAGSAS(ph)PTPTFK_ 4.9389
Friend leukemia integration 1 transcription factor P26323 241 _GAWNNNMNSGLNKS(ph)PLLGGSQTMGK_ 2.3651
Fructose-bisphosphate aldolase A6ZI44 91 _GILAADES(ph)TGSIAKR_ 3.0977
FTS and Hook-interacting protein Q3U2I3 510 _QQS(ph)LGGSESPGPVPR_ 10.3070
FYVE, RhoGEF and PH domain-containing protein 6 Q69ZL1 708 _HTS(ph)CTGDFGPEYENVR_ 3.0921
Gag protein Q6YIY0 530 _GPRPQTS(ph)LLTLDD_ 2.5379
Gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 A3KG53 3 _GWS(ph)VLSSRSRR_ 85.5850
Gamma-PAK Q8CIN4 58 _IIS(ph)IFS(ph)GTEK_ 6.3941
GAP-related-interacting partner to E12 Q6GYP7 720 _GWS(ph)RDQPGQAPM(ox)R_ 9.0278
GAP-related-interacting partner to E12 Q6GYP7 753 _QKT(ph)VDIDDAQILPR_ 3.2070
GAP1(IP4BP) Q60790 809 _YGS(ph)QEHPIGDK_ 8.9464
GAPex-5 Q6PAR5 908 _SRS(ph)SDIVSSVR_ 2.9128
Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog Q6GTF2 50 _TSSVFPQPTS(ph)PAFLNTGNMR_ 2.0713
GATA zinc finger domain-containing protein 2A Q8CHY6 185 _EATAQKPTASSGSTVTT(ph)PPPLVR_ 2.3728
GDI-1 Q99PT1 62 _VAVS(ph)ADPNVPNVIVTR_ 16.6590
Gem-associated protein 7 Q9CWY4 3 _(ac)M(ox)QS(ph)PLTIPVPVPVLR_ 10.3900
General transcription factor IIE subunit 2 Q9D902 18 _ALS(ph)TPVVEKR_ 4.5777
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General transcription factor IIF, polypeptide 1 Q8R5B7 384 _GT(ph)SRPGTPS(ph)AEAASTSSTLR_ 5.9095
General transcription factor IIF, polypeptide 1 Q8R5B7 385 _GT(ph)SRPGTPS(ph)AEAASTSSTLR_ 2.9828
Glucocorticoid receptor Q06VW2 284 _IQDTGDTILSS(ph)PSSVALPQVK_ 12.8080
Glucocorticoid receptor DNA-binding factor 1 Q91YM2 589 _NQKNS(ph)LSDLNIDR_ 5.4460
Glucocorticoid receptor DNA-binding factor 1 Q91YM2 1150 _KVS(ph)AVSKPVLYR_ 2.8754
Glycogen synthase kinase-3 beta Q9WV60 216 _GEPNVSY(ph)ICSR_ 4.4777
Glycylpeptide N-tetradecanoyltransferase 1 O70310 83 _MTS(ph)LPAER_ 18.3830
Golgb1 protein B2RWW2 651 _ASEAGPLNDAGMELS(ph)SPKLDGVDK_ 17.3050
Golgb1 protein B2RWW2 652 _ASEAGPLNDAGMELS(ph)SPKLDGVDK_ 3.9792
Golgin subfamily A member 3 P55937 1479 _LHNQNS(ph)VPRDGLGQ_ 25.2850
GPN-loop GTPase 1 Q8VCE2 314 _GNAS(ph)PVLDPSDLILTR_ 5.0412
GRB2-associated binder 2 Q9Z1S8 143 _S(ph)SPAEFSSS(ph)QHLLR_ 11.9620
GRB2-associated binder 2 Q9Z1S8 532 _NNTVIDELPFKS(ph)PVTK_ 4.6448
Growth factor-inducible nuclear protein NUP475 P22893 316 _RLPIFNRIS(ph)VSE_ 6.4714
Growth factor-inducible nuclear protein NUP475 P22893 178 _QSIS(ph)FSGLPSGR_ 2.5378
GRP1 binding protein GRSP1 Q920B1 693 _S(ph)GSLESQSHLLSEMDSDKPFFTLSK_ 4.1843
GTPase Ran P62827 135 _AKS(ph)IVFHR_ 4.6278
GTPase-activating protein RAB7 Q9CXF4 32 _ANDQDS(ph)LISGILR_ 3.1370
Guanine nucleotide exchange factor H1 Q60875 646 _LES(ph)FESLRGER_ 7.5929
Guanine nucleotide exchange factor H1 Q60875 151 _SVS(ph)TTNIAGHFNDESPLGLR_ 6.4508
Guanine nucleotide exchange factor H1 Q60875 122 _ERPTS(ph)AIYPSDSFR_ 2.2643
Heat shock protein-binding protein 1 Q99P31 349 _LLQTCFSS(ph)PTDDSMDR_ 2.6067
Hematological and neurological expressed 1 protein P97825 87 _SNS(ph)SEASSGDFLDLK_ 4.6084
Hepatoma-derived growth factor-related protein 2 Q3UMU9 459 _KRS(ph)EGLSLER_ 13.4470
Heterogeneous nuclear ribonucleoprotein F Q9Z2X1 104 _HSGPNS(ph)ADSANDGFVR_ 9.8420
Heterogeneous nuclear ribonucleoprotein H1 Q8C2Q7 104 _HTGPNS(ph)PDTANDGFVR_ 8.6986
Heterogeneous nuclear ribonucleoproteins C1/C2 Q3U6P5 138 _MYS(ph)YPAR_ 4.4049
High mobility group box transcription factor 1 Q8R316 392 _RASLS(ph)CGGGPGTGQEFSGSEFSK_ 8.6150
High mobility group protein 2 P30681 100 _RPPS(ph)AFFLFCSENRPK_ 3.6369
Histone acetyltransferase KAT5 Q8CHK4 191 _KVEVVS(ph)PATPVPSETAPASVFPQNGSAR_ 2.0130
Histone deacetylase 1 O09106 409 _ISICS(ph)SDKR_ 8.7385
Histone deacetylase 1 O09106 410 _ISICS(ph)SDKR_ 8.7385
Histone deacetylase 6 Q9Z2V5 21 _HNPQS(ph)PLQESSATLKR_ 2.4886
Histone deacetylase complex subunit SAP130 Q8BIH0 416 _VVPQQITHTS(ph)PR_ 4.9384
Histone deacetylase complex subunit Sin3a Q60520 431 _RHS(ph)GTGATPPVK_ 12.8260
Histone deacetylase complex subunit Sin3a Q60520 10 _RLDDQES(ph)PVYAAQQR_ 4.7182
Histone demethylase JARID1C P41230 317 _NHS(ph)NAQFIESYVCR_ 2.0268
Histone H3 methyltransferase DOT1 variant b Q679P5 1247 _STFS(ph)PISDLGLAK_ 2.3296
HIV Tat-specific factor 1 homolog Q8BGC0 404 _HFS(ph)EHPS(ph)MSNMK_ 3.6044
HLA-B-associated transcript 2 Q7TSC1 808 _LAWVGDVFTTTPTDPRPLT(ph)SPLR_ 2.3972
HLA-B-associated transcript 2 Q7TSC1 807 _LAWVGDVFTTTPTDPRPLT(ph)SPLR_ 2.3972
HLA-B-associated transcript 2 Q7TSC1 1217 _LISGPLS(ph)PMSR_ 2.2999
Host cell factor C1 B1AUX1 666 _TITLVKS(ph)PISVPGGSALISNLGK_ 6.2506
Host cell factor C1 B1AUX1 598 _VASS(ph)PVM(ox)VSNPATR_ 3.9100
Host cell factor C1 B1AUX1 2029 _RPMS(ph)SPEMK_ 8.4812
HpaII tiny fragments locus 9a protein P34022 60 _FAS(ph)ENDLPEWK_ 3.5266
I-mfa domain-containing protein Q8BX65 139 _IQSS(ph)LSVNNDISKK_ 2.6066
IK cytokine Q3TJY5 225 _SKS(ph)YERNELFLPGR_ 2.7159
Immediate early protein GLY96 P46694 18 _APS(ph)PAPSTGPELR_ 3.5283
Inhibitor of kappa B-related protein Q6NZL6 873 _LTS(ph)LDGWCAR_ 5.5815
Inner centromere protein Q9WU62 862 _TSS(ph)AVWNSPPLK_ 7.4017
Inositol 1,4,5-trisphosphate 3-kinase B B2RXC2 125 _ILS(ph)PPGPEEAQR_ 12.7730
Inositol polyphosphate-5-phosphatase of 145 kDa Q9ES52 173 _LQS(ph)MDTSGLPEEHLK_ 21.2010
Inositol polyphosphate-5-phosphatase of 145 kDa Q9ES52 889 _NLT(ph)SHDPMRQWEPSGR_ 8.8406
Inositol polyphosphate-5-phosphatase of 145 kDa Q9ES52 935 _S(ph)TLSPDQQLTAWSYDQLPK_ 8.1042
Integrator complex subunit 1; Q6P4S8 40 _RPS(ph)AAAKPSGHPPPGDFIALGSK_ 7.5409
Integrin beta-7 P26011 798 _SPS(ph)LSLTR_ 5.7534
Integrin-linked protein kinase O55222 181 _NGT(ph)LNKHSGIDFK_ 2.8340
Interacting protein of Rab1 Q80U22 525 _M(ox)LS(ph)CPVR_ 2.3797
Interleukin-1 receptor-associated kinase-like 2 Q8CFA1 136 _S(ph)LLDTGPIMAGAQR_ 8.1867
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Interleukin-1 receptor-associated kinase-like 2 Q8CFA1 506 _GQLS(ph)LPWSR_ 4.2326
IQ motif and SEC7 domain-containing protein 1 Q8R0S2 924 _RSS(ph)AGSLESNVEGSIISSPHMR_ 4.9152
IQ motif and SEC7 domain-containing protein 1 Q8R0S2 496 _NS(ph)WDSPAFSNDVIR_ 2.9294
IQ motif and SEC7 domain-containing protein 1 Q8R0S2 165 _MQFS(ph)FEGPEK_ 2.6188
IQ motif and SEC7 domain-containing protein 1 Q8R0S2 74 _LQHSTS(ph)VLRK_ 2.4690
IRS-1 PH domain-binding protein Q8VDD9 1315 _AQS(ph)YDIQAWKK_ 34.9850
IRS-1 PH domain-binding protein Q8VDD9 674 _VNRGS(ph)VSSTSEVHSPPNIGLR_ 5.8098
JmjC domain-containing histone demethylation protein 3C Q8VCD7 477 _ASAVISPS(ph)QLK_ 8.2252
JRAB Q3TN34 936 _LMDKPEGLKS(ph)PQDR_ 5.9916
Jun dimerization protein 2 P97875 148 _TDSVRT(ph)PESEGNPLLEQLDKK_ 2.2863
Juvenile spermatogonial depletion-like X-linked protein Q640M1 182 _ART(ph)PLEQEVFNLLHK_ 40.1150
Juvenile spermatogonial depletion-like X-linked protein Q640M1 205 _NKQPVTDPLLT(ph)PVEK_ 24.6310
KH and NYN domain-containing protein Q80U38 214 _EVGSSGLLS(ph)PQFQGVR_ 14.6730
Kinesin-associated protein 3 P70188 60 _LKS(ph)LNANTDITSLAR_ 16.3070
Kinesin-like protein KIF21B Q9QXL1 1150 _AVS(ph)AECLGPPLDSSTK_ 6.1907
KRAB-A-interacting protein Q62318 473 _SRS(ph)GEGEVSGLLR_ 13.3040
KRAB-A-interacting protein Q62318 489 _VS(ph)LERLDLDLTSDSQPPVFK_ 10.9680
La ribonucleoprotein domain family member 1 Q6ZQ58 801 _HSS(ph)NPPLESHVGWVMDSR_ 2.0833
La ribonucleoprotein domain family member 4B Q6A0A2 570 _NLS(ph)TDASTNTVPVVGPR_ 5.8056
Lamin-A/C P48678 637 _SVGGS(ph)GGGS(ph)FGDNLVTR_ 2.7417
Lamin-B1 P14733 21 _ASAPAT(ph)PLSPTR_ 4.5088
Lamin-B2 P21619 494 _QVLEGEDIAYKFT(ph)PK_ 2.0880
Lamina-associated polypeptide 1B Q1EQW1 252 _S(ph)SNSLESRDEATPAAGNHPDSLR_ 8.6762
Lamina-associated polypeptide 1B Q1EQW1 201 _TPEASVMNEDPISNLCRPPLRS(ph)PR_ 2.9900
Lamina-associated polypeptide 2, isoforms beta/gamma P42167 278 _IDGAVISES(ph)TPIAETIK_ 2.6884
Lariat debranching enzyme Q923B1 505 _CGETVES(ph)GDEKDLAKFPLK_ 5.5790
Lbc’s second cousin Q61210 964 _LRPLLSQLGGTLS(ph)PNLAAPER_ 7.0172
Leucine zipper- and sterile alpha motif kinase ZAK Q9ESL4 638 _SSS(ph)PTQYGLSR_ 3.7345
Leucine zipper- and sterile alpha motif kinase ZAK Q9ESL4 2 _(ac)S(ph)SLGASFVQIK_ 18.5530
Leucine-rich repeat serine/threonine-protein kinase 2 Q5S006 935 _HSNS(ph)LGPVFDHEDLLR_ 15.1520
Leucine-rich repeat-containing protein 41 Q8K1C9 276 _APS(ph)RDEGSLLLGSR_ 25.3140
Leukemia-associated gene protein P54227 25 _RAS(ph)GQAFELILS(ph)PR_ 13.0330
Leukemia-associated gene protein P54227 38 _SKESVPDFPLS(ph)PPKK_ 2.3114
Leukemia-associated RhoGEF Q8R4H2 190 _IT(ph)SPVLVGEENNVVHNQK_ 41.9510
Luzp1 protein B7ZW89 992 _NMEATNAYTQRS(ph)PTDFLELEQPR_ 3.6571
Luzp1 protein B7ZW89 556 _TFS(ph)DSTHVSVPNDIVGK_ 16.9080
Lymphocyte cytosolic protein 2 Q60787 210 _NHSPLS(ph)PPHPNHEEPSR_ 2.4209
Lymphocyte-specific helicase Q60848 498 _S(ph)INYSELDQFPSELEK_ 23.1590
M-phase phosphoprotein 8 A6H600 379 _GISNLELNKLPS(ph)PVFAQTLK_ 2.4695
Macropain iota chain Q9QUM9 17 _HITIFS(ph)PEGR_ 12.5020
Macropain subunit C8 O70435 250 _ESLKEEDES(ph)DDDNM_ 2.2891
Macropain zeta chain Q9Z2U1 56 _RITS(ph)PLM(ox)EPSSIEK_ 6.0051
Mammalian STE20-like protein kinase 1 Q9JI11 174 _LADFGVAGQLTDT(ph)MAK_ 7.3359
Mammary gland factor P42230 128 _EANNCSS(ph)PAGVLVDAMSQK_ 12.7460
MAP kinase signal-integrating kinase 1 O08605 344 _GLPT(ph)PQVLQR_ 6.8470
MAPK/ERK kinase kinase 1 P53349 502 _SHDFYSHELSS(ph)PVESPASLR_ 2.5762
MAPK/ERK kinase kinase 3 Q61084 166 _HLS(ph)VSSQNPGR_ 4.1165
Maternal-embryonic 3 Q9EQH3 7 _PTTQQS(ph)PQDEQEKLLDEAIQAVK_ 8.3760
Matrin-3 Q8K310 188 _RDS(ph)FDDRGPSLNPVLDYDHGSR_ 8.8611
Matrin-3 Q8K310 533 _MKS(ph)QAFIEMETR_ 5.0572
MCG15924, isoform CRA_a O70349 890 _DKGPAT(ph)PDVPHPDDLIGFK_ 13.9080
Mediator of DNA damage checkpoint protein 1 Q5PSV9 1299 _TPEASVPTT(ph)PELQPFTSK_ 4.4493
Metastasis inhibition factor NM23 P15532 122 _NIIHGSDS(ph)VK_ 5.6600
Metastasis-associated protein MTA1 Q8K4B0 538 _LPEASQS(ph)PLVLK_ 2.2262
Methyltransferase-like protein 1 Q9Z120 21 _AHS(ph)NPMADHTLR_ 19.2400
MICAL-like protein 1 Q8BGT6 305 _KAS(ph)ESSALTPPTPR_ 4.9360
Microphthalmia-associated transcription factor Q08874 414 _AHGLSLIPSTGLCS(ph)PDLVNR_ 2.1836
Microrchidia 3 A6H605 791 _RQCS(ph)ALQQVK_ 21.5620
Microsomal endopeptidase Q91YP2 32 _EAAS(ph)PLQAMSSYTAAGR_ 9.0561
Microtubule-actin crosslinking factor 1 B1ARU4 2823 _KIS(ph)VEMEGQR_ 7.0353
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Microtubule-actin crosslinking factor 1 B1ARU4 1376 _M(ox)IS(ph)SSDAITQEFMDLR_ 14.7100
Microtubule-actin crosslinking factor 1 B1ARU4 3889 _QGS(ph)FSEDVISHK_ 7.7334
Microtubule-actin crosslinking factor 1 B1ARU4 534 _KGHFS(ph)SLELVPPSTLTTTHLK_ 27.5100
Microtubule-actin crosslinking factor 1 B1ARU4 533 _KGHFS(ph)SLELVPPSTLTTTHLK_ 5.7404
Microtubule-actin crosslinking factor 1 B1ARU4 4611 _RQQHEQLNEAAQGILTGPGDMS(ph)PSASQVHK_ 3.4793
Microtubule-associated protein 4 P27546 475 _DMS(ph)PLPESEVTLGKDVVILPETK_ 3.0097
Microtubule-associated protein 4 P27546 517 _VAEFNNVTPLSEEEVTSVKDMS(ph)PSAETEAPLAK_ 2.0439
Microtubule-associated protein 4 P27546 847 _NTT(ph)PTGAAPPAGM(ox)TSTR_ 2.4528
Microtubule-associated serine/threonine-protein kinase 2 Q60592 1037 _LLS(ph)GDSIEKR_ 11.9500
Microtubule-associated serine/threonine-protein kinase 2 Q8C0P0 389 _EIS(ph)WEARDPDNENMTIDK_ 4.1520
Microtubule-interacting protein associated with TRAF3 Q149C2 316 _KLS(ph)DGSFKDVK_ 6.5292
Microtubule-interacting protein associated with TRAF3 Q149C2 319 _KLS(ph)DGSFKDVK_ 2.9619
Minor histocompatibility protein HA-1 Q3TBD2 886 _QGGS(ph)ESEAATLAMVGR_ 19.2090
Mitochondrial dynamics protein MID51 Q8BGV8 58 _AISAPT(ph)SPTR_ 2.0966
Mitochondrial import receptor subunit TOM22 homolog Q9CPQ3 15 _(ac)AAAVAAAGAGEPLS(ph)PEELLPK_ 19.2940
mJumpy Q8VEL2 527 _MGS(ph)SPLEVPKPR_ 3.2080
MKIAA0177 protein Q6A0B1 1452 _FSQGPNNISFS(ph)PK_ 10.8950
MKIAA0380 protein Q5DU33 702 _SLENPTPPFT(ph)PK_ 8.6698
MKIAA0629 protein Q6ZQ80 1563 _ITYAEKLS(ph)PLINEACR_ 2.4476
MKIAA0826 protein Q8CHD0 2273 _AYGVDVGS(ph)PEISFAK_ 4.6838
MKIAA0857 protein Q6ZQ33 626 _ASLAPLAS(ph)PGK_ 5.2543
MKIAA0857 protein Q6ZQ33 1313 _IM(ox)ETSPTLLQIS(ph)PGPPK_ 14.9890
MKIAA0857 protein Q6ZQ33 1212 _T(ph)SLSTALSSGLER_ 8.2751
MKIAA1250 protein Q80TG7 1702 _T(ph)PSTVTLNNNTAPTNR_ 4.6090
MKIAA1574 protein Q69ZG0 582 _T(ph)PENLITDIR_ 14.4110
MKIAA1991 protein Q69Z47 679 _RKGS(ph)VDQYLLR_ 4.3570
Table 2 of 2
Protein Name Uniprot Position Peptide Sequence Ratio M/L
MKL/myocardin-like protein 2 P59759 77 _EQLVDQGIMPPLKS(ph)PAAFHEQIK_ 9.0808
Mll2 protein Q3USG3 2299 _ASQVEPQS(ph)PGLGLR_ 2.0722
Motor domain of KIF13B O35063 1409 _GRWES(ph)QQDVSQTLVSR_ 2.2670
mRNA (guanine-N(7)-)-methyltransferase Q9D0L8 34 _LPENT(ph)PPCQQVDQPK_ 5.8982
Mszf35 O88252 223 _MEDVAPVLS(ph)PR_ 2.9084
Mszf6 O88217 148 _VLPVS(ph)PGAFQNQK_ 7.4075
MutY homolog (E. coli) A2AGE3 27 _ALS(ph)SSQAKPSSLDGLAK_ 14.6350
Myc-binding protein 2 Q7TPH6 3550 _SYS(ph)VVASEYDKQHSILPAR_ 2.8259
Myc-induced SUN domain-containing protein Q1HFZ0 723 _KKEGVILTNENAAS(ph)PEQPGDEDAK_ 6.9403
Myelin A1 protein P04370 112 _DRPS(ph)ESDELQTIQEDPTAASGGLDVMASQK_ 3.7140
Myelin expression factor 2 Q8C854 511 _LGS(ph)KGNQIFVR_ 18.9740
Myocyte-specific enhancer factor 2D Q63943 121 _RAS(ph)EELDGLFRR_ 8.4850
Myomegalin Q80YT7 195 _SIS(ph)YAPSSR_ 10.9260
Myosin phosphatase Rho-interacting protein P97434 617 _MDIDRS(ph)PGLLGTPDLK_ 3.9940
Myosin phosphatase-targeting subunit 1 Q9DBR7 299 _S(ph)PLIESTANMENNQPQK_ 42.7770
Myosin regulatory light chain 2, smooth muscle isoform Q9CQ19 19 _AT(ph)SNVFAMFDQSQIQEFK_ 6.6230
Myosin-Ixb Q9QY06 2036 _GRPTS(ph)FVTVR_ 3.2166
Myotubularin-related protein 3 Q8K296 8 _(ac)MDEEMRHS(ph)LECIQANQIFPR_ 3.7995
N-myc downstream-regulated gene 1 protein Q62433 330 _TAS(ph)GSSVTSLEGTR_ 3.8189
NAD kinase P58058 62 _T(ph)RSLHGPCPVTTFGPK_ 3.7584
NAD kinase P58058 64 _T(ph)RSLHGPCPVTTFGPK_ 3.5019
NAD kinase P58058 48 _SRSLS(ph)ASPALGSTK_ 2.1757
Nck-associated protein 5-like Q6GQX2 494 _NSGSDGSPS(ph)PLLAR_ 5.7340
Ndrg3 protein Q8VCV2 344 _THS(ph)TSSSIGSGESPFSR_ 2.1261
NEDD4-binding protein 1 Q6A037 299 _KQFS(ph)LENVPEGELLPDGK_ 3.3362
Negative elongation factor E P19426 131 _S(ph)LYESFVSSSDR_ 3.3573
Nek1 protein B2RXX0 251 _DRPSVNS(ph)ILEK_ 102.6600
Nercc1 kinase Q8K1R7 800 _GTMEADRGMEGLIS(ph)PTEAVGNSCGASSSCPGWLR_ 16.0620
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Neurabin-2 Q6R891 100 _ASS(ph)LNENVDHSALLK_ 29.8050
Neurite outgrowth inhibitor Q99P72 344 _VVKEDGVMS(ph)PEKTMDIFNEM(ox)K_ 2.6404
Neuron navigator 1 Q8CH77 998 _GQLTNIVS(ph)PTAATTPR_ 3.4660
Neuropathy target esterase Q3TRM4 405 _CIS(ph)MPVDISGLQGGPR_ 9.3911
Neutrophil cytosol factor 2 O70145 332 _LQLS(ph)PGHK_ 8.4491
Neutrophil cytosol factor 2 O70145 385 _LALS(ph)PEHTK_ 5.6173
Neutrophil cytosol factor 4 P97369 161 _IKGVS(ph)PQGAIMDR_ 6.2677
NF-E2 inducible protein Q76LS9 103 _VETAEVCSRPQELPQS(ph)PR_ 7.0833
NIK- and IKBKB-binding protein Q3U0M1 953 _MAIQVDKFNFESVPES(ph)PGEKGHFANLK_ 6.0856
NSFL1 cofactor p47 Q9CZ44 178 _RRHS(ph)GQDVHVVLK_ 2.1097
Nuclear cap-binding protein subunit 1 Q3UYV9 22 _TS(ph)DANETEDHLESLICK_ 4.8832
Nuclear fragile X mental retardation-interacting protein 2 Q5F2E7 649 _NDS(ph)WGSFDLR_ 2.1338
Nuclear mitotic apparatus protein 1 Q3TH77 398 _LQES(ph)PAPEKGEVLGDALQLDTLKQEAAK_ 5.4628
Nuclear mitotic apparatus protein 1 Q3TH77 1844 _LGS(ph)PDDGNSALLSLPGY(ph)RPT(ph)TR_ 5.0114
Nuclear protein 220 Q61464 1571 _KEALKISPS(ph)PELNLK_ 2.6955
Nuclear protein 220 Q61464 381 _DYQSEADLPIRS(ph)PFGIVK_ 25.9600
Nuclear receptor coactivator 6 Q3UQD5 2024 _RNS(ph)RTEEPTMASESVENGHR_ 2.0875
Nuclear receptor coactivator 6-interacting protein Q923W1 103 _MS(ph)SHENFEMSMNAR_ 12.6530
Nuclear SET domain-containing protein 2 Q8BVE8 605 _NRAS(ph)ATASSALGFNK_ 10.7660
Nuclear transcription factor, X box-binding protein 1 B1AY10 81 _S(ph)PQGFFQSSNK_ 2.0843
Nuclear-interacting partner of ALK Q80YV2 343 _SQDATVSPGSEQSEKS(ph)PGPIVSR_ 3.3738
Nucleolar protein 1 Q922K7 59 _AGS(ph)VDVPKPNKSPGIK_ 7.8362
Nucleolar protein 56 Q9D6Z1 554 _RKFS(ph)EEPEVAANFTK_ 16.8010
Nucleolar protein EMG1 homolog O35130 16 _RFS(ph)VQEQDWET(ph)TPPKK_ 2.6074
Nucleolin P09405 307 _VEGSEPTT(ph)PFNLFIGNLNPNK_ 24.4820
Nucleolin P09405 616 _GFGFVDFNS(ph)EEDAKAAK_ 8.5657
Nucleoporin 153 Q3TA10 339 _RIPSAVS(ph)SPLNS(ph)PLDR_ 12.8410
Nucleoporin 153 Q3TA10 520 _VQMTSLGSTGS(ph)PVFTFSSPIVK_ 4.3421
Nucleoporin 98 B2RQL0 79 _PIPQT(ph)PESVGNK_ 3.4793
Nucleoporin Nup107 Q8BH74 11 _SGFGGMS(ph)SPVIR_ 3.3876
Nucleoporin Nup133 Q8R0G9 71 _IFPHHS(ph)ISESVNYDVR_ 11.7200
Nucleoporin Nup133 Q8R0G9 40 _RGLSLGS(ph)AVNSPVLFSPAGR_ 2.1082
Nucleoporin Nup214 Q80U93 964 _SAFLS(ph)QR_ 11.2080
Nucleoporin Nup214 Q80U93 492 _SSAS(ph)VTGEPPLYPTGSDSSR_ 3.7366
Nucleoporin Nup35 Q8R4R6 258 _GVLSS(ph)PSLAFTT(ph)PIR_ 3.1062
O-phosphoserine phosphohydrolase Q99LS3 3 _MVS(ph)HSELRK_ 6.8846
Oxysterol-binding protein-related protein 3 Q9DBS9 272 _LHSS(ph)NPNLSTLDFGEEK_ 6.9326
Oxysterol-binding protein-related protein 3 Q9DBS9 340 _QLMELDTSPS(ph)PSAQVVGLK_ 3.7611
p150 target of rapamycin (TOR)-scaffold protein Q8K4Q0 863 _ILDTSSLTQS(ph)APAS(ph)PTNK_ 9.1376
p80 Q62311 532 _AAAPPQPS(ph)PPPTK_ 7.9577
p94-Fer P70451 434 _HSIAGIIKS(ph)PK_ 9.5165
PAI1 RNA-binding protein 1 Q9CY58 234 _GGSGSHNWGTVKDELTES(ph)PKYIQK_ 2.1421
PAI1 RNA-binding protein 1 Q9CY58 329 _S(ph)KSEEAHAEDSVM(ox)DHHFR_ 15.3280
PAI1 RNA-binding protein 1 Q9CY58 327 _S(ph)KSEEAHAEDSVM(ox)DHHFR_ 14.3730
PAP-associated domain-containing protein 5 Q68ED3 592 _VGS(ph)QDVSLEVSQAVGK_ 10.2850
Paxillin Q8VI36 83 _YAHQQPPS(ph)PLPVYSSSAK_ 5.9487
Pb1 protein Q8R134 39 _RRLS(ph)NLPTVDPIAVCHELYNTIR_ 5.0894
PCF11 A5HLW0 785 _IDGPPT(ph)PGSLR_ 10.6010
PCF11 A5HLW0 777 _MIFEGPNKLS(ph)PR_ 2.5405
PDH-containing protein JUNE-1 Q8BSN5 398 _RLGGLPKS(ph)GEP_ 4.8712
PDZ and LIM domain protein 2 Q8R1G6 210 _FSS(ph)LDLEEDSEVFK_ 21.1050
PDZ and LIM domain protein 2 Q8R1G6 199 _VLLHS(ph)PGRPS(ph)SPR_ 2.4060
Pericentriolar material 1 protein Q9R0L6 93 _YM(ox)TQMS(ph)VPEQAELEK_ 7.4516
PH domain leucine-rich repeat-containing protein phosphatase 2 Q8BXA7 1207 _RQNS(ph)VNSGILLPANR_ 2.2550
PH domain-containing adaptor PHAD47 Q9ERS5 314 _SIS(ph)LTRPGSSTLTSAPNSILSR_ 4.6209
Phf3 protein A0PJJ1 1909 _FYS(ph)DSHHLKR_ 50.2070
Phf3 protein A0PJJ1 1529 _NSGEETSSVGSSSIS(ph)PGPLASLSLR_ 16.2510
Phf3 protein A0PJJ1 1882 _RHS(ph)DPWGR_ 5.8488
Phosphatase 2A inhibitor I2PP2A Q9EQU5 28 _S(ph)AS(ph)PGLPKGEK_ 4.0505
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Q6P549 241 _VFDQQSS(ph)PM(ox)VTR_ 2.8036
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Phosphatidylinositol 4-kinase type 2-alpha Q2TBE6 462 _SAS(ph)ESYTQSFQSR_ 4.7681
Phosphoacetylglucosamine mutase Q9CYR6 64 _STIGVM(ox)VTAS(ph)HNPEEDNGVK_ 6.5139
Phosphoglucomutase 2 A2CEK3 133 _AIGGIILT(ph)ASHNPGGPNGDFGIK_ 6.0035
Phosphoinositide 3-kinase-C2-alpha Q61194 1553 _SAGAVPFS(ph)PTLGQIGGAVK_ 25.1520
Phosphoinositide 3-kinase-C2-alpha Q61194 261 _ASVCNLQIS(ph)PK_ 5.2042
Phospholipase C, beta 4 A2AT93 263 _DGPQTSNSS(ph)MKLQSAN_ 2.4159
Phostensin Q8BQ30 194 _WRLS(ph)PGETPEESLR_ 2.5487
Pinin Q3TUQ5 68 _RGFSDS(ph)GGGPPAK_ 19.8540
Plastin-2 Q61233 84 _VFHGLKST(ph)EVAK_ 23.1750
Plastin-2 Q61233 291 _ITNFST(ph)DIKDSK_ 9.4221
Plastin-2 Q61233 5 _MARGS(ph)VSDEEMMELR_ 6.9467
Pleckstrin homology domain-containing family G member 5 Q66T02 938 _SKS(ph)EASLLQLLSGTPAAR_ 9.5467
Pleckstrin homology domain-containing family M member 1 Q7TSI1 466 _SAAGLCTS(ph)PVQDTPESR_ 15.9130
Pleckstrin homology domain-containing family M member 3 Q8BM47 150 _S(ph)RSDVTHVDWR_ 5.5934
Pleckstrin homology domain-containing family M member 3 Q8BM47 350 _SSGLLAS(ph)PVLDSPK_ 4.7470
Plectin-1-10 Q9QXS1 4261 _T(ph)QLASWSDPTEETGPVAGILDTETLEK_ 5.6297
Plectin-1-10 Q9QXS1 3889 _QIT(ph)VEELVR_ 2.0613
Plenty-of-prolines 101 Q52KI8 387 _RLS(ph)PSASPPR_ 12.9070
Plenty-of-prolines 101 Q52KI8 389 _RLS(ph)PSASPPR_ 4.3213
Poly [ADP-ribose] polymerase 12 Q8BZ20 273 _DSSGPVS(ph)PGTPSQEESEQICLYHIR_ 2.1442
Polycomb protein EED Q921E6 61 _NMS(ph)EREVSTAPAGTDMPAAK_ 4.8952
Polypyrimidine tract binding protein 1 Q3U5I2 437 _HQS(ph)VQLPR_ 7.5275
PP2A B subunit isoform B56-alpha Q3ULN8 53 _SQGS(ph)QAELHPLPQLK_ 15.0220
PP2A B subunit isoform B56-epsilon Q61151 7 _(ac)SSAPTT(ph)PPSVDKVDGFSR_ 2.2873
PR domain containing 2, with ZNF domain A2A7B5 1395 _RLS(ph)FNVELSK_ 8.3566
Programmed cell death protein 4 Q61823 457 _RFVS(ph)EGDGGR_ 22.3480
Programmed cell death protein 4 Q61823 94 _SGVAVPTS(ph)PKGR_ 7.4252
Proline-rich AKT1 substrate 1 Q9D1F4 318 _LNT(ph)SDFQK_ 8.2387
Proteasome inhibitor PI31 subunit Q8BHL8 189 _QPAWRDPLS(ph)PFAVGGDDLDPFGCQR_ 4.8460
Protein A6 Q91YR1 143 _YLLSQSS(ph)PAPLTAAEEELR_ 4.8856
Protein capicua homolog Q924A2 1644 _SAAAATS(ph)PAPHLVAGPLLGTVGK_ 19.6180
Protein capicua homolog Q924A2 1625 _VPGGS(ph)PMGVSLVYSDKK_ 14.0570
Protein capicua homolog Q924A2 1403 _KVFS(ph)PVIR_ 2.0093
Protein DDI1 homolog 2 A2ADY9 194 _LFS(ph)ADPFDLEAQAK_ 32.6830
Protein FAM114A2 Q8VE88 119 _AETSLGIPS(ph)PTEISAEVK_ 25.3730
Protein FAM122A Q9DB52 144 _RIDFIPVS(ph)PAPS(ph)PTR_ 6.3232
Protein FAM126B Q8C729 564 _ELLS(ph)PGAPLTK_ 13.5080
Protein FAM193A Q8CGI1 648 _RPPS(ph)IGDVFHGLNK_ 2.6787
Protein FAM86A Q3UZW7 212 _GNVLLNGFSLEPHT(ph)PIDAGSSK_ 19.7820
Protein ftsJ homolog 3 Q9DBE9 633 _GRGS(ph)KADEDGFEVVPIQDPVK_ 5.0952
Protein HIRA Q61666 659 _LLPMSLSVQS(ph)PAALSTEK_ 9.4993
Protein incorporated later into tight junctions Q9DCD5 407 _AFVDRT(ph)PPPAAVVQR_ 2.0857
Protein kinase C-like 1 Q3UEA6 545 _LIPSAVATGTFS(ph)PNAS(ph)PGAEIR_ 10.5040
Protein kinase C-like 2 Q8BWW9 619 _S(ph)KSEYELSIPDSGR_ 19.3420
Protein kinase C-like 2 Q8BWW9 305 _SS(ph)VVIEELSLVAS(ph)PTLS(ph)PR_ 3.1874
Protein LAP4 Q80U72 821 _MVEPENAVTITPLRPEDDYS(ph)PR_ 3.0921
Protein lin-54 homolog Q571G4 264 _AVTGQTTQAS(ph)PPVVTGR_ 10.8030
Protein lin-54 homolog Q571G4 314 _IAIS(ph)PLKS(ph)PNK_ 2.4211
Protein lin-9 homolog Q8C735 65 _LFS(ph)DEDDRQINTK_ 4.0034
Protein lunapark Q7TQ95 411 _ADS(ph)VPNLEPSEESLVTK_ 8.9938
Protein LYRIC Q80WJ7 491 _TM(ox)S(ph)TSDPAEVLIK_ 4.0607
Protein LYRIC Q80WJ7 96 _KREEAAPPT(ph)PAPDDLAQLK_ 2.5546
Protein NEDD1 P33215 411 _NSLGDMFS(ph)PIRDDAVVSK_ 17.2010
Protein NEDD1 P33215 379 _SKS(ph)TDIFSK_ 7.1658
Protein numb homolog Q9QZS3 636 _TNPS(ph)PTNPFSSDLQK_ 16.4200
Protein RIC1 homolog Q69ZJ7 1171 _SQS(ph)WLSNIGPTHR_ 13.7530
Protein RW1 O70472 2032 _IWS(ph)PTVGR_ 5.6217
Protein Smaug homolog 2 Q80XS6 585 _M(ox)GLLS(ph)PSGIGGVSPR_ 5.0295
Protein SON Q9QX47 94 _CVS(ph)VQTDPTDEVPTKK_ 6.5585
Protein tyrosine phosphatase, non-receptor type 12 Q80UM4 448 _KVPLQEGPKS(ph)FDGNTLLNR_ 5.1905
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Protein tyrosine phosphatase, non-receptor type 12 Q80UM4 434 _NLS(ph)FEIKK_ 2.0152
Protein tyrosine phosphatase, non-receptor type 12 Q80UM4 748 _S(ph)PAEVTDIGFGNR_ 10.0730
Protein tyrosine phosphatase, non-receptor type 12 Q80UM4 746 _DQIT(ph)KSPAEVTDIGFGNR_ 3.8555
Protein tyrosine phosphatase, non-receptor type 22 (Lymphoid) B0V3P7 450 _T(ph)KSTPFELIQQR_ 9.2823
Protein tyrosine phosphatase, non-receptor type 22 (Lymphoid) B0V3P7 634 _TPESFIVVEEAGEPS(ph)PR_ 3.7353
Protein Wiz O88286 1015 _GLTHPSS(ph)SPLLKK_ 5.6918
PtdIns-4,5-P2 4-Ptase I Q3TWL2 169 _IINLGPVHPGPLS(ph)PEPQPMGVR_ 4.9231
Putative RNA-binding protein 15B Q6PHZ5 559 _RNS(ph)LEGYSR_ 3.9249
Putative uncharacterized protein Q3U048 557 _SSSQSTFHIPLS(ph)PVEVKPGNVR_ 3.3073
Putative uncharacterized protein Q3U224 564 _S(ph)TRVPGTDAAAQAEDLNVK_ 13.2600
Putative uncharacterized protein Q3U224 34 _EQPPPLQS(ph)PPQSLR_ 6.1908
Putative uncharacterized protein Q3UUE0 540 _VEADVAPPQVQGDLKT(ph)PDLSVQLPSADLELK_ 74.7370
Putative uncharacterized protein Q8BJC6 71 _S(ph)PTGAQPAAAKPPPLSAK_ 4.5726
Pyk2/RAFTK-associated protein Q3UND0 5 _(ac)PNPS(ph)CTS(ph)SPGPLPEEIR_ 7.9606
Pyk2/RAFTK-associated protein Q3UND0 8 _(ac)PNPS(ph)CTS(ph)SPGPLPEEIR_ 7.3893
Pyridoxal-dependent decarboxylase domain-containing protein 1 Q99K01 691 _VQGTGVT(ph)PPPT(ph)PLGTR_ 2.5262
Pyruvate kinase isozymes M1/M2 P52480 6 _PKPHS(ph)EAGTAFIQTQQLHAAMADTFLEHMCR_ 3.4987
R3H domain-containing protein 2 Q80TM6 381 _ASS(ph)FSGISILTR_ 3.5321
R3hdm1 protein B9EHE8 299 _DRIFS(ph)QDSLCSQENYIIDKR_ 5.8272
Rab GTPase-binding effector protein 1 O35551 407 _RAQS(ph)TDSLGTSSSLQSK_ 3.0421
Rab-3A-interacting protein Q68EF0 218 _TLVLSSSPTS(ph)PTQEPLAAAK_ 3.7894
RAB3 GTPase-activating protein 130 kDa subunit Q3TPB6 536 _KTS(ph)LSDSTTSAYPGDAGK_ 7.8367
Rab3 GTPase-activating protein 150 kDa subunit Q8BMG7 449 _GGFS(ph)PFGNTQGPSR_ 27.7580
RAB34, member of RAS oncogene family B1AQD4 247 _INS(ph)DDKNLYLTASK_ 3.1560
Rab4-interacting protein Q8BIJ7 52 _SQLPS(ph)PGELR_ 9.9709
RACK1 P68040 276 _IIVDELKQEVIS(ph)TSSK_ 3.1613
RACK1 P68040 316 _VWQVTIGT(ph)R_ 2.5862
Rap1-interacting factor 1 homolog Q6PR54 1051 _LLEEEKS(ph)TDFVFIPPEGK_ 4.0256
Rap1-interacting factor 1 homolog Q6PR54 1050 _LLEEEKS(ph)TDFVFIPPEGK_ 3.6671
Rap1-interacting factor 1 homolog Q6PR54 1535 _RAS(ph)QGLISAVENSESDSSEAKEEVSR_ 2.8987
Rapgef6 protein B2RUJ6 1076 _S(ph)LSQGSTNSNMLDVQGGAHK_ 2.1923
Rapgef6 protein B2RUJ6 1078 _S(ph)LSQGSTNSNMLDVQGGAHK_ 2.1139
Ras and Rab interactor 3 B2RQF8 501 _QATGASWEGLS(ph)PVR_ 3.2964
RAS protein activator like 2 Q0VAV5 810 _LKS(ph)PSQDNTDSYFR_ 6.4198
RAS protein activator like 2 Q0VAV5 1101 _QQTQQVQSPVDSATMS(ph)PVER_ 2.1460
RAS protein activator like-3 Q8C2K5 73 _VLS(ph)APPKESR_ 16.9760
RAS protein activator like-3 Q8C2K5 52 _ALS(ph)HQEPMVNSQPAPR_ 3.4836
Ras-related protein Rab-1B Q9D1G1 179 _MGPGAAS(ph)GGERPNLK_ 2.7575
Regulation of nuclear pre-mRNA domain-containing protein 2 Q6NXI6 1117 _RMS(ph)GEPIKTVESIR_ 5.1425
Regulator of G-protein signaling 10 Q9CQE5 16 _KRPPS(ph)DIHDGDGSSSSGHQSLK_ 24.6330
Regulator of ubiquitous kinase Q8R550 274 _S(ph)IEVENDFLPVEK_ 4.5028
Retinoblastoma-like protein 1 Q64701 350 _LTSQAS(ph)VECNLQQHFEK_ 13.0210
Rho GTPase activating protein 1 A2AGT9 91 _S(ph)SSPEPVTHLKWDDPYYDIAR_ 13.2550
Rho GTPase activating protein 14 Q812A2 837 _NDLQS(ph)PTEHISDYGFGGVMGR_ 24.3800
Rho GTPase activating protein 14 Q812A2 858 _LRS(ph)DGAAIPR_ 2.9898
Rho GTPase activating protein 25 Q8BYW1 363 _SKDAPIS(ph)PPAQK_ 5.6758
Rho GTPase activating protein 30 Q640N3 876 _GVGDHLEEGALSEGPGVELLRVDS(ph)TEEINEQTSEMK_ 6.2132
Rho GTPase activating protein 30 Q640N3 966 _IHVAPAS(ph)PCPRPGR_ 3.5546
Rho GTPase activating protein 30 Q640N3 996 _NGGSLS(ph)FDAAVALAR_ 2.2490
Rho GTPase activating protein 5 B9EKC3 591 _LYHDS(ph)TNIDKVNLFILGK_ 23.5020
Rho GTPase activating protein 5 B9EKC3 590 _LYHDS(ph)TNIDKVNLFILGK_ 16.3200
Rho GTPase activating protein 5 B9EKC3 968 _ESTHQSEDVFLPS(ph)PR_ 3.3943
Rho GTPase-activating protein 27 A2AB59 195 _PLAPS(ph)DSENVYEAIPDLR_ 16.2680
Rhomboid family member 2 Q80WQ6 83 _RQAS(ph)LSQSIR_ 2.7136
Ribosomal protein S6 kinase alpha-3 P18654 386 _GFS(ph)FVAIT(ph)SDDESQAMQTVGVHSIVQQLHR_ 5.4217
Ribosomal protein S6 kinase polypeptide 1 Q3TIM6 28 _SRIS(ph)QTLPGPGPGPQQDSDEAILK_ 2.2021
Ribosomal protein S6 kinase polypeptide 1 Q3TIM6 380 _GFS(ph)FVATGLMEDDGKPR_ 3.4219
Ribosomal protein S6 kinase polypeptide 1 Q3TIM6 577 _AENGLLM(ox)T(ph)PCYTANFVAPEVLKR_ 23.5260
Ribosomal RNA processing protein 1 homolog B Q91YK2 672 _SILVS(ph)PTGLSR_ 2.4447
RIO kinase 3 Q9DBU3 512 _KAASFLKDDGS(ph)PPVLSAD_ 5.1255
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RNA polymerase II subunit A C-terminal domain phosphatase Q7TSG2 830 _RQPS(ph)MSEAMPLYTLCK_ 12.0530
RNA polymerase II-associated protein 3 Q9D706 88 _IKS(ph)YDYDAWAK_ 19.1660
RNA-binding motif protein 14 Q8C2Q3 618 _RLS(ph)ESQLSFR_ 2.2791
RNA-binding motif protein 14 Q8C2Q3 256 _AQPS(ph)ASLGVGYR_ 3.7682
RNA-binding motif protein 14 Q8C2Q3 280 _AQPSVS(ph)LGAPYR_ 2.1477
RNA-binding motif protein 7 Q9CQT2 125 _TVGNVS(ph)PTAQMVQR_ 5.4646
RNA-binding motif protein 7 Q9CQT2 136 _SFS(ph)SPEDYQR_ 3.5978
S100P-binding protein Q9D5K4 294 _MFS(ph)QSELEK_ 17.6010
Salt-inducible kinase 3 Q6P4S6 1218 _NKVPS(ph)RESVLGNCLER_ 2.1122
SAPS domain family member 1 Q7TSI3 739 _EADMSSIQIPS(ph)SPPAHGS(ph)PQLR_ 2.2484
Sarcolemmal membrane-associated protein Q3URD3 148 _LRSDVIHAPLPS(ph)PVDK_ 10.4710
SEC16 homolog A (S. cerevisiae) A2AIX1 2101 _APS(ph)LTSDSEGKKPAQAVK_ 2.8870
Sec23ip protein A0AUN0 600 _S(ph)PGSVAVSNGVIK_ 4.1039
SECIS binding protein 2 Q3TGQ4 229 _LDFPELQS(ph)PK_ 13.0950
Serine/arginine repetitive matrix protein 2 Q8BTI8 2224 _TPAAAAAMNLAS(ph)PR_ 4.2931
Serine/threonine kinase 10 A1A553 416 _SRPLS(ph)MDAR_ 5.2346
Serine/threonine-protein kinase 24 Q99KH8 4 _(ac)AHS(ph)PVQSGLPGMQNLKADPEELFTKLEK_ 15.1790
SH3 domain-binding protein 1 P55194 182 _SLTSLDTALAELRDNHNQADHS(ph)PLTTAAPFSR_ 2.8813
SH3 domain-binding protein 1 P55194 553 _RLPAS(ph)PVISNMPAQVDQGVATEDR_ 3.7840
Shootin-1 Q8K2Q9 494 _LTAEADSS(ph)SPTGILATSESK_ 5.5390
Shootin-1 Q8K2Q9 3 _(ac)MNS(ph)SDEEKQLQLITSLK_ 2.6554
Signal transducer and activator of transcription 1 P42225 733 _LQTTDNLLPMS(ph)PEEFDEMSR_ 3.7019
Smad-interacting protein 1 Q9R0G7 647 _GLTS(ph)PINPYKDHM(ox)SVLK_ 5.8764
Smith-Magenis syndrome chromosomal region candidate gene 8 protein Q3UMB5 416 _VLISVGS(ph)YK_ 3.0089
SNARE-associated protein Snapin Q9Z266 14 _(ac)AAAGSAAVSGAGT(ph)PVAGPTGR_ 2.8061
Solute carrier family 25 member 46 Q9CQS4 45 _SFGSGTELGHWVTT(ph)PPDIPGSR_ 5.3396
Solute carrier family 7 member 6 Q8BGK6 8 _(ac)MEAQELGS(ph)PTPTYHLLPK_ 8.8644
Son of sevenless homolog 1 Q62245 1120 _SAS(ph)VSSISLSK_ 8.8987
Sorting nexin-2 Q9CWK8 104 _ELILSSEPSPAVTPVT(ph)PTTLIAPR_ 13.5560
Sorting nexin-9 Q91VH2 175 _SSS(ph)PYFKDSEPAEAGGIQR_ 2.6030
Spectrin alpha 2 A3KGU5 1197 _WRS(ph)LQQLAEER_ 3.8006
SPEN homolog, transcriptional regulator (Drosophila) A2ADB0 1075 _LNS(ph)ALSPK_ 10.0980
Spleen tyrosine kinase P48025 270 _IGAQMGHPGS(ph)PNAHPVT(ph)WSPGGIISR_ 10.6490
Splicing factor that interacts with PQBP-1 and PP1 Q923D5 600 _GATAVPQRRS(ph)EDDSAVPVAK_ 37.8100
Striatin O55106 259 _AKS(ph)VIDTSTIVR_ 2.2206
Sucrose nonfermenting protein 2 homolog Q91ZW3 136 _QNLLS(ph)VGDYR_ 3.6756
Sugen kinase 223 Q571I4 131 _GLQKPAS(ph)PLACTDGNSR_ 2.8420
Sugen kinase 223 Q571I4 472 _TIYLSS(ph)PDSAVGVQWPR_ 2.5135
Sugen kinase 223 Q571I4 802 _AAS(ph)SPDGFFWTQGS(ph)PKPR_ 2.0800
Symplekin Q80X82 510 _RLS(ph)VQGQAISVVGSQSTMS(ph)PLEEEVPQAK_ 57.7190
Syntaxin-4 P70452 36 _LGS(ph)PDDEFFQK_ 2.6491
SZT2 A2A9C3 1115 _SSIS(ph)AQPPQWHCYAR_ 15.1750
SZT2 A2A9C3 2433 _ANTFPCTPVSGEPVT(ph)PPSK_ 7.8526
Target of EGR1 protein 1 Q9D2E2 349 _S(ph)LQSQPGTQTLAEAEDGPPTK_ 10.9010
Target of Myb protein 1 Q3UDC3 160 _KGLEFPMTDLDMLS(ph)PIHTPQR_ 38.5490
Targeting protein for Xklp2 A2APB8 482 _VIPAT(ph)VPKSPVFALK_ 4.4393
TBC1 domain family member 5 Q3U325 546 _SES(ph)MPVQLNK_ 4.7294
TBC1 domain family, member 17 Q3TCA5 20 _GGVYLHT(ph)SARK_ 17.8180
TBP-associated factor 3 Q5HZG4 669 _EM(ox)ALPLFS(ph)PSAVR_ 12.7080
Telomeric repeat-binding factor 2-interacting protein 1 Q91VL8 43 _RLS(ph)TLILHGGGTVCR_ 21.2580
Tensin-3;Tensin-like SH2 domain-containing protein 1 Q5SSZ5 648 _GIS(ph)NGPNPPDTQQLCPGK_ 14.9560
Terminal uridylyltransferase 4 B2RX14 176 _T(ph)PRSPLEPENVPSLLLK_ 2.2269
Testicular zinc finger protein Q99PP2 1878 _VVIELS(ph)PSLPSKR_ 3.8501
Tether containing UBX domain for GLUT4 Q8VBT9 279 _LGGPSASLRPLT(ph)SPSANSSK_ 6.9735
THO complex 5 Q5SVF8 340 _RRPT(ph)LGVQLDDK_ 10.2260
THUMP domain-containing protein 1 Q99J36 119 _FQS(ph)VESGANNVVFIR_ 14.2010
THUMP domain-containing protein 1 Q99J36 88 _FIDKDQQPS(ph)GS(ph)EGEDDDAEAALKK_ 12.4680
THUMP domain-containing protein 1 Q99J36 86 _FIDKDQQPS(ph)GS(ph)EGEDDDAEAALKK_ 2.3066
Thyroid hormone receptor-associated protein 3 Q569Z6 253 _SPALKS(ph)PLQSVVVR_ 4.0951
Thyroid hormone receptor-associated protein 3 Q569Z6 572 _MDS(ph)FDEDLARPSGLLAQER_ 7.1723
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TNF receptor-associated factor 2 P39429 11 _(ac)AAASVTSPGS(ph)LELLQPGFSK_ 4.4737
TNFAIP3-interacting protein 1 Q9WUU8 279 _EGLCGQPSS(ph)PKPEGAGK_ 2.0393
TopBP1-interacting checkpoint and replication regulator Q8BQ33 1763 _FLS(ph)AKEESEYK_ 4.7921
Tpr protein Q05CS8 2204 _TVPS(ph)TPTLVVPHR_ 10.1200
Tpr protein Q05CS8 2223 _TDGFAEAIHS(ph)PQVAGVPR_ 2.2129
Tpr protein Q05CS8 453 _KGAILSEEELAAMS(ph)PTAAAVAK_ 7.0957
Tpr protein Q05CS8 1730 _GIAS(ph)TSDPPTANIKPTPVVSTPSK_ 70.6920
Tra1 homolog Q80YV3 2049 _GLS(ph)VDSAQEVKR_ 16.9470
Tra1 homolog Q80YV3 2073 _S(ph)QSLPGADSLLAKPIDKQHTDTVVNFLIR_ 4.3810
TRAF family member-associated NF-kappa-B activator P70347 258 _GLGRDEEDTS(ph)FESLSK_ 17.2570
Trafficking protein particle complex subunit 10 Q3TLI0 809 _RQES(ph)GSSLEPPSGLALEDGAHVLR_ 2.2456
Transcription factor E2F8 Q58FA4 20 _GLMKS(ph)PLHPSSK_ 2.1076
Transcription factor EB, isoform CRA_b Q3U327 524 _RS(ph)SFSMEEGDVL_ 2.4345
Transcription factor HIVEP3 A2A884 555 _GS(ph)YS(ph)FDDHVADPEVPS(ph)R_ 5.4459
Transforming acidic coiled-coil-containing protein 1 Q6Y685 284 _GSGAQRS(ph)PLNLK_ 4.1761
Transforming acidic coiled-coil-containing protein 2 Q9JJG0 763 _QALYLMFDTPQES(ph)PVKSPPVR_ 3.6910
Trinucleotide repeat-containing gene 6B protein Q8BKI2 422 _NGNTNSLNLS(ph)SPNPMENK_ 15.2230
Triosephosphate isomerase P17751 130 _VTNGAFTGEIS(ph)PGMIK_ 5.8263
tRNA-intron endonuclease Sen54 Q8C2A2 178 _FQLSSVVS(ph)PYER_ 2.9312
Tuberin Q61037 1367 _AIS(ph)SEGARPAVDLSFQPSQPLSK_ 25.2700
Tuberin Q61037 1130 _VRS(ph)MSGGHGLR_ 19.4160
Tuberin Q61037 1366 _AIS(ph)SEGARPAVDLSFQPSQPLSK_ 13.8190
Tuberin Q61037 1254 _SLS(ph)VPAAGTAKPPTLPR_ 6.0723
Tudor domain-containing protein 3 Q91W18 438 _DTPTSKS(ph)TVENSVLSR_ 17.2800
Tumor protein D52 Q62393 158 _ASAAFSSVGS(ph)VITK_ 14.3170
Tumor protein D52-like 2 A2AUD5 12 _(ac)MDSASQDINLNS(ph)PNKGVLSDFMTDVPVDPGVVHR_ 2.0183
Twinfilin-2 Q9Z0P5 349 _LIRGPGENGEDS(ph)_ 2.4880
Type III PIP kinase Q9Z1T6 307 _SAS(ph)ITNLSLDR_ 2.2847
Tyrosine-protein phosphatase non-receptor type 6 P29351 536 _GQES(ph)EYGNITYPPAVR_ 3.0442
Tyrosine-protein phosphatase non-receptor type 7 Q8BUM3 147 _AQSQEDS(ph)DYINANYIR_ 17.3690
U2 small nuclear ribonucleoprotein A’ P57784 178 _S(ph)KTFNPGAGLPTDKK_ 2.5192
Ubiquitin-activating enzyme E1 Q02053 13 _RVS(ph)GPDPKPGSNCSPAQSALSEVSSVPTNGMAK_ 2.5835
Ubiquitin-associated protein 1 Q8BH48 146 _VLS(ph)PPHTK_ 10.9450
Ubiquitin-associated protein 2-like Q80X50 43 _LAQMIS(ph)DHNDADFEEK_ 18.1550
Ubiquitin-associated protein 2-like Q80X50 630 _YPSS(ph)ISSS(ph)PQKDLTQAK_ 2.9576
Ubiquitin-conjugating enzyme E2O A2A7X3 836 _NMTVEQLLTGSPTS(ph)PTVEPEKPTR_ 3.5821
UBX domain-containing protein 7 Q3UGV7 280 _SES(ph)LIDASEDSQLEAAIR_ 2.6837
UDP-glucose 6-dehydrogenase O70475 474 _RIPYT(ph)PGEIPK_ 23.6320
Uncharacterized protein C10orf78 homolog Q8BP27 141 _S(ph)SSHSFCSVVK_ 2.1859
Uncharacterized protein C12orf35 homolog Q5DTW7 1482 _SLS(ph)ADEFEILQNPVK_ 7.9504
Uncharacterized protein C3orf63 homolog Q69ZR9 1078 _VVS(ph)ISSSDFSAK_ 34.6290
Uncharacterized protein FLJ45252 homolog Q6PIU9 115 _AS(ph)DDLGEPDVFATAPFR_ 5.2484
UPF0414 transmembrane protein C20orf30 homolog Q8CIB6 24 _LAS(ph)TDDGYIDLQFKK_ 3.2235
UPF0485 protein C1orf144 homolog Q6NXN1 107 _ILGSAS(ph)PEEEQEKPILDRPTR_ 5.0958
UPF0557 protein C10orf119 homolog Q8R3C0 154 _VS(ph)PSTSYTPSR_ 3.3294
UPF0684 protein C5orf30 homolog Q8VEB3 256 _S(ph)LDYLNLDK_ 2.1975
UPF0688 protein C1orf174 homolog Q80WR5 20 _S(ph)YSSASLASAR_ 12.7080
USP6 N-terminal-like protein Q80XC3 671 _HVPTAHSGFVSTQIS(ph)PRPQINPSR_ 6.0824
Vacuolar protein sorting-associated protein 13C Q8BX70 1397 _EVS(ph)TPQDVHTTQGVPAAR_ 19.7370
Vacuolar protein sorting-associated protein 13C Q8BX70 1396 _EVS(ph)TPQDVHTTQGVPAAR_ 4.2443
Vacuolar protein sorting-associated protein 26B Q8C0E2 304 _SMS(ph)HQAAIASQR_ 5.5528
Vimentin P20152 426 _ET(ph)NLESLPLVDTHSKR_ 17.0780
WASH complex subunit FAM21 Q6PGL7 866 _IRS(ph)SVPSGGSLFGDDEDDDLFSSAK_ 10.3130
WASH complex subunit FAM21 Q6PGL7 833 _TDSRPKS(ph)TGVFQDEELLFSHK_ 27.4260
WASH complex subunit FAM21 Q6PGL7 284 _SKRPTS(ph)FADELAAR_ 20.2260
WASH complex subunit FAM21 Q6PGL7 832 _TDSRPKS(ph)TGVFQDEELLFSHK_ 6.3458
WASH complex subunit FAM21 Q6PGL7 723 _VPLLFS(ph)DEEDSEVPSGVKPEDLK_ 2.4678
WASH complex subunit FAM21 Q6PGL7 533 _GLFS(ph)DEEDSEDLFSSQSSSKPK_ 2.1323
WD repeat and FYVE domain-containing protein 3 Q6VNB8 970 _VHKPSS(ph)LSFEPEMR_ 4.2021
WD repeat and FYVE domain-containing protein 3 Q6VNB8 818 _HAFHCVST(ph)PPVYPAK_ 2.6557
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WD repeat domain 47 A2AGC7 304 _RPQS(ph)ADAYMTR_ 13.5340
WD repeat domain 47 A2AGC7 296 _LSPYPS(ph)SPM(ox)R_ 2.0465
WD repeat domain 47 A2AGC7 297 _LSPYPS(ph)SPM(ox)R_ 2.0465
WD repeat-containing protein 13 Q91V09 79 _AYS(ph)NSIVR_ 7.2705
WD repeat-containing protein 70 Q3TWF6 641 _TMFAQVES(ph)DDEESKNEPEWK_ 2.1590
Wdr20a protein Q3ULP2 492 _S(ph)SDKLNLVTK_ 8.6536
YTH domain family 1 A2AWN8 209 _APGMNS(ph)LEQGMVGLK_ 7.2693
YTH domain family 2 Q3UNH5 39 _DGLNDDDFEPYLS(ph)PQAR_ 2.9350
Zinc finger CCCH domain-containing protein 11A Q6NZF1 741 _RLS(ph)S(ph)ASTGKPPLSVEDDFEK_ 73.5500
Zinc finger CCCH domain-containing protein 11A Q6NZF1 289 _KLS(ph)VGGDSDPPLKR_ 3.8626
Zinc finger CCCH domain-containing protein 14 Q8BJ05 343 _RPS(ph)LPPSK_ 3.6450
Zinc finger CCCH domain-containing protein 4 Q6ZPZ3 1276 _TGTGSPFAGNS(ph)PAREGEQDAGSLKDVFK_ 2.2737
Zinc finger CCCH type containing 13 B9EHN9 1427 _LIS(ph)DPMER_ 12.4620
Zinc finger CCHC domain-containing protein 2 Q69ZB8 455 _SIS(ph)SESQHNFNNLQSSLK_ 9.1330
Zinc finger MYM-type protein 2 Q9CU65 305 _QQGVDSLS(ph)PVASLPK_ 15.5150
Zinc finger protein 451 Q8C0P7 429 _ILS(ph)VKESSAEDCIVPTKK_ 15.5520
Zinc finger protein 462 A2SW42 351 _S(ph)PHNSGLVNLTER_ 6.2775
Zinc finger protein 609 Q8BZ47 467 _TNS(ph)MGSATGPLPGTK_ 2.3661
Zinc finger protein 687 Q9D2D7 1120 _SSGS(ph)AEQSLVGLR_ 27.1150
Zinc finger transcription factor Trps1 Q925H1 830 _TLRDS(ph)PNVEAAHLAR_ 2.1444
Zinc finger ZZ-type and EF-hand domain-containing protein 1 Q5SSH7 1535 _LLS(ph)FRS(ph)M(ox)EETRPVPTVK_ 3.9386
Zinc finger, C3H1-type containing B2RT41 356 _RLS(ph)ASDIVSEK_ 3.3305
Zinc finger, C3H1-type containing B2RT41 1049 _S(ph)FLESNSFTKPNLK_ 3.1372
Zyxin Q3TCR9 336 _S(ph)PGGPGPLTLK_ 12.2680
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Appendix D- ERK5 in macrophages
One of the original aims of this thesis was to examine the role of ERK5 in cytokine
production in macrophages. Studies with a LRRK2 inhibitor demonstrated an off-target
effect of this inhibitor was to inhibit cytokine production in LPS-stimulated macrophages
(data not shown). Screening of this inhibitor identifed ERK5 as being strongly inhibited.
A more selective ERK5 inhibitor was obtained (Deng et al., 2013). Sorbitol treatment of
HeLa cells led to band shift of ERK5 which is indicative of activation by MEK5 which
results in further autophosphorylation events (Mody et al., 2003). Treatment of cells
with 5 µM ERK5-IN-1 completely blocked ERK5 bandshift (See Appendix D- Figure 1).
Activation of ERK1/2 was unaffected by ERK5-IN-1.
Appendix D- Figure 1: ERK5-IN-1 blocks ERK5 autophosphorylation
Cells were serum-starved overnight and then incubated with indicated concentrations of ERK5-IN-1 for 1
hour. Cells were then stimulated with 0.5M Sorbitol for 30 mins. Cells were lysed and proteins separated
by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and immunoblotted with antibodies
to ERK5, phospho ERK1/2 and ERK1/2. Results are representative of three independent experiments.
The LRRK2 inhibitor blocked cytokine production in macrophages independently of
LRRK2 (unpublished observations- Nic Dzamko/Dario Alessi). ERK5 was suggested
as a potential target of this inhibitor and therefore the role of ERK5 in macrophages was
investigated. Macrophages were stimulated with LPS and Zymosan and ERK5 bandshift
was examined. Sorbitol treatment of HeLa cells caused an upward shift of the ERK5 band
compared to unstimulated cells. Neither LPS or Zymosan treatment of BMDMs caused
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an upward mobility shift of the ERK5 band, which suggests ERK5 is not activated in
response to these agonists (see Appendix D- Figure 2).
Appendix D- Figure 2: ERK5 does not bandshift in LPS-stimulated cells
BMDMs were stimulated with 100 ng/ml LPS or 200 µg/ml Zymosan for 30 mins. HeLa cells were
stimulated with 0.5M Sorbitol for 30 mins. Cells were lysed and proteins separated by SDS-PAGE. Proteins
were transferred to nitrocellulose membranes and immunoblotted with antibodies to ERK5. Results are
representative of three independent experiments.
In order to exclude a role for ERK5 in promoting cytokine production in LPS-stimulated
macrophages, BMDMs were cultured from ERK5 conditional knockout mice and stim-
ulated with LPS in the presence or absence of ERK5-IN-1. LPS stimulation induced
transcription of IL-6, IL-12b and IL-1b in wildtype macrophages during the timecourse.
Addition of ERK5-IN-1 reduced cytokine transcription in wildtype cells (see Appendix
D- Figure 3). Macrophages lacking ERK5 were stimulated with LPS and transcrip-
tion of IL-6, IL-12b and IL-1b was induced to similar or higher levels as seen in wild-
type macrophages. Treatment of ERK5-deficient macrophages with ERK5-IN-1 reduced
transcription of cytokines in response to LPS compared to LPS-stimulated ERK5 cKO
macrophages. These data suggest that ERK5-IN-1 suppresses cytokine transcription in
response to LPS independently of ERK5.
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Appendix D- Figure 3: ERK5-IN-1 represses cytokine production in the absence of ERK5
Wildtype or ERK5 conditional KO BMDMs were stimulated with 100 ng/ml LPS for the times indicated
in the presence or absence of 5 µM ERK5-IN-1. Cells were lysed with RLT buffer (Qiagen) and total
RNA purified using the Qiagen microRNeasy kit. Total RNA was reverse transcribed using iScript (Bio-
Rad) and qPCR was carried out using SYBR-green based detection methods. Levels of 18S were used as
a normalization control, and fold induction was calculated for IL-6, IL-12b and IL-1b mRNA. n=4, error
bars represent the standard deviation from independent cultures from four mice per genotype.
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Appendix E: MEF2D targeting strategy
Appendix E- Figure 1: MEF2D targeting strategy
A targeting vector was constructed to delete exons 2-3 of the murine MEF2D gene through replacement
with a neomycin selection cassette (NEO). The thymidine kinase cassette (TK) acts as a negative selection
marker. The following primers were used to generate targeting vectors: ARM1 SENSE TGCGGCCGC-
CGCCTAATGAGAGCAGTTCCCTAGCTG,ARM1 ANTISENSE TCATATGATAACTTCGTATAGCAT-
ACATTATACGAAGTTATAAAGCTTATGCACTGTATTGTTGTACGCTGCCGAC, DELETION SENSE
TGCGGCCGCTTATTCATATGAATACAGCCCAACAAGCTCTATAGAGAAC, DELETION ANTI-
SENSE AAAGCTTGGCCGGCCATAACTTCGTATAGCATACATTATACGAAGTTATAGCCCAGTC-
CCTTAACATTTCACAGATGAC, ARM2 SENSE TGGCGCGCCTCTGGCCTTTCCTTGCCATGT-
GACTTTAG, ARM2 ANTISENSE CTCGAGTCGACGCACTTTGCAATACAGCTCTGACCCAAG,
SD SENSE AACCGGTGTGCCATGGACAAGGTGCTGCTCAAGTACAC, SD ANTISENSE AACCG-
GTACCTCCTCAGACTGGCAGATCACAG.Vectors were injected into embryonic stem cells and crossed
to flp mice to remove the neomycin selection casette. Mice were then crossed to Bal1 cre mice to delete
exons 2 and 3 from the MEF2D gene.
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